0001125376-21-000077.txt : 20210429 0001125376-21-000077.hdr.sgml : 20210429 20210429160548 ACCESSION NUMBER: 0001125376-21-000077 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210429 DATE AS OF CHANGE: 20210429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 21870460 BUSINESS ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-Q 1 ensg-20210331.htm 10-Q ensg-20210331
0001125376December 312021Q1falseP3Y0M0DP4M0DP5Y0MP10Y0MP10Y0MP5Y0MP3Y0M00011253762021-01-012021-03-31xbrli:shares00011253762021-04-26iso4217:USD00011253762021-03-3100011253762020-12-31iso4217:USDxbrli:shares0001125376us-gaap:ServiceMember2021-01-012021-03-310001125376us-gaap:ServiceMember2020-01-012020-03-310001125376ensg:RentalMember2021-01-012021-03-310001125376ensg:RentalMember2020-01-012020-03-3100011253762020-01-012020-03-310001125376us-gaap:CommonStockMember2020-12-310001125376us-gaap:AdditionalPaidInCapitalMember2020-12-310001125376us-gaap:RetainedEarningsMember2020-12-310001125376us-gaap:TreasuryStockMember2020-12-310001125376us-gaap:NoncontrollingInterestMember2020-12-310001125376us-gaap:CommonStockMember2021-01-012021-03-310001125376us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001125376us-gaap:TreasuryStockMember2021-01-012021-03-3100011253762020-07-012020-09-300001125376us-gaap:RetainedEarningsMember2021-01-012021-03-310001125376us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001125376us-gaap:CommonStockMember2021-03-310001125376us-gaap:AdditionalPaidInCapitalMember2021-03-310001125376us-gaap:RetainedEarningsMember2021-03-310001125376us-gaap:TreasuryStockMember2021-03-310001125376us-gaap:NoncontrollingInterestMember2021-03-310001125376us-gaap:CommonStockMember2019-12-310001125376us-gaap:AdditionalPaidInCapitalMember2019-12-310001125376us-gaap:RetainedEarningsMember2019-12-310001125376us-gaap:TreasuryStockMember2019-12-310001125376us-gaap:NoncontrollingInterestMember2019-12-3100011253762019-12-310001125376us-gaap:CommonStockMember2020-01-012020-03-310001125376us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100011253762019-07-012019-09-300001125376us-gaap:RetainedEarningsMember2020-01-012020-03-310001125376us-gaap:TreasuryStockMember2020-01-012020-03-310001125376us-gaap:NoncontrollingInterestMember2020-01-012020-03-310001125376us-gaap:CommonStockMember2020-03-310001125376us-gaap:AdditionalPaidInCapitalMember2020-03-310001125376us-gaap:RetainedEarningsMember2020-03-310001125376us-gaap:TreasuryStockMember2020-03-310001125376us-gaap:NoncontrollingInterestMember2020-03-3100011253762020-03-31ensg:facilityensg:bed0001125376us-gaap:WhollyOwnedPropertiesMember2021-03-310001125376ensg:ThePennantGroupInc.Memberus-gaap:SpinoffMemberensg:SeniorLivingFacilitiesMember2021-03-310001125376us-gaap:SpinoffMemberensg:RemainingCompanyMemberensg:SkilledNursingOperationsMember2021-03-31ensg:segment0001125376srt:MinimumMember2021-01-012021-03-310001125376srt:MaximumMember2021-01-012021-03-310001125376srt:MinimumMemberensg:AssembledOccupancyAcquiredMember2021-01-012021-03-310001125376srt:MaximumMemberensg:AssembledOccupancyAcquiredMember2021-01-012021-03-310001125376us-gaap:TradeNamesMember2021-01-012021-03-310001125376us-gaap:CustomerRelationshipsMember2021-01-012021-03-310001125376us-gaap:GeneralLiabilityMemberensg:SelfInsuranceRetentionPerClaimMembersrt:ParentCompanyMember2021-03-310001125376us-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMemberstpr:CAsrt:ParentCompanyMember2021-03-310001125376us-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMemberensg:NonCaliforniaMembersrt:ParentCompanyMember2021-03-310001125376us-gaap:GeneralLiabilityMemberensg:AllStatesExceptColoradoMemberensg:PerOccurenceMembernaics:ZZ5242922021-03-310001125376us-gaap:GeneralLiabilityMemberensg:AllStatesExceptColoradoMemberensg:PerFacilityMembernaics:ZZ5242922021-03-310001125376us-gaap:GeneralLiabilityMemberensg:BlanketAggregateMemberensg:AllStatesExceptColoradoMembernaics:ZZ5242922021-03-310001125376us-gaap:GeneralLiabilityMemberstpr:COensg:PerOccurenceMembernaics:ZZ5242922021-03-310001125376us-gaap:GeneralLiabilityMemberstpr:COensg:PerFacilityMembernaics:ZZ5242922021-03-310001125376us-gaap:ProfessionalMalpracticeLiabilityMember2021-03-310001125376us-gaap:ProfessionalMalpracticeLiabilityMember2020-12-310001125376us-gaap:WorkersCompensationInsuranceMember2021-03-310001125376us-gaap:WorkersCompensationInsuranceMemberstpr:TX2021-03-310001125376us-gaap:WorkersCompensationInsuranceMemberensg:OtherStatesExceptCaliforniaTexasAndWashingtonMemberensg:LossSensitivelimitperclaimMemberMember2021-03-310001125376us-gaap:WorkersCompensationInsuranceMember2021-03-310001125376us-gaap:WorkersCompensationInsuranceMember2020-12-310001125376us-gaap:GeneralLiabilityMemberensg:SelfInsuranceRetentionPerClaimMember2021-04-010001125376ensg:HealthLiabilityInsuranceMemberensg:StopLossInsuranceLimitPerClaimMember2021-03-310001125376us-gaap:HealthInsuranceProductLineMember2021-03-310001125376us-gaap:HealthInsuranceProductLineMember2020-12-310001125376us-gaap:SubsequentEventMember2021-04-012021-04-0100011253762020-07-012020-07-3100011253762021-03-012021-03-31xbrli:pure0001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:MedicaidMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:MedicaidMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:MedicareMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicareMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:MedicareMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicareMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberensg:MedicaidSkilledMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:TotalMedicaidAndMedicareRevenueMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:TotalMedicaidAndMedicareRevenueMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:ManagedCareMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:ManagedCareMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:ManagedCareMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:ManagedCareMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001125376ensg:MedicaidMember2021-03-310001125376ensg:MedicaidMember2020-12-310001125376ensg:ManagedCareMember2021-03-310001125376ensg:ManagedCareMember2020-12-310001125376ensg:MedicareMember2021-03-310001125376ensg:MedicareMember2020-12-310001125376ensg:PrivatePayAndOtherMember2021-03-310001125376ensg:PrivatePayAndOtherMember2020-12-310001125376us-gaap:FairValueInputsLevel1Member2021-03-310001125376us-gaap:FairValueInputsLevel1Member2020-12-310001125376us-gaap:FairValueInputsLevel2Member2021-03-310001125376us-gaap:FairValueInputsLevel2Member2020-12-310001125376us-gaap:DomesticCorporateDebtSecuritiesMember2021-03-310001125376us-gaap:DomesticCorporateDebtSecuritiesMember2020-12-3100011253762020-01-012020-09-300001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMember2021-01-012021-03-310001125376ensg:RealEstateSegmentMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376us-gaap:ServiceMembersrt:ConsolidationEliminationsMember2021-01-012021-03-310001125376us-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:RentalMember2021-01-012021-03-310001125376ensg:RealEstateSegmentMemberus-gaap:OperatingSegmentsMemberensg:RentalMember2021-01-012021-03-310001125376ensg:RentalMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376srt:ConsolidationEliminationsMemberensg:RentalMember2021-01-012021-03-310001125376us-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMember2021-01-012021-03-310001125376ensg:RealEstateSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001125376us-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376srt:ConsolidationEliminationsMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMember2020-01-012020-03-310001125376ensg:RealEstateSegmentMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310001125376us-gaap:ServiceMembersrt:ConsolidationEliminationsMember2020-01-012020-03-310001125376us-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:RentalMember2020-01-012020-03-310001125376ensg:RealEstateSegmentMemberus-gaap:OperatingSegmentsMemberensg:RentalMember2020-01-012020-03-310001125376ensg:RentalMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310001125376srt:ConsolidationEliminationsMemberensg:RentalMember2020-01-012020-03-310001125376us-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMember2020-01-012020-03-310001125376ensg:RealEstateSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310001125376us-gaap:CorporateNonSegmentMember2020-01-012020-03-310001125376srt:ConsolidationEliminationsMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:MedicaidMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberensg:MedicaidMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:MedicareMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberensg:MedicareMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:MedicaidSkilledMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:TotalMedicaidAndMedicareRevenueMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:ManagedCareMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:ManagedCareMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:PrivatePayAndOtherMemberensg:TransitionalandSkilledServicesSegmentMember2021-01-012021-03-310001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:MedicaidMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberensg:MedicaidMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:MedicareMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberensg:MedicareMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:MedicaidSkilledMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:MedicaidSkilledMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:TotalMedicaidAndMedicareRevenueMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMemberensg:ManagedCareMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:ManagedCareMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-310001125376us-gaap:ServiceMemberus-gaap:OperatingSegmentsMemberensg:PrivatePayAndOtherMemberensg:TransitionalandSkilledServicesSegmentMember2020-01-012020-03-310001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:CorporateNonSegmentMember2020-01-012020-03-31ensg:operation0001125376ensg:SkilledNursingOperationsMember2021-01-012021-03-310001125376ensg:SkilledNursingOperationsMember2021-03-310001125376sic:Z8051us-gaap:SubsequentEventMember2021-04-012021-04-010001125376sic:Z8051us-gaap:SubsequentEventMember2021-04-010001125376ensg:SkilledNursingOperationsMember2020-01-012020-03-310001125376ensg:SeniorLivingFacilitiesMember2020-01-012020-03-310001125376ensg:OwnedPropertiesMember2020-01-012020-03-310001125376ensg:SkilledNursingOperationsMember2020-03-310001125376ensg:SeniorLivingFacilitiesMember2020-03-310001125376ensg:AssetAcquisitionMemberus-gaap:BuildingAndBuildingImprovementsMember2020-01-012020-03-310001125376us-gaap:LandMemberensg:AssetAcquisitionMember2020-01-012020-03-310001125376us-gaap:FurnitureAndFixturesMemberensg:AssetAcquisitionMember2020-01-012020-03-310001125376ensg:AssetAcquisitionMemberensg:AssembledOccupancyAcquiredMember2020-01-012020-03-310001125376ensg:ThePennantGroupInc.Memberensg:SeniorLivingFacilitiesMember2020-03-310001125376us-gaap:LandMember2021-03-310001125376us-gaap:LandMember2020-12-310001125376us-gaap:BuildingAndBuildingImprovementsMember2021-03-310001125376us-gaap:BuildingAndBuildingImprovementsMember2020-12-310001125376us-gaap:LeaseholdImprovementsMember2021-03-310001125376us-gaap:LeaseholdImprovementsMember2020-12-310001125376us-gaap:EquipmentMember2021-03-310001125376us-gaap:EquipmentMember2020-12-310001125376us-gaap:FurnitureAndFixturesMember2021-03-310001125376us-gaap:FurnitureAndFixturesMember2020-12-310001125376us-gaap:ConstructionInProgressMember2021-03-310001125376us-gaap:ConstructionInProgressMember2020-12-310001125376ensg:AssembledOccupancyAcquiredMember2021-01-012021-03-310001125376ensg:AssembledOccupancyAcquiredMember2021-03-310001125376ensg:AssembledOccupancyAcquiredMember2020-12-310001125376us-gaap:TradeNamesMember2021-03-310001125376us-gaap:TradeNamesMember2020-12-310001125376us-gaap:CustomerRelationshipsMember2021-03-310001125376us-gaap:CustomerRelationshipsMember2020-12-310001125376ensg:DepreciationAndAmortizationMember2021-01-012021-03-310001125376ensg:DepreciationAndAmortizationMember2020-01-012020-03-310001125376us-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMember2021-03-310001125376us-gaap:OperatingSegmentsMemberensg:TransitionalandSkilledServicesSegmentMember2020-12-310001125376us-gaap:CorporateNonSegmentMember2021-03-310001125376us-gaap:CorporateNonSegmentMember2020-12-310001125376us-gaap:TradeNamesMember2021-03-310001125376us-gaap:TradeNamesMember2020-12-310001125376ensg:MedicareandMedicaidLicensesMember2021-03-310001125376ensg:MedicareandMedicaidLicensesMember2020-12-310001125376us-gaap:NotesPayableOtherPayablesMemberus-gaap:CollateralizedDebtObligationsMember2021-03-310001125376us-gaap:NotesPayableOtherPayablesMemberus-gaap:CollateralizedDebtObligationsMember2020-12-310001125376us-gaap:MortgagesMemberus-gaap:CollateralizedDebtObligationsMember2021-03-310001125376srt:MinimumMemberus-gaap:NotesPayableToBanksMemberus-gaap:CollateralizedDebtObligationsMember2021-03-310001125376srt:MaximumMemberus-gaap:NotesPayableToBanksMemberus-gaap:CollateralizedDebtObligationsMember2021-03-310001125376srt:MinimumMemberus-gaap:MortgagesMemberus-gaap:CollateralizedDebtObligationsMember2021-01-012021-03-310001125376us-gaap:MortgagesMembersrt:MaximumMemberus-gaap:CollateralizedDebtObligationsMember2021-01-012021-03-310001125376ensg:PromissoryNote53Memberus-gaap:CollateralizedDebtObligationsMember2015-05-010001125376ensg:PromissoryNote53Membersrt:MinimumMemberus-gaap:CollateralizedDebtObligationsMember2015-05-012015-05-010001125376ensg:TruistBankMemberensg:ThirdAmendedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2019-10-010001125376srt:MinimumMemberensg:TruistBankMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2019-10-012019-10-010001125376ensg:TruistBankMemberus-gaap:BaseRateMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2019-10-012019-10-010001125376srt:MinimumMemberensg:TruistBankMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2019-10-012019-10-010001125376ensg:TruistBankMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2019-10-012019-10-010001125376srt:MinimumMemberensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2019-10-012019-10-010001125376ensg:TruistBankMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2019-10-012019-10-010001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2019-10-010001125376ensg:TruistBankMemberensg:ThirdAmendedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-03-31ensg:plan0001125376ensg:A2017PlanMember2017-05-250001125376us-gaap:SpinoffMemberensg:A2017PlanMember2019-10-010001125376ensg:A2017PlanMember2017-05-252017-05-25ensg:installment0001125376us-gaap:ShareBasedPaymentArrangementNonemployeeMemberensg:A2017PlanMember2017-05-252017-05-250001125376ensg:A2017PlanMember2021-03-310001125376ensg:ExercisePriceRangeZeroMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeZeroMember2021-03-310001125376ensg:ExercisePriceRangeOneMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeOneMember2021-03-310001125376ensg:ExercisePriceRangeTwoMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeTwoMember2021-03-310001125376ensg:ExercisePriceRangeThreeMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeThreeMember2021-03-310001125376ensg:ExercisePriceRangeFourMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeFourMember2021-03-310001125376ensg:ExercisePriceRangeFiveMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeFiveMember2021-03-310001125376ensg:ExercisePriceRangeSixMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeSixMember2021-03-310001125376ensg:ExercisePriceRangeSevenMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeSevenMember2021-03-310001125376ensg:ExercisePriceRangeEightMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeEightMember2021-03-310001125376ensg:ExercisePriceRangeNineMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeNineMember2021-03-310001125376ensg:ExercisePriceRangeTenMember2021-01-012021-03-310001125376ensg:ExercisePriceRangeTenMember2021-03-310001125376us-gaap:EmployeeStockOptionMember2021-03-310001125376us-gaap:EmployeeStockOptionMember2020-12-310001125376us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001125376us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001125376srt:MinimumMember2020-01-012020-03-310001125376srt:MaximumMember2020-01-012020-03-310001125376us-gaap:ShareBasedPaymentArrangementNonemployeeMember2021-01-012021-03-310001125376srt:MinimumMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2021-01-012021-03-310001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2019-08-270001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2019-08-272019-08-270001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2021-01-012021-03-310001125376ensg:A2019LTIPlanMemberus-gaap:SpinoffMember2020-01-012020-03-310001125376us-gaap:RestrictedStockMember2021-01-012021-03-310001125376us-gaap:RestrictedStockMember2020-01-012020-03-310001125376ensg:StockAwardsMember2021-01-012021-03-310001125376ensg:StockAwardsMember2020-01-012020-03-310001125376us-gaap:RestrictedStockMember2021-03-310001125376ensg:CareTrustREITMember2021-03-310001125376ensg:ThirdPartyTenantsUnderTripleNetLeaseArrangementsMemberensg:CareTrustREITMember2021-03-31ensg:agreement0001125376srt:MinimumMemberensg:CareTrustREITMember2021-03-310001125376srt:MaximumMemberensg:CareTrustREITMember2021-03-31ensg:renewal0001125376ensg:CareTrustREITMemberensg:PurchaseOptionMember2021-03-310001125376ensg:CareTrustREITMember2021-01-012021-03-310001125376ensg:CareTrustREITMember2020-01-012020-03-310001125376srt:MinimumMemberensg:VariousLandlordsMemberMember2021-03-310001125376srt:MaximumMemberensg:VariousLandlordsMemberMember2021-03-310001125376ensg:VariousLandlordsMemberMember2021-03-310001125376srt:MinimumMemberus-gaap:EquipmentMemberensg:VariousLandlordsMemberMember2021-03-310001125376srt:MaximumMemberus-gaap:EquipmentMemberensg:VariousLandlordsMemberMember2021-03-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2021-01-012021-03-310001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2020-01-012020-03-310001125376ensg:RentCostOfServicesMember2021-01-012021-03-310001125376ensg:RentCostOfServicesMember2020-01-012020-03-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001125376us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001125376ensg:CostOfServicesMember2021-01-012021-03-310001125376ensg:CostOfServicesMember2020-01-012020-03-310001125376ensg:ThePennantGroupInc.Memberus-gaap:SpinoffMemberensg:SeniorLivingFacilitiesMember2019-10-010001125376srt:MinimumMemberus-gaap:SpinoffMember2019-10-010001125376srt:MaximumMemberus-gaap:SpinoffMember2019-10-010001125376ensg:ThePennantGroupInc.Member2021-01-012021-03-310001125376ensg:ThePennantGroupInc.Member2020-01-012020-03-310001125376ensg:ThirdPartyTenantsMember2021-01-012021-03-310001125376ensg:ThirdPartyTenantsMember2020-01-012020-03-310001125376ensg:ThePennantGroupInc.Member2021-01-012021-03-310001125376ensg:ThePennantGroupInc.Member2020-01-012020-03-310001125376us-gaap:SubsequentEventMember2021-04-010001125376us-gaap:AccountsReceivableMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:AccountsReceivableMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001125376us-gaap:SalesRevenueNetMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001125376us-gaap:SalesRevenueNetMemberensg:TotalMedicaidAndMedicareRevenueMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001125376us-gaap:SubsequentEventMember2021-04-26ensg:numberOfRepurchasePrograms00011253762020-03-130001125376ensg:March42020RepurchaseProgramMember2020-03-040001125376ensg:March132020RepurchaseProgramMember2020-03-130001125376ensg:March132020RepurchaseProgramMember2020-03-132020-03-130001125376ensg:March42020RepurchaseProgramMember2020-03-042020-03-040001125376ensg:March42020RepurchaseProgramMember2020-01-012020-03-310001125376ensg:March132020RepurchaseProgramMember2020-01-012020-03-310001125376ensg:August262019RepurchaseProgramMember2019-08-260001125376ensg:August262019RepurchaseProgramMember2019-08-262019-08-260001125376ensg:August262019RepurchaseProgramMember2019-01-012019-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended March 31, 2021.
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from                      to                     .
Commission file number: 001-33757
_____________________________
ensg-20210331_g1.jpg
THE ENSIGN GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware33-0861263
(State or Other Jurisdiction of(I.R.S. Employer
Incorporation or Organization)Identification No.)
29222 Rancho Viejo Road, Suite 127
San Juan Capistrano, CA 92675
(Address of Principal Executive Offices and Zip Code)
(949487-9500
(Registrant’s Telephone Number, Including Area Code)
_____________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareENSGNASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark:
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.þYesNo
whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).þYesNo
whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filerþAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.YesNo
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesþNo
As of April 26, 2021, 54,977,473 shares of the registrant’s common stock, $0.001 par value, were outstanding.


THE ENSIGN GROUP, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE MONTHS ENDED MARCH 31, 2021
TABLE OF CONTENTS


Pg.






PART I.
Item 1.        FINANCIAL STATEMENTS

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, 2021December 31, 2020
(In thousands, except par values)
Assets   
Current assets:   
Cash and cash equivalents$155,527 $236,562 
Accounts receivable—less allowance for doubtful accounts of $11,090 and $8,718 at March 31, 2021 and December 31, 2020, respectively
312,578 305,062 
Investments—current14,623 13,449 
Prepaid income taxes 1,224 
Prepaid expenses and other current assets30,588 26,659 
Total current assets513,316 582,956 
Property and equipment, net779,269 778,244 
Right-of-use assets 1,050,506 1,025,510 
Insurance subsidiary deposits and investments34,370 32,105 
Escrow deposits350 100 
Deferred tax assets32,424 32,424 
Restricted and other assets 41,422 33,155 
Intangible assets, net 2,828 2,899 
Goodwill 54,469 54,469 
Other indefinite-lived intangibles 3,546 3,716 
Total assets$2,512,500 $2,545,578 
Liabilities and equity  
Current liabilities:  
Accounts payable$53,942 $50,901 
Accrued wages and related liabilities (Note 3)
203,420 236,614 
Lease liabilities—current 50,056 48,187 
Accrued self-insurance liabilities—current35,135 34,396 
Advance payment liabilities (Note 3)
 102,023 
Other accrued liabilities 97,639 87,318 
Current maturities of long-term debt2,828 2,960 
Total current liabilities443,020 562,399 
Long-term debt—less current maturities111,859 112,544 
Long-term lease liabilities—less current portion 973,679 950,320 
Accrued self-insurance liabilities—less current portion66,742 62,402 
Other long-term liabilities (Note 3)
41,620 39,686 
Total liabilities$1,636,920 $1,727,351 
Commitments and contingencies (Notes 15, 17 and 18)
Equity  
Ensign Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 100,000 shares authorized; 57,744 and 54,953 shares issued and outstanding at March 31, 2021, respectively, and 57,417 and 54,626 shares issued and outstanding at December 31, 2020, respectively
58 58 
Additional paid-in capital349,836 338,177 
Retained earnings597,375 551,055 
Common stock in treasury, at cost, 2,791 shares at both periods ended March 31, 2021 and December 31, 2020 (Note 19)
(71,222)(71,213)
Total Ensign Group, Inc. stockholders' equity876,047 818,077 
Non-controlling interest(467)150 
Total equity
875,580 818,227 
Total liabilities and equity$2,512,500 $2,545,578 
See accompanying notes to condensed consolidated financial statements.
1

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended March 31,
 20212020
(In thousands, except per share data)
Revenue:
Service revenue$623,276 $585,951 
Rental revenue3,977 3,662 
Total revenue $627,253 $589,613 
Expense:
Cost of services482,186 454,521 
Rent—cost of services 33,456 32,330 
General and administrative expense34,273 32,249 
Depreciation and amortization13,659 13,720 
Total expenses563,574 532,820 
Income from operations63,679 56,793 
Other income (expense):
Interest expense(1,641)(3,665)
Interest and other income748 698 
Other expense, net(893)(2,967)
Income before provision for income taxes62,786 53,826 
Provision for income taxes12,949 12,625 
Net income 49,837 41,201 
Less:
Net income attributable to noncontrolling interests631 352 
Net income attributable to The Ensign Group, Inc.$49,206 $40,849 
Net income per share attributable to The Ensign Group, Inc.:
Basic $0.91 $0.76 
Diluted$0.86 $0.73 
Weighted average common shares outstanding:
Basic54,192 53,475 
Diluted56,891 55,796 

See accompanying notes to condensed consolidated financial statements.
2

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 Common Stock Additional Paid-In Capital Retained Earnings Treasury StockNon-Controlling Interest
(In thousands)Shares Amount   Shares AmountTotal
Balance - January 1, 202154,626 $58 $338,177 $551,055 2,791 $(71,213)$150 $818,227 
Issuance of common stock to employees and directors resulting from the exercise of stock options246  3,880     3,880 
Issuance of restricted stock, net of forfeitures81  3,725     3,725 
Shares of common stock used to satisfy tax withholding obligations     (9) (9)
Dividends declared ($0.0525 per share)
   (2,886)   (2,886)
Employee stock award compensation  4,054     4,054 
Net income attributable to noncontrolling interest      631 631 
Distribution to noncontrolling interest holder      (1,248)(1,248)
Net income attributable to the Ensign Group, Inc.   49,206    49,206 
Balance - March 31, 202154,953 $58 $349,836 $597,375 2,791 $(71,222)$(467)$875,580 



 Common Stock Additional Paid-In Capital Retained Earnings Treasury StockNon-Controlling Interest
(In thousands)Shares Amount   Shares AmountTotal
Balance - January 1, 202053,487 $56 $307,914 $391,523 2,079 $(45,296)$1,947 $656,144 
Issuance of common stock to employees and directors resulting from the exercise of stock options148 — 1,552 — — — — 1,552 
Issuance of restricted stock, net of forfeitures723 1 3,085 — — — — 3,086 
Dividends declared ($0.0500 per share)
— — — (2,683)— — — (2,683)
Employee stock award compensation— — 3,235 — — — — 3,235 
Repurchase of common stock (Note 19)
(692)— — — 692 (25,000)— (25,000)
Net income attributable to noncontrolling interest— — — — — — 352 352 
Distribution to noncontrolling interest holder— — — — — — (720)(720)
Net income attributable to the Ensign Group, Inc.— — — 40,849 — — — 40,849 
Balance - March 31, 202053,666 $57 $315,786 $429,689 2,771 $(70,296)$1,579 $676,815 

See accompanying notes to condensed consolidated financial statements.

3

7THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended March 31,
(In thousands)20212020
Cash flows from operating activities:  
Net income $49,837 $41,201 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization13,659 13,720 
Amortization of deferred financing fees210 210 
Non-cash leasing arrangement 112 125 
Deferred income taxes  1,003 
Provision for doubtful accounts 2,560 1,312 
Stock-based compensation4,054 3,235 
(Gain)/loss on sale of asset disposals(236)101 
Change in operating assets and liabilities 
Accounts receivable (15,449)(21,845)
Prepaid income taxes1,224 739 
Prepaid expenses and other assets(4,271)(1,589)
Cash surrender value of life insurance policy premiums(7,440)(3,712)
Operating lease obligations(133)(181)
Deferred compensation liability7,459 3,660 
Accounts payable2,768 (3,257)
Accrued wages and related liabilities(34,562)(16,381)
Income taxes payable11,791 10,882 
Other accrued liabilities(1,737)(4,040)
Accrued self-insurance liabilities4,615 1,985 
Other long-term liabilities(167)(45)
Net cash provided by operating activities34,294 27,123 
Cash flows from investing activities:  
Purchase of property and equipment(15,334)(15,810)
Cash payments for asset acquisitions (Note 8)
 (14,054)
Escrow deposits(250) 
Escrow deposits used to fund acquisitions 14,050 
Cash proceeds from insurance proceeds6,250  
Cash proceeds from the sale of assets and ancillary business840 121 
Purchases of investments(6,869)(1,008)
Maturities of investments3,430 1,396 
Other restricted assets(279)(237)
Net cash used in investing activities(12,212)(15,542)
Cash flows from financing activities:  
Proceeds from revolving credit facility and other debt (Note 15)
 260,000 
Payments on revolving credit facility and other debt (Note 15)
(849)(240,666)
Issuance of common stock upon exercise of options3,880 1,552 
Repurchase of shares of common stock to satisfy tax withholding obligations(9) 
Repurchase of shares of common stock (Note 19)
 (25,000)
Dividends paid(2,868)(2,705)
Non-controlling interest distribution(1,248)(720)
Proceeds from CARES Act Provider Relief Fund (Note 3)
9,139  
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment
Program(Note 3)
(111,162) 
Net cash used in financing activities(103,117)(7,539)
Net (decrease)/increase in cash and cash equivalents(81,035)4,042 
Cash and cash equivalents beginning of period236,562 59,175 
Cash and cash equivalents end of period$155,527 $63,217 
See accompanying notes to condensed consolidated financial statements.
4

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - (Continued)
Three Months Ended March 31,
(In thousands)20212020
Supplemental disclosures of cash flow information:  
Cash paid during the period for:  
Interest$1,427 $4,835 
Lease liabilities$33,339 $32,481 
Non-cash financing and investing activity: 
Accrued capital expenditures$3,800 $3,300 
Accrued dividends declared$2,886 $2,683 
Right-of-use assets obtained in exchange for new operating lease obligations$37,471 $8,370 

See accompanying notes to condensed consolidated financial statements.

5

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars, shares and options in thousands, except per share data)

1. DESCRIPTION OF BUSINESS
The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties, and other ancillary businesses. As of March 31, 2021, the Company operated 232 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 23,600 operational skilled nursing beds and 2,200 senior living units. As of March 31, 2021, the Company operated 168 facilities under long-term lease arrangements, and had options to purchase 11 of those 168 facilities. The Company's real estate portfolio includes 94 owned real estate properties, which included 64 facilities operated and managed by the Company, 31 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019, and the Service Center location. Of those 31 senior living operations, two are located on the same real estate properties as skilled nursing facilities that the Company owns and operates.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

Segment Updates In the fourth quarter of 2020, the Company began reporting the results of its real estate portfolio as a new segment. The Company has two reportable segments: (1) transitional and skilled services and (2) real estate. Refer to Note 7, Business Segments, for additional information. Corresponding items of segment information for prior periods have been recast to reflect the change of the Company’s segment structure. This structure reflects its current operational and financial management, and provides the best structure for the Company to focus on growth and investing opportunities while maintaining financial discipline.

Other Information The accompanying condensed consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2021 and 2020 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2020 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.


6

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three months ended March 31, 2021 and 2020.
ReclassificationsCertain prior period results have been reclassified to be consistent with the current period presentation. Prior period results also reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure. Refer to Note 7, Business Segments, for additional information related to segments. Prior to the fourth quarter of 2020, the Company only presented total revenue for all revenue services. As a result of the change in segments, the presentation of the Company's service revenue and rental revenue are presented separately on the Company's Condensed Consolidated Statements of Income. The reclassifications had no effect on the reported condensed consolidated results of operations.
Estimates and Assumptions The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use-assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.

Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The fair value of the pooled investment funds is derived using Level 2 inputs.

Service Revenue RecognitionThe Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 4, Revenue and Accounts Receivable.

Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable (ASC 842). See Note 4, Revenue and Accounts Receivable.
Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence.
Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
7

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. As of March 31, 2021, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.

The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.

The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.

Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three months ended March 31, 2021 and 2020.
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the three months ended March 31, 2021 and 2020.
Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
8

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
The self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $60,761 and $57,628 as of March 31, 2021 and December 31, 2020, respectively.
 The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per occurrence. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,078 and $24,499 as of March 31, 2021 and December 31, 2020, respectively.
Effective April 1, 2021, the Company's operating subsidiaries in Washington are covered under the Company's self-insured program and the Company purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence.
In addition, the Company has recorded an asset and equal liability of $7,602 and $7,138 as of March 31, 2021 and December 31, 2020, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12 Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $500 for each covered person for fiscal year 2021. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $8,436 and $7,533 as of March 31, 2021 and December 31, 2020, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.

9

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12 "Simplifying the Accounting for Income Taxes (Topic 740)" as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's financial position, results of operations and liquidity.

In May 2020, the SEC issued Final Rule Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses” (“SEC Rule 33-10786”), which amends the disclosure requirements applicable to acquisitions and dispositions of businesses. Amendments within SEC Rule 33-10786 primarily impact (1) the tests and thresholds used to determine the significance of acquisitions and dispositions; (2) the form and content of pro forma information required to be disclosed in connection with significant acquisitions and dispositions; (3) acquiree financial statement requirements; and (4) thresholds used to determine the significance of acquisitions and dispositions of real estate operations, and related financial statement requirements, among others. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's condensed consolidated financial statements.


10

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Accounting Standards Recently Issued but Not Yet Adopted by the Company

In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on its financial position, results of operations and liquidity.

In November 2020, the SEC issued final rules 33-10890 and 34-90459 “Management’s Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information,” which modernizes and simplifies certain disclosure requirements of Regulation S-K. Certain key rule amendments eliminate the requirement to disclose Selected Financial Data; Selected Quarterly Financial Data, with certain exceptions; the impact of inflation and changing prices, provided the impact is not material; off-balance sheet arrangements in tabular form; and the aggregate amount of contractual obligations in tabular form. The final rules also amended various aspects of Item 303, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” among others. The final rules are effective for all registration statements, annual reports and quarterly reports filed on or after August 9, 2021, with early adoption permitted. The Company is currently evaluating the impact of the disclosure changes in its annual and quarterly report.

3. COVID-19 UPDATE

The Company's affiliated operations continued to be impacted by the worldwide outbreak of the 2019 coronavirus disease (COVID-19). The Company received cash distribution of relief fund payments (Provider Relief Funds) from the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care facilities from the impact of COVID-19 throughout 2020 and continued into 2021. During the first quarter of 2021, the Company received $9,139 in Provider Relief Funds and as of March 31, 2021 had returned all of the funds. The Company may continue to receive additional funding in future periods. Subsequent to March 31, 2021, the Company received and returned another $2,083 in Provider Relief Funds.
Additionally, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act during fiscal year 2020. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in July 2020. In March 2021, the Company repaid the remaining funds of $102,023.

The Family First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of December 31, 2020, the Company had $6,520 in unapplied state relief funds. During the three months ended March 31, 2021, the Company received an additional $15,645 in state relief funding and recognized $16,465 as revenue. For the three months ended March 31, 2020, the Company received and recognized $730 in state relief funding.

The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020. The total short-term balance of $24,155 is included in accrued wages and related liabilities and the remaining $24,154 is included in other long-term liabilities within the condensed consolidated balance sheets as of March 31, 2021 and December 31, 2020.
11

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
4.  REVENUE AND ACCOUNTS RECEIVABLE

Service Revenue

The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in transitional and skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 74.1% and 71.0% of all service revenue for the three months ended March 31, 2021 and 2020, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue for the three months ended March 31, 2021 and 2020.

Rental Revenue
The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. This single component practical expedient requires the Company to account for the lease component and non-lease component(s) associated with that lease as a single component if (1) the timing and pattern of transfer of the lease component and the non-lease component(s) associated with it are the same and (2) the lease component would be classified as an operating lease if it were accounted for separately. If the Company determines that the lease component is the predominant component, it accounts for the single component as an operating lease in accordance with the new lease standards. Conversely, the Company is required to account for the combined component under the revenue recognition standard if it determines that the non-lease component is the predominant component. As a result of this assessment, rental revenues from the lease of real estate assets that qualify for this expedient are accounted for as a single component under the new lease standards. The components of the Company's operating leases qualify for the single component presentation.
Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.


12

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenue by Payor
The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
Service revenue for the three months ended March 31, 2021 and 2020 is summarized in the following tables:
 Three Months Ended March 31,
20212020
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$231,358 37.1 %$224,195 38.3 %
Medicare190,303 30.5 155,584 26.6 
Medicaid — skilled39,993 6.5 36,009 6.1 
Total Medicaid and Medicare461,654 74.1 415,788 71.0 
Managed care108,345 17.4 102,029 17.4 
Private and other(2)
53,277 8.5 68,134 11.6 
Service revenue$623,276 100.0 %$585,951 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2021 and 2020.
(2) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended March 31, 2021 and 2020.
In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662, respectively for the three months ended March 31, 2021 and 2020.

Balance Sheet Impact
Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of March 31, 2021 and December 31, 2020, or activity during the three months ended March 31, 2021 and 2020.
Accounts receivable as of March 31, 2021 and 2020, is summarized in the following table:
March 31, 2021December 31, 2020
Medicaid$121,942 $102,077 
Managed care71,830 61,743 
Medicare63,095 80,904 
Private and other payors66,801 69,056 
 323,668 313,780 
Less: allowance for doubtful accounts(11,090)(8,718)
Accounts receivable, net$312,578 $305,062 
Practical Expedients and Exemptions
As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
13

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
5. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
Three Months Ended March 31,
 20212020
Numerator:  
Net income$49,837 $41,201 
Less: net income attributable to noncontrolling interests 631 352 
Net income attributable to The Ensign Group, Inc. $49,206 $40,849 
Denominator: 
Weighted average shares outstanding for basic net income per share54,192 53,475 
Basic net income per common share:$0.91 $0.76 

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:
Three Months Ended March 31,
 20212020
Numerator:  
Net income $49,837 $41,201 
Less: net income attributable to noncontrolling interests631 352 
Net income attributable to The Ensign Group, Inc. $49,206 $40,849 
Denominator:  
Weighted average common shares outstanding54,192 53,475 
Plus: incremental shares from assumed conversion (1)
2,699 2,321 
Adjusted weighted average common shares outstanding56,891 55,796 
Diluted net income per common share:$0.86 $0.73 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 28 and 787 for the three months ended March 31, 2021 and 2020, respectively.

6. FAIR VALUE MEASUREMENTS
Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The fair value of cash and cash equivalents of $155,527 and $236,562 as of March 31, 2021 and December 31, 2020, respectively, is derived using Level 1 inputs. The Company's other financial assets include contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. As of March 31, 2021, and December 31, 2020, the fair value of the pooled investment funds of $14,017 and $6,577, respectively, is derived using Level 2 inputs. The pooled investment funds are included in restricted and other assets in the Condensed Consolidated Balance Sheets. See Note 12 Restricted and Other Assets.

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
14

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Debt Security Investments - Held to Maturity

As of March 31, 2021 and December 31, 2020, the Company had approximately $48,993 and $45,554, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of March 31, 2021, the debt security investments were held in AA, A and BBB rated debt securities. The Company believes its debt security investments that were in an unrealized loss position as of March 31, 2021 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.

7. BUSINESS SEGMENTS
In the fourth quarter of 2020, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of the Company's real estate portfolio. Accordingly, the Company began reporting a new segment as it continues to expand its real estate investment strategy. The Company has two reportable segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) real estate, which is comprised of properties owned by the Company and leased to skilled nursing and assisted living operations where the properties are subject to triple-net long-term leases, including operations that are owned and operated by the Company. Prior to this new segment structure, the Company had one reportable segment, transitional and skilled services. Corresponding items of segment information for prior periods have been recast to reflect the change of the Company’s segment structure.

As of March 31, 2021, the transitional and skilled services segment includes 200 skilled nursing operations and 23 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's real estate segment includes 94 owned real estate properties. These properties include 64 operations the Company operated and managed, real estate properties of 31 senior living operations that are leased to and operated by Pennant and the Service Center location, which continues to lease office space to various third parties. Of the 31 real estate operations leased to Pennant, two senior living operations are located on the same real estate properties as skilled nursing facilities that the Company owns and operates. The Company also reports an “All Other” category that includes results from its senior living operations, which includes nine stand-alone senior living operations and 23 campus operations that provide both skilled nursing and rehabilitative care services and senior living services, mobile diagnostics, medical transportation and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

Beginning in the fourth quarter of 2020, segment income and loss was changed from profit or loss from operations before interest and provision for income taxes to profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment charges from operations. Prior period presentation has been revised to reflect the new measurement.

With the exception of intercompany rental revenue, the accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Rental revenue from Ensign-affiliated operations are based on mutually agreed-upon base rent that are subject to change from time to time. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of the related healthcare facilities. Included in the real estate segment income is interest expense related to the borrowings to fund real estate acquisitions. Interest revenue is related to the investment accounts that the Service Center manages on behalf of the Company and is included in the "All Other" category.


15

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
The following tables set forth financial information for the segments:

 Three Months Ended March 31, 2021
 Transitional and Skilled ServicesReal Estate
All Other(1)
Intercompany Elimination(2)
Total
Service revenue$601,036 $ $22,240 $ $623,276 
Rental revenue  15,879  (11,902)3,977 
Total revenue$601,036 $15,879 $22,240 $(11,902)$627,253 
Segment income (loss)88,931 8,821 (35,406) 62,346 
Gain on sale of real estate440 
Income before provision for income taxes $62,786 
Depreciation and amortization7,475 4,693 1,491  13,659 
Other expense (income), net(3)
$ $1,641 $(748)$ $893 
(1) General and administrative expense are included in the "all other" category.
(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.
(3) Other expense (income), net includes interest expense and interest revenue.

 Three Months Ended March 31, 2020
 Transitional and Skilled ServicesReal Estate
All Other(1)
Intercompany Elimination(2)
Total
Service revenue$558,304 $ $27,647 $ $585,951 
Rental revenue 14,944  (11,282)3,662 
Total revenue$558,304 $14,944 $27,647 $(11,282)$589,613 
Segment income (loss)80,591 6,325 (33,090) 53,826 
Income before provision for income taxes $53,826 
Depreciation and amortization7,148 4,515 2,057  13,720 
Other expense (income), net(3)
$ $3,665 $(698)$ $2,967 
(1) General and administrative expense is included in the "all other" category
(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.
(3) Other expense (income), net includes interest expense and interest revenue.

Service revenue by major payor source were as follows:

 Three Months Ended March 31, 2021
 Transitional and Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid$227,741 $3,617 (1)$231,358 37.1 %
Medicare190,303  190,303 30.5 
Medicaid-skilled39,993  39,993 6.5 
Subtotal458,037 3,617 461,654 74.1 
Managed care108,345  108,345 17.4 
Private and other34,654 18,623 (2)53,277 8.5 
Total service revenue$601,036 $22,240 $623,276 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2021.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2021.

16

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
 Three Months Ended March 31, 2020
 Transitional and Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid$220,969 $3,226 (1)$224,195 38.3 %
Medicare155,584  155,584 26.6 
Medicaid-skilled36,009  36,009 6.1 
Subtotal412,562 3,226 415,788 71.0 
Managed care102,029  102,029 17.4 
Private and other43,713 24,421 (2)68,134 11.6 
Total service revenue$558,304 $27,647 $585,951 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2020.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2020.

In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662 for the three months ended March 31, 2021 and 2020, respectively. This revenue is included in our real estate segment.

8. OPERATION EXPANSIONS
The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the accompanying Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.

2021 Expansions
During the three months ended March 31, 2021, the Company expanded its operations through long-term leases, with the addition of four stand-alone skilled nursing operations. These new operations added a total of 447 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
Subsequent to March 31, 2021, the Company expanded its operations through long-term leases with the addition of three stand-alone skilled nursing operations. These new operations added 322 operational skilled nursing beds to be operated by the Company's affiliated operating subsidiaries.
2020 Expansions
During the three months ended March 31, 2020, the Company expanded its operations through a combination of a long-term lease and real estate purchases, with the addition of three stand-alone skilled nursing operations and one stand-alone senior living operation. Of these additions, two are related to purchases of owned properties, further expanding our real estate portfolio. These new operations added a total of 247 operational skilled nursing beds and 162 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the three months ended March 31, 2020 was $14,054.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The fair value of assets for our purchases of these properties was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. The purchase price for the asset acquisitions consists of building and improvements of $9,669; land of $4,080; equipment, furniture and fixtures of $236; and assembled occupancy of $69.
During the first quarter of 2020, the Company entered into a long-term lease agreement to transfer two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these two senior living communities.    
17

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the three months ended March 31, 2021 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the March 31, 2021 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control.
9. PROPERTY AND EQUIPMENT - NET
Property and equipment, net consists of the following:
March 31, 2021December 31, 2020
Land$101,236 $101,236 
Buildings and improvements557,616 555,416 
Leasehold improvements131,911 129,727 
Equipment239,867 233,453 
Furniture and fixtures4,498 4,409 
Construction in progress5,657 3,008 
 1,040,785 1,027,249 
Less: accumulated depreciation(261,516)(249,005)
Property and equipment, net$779,269 $778,244 
See also Note 8, Operation Expansions for information on acquisitions during the three months ended March 31, 2021 and 2020.

10. INTANGIBLE ASSETS - NET
 March 31, 2021December 31, 2020
Weighted Average Life (Years)
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.4$39 $(39)$ $39 $(26)$13 
Facility trade name30.0733 (372)361 733 (366)367 
Customer relationships18.44,582 (2,115)2,467 4,640 (2,121)2,519 
Total $5,354 $(2,526)$2,828 $5,412 $(2,513)$2,899 

During the three months ended March 31, 2021 and 2020, amortization expense was $361 and $674, respectively, of which $290 and $354 was related to the amortization of right-of-use assets, respectively. Additionally, the Company identified intangible assets which became fully amortized during the prior year and removed these fully amortized balances from the gross asset and accumulated amortization amounts.
Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2021 (remainder)$176 
2022234 
2023234 
2024234 
2025234 
2026234 
Thereafter1,482 
 $2,828 
18

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

11. GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of March 31, 2021.

The Company's expansions during the three months ended March 31, 2021 were all through long-term leases and accordingly, no goodwill was recognized for these acquisitions. There were no activities in goodwill during the three months ended March 31, 2021. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's real estate segment appropriately does not carry a goodwill balance. The following table represents the goodwill value by transitional and skilled service segment and "all other" category, which includes other ancillary services, as of March 31, 2021 and December 31, 2020:

 Transitional and Skilled ServicesAll OtherTotal
Goodwill$45,486 $8,983 $54,469 

Other indefinite-lived intangible assets consist of the following:
March 31, 2021December 31, 2020
Trade name$889 $889 
Medicare and Medicaid licenses2,657 2,827 
 $3,546 $3,716 

19

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
12. RESTRICTED AND OTHER ASSETS
Restricted and other assets consist of the following:
March 31, 2021December 31, 2020
Debt issuance costs, net$2,486 $2,664 
Long-term insurance losses recoverable asset7,602 7,138 
Deposits with landlords12,637 12,400 
Capital improvement reserves with landlords and lenders4,680 4,376 
Cash surrender value of life insurance related to deferred compensation plan14,017 6,577 
Restricted and other assets$41,422 $33,155 

Included in restricted and other assets as of March 31, 2021 and December 31, 2020 are anticipated insurance recoveries related to the Company's workers' compensation liabilities and general and professional liability claims that are recorded on a gross rather than net basis in accordance with ASU issued by the FASB.

The Company implemented a non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain executives and was expanded to other highly compensated employees on January 1, 2020. The plan allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to informally fund savings plans of this nature. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The Company recorded a gain on the deferral investment of $306, which is included in interest and other income, and an offsetting expense of $351 between cost of services and general and administrative expenses in the accompanying consolidated statements of income for the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company had an expense of $87, which was recorded between cost of services and general and administrative expenses.

13. OTHER ACCRUED LIABILITIES

Other accrued liabilities consists of the following:
March 31, 2021December 31, 2020
Quality assurance fee$7,103 $6,631 
Refunds payable39,590 36,323 
Resident advances6,049 8,558 
Unapplied state relief funds5,700 6,520 
Cash held in trust for patients5,611 6,052 
Dividends payable2,886 2,868 
Property taxes7,656 9,222 
Income tax payable11,927 136 
Other11,117 11,008 
Other accrued liabilities$97,639 $87,318 

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying condensed consolidated balance sheets.

20

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
14. INCOME TAXES
The Company recorded income tax expense of $12,949 and $12,625 during the three months ended March 31, 2021 and 2020, respectively, or 20.6% of earnings before income taxes for the three months ended March 31, 2021, compared to 23.5% for the three months ended March 31, 2020. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 Federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the three months ended March 31, 2021 and 2020.

15. DEBT
Debt consists of the following:
March 31, 2021December 31, 2020
Mortgage loans and promissory notes$116,957 $117,806 
Less: current maturities(2,828)(2,960)
Less: debt issuance costs, net(2,270)(2,302)
Long term debt less current maturities$111,859 $112,544 

Mortgage Loans and Promissory Notes
As of March 31, 2021, the Company's operating subsidiaries had $116,957 outstanding under the mortgage loans and notes, of which $2,828 is classified as short-term and the remaining $114,129 is classified as long-term. The Company was in compliance with all loan covenants as of March 31, 2021.

As of March 31, 2021, 19 of the Company's subsidiaries have mortgage loans insured with the Department of Housing and Urban Development (HUD) in the aggregate amount of $113,304, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear fixed interest rates ranging from 2.6% to 3.5% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, renovate and upgrade existing and future facilities, cover working capital needs and other business purposes.

In addition to the HUD mortgage loans above, the Company has a promissory note in connection with an acquisition. The note bears a fixed interest rate of 5.3% per annum and the term of the note is 12 years. The note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.

Credit Facility with a Lending Consortium Arranged by Truist
The Company maintains a revolving credit facility under the Third Amended and Restated Credit Agreements, dated as of October 1, 2019, between the Company and Truist Financial Corporation (Truist) (formerly known as SunTrust Bank, Inc.) (the Credit Facility). The Credit Facility includes a revolving line of credit of up to $350,000 in aggregate principal amount. The maturity date of the Credit Facility is October 1, 2024. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.50% to 1.50% per annum or LIBOR plus a margin range from 1.50% to 2.50% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company pays a commitment fee on the unused portion of the commitments that ranges from 0.25% to 0.45% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.

21

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of March 31, 2021, and April 26, 2021, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of March 31, 2021.

Off-Balance Sheet Arrangements
As of March 31, 2021, the Company had approximately $7,580 on the Credit Facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.

16. OPTIONS AND AWARDS
Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three months ended March 31, 2021 and 2020 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
2017 Omnibus Incentive Plan - The Company has one active stock incentive plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The 2017 Plan provided for the issuance of 6,881 shares of common stock which are to be proportionally adjusted in the event of any Equity Restructuring. The number of shares available to be issued under the 2017 Plan were adjusted to 8,118 shares of common stock in order to reflect the proportional adjustments as part of the spin-off transaction that occurred in October 2019. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. As of March 31, 2021, there were approximately 2,839 unissued shares of common stock available for issuance under this plan.
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time.

Stock Options
The Company granted 136 stock options during the three months ended March 31, 2021. The Company used the following assumptions for stock options granted during the three months ended March 31, 2021 and 2020:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20211360.8%6.3 years42.2%0.2%
20201451.3%6.2 years32.1%0.4%


22

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
For the three months ended March 31, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2021136$83.64 $33.99 
2020145$51.20 $16.60 
The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended March 31, 2021 and 2020 and therefore, the intrinsic value was $0 at the date of grant.


The following table represents the employee stock option activity during the three months ended March 31, 2021:

Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20214,038 $27.71 2,148 $16.66 
Granted136 83.64 
Forfeited(33)41.27 
Exercised(246)15.78 
March 31, 20213,895 $30.30 2,034 $17.73 

The following summary information reflects stock options outstanding, vested and related details as of March 31, 2021:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
2011$5.00-$6.7714 $38 014 
20125.56-6.7588 267 188 
20136.76-9.74165 712 2165 
20148.94-16.05676 3,231 3676 
201518.20-21.39303 2,362 4303 
201615.93-16.86275 1,618 5219 
201715.80-19.41336 1,977 6184 
201822.49-32.71566 5,855 7214 
201941.07-45.76698 10,955 8147 
202044.84-59.49638 12,511 924 
2021$83.64136 4,625 10 
Total 3,895 $44,151  2,034 
The aggregate intrinsic value of options outstanding, vested and expected to vest as of March 31, 2021 and December 31, 2020 is as follows:
OptionsMarch 31, 2021December 31, 2020
Outstanding$247,457 $182,552 
Vested154,841 120,867 
Expected to vest80,008 53,366 

The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the three months ended March 31, 2021 and 2020 was $8,545 and $2,084, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2021 and 2020 was $17,241 and $5,621, respectively.

23

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Restricted Stock Awards
The Company granted 90 and 113 restricted stock awards during the three months ended March 31, 2021 and 2020, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the three months ended March 31, 2021 and 2020 ranged from $83.64 to $84.70 and $42.02 to $51.20, respectively. The fair value per share includes quarterly stock awards to non-employee directors.

A summary of the status of the Company's non-vested restricted stock awards as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Nonvested at January 1, 2021591 $38.90 
Granted90 83.71 
Vested(80)64.35 
Forfeited(9)45.18 
Nonvested at March 31, 2021592 $42.16 
During the three months ended March 31, 2021, the Company granted 6 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards was $84.70 based on the market price on the grant date.
Long-Term Incentive Plan
On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off transaction that occurred in October 2019 are granted shares of restricted stock upon the successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $201 and $194 for the three months ended March 31, 2021 and 2020, respectively.
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three months ended March 31, 2021 and 2020 was as follows:
Three Months Ended March 31,
 20212020
Stock-based compensation expense related to stock options$1,733 $1,419 
Stock-based compensation expense related to restricted stock awards1,838 1,598 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors483 218 
Total$4,054 $3,235 

In future periods, the Company expects to recognize approximately $27,178 and $26,072 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of March 31, 2021. Future stock-based compensation expense will be recognized over 3.8 and 3.5 weighted average years for unvested options and restricted stock awards, respectively. There were 1,861 unvested and outstanding options as of March 31, 2021, of which 1,726 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of March 31, 2021 was 6.1 years.


24

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
17. LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 89 affiliated skilled nursing and senior living facilities used in the Company’s operations, 88 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 89 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $14,080 and $13,125 for the three months ended March 31, 2021 and 2020, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of March 31, 2021.
In connection with the spin-off transaction that occurred in October 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $33,476 and $32,347 for the three months ended March 31, 2021 and 2020, respectively.
Forty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.




25

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
The components of operating lease expense are as follows:
Three Months Ended March 31,
20212020
Rent - cost of services(1)
$33,456 $32,330 
General and administrative expense20 17 
Depreciation and amortization(2)
290 354 
Variable lease costs(3)
3,443 3,211 
$37,209 $35,912 
(1)Rent- cost of services includes deferred rent expense adjustments of $112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of March 31, 2021 are as follows:
YearAmount
2021 (remainder)$98,448 
2022131,211 
2023129,521 
2024128,600 
2025128,506 
2026128,383 
Thereafter957,340 
Total lease payments1,702,009 
Less: present value adjustment (678,274)
Present value of total lease liabilities1,023,735 
Less: current lease liabilities(50,056)
Long-term operating lease liabilities$973,679 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of March 31, 2021, the weighted average remaining lease term is 13.7 years and the weighted average discount rate used to determine the operating lease liabilities is 8.2%.

Subsequent to March 31, 2021, the Company expanded its operations through long-term lease arrangements with the addition of three stand-alone skilled nursing facilities under a new triple-net master lease, adding a total of 322 operational skilled nursing beds operated by the Company’s affiliated operating subsidiaries. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to new master lease is estimated to be approximately $20,005.

Lessor Activities

In connection with the spin-off transaction that occurred in October 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. During the first quarter of 2020, the Company transferred the operations of an additional two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these 31 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.


26

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:

Three Months Ended March 31,
20212020
Pennant(1)
$3,488 $3,101 
Other third-party489 561 
$3,977 $3,662 
(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020.


Future annual rental income for all leases as of March 31, 2021 were as follows:

Year
Amount(1)
2021 (remainder)$11,671 
202215,053 
202314,790 
202414,170 
202513,952 
202613,772 
Thereafter85,281 
Total$168,689 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021.

18. COMMITMENTS AND CONTINGENCIES
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations can likewise be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996, which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information.
Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment or other relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.

In connection with the spin-off transaction that occurred in October 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.
27

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company has fully cooperated with the U.S. Department of Justice and promptly responded to the requests for information, and has been advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.

U.S. House of Representatives Select Subcommittee Request The U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis has launched a nation-wide investigation into the COVID-19 pandemic, which includes the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation or whether and what other investigations or regulatory responses may result from the investigation and could have a material adverse effect on our reputation, business, financial condition, and results of operations.

Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.
In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the qui tam relator has continued on with the lawsuit and is pursuing claims that the Company has allegedly violated the False Claims Act and/or the Anti-Kickback Statute.
In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

28

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.
The Company and its independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims filed by residents and responsible parties related to patient care and treatment (professional negligence claims), as well as employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.

The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its operating subsidiaries going forward under a corporate integrity agreement and/or other such arrangement.

Medicare Revenue Recoupments The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. As of March 31, 2021, two of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process. Subsequently, during April, one facility review was resolved and closed. The Company anticipates that these Reviews could increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of March 31, 2021, the Company's independent operating subsidiaries have responded to the requests with respect to the claims currently under review, on appeal or in a dispute resolution process.

Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 57.2% and 58.3% of its total accounts receivable as of March 31, 2021 and December 31, 2020, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 74.1% and 71.0% of the Company's service revenue for the three months ended March 31, 2021 and 2020, respectively.

29

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of April 26, 2021, the Company had approximately $424 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.

19. COMMON STOCK REPURCHASE PROGRAM
As approved by the Board of Directors on March 4, 2020 and March 13, 2020, the Company entered into two stock repurchase programs pursuant to which the Company was authorized to repurchase up to $20,000 and $5,000, respectively, of its common stock under the programs for a period of approximately 12 months. Under these programs, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2020, the Company repurchased 503 and 189 shares of its common stock for $20,000 and $5,000, respectively. These repurchase programs expired upon the repurchase of the full authorized amount under the two plans.

As approved by the Board of Directors on August 26, 2019, the Company entered into a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company repurchased 138 shares of its common stock for a total of $6,406 in fiscal year 2019 before the repurchase program was cancelled in the first quarter of 2020.

Item 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the condensed consolidated financial statements and accompanying notes, which appear elsewhere in this Quarterly Report on Form 10-Q. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020 (Annual Report), which discusses our business and related risks in greater detail, as well as subsequent reports we may file from time to time on Form 10-Q and Form 8-K, for additional information. The section entitled “Risk Factors” contained in Part II, Item 1A of this Quarterly Report on Form 10-Q, and similar discussions in our other SEC filings, also describe some of the important risk factors that may affect our business, financial condition, results of operations and/or liquidity. You should carefully consider those risks, in addition to the other information in this Quarterly Report on Form 10-Q and in our other filings with the SEC, before deciding to purchase, hold or sell our common stock.
This Quarterly Report on Form 10-Q contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Additionally, our business and operations for 2021 continue to be impacted by the COVID-19 pandemic. Because of the unprecedented nature of the pandemic, we are unable to predict the full extent and duration of the financial impact of COVID-19 on our business, financial condition and results of operations. Our actual results could differ materially from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” contained in Part II, Item 1A of this Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q, and are based on our current expectations, estimates and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.
As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, the words, "Ensign," "Company," “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our affiliated operations, the Service Center and the Captive are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. The use of "Ensign," "Company," “we,” “us,” “our” and similar verbiage in this Quarterly Report on Form 10-Q is not meant to imply that any of our affiliated operations, the Service Center or the Captive are operated by the same entity. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our consolidated financial statements and related notes included the Annual Report.
30

Overview
We are a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties, and other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Our operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. As of March 31, 2021, we offered skilled nursing, senior living and rehabilitative care services through 232 skilled nursing and senior living facilities. Of the 232 facilities, we operated 168 facilities under long-term lease arrangements, and have options to purchase 11 of those 168 facilities. Our real estate portfolio includes 94 owned real estate properties, which included 64 facilities operated and managed by us, 31 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019 (Spin-Off), and the Service Center location. Of the 31 real estate operations leased to Pennant, two senior living operations are located on the same real estate properties as skilled nursing facilities that the Company owns and operates.
The following table summarizes our affiliated facilities and operational skilled nursing beds and senior living units by ownership status as of March 31, 2021:

Owned and OperatedLeased (with a Purchase Option)Leased (without a Purchase Option)Total for Facilities Operated
Number of facilities64 11 157 232 
Percentage of total27.6 %4.7 %67.7 %100.0 %
Operational skilled nursing beds6,258 1,145 16,216 23,619 
Percentage of total26.5 %4.8 %68.7 %100.0 %
Senior living units1,461 178 606 2,245 
Percentage of total65.1 %7.9 %27.0 %100.0 %
Ensign is a holding company with no direct operating assets, employees or revenues. Our operating subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly owned subsidiaries, referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. We also have a wholly-owned captive insurance subsidiary (or the Captive) that provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.
Recent Activities
Coronavirus UpdateWe are continuing to closely monitor the impact of the global COVID-19 pandemic on our business and are taking proactive steps designed to protect the health and safety of our residents and employees and to maintain business continuity. As the vaccines became more accessible in all 50 states, we began to see a significant decline in COVID-19 cases in our affiliated operations as we worked diligently to vaccinate all of our willing residents and staff. Our primary focus throughout the COVID-19 pandemic has remained ensuring the health and safety of our patients, residents, employees, and their respective families. We continue to implement measures necessary to provide the safest possible environment within our sites of service, taking into consideration the vulnerable nature of our patients and the unique exposure risks of our staff.
31

As the vaccine distribution commenced and infection rates are began to decline, we experienced a recovery in occupancy rates throughout the first quarter of 2021, when compared to the fourth quarter of 2020. The improvements in occupancy were due to our operations developing innovative approaches to confront the occupancy declines, including strategic partnerships with upstream and downstream continuum partners and increasing clinical competencies to treat high-acuity patients, including those that are COVID-19 positive. Additionally, we have seen increases in hospital volumes for surgeries. Some operations added COVID-19 wings, while others become COVID-19 dedicated facilities, enabling an important offloading of strained hospital capacity. As a result of our local, one operation at a time approach, our Same Facilities and Transitioning Facility occupancy rebounded by 0.4% and 1.6%, respectively, during the first quarter of 2021 compared the fourth quarter of 2020. By strengthening existing partnerships and creating new partnerships, and most importantly, demonstrating clinical capabilities and favorable outcomes, our census has continued to stabilize. We believe that our operations are prime to rebuild occupancies and continue to gain additional market share as a result of relationships with acute care providers and other health care partners.
During the three months ended March 31, 2021, we received approximately $9.1 million in provider relief fund distributions (Provider Relief Fund) from the Coronavirus Aid, Relief and Economic Security Act of 2020 (the CARES Act) from the federal government. As of March 31, 2021, and the date hereof, we have returned all Provider Relief Funds that we received related to this distribution. We may receive additional relief fund payments in the future. Further, we repaid the remaining $102.0 million of Medicare Accelerated and Advance Payment Program funds in March 2021.
During the three months ended March 31, 2021, we received an additional $15.6 million in state relief funding and recognized $16.5 million as revenue, of which $6.5 million was classified as unapplied state funding included in our liabilities as of December 31, 2020. See Note 3, COVID-19 Update in the Notes to the Condensed Consolidated Financial Statements.
The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. We recorded $48.3 million of deferred payments of social security taxes as a liability in 2020, of which $24.2 million will be paid out in the fourth quarter of 2021 and the remaining liabilities in 2022.
Until the COVID-19 pandemic has been resolved as a public health crisis, it has the potential to cause further and more severe disruption of the global and national economies. Despite these challenges, we believe we are well-positioned to operate effectively in the current environment. Our forecasted metrics may be modified as the pace of the recovery in our volumes become clearer over the coming months.
We continue to focus on navigating the challenges presented by COVID-19 through utilizing the infrastructure of our local operational approach. Each location is partnering with its local leaders and community outreach to ensure the operations are well equipped to deliver quality care. Consistent with previous hurdles, our local leaders are adjusting their operation to meet the clinical and financial challenges, including utilizing the expertise of our Service Center resources to implement best practices.

32

Facility Information
The following table sets forth the location of our operated and owned facilities by type as well as the number of beds and units located at operated and owned facilities as of March 31, 2021:
TXCAAZUTCOWAIDNEIASCWINVKSTotal
Number of operated facilities
Skilled nursing operations59 50 29 18 11 — 200 
Senior living operations— — — — — — — — — 
Campuses(1)— — — — 23 
Number of operated beds/units
Operational skilled nursing beds7,679 5,080 4,203 1,940 972 841 904 413 368 426 100 92 601 23,619 
Senior living units505 65 315 165 620 — 37 301 31 — — — 206 2,245 
Number of owned and operated facilities
Skilled nursing properties14 — — — 51 
Senior living communities— — — — — — — — — — 
Campuses(1)— — — — — — — 0— 
Number of owned and operated beds/units
Owned skilled nursing beds1,830 691 1,264 633 348 204 454 88 — 426 100— 220 6,258 
Owned Senior living units439 — 315 — 355 — 16 262 — — — — 74 1,461 
(1) Campuses represent facilities that offer both skilled nursing and senior living services.
During the three months ended March 31, 2021, we expanded our operations through long-term leases with the addition of four stand-alone skilled nursing operations. These new operations added a total of 447 operational skilled nursing beds operated by our affiliated operating subsidiaries.
Subsequent to March 31, 2021, we expanded our operations through long-term leases with the addition of three stand-alone skilled nursing operations. These new operations added 322 operational skilled nursing beds to be operated by our affiliated operating subsidiaries.
For further discussion of our acquisitions, see Note 8, Operation Expansions in the Notes to the Condensed Consolidated Financial Statements.
Key Performance Indicators
We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics is generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, ASC 606. These indicators and their definitions include the following:
Transitional and Skilled Services
Routine revenue Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.
Skilled revenue The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients who are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.
33

Skilled mix The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.
Average daily rates The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period. These rates exclude additional FMAP payments we recognized as part of The Family First Coronavirus Response Act.
Occupancy percentage (operational beds) The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.
Number of facilities and operational beds The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.
Skilled Mix. Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:

Three Months Ended March 31,
Skilled Mix:20212020
Days34.4 %29.3 %
Revenue55.6 %50.1 %
Occupancy We define occupancy derived from our transitional and skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of licensed beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.

The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:

Three Months Ended March 31,
Occupancy for transitional and skilled services:20212020
Operational beds at end of period23,619 22,883 
Available patient days2,122,096 2,070,732 
Actual patient days1,509,600 1,643,390 
Occupancy percentage (based on operational beds)71.1 %79.4 %
Segments
In the fourth quarter of fiscal year 2020, we began reporting the results of our real estate portfolio as a new segment as we continue to expand our real estate investment strategy. We have two reportable segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) real estate, which is comprised of properties owned by us and leased to skilled nursing and assisted living operations, including our own operating subsidiaries and third party operators, and are subject to triple-net long-term leases. Prior to this new segment structure, we had one reportable segment, transitional and skilled services.
34

We also reported an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation and other ancillary operations. Our senior living, mobile diagnostics, transportation and other ancillary operations businesses are neither significant individually nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level. We have presented our segment results in this Quarterly Report on Form 10-Q on a comparative basis to conform to the new segment structure.

Revenue Sources

The following table sets forth our total service revenue by payor source generated by our transitional and skilled services and our "Other" category and as a percentage of total revenue for the periods indicated (dollars in thousands):
 Three Months Ended March 31,
Transitional and Skilled Services
Other(1)
Total
202120202021202020212020
Medicaid(2)
$227,741 $220,969 $3,617 $3,226 $231,358 $224,195 
Medicare190,303 155,584  — 190,303 155,584 
Medicaid-skilled39,993 36,009  — 39,993 36,009 
Subtotal458,037 412,562 3,617 3,226 461,654 415,788 
Managed care108,345 102,029  — 108,345 102,029 
Private and other34,654 43,713 18,623 24,421 53,277 68,134 
Total revenue$601,036 $558,304 $22,240 $27,647 $623,276 $585,951 

 Three Months Ended March 31,
Transitional and Skilled Services
Other(1)
Total
202120202021202020212020
Medicaid(2)
37.9 %39.6 %16.3 %11.7 %37.1 %38.3 %
Medicare31.7 27.9  — 30.5 26.6 
Medicaid-skilled6.6 6.5  — 6.5 6.1 
Subtotal76.2 74.0 16.3 11.7 74.1 71.0 
Managed care18.0 18.3  — 17.4 17.4 
Private and other5.8 7.7 83.7 88.3 8.5 11.6 
Total revenue100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %
(1) Private and other payors in our "all other" category includes revenue from rental income, senior living operations and all payors generated in our other ancillary operations.
(2) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
In addition to the service revenue above, our rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662, respectively for the three months ended March 31, 2021 and 2020.

Transitional and Skilled Services

Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.

We are participating in supplemental payment programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Several of our operating subsidiaries entered into transactions with several such hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected operating subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.

35

Real Estate
We generate rental revenue primarily by leasing post-acute care properties we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance, and maintenance and repair costs, subject to certain exceptions. As of March 31, 2021, our real estate portfolio was comprised of 94 real estate properties. Of these properties, 64 are leased to affiliated skilled nursing facilities wholly-owned and managed by us, 31 are leased to senior living operations wholly-owned and managed by Pennant, and our Service Center property, which is leased to our Service Center and numerous third parties for commercial office space. Of the 31 real estate operations leased to Pennant, two senior living operations are located on the same real estate properties as skilled nursing facilities that the Company owns and operates. During the year ended March 31, 2021, we generated rental revenues of $15.9 million, of which $11.9 million was derived from affiliated wholly-owned healthcare operators, and therefore eliminated in consolidation.

Other

Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid payors or through other state-specific programs. In addition, we hold majority membership interests in our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The preparation of these financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, we review our judgments and estimates, including but not limited to those related to the variable considerations to arrive at the transaction price for revenue recognition, income taxes, intangible assets and loss contingencies. We base our estimates and judgments upon our historical experience, knowledge of current conditions and our belief of what could occur in the future considering available information, including assumptions that we believe to be reasonable under the circumstances. By their nature, these estimates and judgments are subject to an inherent degree of uncertainty, and actual results could differ materially from the amounts reported. While we believe that our estimates, assumptions, and judgments are reasonable, they are based on information available when the estimate was made. Refer to Note 2, Summary of Significant Accounting Policies, within the Notes to the Condensed Consolidated Financial Statements for further information on our critical accounting estimates and policies, which are as follows:
Revenue recognition the estimate of variable considerations to arrive at the transaction price, including methods and assumptions used to determine settlements with Medicare and Medicaid payors or retroactive adjustments due to audits and reviews;
Self-insurance the valuation methods and assumptions used in estimating costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported;
Acquisition accounting the assumptions used to allocate the purchase price paid for assets acquired and liabilities assumed in connection with our acquisitions; and
Income taxes the estimation of valuation allowance or the need for and magnitude of liabilities for uncertain tax position.

36

Industry Trends
The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:
Shift of Patient Care to Lower Cost Alternatives The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher-acuity patients than in the past.
Significant Acquisition and Consolidation Opportunities The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities.
Improving Supply and Demand Balance The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.
Increased Demand Driven by Aging Populations As seniors account for an increasing percentage of the total U.S. population, we believe the demand for skilled nursing and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2020, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 16% to 21%. The Bureau expects this segment to increase nearly 50% to 73 million, as compared to the total U.S. population which is projected to increase by 10% over that time period. Furthermore, the generation currently retiring has accumulated less savings than prior generations, creating demand for more affordable senior housing and skilled nursing services. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.
Transition to Value-Based Payment Models In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.
Accountable Care Organizations and Reimbursement Reform A significant goal of U.S. federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support the quality and safety of care that providers deliver, increase efficiency, and reduce growth in spending. Reimbursement models that provide financial incentives to encourage efficiency, affordability, and high-quality care have been developed and implemented by government and commercial third-party payers. The most prolific of these models, the Accountable Care Organization (ACO) model, incentivizes groups of providers to share in savings that are achieved through the coordination of care and chronic disease management of an assigned patient population.  Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality, and patient satisfaction metrics.  In addition, the Centers for Medicare and Medicaid Services (CMS) has implemented Episode-based demonstration, voluntary and mandatory payment initiatives that bundle acute care and post-acute care reimbursement. These bundled payment models incentivize cross-continuum care coordination and include financial and performance accountability for episodes of care. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. Many of our operations already participate in ACOs. With our focus on quality care and strong clinical outcomes, Ensign is well-positioned to benefit from these outcome-based payment models.
We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size, and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.
37


GOVERNMENT REGULATION
General
Healthcare is an area of extensive and frequent regulatory change. Changes in the law or new interpretations of existing laws may have a significant impact on our revenue, costs and the way we operate our business. Our subsidiaries that provide healthcare services are subject to federal, state and local laws relating to, among other things, licensure, delivery, quality and adequacy of care, physical plant requirements, life safety, personnel and operating policies. In addition, our provider subsidiaries are subject to federal and state laws that govern billing and reimbursement, relationships with vendors and business relationships with physicians, and workplace protection for healthcare staff. Such laws include the Anti-Kickback Statue, the federal False Claims Act (FCA), the Stark Law and state corporate practice of medicine statutes.
Governmental and other authorities periodically inspect our skilled nursing facilities, senior living facilities and outpatient rehabilitation agencies to verify that we continue to comply with the applicable regulations and standards. We must pass these inspections to remain licensed under state laws and to comply with our Medicare and Medicaid provider agreements. We can only participate in these third-party payment programs if inspections by regulatory authorities reveal that our operations are in substantial compliance with applicable requirements. In the ordinary course of business, we may receive notices from federal or state regulatory authorities alleging deficiencies in certain regulatory practices. These statements of deficiency may require us to take corrective action to regain and maintain compliance. In some cases, federal or state regulators may impose other remedies including imposition of civil monetary penalties, temporary payment bans, loss of certification as a provider in Medicare or Medicaid program, or revocation of a state operating license.
We believe that the regulatory environment surrounding the healthcare industry subjects providers to intense scrutiny. In the ordinary course of business, providers are subject to inquiries, investigations and audits by federal and state agencies related to compliance with participation and payment rules under government payment programs. These inquiries may originate from the HHS Office of the Inspector General (OIG) audits, state Medicaid agencies, local and state ombudsman offices and CMS Recovery Audit Contractors, among other agencies. In response to the inquiries, investigations and audits, the federal and state governments continue to impose citations for regulatory deficiencies and other regulatory penalties, including demands for refund of overpayments, expanded civil monetary penalties that extend over long periods of time and date back to incidents long before surveyor visits, Medicare and Medicaid payment bans and terminations from the Medicare and Medicaid programs. We vigorously contest each such matter when appropriate; however, there are significant legal and other expenses involved that consume our financial and personnel resources. Expansion of enforcement activity could adversely affect our business, financial condition or the results of our operations.
Coronavirus
In an effort to promote efficient care delivery and to decrease the spread of COVID-19, federal, state and local regulators have both implemented new regulations and waived certain existing regulations, including those set forth below.
Temporary suspension of certain patient coverage criteria and documentation and care requirements - The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act) and a series of temporary waivers and guidance issued by CMS suspended various Medicare patient coverage criteria to ensure patients continue to have adequate access to care, notwithstanding the burdens placed on healthcare providers as related to the COVID-19 pandemic. Many of these regulatory waivers were issued pursuant to Section 1135 of the Social Security Act, which authorizes the HHS Secretary to temporarily waive or modify Medicare and Medicaid requirements for affected health care providers and facilities following the declaration of a public health emergency (Section 1135 Waivers). HHS also waived requirements specific to skilled nursing facilities pursuant to its authority under Section 1812(f) of the Social Security Act (Section 1812(f) Waiver, and together with the Section 1135 Waivers, the Emergency Waivers). While many of the Emergency Waivers are expected to last throughout the duration of the COVID-19 public health emergency, CMS has announced that will end several Emergency Waivers that are no longer needed as early as May 10, 2021.
38


Examples of requirements that were waived due to the COVID-19 emergency declaration include the following: (1) approving temporary expansion sites to ensure that local hospitals and health systems have the capacity to handle a potential surge of COVID-19 patients (e.g. CMS Hospital Without Walls); (2) removing barriers for physicians, nurses, and other clinicians from the community or from other states to allow healthcare systems to provide clinical and workforce support where needed; (3) increasing access to telehealth and corresponding reimbursement through Medicare to ensure patients have access to healthcare while remaining safe at home; (4) expanding in-place COVID-19 testing to allow for more testing at home or in community based settings; and (5) temporarily waiving certain documentation, reporting and audit requirements to allow providers, health care facilities, Medicare Advantage and Part D plans, and states to focus on the provision of care (e.g., Patients Over Paperwork). Many states have also waived regulations to ease regulatory burdens on the healthcare industries. It remains uncertain when federal and state regulators will resume enforcement of those regulations, which remain waived or are otherwise not being enforced during the public health emergency. We believe these regulatory actions could contribute to changes in skilled mix potentially impacting the timing, amount or duration, which may have been different without the existence of the waivers.
Pursuant to the Emergency Waivers, CMS also authorized temporary waivers on medical review requirements, effective March 1, 2020, for the duration of the public health emergency. In addition, CMS is re-prioritizing scheduled program audits and contract-level Risk Adjustment Data Validation audits for Medicare Advantage (MA) organizations, Part D sponsors, Medicare-Medicaid Plans, and Programs of All-Inclusive Care for the Elderly organizations. Re-prioritizing these audit activities will allow providers, CMS and organizations to focus on patient care.
In July 2020, CMS updated their COVID-19 Provider Burden Relief Frequently Asked Questions (FAQs) related to claim audit waivers for multiple services. On March 30, 2020, CMS suspended most Medicare Fee-For-Service (FFS) medical reviews because of the COVID-19 pandemic. This included pre-payment medical reviews conducted by Medicare Administrative Contractors (MACs) under the Targeted Probe and Educate program and post-payment reviews conducted by the MACs, Supplemental Medical Review Contractors (SMRC) reviews and Recovery Audit Contractors (RAC). CMS authorized MACs to resume these audit activities beginning on August 3, 2020, regardless of the status of the public health emergency. All reviews will be conducted in accordance with statutory and regulatory provisions, as well as related billing and coding requirements. Available waivers and flexibilities for the claims selected for review will also be applied.
Under the Emergency Waivers, CMS is also allowing skilled nursing facilities to provide a skill-in-place program for Medicare beneficiaries who are residents of the skilled nursing facilities that meet the skill-in-place criteria, foregoing the usual three-day qualifying hospital stay. As patients qualify for skill-in-place for Medicare Part A stays, we could see a decrease in long-term care Medicare Part B programs. This waiver remains valid for the duration of the COVID-19 public health emergency.
On August 24, 2020, CMS released a Medicaid Informational Bulletin providing guidance to states on flexibilities that are available to increase reimbursement for nursing facilities implementing specific infection control practices.
Resuming visitation and resident rights — CMS has issued guidance to facilities throughout the public health emergency regarding patients’ rights to visitors. While the CMS guidance issued in March 2020 directed that facilities severely restrict visitation, through the course of the Pandemic, CMS has subsequently provided guidance that broadens visitation.
Testing requirements — Beginning in April 2020, authorities in several states in which we operate began to mandate widespread COVID-19 testing at all nursing home and long-term care facilities. This came after the CDC stated that older adults are at a higher risk for serious illness from the coronavirus and issued updated testing guidelines for nursing homes. On July 22, 2020, CMS announced that nursing homes in states with a 5% or greater positivity rate for COVID-19 will be required to test all nursing home staff each week. On August 26, 2020, CMS issued new parameters for testing, requiring routine monthly testing of all facility staff if the facility’s county positivity rate is less than 5%; weekly testing if the county positivity rate is between 5% and 10%; and twice weekly testing if the county positivity rate exceeds 10%. On April 27, 2021, CMS again issued revised parameters for testing, specifying that the requirement for routine testing of staff applies only to those staff members that are unvaccinated - fully vaccinated staff do not have to be routinely tested. The routine testing requirements are in addition to obligations to screen staff each shift, residents daily, and all persons entering the facility for signs and symptoms of COVID-19. Facilities must test any staff or resident, regardless of vaccination status, who has signs or symptoms of COVID-19. In the event of a COVID-19 outbreak in the facility, all staff and residents must be tested at regular intervals until repeat testing identifies no new cases of COVID-19 infection among staff or residents for a 14-day period. In addition to CMS's testing mandates, some states have imposed their own testing requirements for residents and staff or are enforcing testing mandates under existing or expanded workplace safety regulations. Non-compliance with state or federal mandates may result in imposition of fines or other administrative action.
39


Reporting requirements Effective May 8, 2020, CMS published an interim final rule requiring skilled nursing facilities to report information related to COVID-19 cases among facility residents and staff directly to the CDC National Health Safety Network no less than weekly. In addition, skilled nursing facilities are required to inform residents, their families and representatives of confirmed or suspected COVID-19 cases in their facilities. This resident/family/representative notification is required to take place by 5:00 p.m. (local time) the next calendar day following the occurrence of: (1) a single confirmed infection of COVID-19, or (2) three or more residents or staff with new-onset of respiratory symptoms that occur within 72 hours of one another. The data collected as a result of the CDC National Health Safety Network reporting is publicly available on a dedicated website. CMS may initiate enforcement activities and/or assess civil monetary penalties for not meeting these reporting requirements. We do not believe these reporting requirements will have a material impact on our Condensed Consolidated Financial Statements.
Survey Activity and Enforcement — On March 20, 2020, CMS announced the initiation of focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. CMS prioritized infection control surveys over annual recertification and complaint surveys at the non-immediate jeopardy level, confirming its commitment to infection prevention and control in the skilled nursing industry. Effective August 17, 2020, CMS provided guidance authorizing resumption of traditional survey activity.
On June 1, 2020 (and subsequently updated in January 2021), CMS introduced an enhanced enforcement program with respect to infection control deficiencies. The program contemplates more significant remedies against facilities with a prior history of infection control deficiencies, and imposes more stringent penalties with deficiencies identified at a higher scope and severity. The spectrum of remedies available to CMS for imposition on skilled nursing facilities in connection with this enhancement includes increased monetary fines, shortened time periods to return to compliance, and other administrative penalties.
Federal COVID-19 Vaccination Program — On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for the prevention of COVID-19, followed by the second EUA for the use of the Moderna COVID-19 vaccine on December 28, 2020, and the third EUA for the Johnson & Johnson vaccine on February 27, 2021. Vaccine distribution is now widespread in all 50 states.
Medicare
Medicare presently accounts for approximately 31.7% of our transitional and skilled nursing services revenue year-to-date, being our second-largest payor. The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins.

Patient-Driven Payment Model (PDPM)
The Skilled Nursing Facility Prospective Payment System (SNF PPS) Rule became effective October 1, 2019. The SNF PPS Rule includes a new case-mix model that focuses on the patient’s condition (clinically relevant factors) and resulting care needs, rather than on the volume of care provided, to determine Medicare reimbursement. The case mix-model is called the Patient-Driven Payment Model (PDPM), which utilizes clinically relevant factors for determining Medicare payment by using ICD-10 diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy, occupational therapy, speech language pathology, nursing and social services and non-therapy ancillary services. It also uses a sixth non-case mix component to cover utilization of skilled nursing facilities resources that do not vary depending on resident characteristics.
PDPM replaces the existing case-mix classification methodology, Resource Utilization Groups, Version IV. The structure of PDPM moves Medicare towards a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care, thereby more accurately addressing costs associated with medically complex patients. PDPM also removes therapy minutes as the basis for therapy payment. Finally, PDPM adjusts the skilled nursing facilities per diem payments to reflect varying costs throughout the stay, through the physician therapy, occupational therapy and non-therapy ancillary services components.
In addition, PDPM is intended to reduce paperwork requirements for performing patient assessments. Under the SNF PPS PDPM system, the payment to skilled nursing facilities and nursing homes is based heavily on the patient’s condition rather than the specific services provided by each skilled nursing facility.
40


Skilled Nursing Facility - Quality Reporting Program (SNF QRP)
The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) imposed new data reporting requirements for certain Post-Acute-Care (PAC) providers. The IMPACT Act requires that each skilled nursing facility submit their quality measures data. Beginning with fiscal year 2018, and each subsequent year, if a skilled nursing facility does not submit required quality data, their payment rates are reduced by 2.0% for each such fiscal year. Application of the 2.0% reduction may result in payment rates for a fiscal year being less than the preceding fiscal year. In addition, reporting-based reductions to the market basket increase factor will not be cumulative; they will only apply for the fiscal year involved. A skilled nursing facility will receive a notification letter from its Medicare administrator contractor if it was non-compliant with the Quality Reporting Program reporting requirements and is subject to the payment reduction.
Updated performance measures mandated for the SNF QRP for fiscal year 2020 were established in the final SNF PPS rule adopted on August 8, 2019 (FY 2020 SNF PPS Rule). The final rule continues implementation of the SNF QRP measures to improve program interoperability, operational quality and safety. Specifically, the rule adopts a number of standardized patient assessment data elements. The SNF QRP applies to freestanding skilled nursing facilities, skilled nursing facilities affiliated with acute care facilities, and all non-critical access hospital swing-bed rural hospitals. Under the SNF QRP, a skilled nursing facility’s annual market basket percentage is reduced by 2.0% if the skilled nursing facility does not submit quality measure data in accordance with thresholds set by the IMPACT Act. Skilled nursing facilities that do not meet the SNF QRP requirements for a program year will receive a notice of non-compliance.
Beginning in March 2020, due to the COVID-19 pandemic, CMS issued a temporary suspension of SNF QRP reporting requirements effective until June 30, 2020. This effectively gave skilled nursing facilities discretion as to whether to report data from the fourth quarter (October 1, 2019 – December 31, 2019), and removed reporting requirements entirely for the first and second quarters of 2020 (January 1, 2020 – June 30, 2020). Skilled nursing facilities were required to resume timely quality data collection and submission of measure and patient assessment data effective June 30, 2020.
Medicare Annual Market Basket
CMS is required to calculate an annual Medicare market-basket update to the payment rates. On July 31, 2020, CMS issued a final rule for fiscal year 2021 that updates the Medicare payment rates and the quality programs for skilled nursing facilities. Under the final rule, effective October 1, 2020, the aggregate payments to skilled nursing facilities increased by 2.2% for fiscal year 2021, compared to fiscal year 2020. This estimated increase is attributable to a 2.2% market basket increase factor.
On April 8, 2021, CMS issued a proposed rule for fiscal year 2022 that updates the Medicare payment rates and the quality programs for skilled nursing facilities. Under the proposed rule, which would become effective October 1, 2021, the aggregate net market basket rate is expected to increase by 1.3%, for fiscal year 2022. This estimated increase is attributable to a 2.3% market basket increase factor with a 0.8% point reduction for forecast error adjustment and a 0.2% point reduction for multifactor productivity adjustment.
On April 12, 2021, CMS revealed its intent to recalibrate PDPM’s parity adjustment up to 5.0% based on the prior year aggregate spending under the new model. The reimbursement change, if proposed and finalized, could adversely impact our reimbursement rates.
Sequestration of Medicare Rates
The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare Fee-For-Service (FFS) claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments. All Medicare rate payments and settlements have incurred this mandatory reduction and it will continue to be in place through at least 2023, unless Congress takes further action. In response to COVID-19, the CARES Act temporarily suspended the automatic 2.0% reduction of Medicare claim reimbursements for the period of May 1, 2020 through December 31, 2020. On December 27, 2020, the Consolidated Appropriations Act further suspended the 2.0% payment adjustment through March 31, 2021. On April 14, 2021, Congress extended the suspension of the 2.0% payment adjustment through December 31, 2021. To pay for the change, Congress would increase the sequester cuts by one year to fiscal year 2030.
41


Skilled Nursing Facility Value-Based Purchasing (SNF-VBP) Program
The SNF-VBP Program rewards skilled nursing facilities with incentive payments based on the quality of care they provide to Medicare beneficiaries, as measured by a hospital readmissions measure. CMS annually adjusts its payment rules for skilled nursing facilities using the SNF-VBP Program. Effective October 1, 2018, CMS began withholding 2.0% to fund the SNF-VBP incentive payment pool and will redistribute 60% of the withheld payments back to skilled nursing facilities through the program. The FY 2020 SNF PPS Rules estimate the economic impact of the SNF-VBP Program to be a reduction of $213.6 million in aggregate payments to skilled nursing facilities during fiscal year 2020. The Rule also introduced two new quality measures to assess how health information is shared and adopted a number of standardized patient assessment data elements that assess factors such as cognitive function and mental status, special services, and social determinants of health. The FY 2021 SNF PPS rule updated the deadlines for baseline period qualify measure quarterly reporting and announced performance periods and standards for the FY 2023 program year, but otherwise made no changes to the measures, scoring or payment policies. In the FY 2022 program, CMS proposed changes to account for COVID-19 impacting readmission rates and SNF admissions during the performance periods of FY 2020. These proposed changes would impact the SNF-VBP rate adjustment.
Part B Rehabilitation Requirements
Some of our revenue is paid by the Medicare Part B program under a fee schedule. Part B services are limited with a payment cap by combined speech-language pathology services (SLP) and physical therapy (PT) services and a separate annual cap for occupational therapy (OT) services. These caps were implemented under the authority of the Balanced Budget Amendments of 1997. These amounts were previously associated with the financial limitation amounts. The Bipartisan Budget Act (BBA) of 2018 repealed those caps while retaining and adding additional limitations to ensure appropriate therapy services. This policy does not limit the amount of medically necessary Medicare Part B therapy services a beneficiary may receive. The BBA establishes coding modifier requirements to obtain payments beyond the updated KX modifier thresholds, discussed below, and reaffirms the specific $3,000 claim audit threshold requirements for the Medicare Administrative Contractors. For PT and SLP combined the threshold for coding modifier requirements is $2,110 for 2021, compared to $2,080 for 2020. The threshold is the same for OT services.

Consistent with CMS’ “Patients over Paperwork” initiative, the agency has also been moving toward eliminating burdensome claims-based functional reporting requirements for Part B therapy services. For example, beginning in January 2019, skilled nursing facilities are no longer required to append selected G-codes or the severity modifiers on outpatient therapy claims. This reduces the reporting burden on therapists providing outpatient services and increases the amount of time that therapists can spend with their patients. Effective January 1, 2021, CMS rescinded 21 problematic National Correct Coding Initiative edits impacting outpatient therapy services, including services furnished under Medicare Part B primarily related to PT and OT services. These code edits were previously implemented on October 1, 2020 and required additional documentation and claim modifier coding burden when procedure codes representing many PT or OT evaluation codes or treatment codes performed under a PT, OT, or SLP plan of care was billed on the same date. This additional burden is no longer required.
On November 1, 2019, CMS issued the calendar year 2020 Physician Fee Schedule (PFS) Final Rule establishing that therapy assistant claim modifiers will be required starting in calendar year 2020. This rule is consistent with the requirement of the Balanced Budget Act (BBA) of 2018, which requires a 15% payment reduction when a physical therapist assistant (PTA) or occupational therapy assistant (OTA) provides services “in whole or in part” on a given day. While the modifiers are required to be applied to the claims beginning in calendar year 2020, the 15% therapist assistant payment reduction will not be applied until calendar year 2022. The final rule clarified that “in whole or in part” means when 10% or more of the services are provided by a PTA or OTA.
On December 1, 2020, CMS issued the calendar year 2021 PFS Final Rule, which reduced the conversion factor (i.e. the number by which CMS determine all current procedural terminology code payments) by 10.2%. These changes will effectively lower the reimbursement rate for therapy Medicare Part B specialty providers, specific to our industry by 9% for PT and OT and by 6% for SLP Codes.
42


The Consolidated Appropriations Act of 2021 (CAA, also referred to as The Omnibus Appropriations Law) was signed into law on December 27, 2020. The CAA includes three components relevant to the Medicare Part B PFS. First, the CAA incorporates a rate relief of approximately 3.75% for fiscal year 2021. Additionally, the CAA incorporates a freeze to the payment for the physician add-on code for three years which would effectively create relief on the initial cuts through 2023. Finally, the relief calls for the 2% sequester to not be applied to the Medicare Part B program for the first quarter of 2021. CMS incorporated the first and second components of the CAA relief into the fiscal year 2021 PFS files which were published on January 5, 2021. While the 2021 PFS Final Rule reduced the fiscal year 2021 factor to $32.4085 (calendar year conversion factor was $36.0896), subsequently, the CAA restored part of the reductions resulting in the final FY 2021 conversion factor of $34.8931. This conversion factor rate does not include the 2% sequester which will also qualify as temporary relief for the first quarter of 2021.
The Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B speech-language pathology, occupational therapy, and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.

On May 27, 2020, pursuant to its authority under the Emergency Waivers, CMS added physical therapy, occupational therapy and speech-language pathology to list of approved telehealth Providers for the Medicare Part B programs provided by a skilled nursing facility. This waiver allows the reimbursement of certain HCPCS codes delivered by PT, OT, SLP through telehealth through the end of the public health emergency. Subsequently, the calendar year 2021 PFS Final Rule added certain of these PT and OT services to the list of Medicare telehealth services on a temporary basis through the end of the calendar year in which the COVID-19 public health emergency ends. The PFS Final Rule also increased the frequency limitation on nursing facility telehealth visits from once every 30 days to once every fourteen days. These services have been used to provide some services to community-based outpatients from our skilled nursing facilities that are eligible through local rules to provide community-based outpatient services.
Pursuant to the Emergency Waivers, CMS allowed for the facility to bill an originating site fee to CMS for telehealth services provided to Medicare Part B beneficiary residents of the facility when the services are provided by a physician from an alternate location, effective March 6, 2020 through the end of the public health emergency, which is currently in effect through July 20, 2021. Our facilities are utilizing this waiver as physicians elect to provide telehealth visits to Medicare Part B beneficiaries residing in the skilled nursing facility.
On December 31, 2020, CMS announced the annual update to the list of codes that describe Medicare Part B outpatient therapy services, effective January 1, 2021. Several existing and new codes introduced during the COVID-19 public health emergency impacting skilled nursing facilities providers for use under physical therapy, occupational therapy, or speech-language pathology plans of care were recently made permanent including several telehealth codes. CMS designated all these new HCPCS/CPT codes as “sometimes therapy,” to permit physicians and certain non-physician practitioners, including nurse practitioners, physician assistants, and clinical nurse specialists, to render these services outside a therapy plan of care when appropriate. “Sometimes Therapy” codes will not have the MPPR applied.

Programs of All-Inclusive Care for the Elderly
CMS issued a final rule on June 3, 2019, which updates the requirements for the Programs of All-Inclusive Care for the Elderly (PACE) under the Medicare and Medicaid programs. The regulation is intended to provide greater operational flexibility, remove redundancies and outdated information and codify existing programs. Such flexibility includes, (i) more lenient standards applicable to the current requirement that the PACE organization be monitored for compliance with the PACE program requirements during and after a 3-year trial period and (ii) relieving certain restrictions placed upon the interdisciplinary team that comprehensively assesses and provides for the individual needs of each PACE participant by allowing one person to fill two roles and permitting secondary participation in the PACE program. Further, non-physician primary care providers can provide certain services in place of primary care physicians.
Preadmission Screening and Resident Review
On February 20, 2020, CMS published a proposed rule which would modernize requirements for the Preadmission Screening and Resident Review process. This process assesses the needs of individuals with mental illness or intellectual disability that are applying to or residing in Medicaid-certified nursing facilities. The proposed rule, if enacted as currently drafted, would impose additional resident review requirements that are not reflected in current regulations, authorize the use of telehealth, and simplify the list of information that must be collected during evaluations.
43


Decisions Regarding Skilled Nursing Facility Payment
Medicare reimbursement rates and rules are subject to frequent change. Historically, adjustments to reimbursement under Medicare have had a significant effect on our revenue. The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.
These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. For a discussion of historic adjustments and recent changes to the Medicare program and related reimbursement rates, see Part I, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry - “Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicaid and Medicare,” “Our future revenue, financial condition and results of operations could be impacted by continued cost containment pressures on Medicaid spending,” “We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations” and “Reforms to the U.S. healthcare system will impose new requirements upon us and may lower our reimbursements.
Patient Protection and Affordable Care Act
Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The recent Congressional elections in the United States and policies implemented by the former Presidential administration have resulted in significant changes in legislation, regulation, implementation of Medicare, Medicaid, and government policy. The recent 2020 Presidential and Congressional elections may significantly alter the current regulatory framework and impact our business and the health care industry. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business.
Requirements of Participation
CMS has requirements that providers, including skilled nursing facilities and other long-term care (LTC) facilities must meet in order to participate in the Medicare and Medicaid Programs. Some requirements can be burdensome and costly, and in recent years, CMS has modified these requirements. For example, beginning in 2016, skilled nursing facilities were required to comply with emergency preparedness requirements, which requirements have since been strengthened via promulgation of additional rules.
Another relevant change is a 2019 final rule that removed the prohibition on the use of pre-dispute, binding arbitration agreements by LTC facilities. The rule imposed specific requirements on the use of these agreements, including requiring the use of plain language in drafting; that facilities post a notice in plain language that describes the policy on the use of agreements for binding arbitration in an area that is visible to residents and visitors; that admission to the facility not be conditioned on the signing of an arbitration agreement; and that the facility expressly inform the resident or his/her representative of the right not to sign the agreement as a condition of admission.

44


Civil and Criminal Fraud and Abuse Laws and Enforcement
Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Health Insurance Portability and Accountability Act of 1996 (HIPAA), and the Balanced Budget Act of 1997 (BBA) expanded the penalties for healthcare fraud. Additionally, in connection with our involvement with federal healthcare reimbursement programs, the government or those acting on its behalf may bring an action under the FCA, alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided, and submitting false or erroneous cost reports. The Fraud Enforcement and Recovery Act of 2009 (FERA) expanded the scope of the FCA by, among other things, creating liability for knowingly and improperly avoiding repayment of an overpayment received from the government and broadening protections for whistleblowers. The FCA clarifies that if an item or service is provided in violation of the Anti-Kickback Statute, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Civil monetary penalties under the FCA range from approximately $11,665 to $23,331 and are adjusted each January for inflation. Under the qui tam or “whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government’s recovery. Due to these whistleblower incentives, lawsuits have become more frequent. Many states also have a false claim prohibition that mirrors or tracks the federal FCA. Federal law also provides that OIG has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions, and exclusion from state or other federal healthcare programs. And, CMS can recover overpayments from health care providers up to five years following the year in which payment was made.
In November 2019, the OIG released a report of its investigation into overpayments to hospitals that did not comply with Medicare’s post-acute-care transfer policy. Hospitals violating this policy transferred patients to certain post-acute-care settings, such as skilled nursing facilities, but claimed the higher reimbursements associated with discharges to homes. A similar OIG audit report, released in February 2019, focused on improper payments for skilled nursing facility services when the Medicare three-day inpatient hospital stay requirement was not met. These investigatory actions by OIG demonstrate their increased scrutiny into post-hospital skilled nursing facility care provided to beneficiaries and may encourage additional oversight or stricter compliance standards.
On numerous occasions, CMS has indicated its intent to vigilantly monitor overall payments to skilled nursing facilities, paying particular attention to facilities that have high reimbursements for ultra-high therapy, therapy resource utilization groups with higher activities of daily living scores, and long average lengths of stay. The OIG recognizes that there is a strong financial incentive for facilities to bill for higher levels of therapies, even when not needed by patients. We cannot predict the extent to which the OIG's recommendations to CMS will be implemented and, what effect, if any, such proposals would have on us. Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.
Federal Healthcare Reform
In 2015, CMS released a final rule addressing, among other things, implementation of certain provisions of Medicare Access and CHIP Reauthorization Act of 2015, which changes the way physicians are paid who participate in Medicare through implementation of the Quality Payment Program. Quality Payment Program creates two tracks for physician payment: (1) the Merit-Based Incentive Payment System (MIPS) that streamlines multiple quality programs; and (2) Alternative Payment Models that give bonus payments for participation in eligible Alternative Payment Models. The final rule also excluded services furnished in skilled nursing facilities from the definition of primary care services for purposes of the Shared Savings Program.

45


The Five-Star Quality Rating system includes a rating of one to five in various categories including the use of antipsychotics in calculating the star ratings, modified calculations for staffing levels, reflect higher standards for nursing homes to achieve a high rating on the quality measure dimension, the rate of hospitalization, emergency room use, community discharge, improvements in function, independently worsened and anxiety or hypnotic medication among nursing home residents. In 2018, (i) a freeze of the Health Inspection Five Star Ratings; (ii) the addition of Payroll Based Journals (PBJ) data to calculate the staffing ratings in the Nursing Home Five Star Quality Rating System; and (iii) the addition of two claims data measures: Medicare spending per beneficiary and rate of successful return to home or community from a skilled nursing facility for quality measures. In 2019, (i) the addition of separate ratings for short stay and long stay care; (ii) changes in staffing thresholds; and (iii) modifications to put more emphasis on registered nurse (RN) staffing, including a set rating for nursing homes that report four or more days in the quarter with no RN on site.

In 2020, in response to the COVID-19 pandemic, a temporary freeze of Skilled Nursing Facilities Quality Reporting Program data, Staffing Data, and Health Inspection data on the Nursing Home Compare website to account for the suspended reporting and inspection obligations due to the COVID-19 pandemic.

CMS predicted that the 2019 changes would result in 47% of all nursing centers to lose stars in their "Quality" ratings, 33% to lose stars in their "Staffing" ratings and some 36% to lose stars in their "Overall" ratings. Unsurprisingly, these changes resulted in a reduction in Ensign’s number of facilities with four or five Star ratings in 2019. In April 2020, CMS began increasing quality measure thresholds by 50% of the average rate of improvement of QM scores every six months. This means if there is an average rate of improvement of 2%, the quality measure threshold will be raised 1%. This frequent adjustment is intended to avoid larger adjustments to thresholds in the future. However, CMS acknowledges that some facilities may see a decline in their overall five Star rating absent any new inspection information. This change could further affect star ratings across the industry.

On April 27, 2016, CMS added six new quality measures to its consumer-based Nursing Home Compare website. These quality measures include the rate of rehospitalization, emergency room use, community discharge, improvements in function, independent worsening of ability to move, and use antianxiety or hypnotic medication among nursing home residents. Beginning in July 2016, CMS incorporated all these measures, except for the antianxiety/hypnotic medication measure, into the calculation of the Nursing Home Five-Star Quality Ratings. In 2018, CMS added PBJ data to be used to calculate the staffing ratings in the Nursing Home Five Star Quality Rating System. In 2019, CMS updated thresholds for assigning stars for both the staffing and quality components of the system and added measures of long-stay hospitalizations and long-stay ED visits were added to the quality measure rating. Since the standards for performance are more difficult to achieve, the number of our 4 and 5 Star facilities could be reduced.

Additionally, in April of 2019, CMS announced a new framework for informing CMS’s work related to the safety and quality in America’s nursing homes. The approach includes the following pillars: Strengthening Oversight, Enhancing Enforcement, Increasing Transparency, Improving Quality, and Putting Patients over Paperwork. As part of the Transparency Pillar, beginning on October 23, 2019 on the Nursing Home Compare website, CMS began displaying a consumer alert icon next to nursing homes that have been cited for incidents of abuse, neglect, or exploitation. The icon will be updated monthly, at the same time CMS inspection results are updated. In February 2020, CMS announced that part of its Enhancing Enforcement efforts would include improved oversight of state survey agencies (SSA) and revisions to the State Performance Standards System, which is the program used to access SSA performance.

In responding to the COVID-19 pandemic, CMS announced a new, targeted inspection plan to focus on urgent patient safety threats and infection control, therefore causing a shift in the number of nursing homes inspected and how the inspections are conducted. As this change would disrupt the inspections conducted as part of the Nursing Home Five Star Quality Rating System, results of inspections conducted on or after March 4, 2020 were not used to calculate a nursing home’s health inspection star ratings. CMS resumed calculating nursing homes' health inspection ratings on January 27, 2021. In addition, beginning on July 29, 2020, data used to calculate staffing measures in the Five Star Quality ratings system for the first and second quarters of 2020 was frozen based upon the waiver of the requirement for facilities to submit staffing data through the PBJ system. This waiver ended in June 2020 for the third and fourth quarters of 2020, and staffing data was reflected in the Five Star ratings January 2021.

Another impact of the COVID-19 pandemic to the Nursing Home Five-Star Quality Rating System is CMS’s decision to make submission of the minimum data set assessment data optional for the fourth quarter of 2019 and excepted for the first and second quarters of 2020. Due to the gap in reported data, CMS did not include the two quality measures that are based on the minimum data set assessment-based data in its quality measure ratings in January 2021.


46


Monitoring Compliance in Our Facilities 
Governmental agencies and other authorities periodically inspect our facilities to assess our compliance with various standards, rules and regulations. The robust regulatory and enforcement environment continues to impact healthcare providers, especially in connection with responses to any alleged noncompliance identified in periodic surveys and other inspections by governmental authorities. Unannounced surveys or inspections generally occur at least annually and may also follow a government agency's receipt of a complaint about a facility. We must pass these inspections to maintain our licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration program at some facilities, and to comply with our provider contracts with managed care clients at many facilities. From time to time, we, like others in the healthcare industry, may receive notices from federal and state regulatory agencies alleging that we failed to substantially comply with applicable standards, rules or regulations. These notices may require us to take corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on skilled nursing facilities such as admission holds, provisional skilled nursing license or increased staffing requirements. If our facilities fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, we could lose our certification as a Medicare or Medicaid provider, or lose our state licenses to operate the facilities.
Facilities with otherwise acceptable regulatory histories generally are normally given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within nine months, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, are not generally given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners (including us, historically) nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before we acquire them and that develop new deficiencies after we acquire them are more likely to have sanctions imposed upon them by CMS or state regulators.

In addition, CMS has increased its focus on facilities with a history of serious quality of care problems through the special focus facility (SFF) initiative. A facility's administrators and owners are notified when it is identified as a special focus facility. This information is also provided to the general public. The SFF designation is based in part on the facility's compliance history typically dating before our acquisition of the facility. Local state survey agencies recommend to CMS that facilities be placed on special focus status. SFFs receive heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over time.
Moreover, sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice. This possibility sometimes leaves affected operators, including us, with the difficult task of deciding whether to continue accepting patients after the potential denial of payment date, thus risking the retroactive denial of revenue associated with those patients' care if the operators are later found to be out of compliance, or simply refusing admissions from the potential denial of payment date until the facility is actually found to be in compliance. In the past and from time to time, some of our affiliated facilities have been or will be in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of the revenue associated with the Medicare and Medicaid patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, these sanctions, entailing various remedies up to and including decertification.

CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state actions. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards, and to identify multi-facility providers with patterns of noncompliance. In addition, HHS has adopted a rule that requires CMS to charge user fees to healthcare facilities cited during regular certification, recertification or substantiated complaint surveys for deficiencies, which require a revisit to assure that corrections have been made. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently.
47


Regulations Regarding Financial Arrangements  
We are also subject to federal and state laws that regulate financial arrangement by healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.
The Anti-Kickback Statute, Section 1128B of the Social Security Act (Anti-Kickback Statute) prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create “safe harbors” for certain conduct and business relationships that are deemed protected under the Anti-Kickback Statute. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors, however, does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities.
Violations of the Anti-Kickback Statute can result in criminal penalties of up to $100,000 and ten years imprisonment. Violations of the Anti-Kickback Statute can also result in civil monetary penalties of up to $100,000 per violation and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. Violation of the Anti-Kickback Statute may also result in an individual's or organization's exclusion from future participation in federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which we operate have adopted or are considering similar legislative proposals, some of which extend beyond the Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care. We believe that business practices of providers and financial relationships between providers have become subject to increased scrutiny as healthcare reform efforts continue on the federal and state levels.
Additionally, Section 1877 of the Social Security Act, commonly known as the “Stark Law,” provides that a physician may not refer a Medicare or Medicaid patient for a “designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, enteral and parenteral feeding and supplies and home health services. Under the Stark Law, a “financial relationship” is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is prohibited from submitting or claiming payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Many of the compensation arrangements exceptions permit referrals if, among other things, the arrangement is set forth in a written agreement signed by the parties, the compensation to be paid is set in advance, is consistent with fair market value and is not determined in a manner that takes into account the volume or value of any referrals or other business generated between the parties. Exceptions may have other requirements. Any funds collected for an item or service resulting from a referral that violates the Stark Law are not eligible for payment by federal healthcare programs and must be repaid to Medicare or Medicaid, any other third-party payor, and the patient. Violations of the Stark Law may result in the imposition of civil monetary penalties, including, treble damages. Individuals and organizations may also be excluded from participation in federal healthcare programs for Stark Law violations. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law.
Regulations Regarding Patient Record Confidentiality
We are also subject to laws and regulations enacted to protect the confidentiality of patient health information. For example, HHS has issued rules pursuant to HIPAA, including the Health Information Technology for Economic and Clinical Health (HITECH) Act which governs our use and disclosure of protected health information of patients. We have established policies and procedures to comply with HIPAA privacy and security requirements at our affiliated facilities and operating subsidiaries. We maintain a company-wide HIPAA compliance plan, which we believe complies with the HIPAA privacy and security regulations. The HIPAA privacy and security regulations have and will continue to impose significant costs on our facilities in order to comply with these standards. There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our operations are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties for privacy and security breaches. Healthcare entities are also required to afford patients with certain rights of access to their health information under HIPAA and the 21st Century Cures Act (Cures Act). Recently, the Office of Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, imposing significant fines for violations largely initiated from patient complaints. The Office of the National Coordinator for Health Information Technology can also investigate and impose separate penalties for information blocking violations under the Cures Act.
48


Antitrust Laws 
We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. In some respects, the application of federal and state antitrust laws to healthcare is still evolving, and enforcement activity by federal and state agencies appears to be increasing. At various times, healthcare providers and insurance and managed care organizations may be subject to an investigation by a governmental agency charged with the enforcement of antitrust laws, or may be subject to administrative or judicial action by a federal or state agency or a private party. Violators of the antitrust laws could be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.
Americans with Disabilities Act
Our facilities must also comply with the American with Disabilities Act, or the ADA, and similar state and local laws to the extent that such facilities are "public accommodations" as defined in those laws. The obligation to comply with the ADA and other similar laws is an ongoing obligation, and we continue to assess our facilities and make appropriate modifications.
REGULATIONS SPECIFIC TO SENIOR LIVING COMMUNITIES
As previously mentioned, senior living services revenue is primarily derived from private pay residents, with a small portion of senior living revenue (approximately 1.9% of total revenue) derived from Medicaid funds. Thus, some of the regulations discussed above applicable to Medicaid providers, also apply to senior living. However, the following provides a brief overview of the regulatory framework applicable specifically to senior living.
A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities under waivers granted by or under Medicaid state plans approved by CMS. State Medicaid programs control costs for senior living and other home and community-based services by various means such as restrictive financial and functional eligibility standards, enrollment limits and waiting lists. Because rates paid to senior living community operators are generally lower than rates paid to skilled nursing facility operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in skilled nursing facilities. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the services at, and physical conditions of, the participating communities. As a result of the growth of senior living in recent years, states have adopted licensing standards applicable to assisted living communities. Most state licensing standards apply to senior living communities regardless of whether they accept Medicaid funding.
Since 2003, CMS has commenced a series of actions to increase its oversight of state quality assurance programs for senior living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid for through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community-based services as alternatives to facility-based services, pursuant to provisions of the ACA, and other authorities, through the use of several programs.
The types of laws and statutes affecting the regulatory landscape of the post-acute industry continue to expand. In addition to this changing regulatory environment, federal, state and local officials are increasingly focusing their efforts on the enforcement of these laws. In order to operate our businesses, we must comply with federal, state and local laws relating to licensure, delivery and adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, fire prevention, rate-setting, billing and reimbursement, building codes and environmental protection. Additionally, we must also adhere to anti-kickback statues, physician referral laws, the ADA, and safety and health standards set by the Occupational Safety and Health Administration. Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Our operating subsidiaries are also subject to various regulations and licensing requirements promulgated by state and local health and social service agencies and other regulatory authorities. Requirements vary from state to state and these requirements can affect, among other things, personnel education and training, patient and personnel records, services, staffing levels, monitoring of patient wellness, patient furnishings, housekeeping services, dietary requirements, emergency plans and procedures, certification and licensing of staff prior to beginning employment, and patient rights. These laws and regulations could limit our ability to expand into new markets and to expand our services and facilities in existing markets.



49

Results of Operations
We believe we exist to dignify and transform post-acute care. We set out a strategy to achieve our goal of ensuring our patients are receiving the best possible care through our ability to acquire, integrate and improve our operations. Our results serve as a strong indicator that our strategy is working and our transformation is underway. As vaccines continue to become more readily available and COVID-19 cases are declining in the communities we serve, we have begun to see a recovery in our census during the quarter ended March 31, 2021, compared to the fourth quarter of 2020. We continue to experience healthy growth and achieve record revenue and net income.
Our total revenue for the quarter increased $37.6 million, or 6.4% while our diluted GAAP earning per share grew more than 17.8%, from $0.73 to $0.86, compared to the first quarter in 2020. Revenue from our transitional and skilled services collectively increased by 7.7%. See Recent Activities for further information. Our one operation at a time approach demonstrates our affiliated operators focus on clinical results and operational fundamentals. We have also strengthened our collection process and identified non-clinical areas where we can manage spending. These operational fundamentals coupled with the reduction of interest expense due to the deferral of payroll tax payments and cash generated from strong performance resulted in strong financial success in the quarter.

The following table sets forth details of operating results for our revenue, expenses and earnings, and their respective components, as a percentage of total revenue for the periods indicated:

Three Months Ended March 31,
 20212020
Revenue:
Service revenue99.4 %99.4 %
Rental revenue0.6 0.6 
Total revenue 100.0 %100.0 %
Expense:
Cost of services76.8 77.1 
Rent—cost of services5.3 5.5 
General and administrative expense5.5 5.5 
Depreciation and amortization2.2 2.3 
Total expenses89.8 90.4 
Income from operations10.2 9.6 
Other income (expense):
Interest expense(0.3)(0.6)
Interest and other income0.1 0.1 
Other expense, net(0.2)(0.5)
Income before provision for income taxes10.0 9.1 
Provision for income taxes2.1 2.1 
Net income 7.9 7.0 
Less: net income attributable to noncontrolling interests 0.1 0.1 
Net income attributable to The Ensign Group, Inc.7.8 %6.9 %

50

 Three Months Ended March 31,
 20212020
Segment Income(1)
(In thousands)
Transitional and skilled services$88,931 $80,591 
Real estate(2)
$8,821 $6,325 
Non-GAAP Financial Measures:
Performance Metrics
EBITDA $76,707 $70,161 
Adjusted EBITDA $80,879 $73,810 
FFO for real estate segment $13,514 $10,840 
Valuation Metric
Adjusted EBITDAR$114,297 
(1) Segment income represents operating results of the reportable segments excluding gain and loss on sale of assets, impairment charges and provision for income taxes. Segment income is reconciled to the Condensed Consolidated Statement of Income in Note 7, Business Segments in Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.
(2) Real estate segment income includes rental revenue from Ensign affiliated tenants and related expenses.

The following discussion includes references to EBITDA, Adjusted EBITDA, Adjusted EBITDAR and Funds from Operations (FFO) which are non-GAAP financial measures (collectively, the Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Securities Exchange Act of 1934, as amended (the Exchange Act), define and prescribe the conditions for use of certain non-GAAP financial information. These Non-GAAP Financial Measures are used in addition to and in conjunction with results presented in accordance with GAAP. These Non-GAAP Financial Measures should not be relied upon to the exclusion of GAAP financial measures. These Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.
We believe the presentation of certain Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as interest expense, net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and
they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use the Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;
to allocate resources to enhance the financial performance of our business;
to assess the value of a potential acquisition;
to assess the value of a transformed operation's performance;
to evaluate the effectiveness of our operational strategies; and
to compare our operating performance to that of our competitors.

We use certain Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as net interest expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

51

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, the Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, certain of our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;
they do not reflect changes in, or cash requirements for, our working capital needs;
they do not reflect the net interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;
they do not reflect any income tax payments we may be required to make;
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and
other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

Management strongly encourages investors to review our condensed consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our condensed consolidated financial statements and related notes included elsewhere in this document.

We use the following Non-GAAP financial measures that we believe are useful to investors as key valuation and operating performance measures:

PERFORMANCE MEASURES:
EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income, adjusted for net losses attributable to noncontrolling interest, before (a) interest expense, net, (b) provision for income taxes, and (c) depreciation and amortization.

Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance.  

52


Adjusted EBITDA is EBITDA adjusted for non-core business items, which for the reported periods includes, to the extent applicable:

results related to operations not at full capacity;
stock-based compensation expense;
gain on sale of assets; and
acquisition related costs.
Funds from Operations (FFO)
We consider FFO to be a useful supplemental measure of the operating performance of our real estate segment. Historical cost accounting for real estate assets in accordance with U.S. GAAP implicitly assumes that the value of real estate assets diminishes predictably over time as evidenced by the provision for depreciation. However, since real estate values have historically risen or fallen with market conditions, many real estate investors and analysts have considered presentations of operating results for real estate companies that use historical cost accounting to be insufficient. In response, the National Association of Real Estate Investment Trusts (NAREIT) created FFO as a supplemental measure of operating performance for REITs, which excludes historical cost depreciation from net income. We define (in accordance with the definition used by NAREIT) FFO to mean net income attributable to common stockholders (NICS), computed in accordance with U.S. GAAP, excluding gains (or losses) from sales of real estate and impairment of depreciable real estate assets and including depreciation and amortization related to real estate to earnings.

VALUATION MEASURE:

Adjusted EBITDAR

 We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.

We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.


53

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

Three Months Ended March 31,
20212020
Consolidated statements of income data:(In thousands)
Net income $49,837 $41,201 
Less: net income attributable to noncontrolling interests631 352 
Add: Interest expense, net893 2,967 
Provision for income taxes12,949 12,625 
Depreciation and amortization13,659 13,720 
EBITDA$76,707 $70,161 
Stock-based compensation expense4,054 3,235 
Results related to operations not at full capacity(a)584 342 
Gain on sale of assets(540)— 
Acquisition related costs(b)36 50 
Rent related to items above38 22 
Adjusted EBITDA$80,879 $73,810 
Rent—cost of services33,456 32,330 
Less: rent related to items above(38)(22)
Adjusted rent 33,418 32,308 
Adjusted EBITDAR $114,297 
(a) Represents results of operations not at full capacity during the period presented.
(b) Costs incurred to acquire operations which are not capitalizable.

Three Months Ended March 31, 2021 Compared to the Three Months Ended March 31, 2020

The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated:
Three Months Ended March 31, 2021
 Transitional and skilled servicesReal estate All OtherEliminationsConsolidated
Total revenue 601,036 15,879 22,240 (11,902)$627,253 
Total expenses, including other expense, net512,105 7,058 57,646 (11,902)564,907 
Segment income (loss)88,931 8,821 (35,406) 62,346 
Gain from sale of real estate(1)
440 
Income before provision for income taxes $62,786 
(1) Gain from sale of real estate includes gains or losses from the sale of real estate, insurance recoveries and impairment charges from operations.

Three Months Ended March 31, 2020
 Transitional and skilled servicesReal estate All OtherEliminationsConsolidated
Total revenue $558,304 $14,944 $27,647 $(11,282)$589,613 
Total expenses, including other expense, net477,713 8,619 60,737 (11,282)535,787 
Segment income (loss)80,591 6,325 (33,090)— 53,826 
Income before provision for income taxes$53,826 

54

Our total revenue increased $37.6 million, or 6.4%, compared to the three months ended March 31, 2020. The increase in revenue was primarily driven by an increase in our skilled mix days and revenue per patient day from our transitional and skilled services operations, along with the impact of acquisitions. Total revenue from operations acquired on or subsequent to January 1, 2020 increased our consolidated revenue by $19.1 million during the three months ended March 31, 2021, when compared to the same period in 2020. In addition, we recorded $16.5 million of state relief revenue, which correlated directly to the additional COVID-19 related expenses incurred. All state relief revenue is included in Medicaid revenue.

Transitional and Skilled Services

Revenue

The following table presents the transitional and skilled services revenue and key performance metrics by category during the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
 20212020Change% Change
Total Facility Results:(Dollars in thousands)  
Transitional and skilled revenue(4)
$601,036 $558,304 $42,732 7.7 %
Number of facilities at period end200 194 3.1 %
Number of campuses at period end*23 22 4.5 %
Actual patient days(4)
1,509,600 1,643,390 (133,790)(8.1)%
Occupancy percentage — Operational beds71.1 %79.4 % (8.3)%
Skilled mix by nursing days34.4 %29.3 % 5.1 %
Skilled mix by nursing revenue55.6 %50.1 % 5.5 %

Three Months Ended March 31,
 20212020Change% Change
Same Facility Results(1):(Dollars in thousands)  
Transitional and skilled revenue(4)
$491,790 $476,896 $14,894 3.1 %
Number of facilities at period end165 165 — — %
Number of campuses at period end*15 15 — — %
Actual patient days(4)
1,219,693 1,371,803 (152,110)(11.1)%
Occupancy percentage — Operational beds72.2 %80.4 % (8.2)%
Skilled mix by nursing days35.4 %31.0 % 4.4 %
Skilled mix by nursing revenue56.6 %52.1 % 4.5 %

Three Months Ended March 31,
20212020Change% Change
Transitioning Facility Results(2):(Dollars in thousands)  
Transitional and skilled revenue(4)
$89,025 $79,027 $9,998 12.7 %
Number of facilities at period end26 26 — — %
Number of campuses at period end*7 — — %
Actual patient days(4)
235,668 263,341 (27,673)(10.5)%
Occupancy percentage — Operational beds66.9 %74.7 % (7.8)%
Skilled mix by nursing days30.6 %20.7 % 9.9 %
Skilled mix by nursing revenue51.2 %38.7 % 12.5 %

55

Three Months Ended March 31,
20212020Change% Change
Recently Acquired Facility Results(3):(Dollars in thousands)  
Transitional and skilled revenue(4)
$20,221 $2,381 $17,840 NM
Number of facilities at period end9 NM
Number of campuses at period end*1 — NM
Actual patient days(4)
54,239 8,246 45,993 NM
Occupancy percentage — Operational beds66.8 %73.6 %NM
Skilled mix by nursing days28.1 %18.1 % NM
Skilled mix by nursing revenue49.5 %31.7 % NM
* Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.
(1)Same Facility results represent all facilities purchased prior to January 1, 2018.
(2)Transitioning Facility results represent all facilities purchased from January 1, 2018 to December 31, 2019.
(3)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2020.
(4)The first quarter of 2021 included 90 days compared to 91 days for the same period in 2020 as a result of the leap year.

Transitional and skilled services revenue increased $42.7 million, or 7.7%, compared to the three months ended March 31, 2020. Of the $42.7 million increase, Medicare revenue increased $34.7 million, or 22.3%, Medicaid custodial revenue increased $6.8 million, or 3.1%, Medicaid skilled revenue increased $4.0 million, or 11.1%, and managed care revenue increased by $6.3 million, or 6.2%. Private and other revenue decreased $9.1 million, or 20.7%.

The increase in revenue was primarily driven by strong performance across our transitional and skilled services operations. The negative impact of COVID-19 on our census started in March 2020 and continues in 2021. Our occupancy decreased by 8.3% compared to the same period in the prior year. The decline is partially offset by the increase in skilled mix days due to a shift toward high acuity patients.

Revenue in our Same Facilities increased $14.9 million, or 3.1% due to greater patient acuity and skilled days, even while occupancy and census declined by 8.2% and 11.1%, respectively, due to COVID-19. The decline in our occupancy is mainly in our non-skilled patient days, which is being primarily offset by a shift to higher Medicare census, which also drove up skilled mix days and revenue. Our skilled mix days increased by 4.4% coupled with an increase from our skilled revenue daily rate of 6.1%, which included the impact of 2% sequestration reversal and 2.2% net market basket Medicare rates. This resulted in an increase in skilled mix revenue of $18.0 million.

We continued to experience decreased Medicaid custodial and private patient census days related to COVID-19. Our Medicaid census decreased by 15.0%, but was offset by an increase in our Medicaid daily rate of 8.6% as a result of our successful participation in the quality improvement programs and the supplemental programs in various states. In addition, included in total revenue for Same Facilities is $13.8 million of Medicaid revenue related to state relief funding.

Revenue generated by our Transitioning Facilities increased $10.0 million, or 12.7%, primarily due to increases in our daily rate and skilled mix days compared to the three months ended March 31, 2020, demonstrating our ability to transition these healthcare operations that were acquired two and three years ago. In addition, we experienced and continued to see a shift toward higher acuity patients, as demonstrated by increased census in all skilled payors. As a result, skilled mix revenue increased by $12.6 million, or 43.7%, compared to the three months ended March 31, 2020. Our skilled days increased by 32.3%, resulting in an increase in our skilled mix revenue daily rate of 8.6%.

Transitional and skilled services revenue generated by facilities purchased on or subsequent to January 1, 2020 (Recently Acquired Facilities) increased by approximately $17.8 million compared to the three months ended March 31, 2020. We acquired seven operations between April 1, 2020 and March 31, 2021 across three states.
In the future, if we acquire additional turnaround or start-up operations, we expect to see lower occupancy rates and skilled mix, and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates, lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth.

56

The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):
Three Months Ended March 31,
 Same FacilityTransitioningAcquisitionsTotal
 20212020202120202021202020212020
Skilled Nursing Average Daily
Revenue Rates:
Medicare$691.83 $663.60 $678.43 $628.33 $737.01 $508.35 $691.34 $657.78 
Managed care505.34 477.01 484.69 438.87 365.48 416.96 500.13 472.74 
Other skilled546.42 523.47 400.72 323.86 512.79 — 533.43 513.89 
Total skilled revenue595.16 560.95 576.89 531.21 604.56 485.19 592.90 557.35 
Medicaid251.41 231.40 241.67 219.18 240.72 232.31 249.38 229.23 
Private and other payors239.48 233.91 241.99 218.82 243.88 228.44 240.06 230.95 
Total skilled nursing revenue$371.89 $333.89 $344.15 $283.62 $343.36 $277.07 $366.53 $325.54 
(1) These rates exclude additional FMAP we recognized and include sequestration reversal of 2%.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 4.3% and 8.0%, respectively, compared to the three months ended March 31, 2020. The increase is attributable to the 2.2% net market basket increase that became effective in October 2020 coupled with our continued shift towards higher acuity patients. Included in revenue for the three months ended March 31, 2021 is the result of the temporary suspension of the 2% Medicare sequestration, which started on May 1, 2020 and will go through March 31, 2021. On April 14, 2021, through passage of An Act to Prevent Across-the-Board Direct Spending Cuts, and for Other Purposes, Congress extended the suspension of the 2.0% payment adjustment through December 31, 2021.

Our average Medicaid rates increased 8.8% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.

Payor Sources as a Percentage of Skilled Nursing Services. We use our skilled mix as measures of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods.

The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:
 Three Months Ended March 31,
 Same FacilityTransitioningAcquisitionsTotal
 20212020202120202021202020212020
Percentage of Skilled
Nursing Revenue:
Medicare29.4 %25.2 %30.9 %24.1 %33.2 %24.8 %29.7 %25.0 %
Managed care19.0 18.9 17.3 13.0 6.4 6.9 18.3 18.0 
Other skilled8.2 8.0 3.0 1.6 9.9 — 7.6 7.1 
Skilled mix56.6 52.1 51.2 38.7 49.5 31.7 55.6 50.1 
Private and other payors5.9 7.7 7.0 10.6 6.9 21.1 6.1 8.1 
Medicaid37.5 40.2 41.8 50.7 43.6 47.2 38.3 41.8 
Total skilled nursing100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

57

 Three Months Ended March 31,
 Same FacilityTransitioningAcquisitionsTotal
 20212020202120202021202020212020
Percentage of Skilled
Nursing Days:
Medicare15.8 %12.7 %15.7 %10.9 %15.5 %13.5 %15.8 %12.4 %
Managed care14.0 13.2 12.3 8.4 6.0 4.6 13.4 12.4 
Other skilled5.6 5.1 2.6 1.4 6.6 — 5.2 4.5 
Skilled mix35.4 31.0 30.6 20.7 28.1 18.1 34.4 29.3 
Private and other payors9.1 11.0 9.9 13.8 9.7 25.6 9.3 11.5 
Medicaid55.5 58.0 59.5 65.5 62.2 56.3 56.3 59.2 
Total skilled nursing100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

Cost of Services

The following table sets forth total cost of services for our transitional and skilled services segment for the periods indicated (dollars in thousands):

 Three Months Ended March 31,Change
20212020$%
Cost of service$462,960 $430,540 $32,420 7.5 %
Revenue percentage77.0 %77.1 %(0.1)%

Cost of services related to our transitional and skilled services segment increased $32.4 million, or 7.5%, primarily due to additional costs related to new acquisitions, which accounted for $13.4 million of the increase to cost of services. Cost of services as a percentage of revenue decreased to 77.0% from 77.1%, a decrease of 0.1%. We experienced an increase in expenses on a per patient day basis related to COVID-19, including wages, supplies and additional ancillary costs. These increases were offset with better collections.

Real Estate Segment

 Three Months Ended March 31,Change
20212020$%
(In thousands)
Rental revenue generated from third-party tenants$3,977 $3,662 $315 8.6 %
Rental revenue generated from Ensign affiliated operations11,902 11,282 620 5.5 
Total rental revenue$15,879 $14,944 $935 6.3 %
Segment income8,821 6,325 2,496 39.5 
Depreciation and amortization4,693 4,515 178 3.9 
FFO$13,514 $10,840 $2,674 24.7 %

Rental revenue. Our rental revenue, including revenue generated from our affiliated facilities, increased by $0.9 million, or 6.3%, to $15.9 million, compared to the three months ended March 31, 2020. The increase in revenue is primarily attributable to acquisitions and CPI increases.

FFO. Our FFO increased $2.7 million, or 24.7% to $13.5 million, compared to the three months ended March 31, 2020. The increase in FFO is primarily related to the increase in rental revenue and the decrease in interest expense.



58


All Other Service Revenue

Our other revenue decreased by $5.4 million, or 19.6%, to $22.2 million, compared to the three months ended March 31, 2020. Other revenue for 2021 includes senior living revenue of $11.8 million and revenue from other ancillary services of $10.4 million. The decrease in other revenue is due to the impact of COVID-19, which negatively impacted services in our other ancillary services.
Consolidated Financial Expenses

Rent — cost of services. Our rent — cost of services as a percentage of total revenue decreased by 0.2% to 5.3%, primarily due to the growth in revenue outpacing the increase in rent expense.
General and administrative expense — General and administrative expense increased $2.0 million or 6.3%, to $34.3 million. This increase was primarily due to increases in wages and benefits due to enhanced performance and growth. In addition, general and administrative expense as a percentage of revenue remained consistent at 5.5%.
Depreciation and amortization — Depreciation and amortization expense decreased $0.1 million, or 0.4%, to $13.7 million. Depreciation and amortization decreased 0.1%, to 2.2%, as a percentage of revenue.
Other expense, net — Other expense, net as a percentage of revenue decreased by 0.3%, to 0.2%. Other expense primarily includes interest expense related to debt. During the quarter, we were able to utilize the funds available from the deferral of social security taxes to reduce the amount outstanding on our revolving credit facility. The deferral of taxes are due to be repaid in part by the end of fiscal year 2021, with the remaining half due at the end of fiscal year 2022.
Provision for income taxes —  Our effective tax rate was 20.6% for the three months ended March 31, 2021, compared to 23.5% for the same period in 2020. The lower effective tax rate reflects an increase in additional tax benefit from share-based payment awards. The lower effective tax rate was partially offset by increases in certain non-taxable and non-deductible items. See Note 14, Income Taxes, in the Notes to the Condensed Consolidated Financial Statements for further discussion.

Liquidity and Capital Resources
Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our Credit Facility. Our liquidity as of March 31, 2021 is impacted by cash generated from strong operational performance and the repayment of Medicare Accelerated and Advance Payment Program funds.
Historically, we have primarily financed the majority of our acquisitions through the financing of our operating subsidiaries through mortgages, our Credit Facility, and cash generated from operations. Total capital expenditures for property and equipment were $15.3 million and $15.8 million for the three months ended March 31, 2021 and 2020, respectively. We currently have approximately $65.0 million budgeted for renovation projects for 2021. We believe our current cash balances, our cash flow from operations and the amounts available under our Credit Facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.

Our cash and cash equivalents as of March 31, 2021 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of March 31, 2021, we held debt security investments of approximately $49.0 million, which were split between AA, A and BBB rated securities. We believe our debt security investments that were in an unrealized loss position as of March 31, 2021 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.

As mentioned above, our primary sources of cash is from our ongoing operations. Our positive cash flows have supported our business and have allowed us to pay regular dividends to our stockholders. We currently anticipate that existing cash and total investments as of March 31, 2021, along with projected operating cash flows and available financing, will support our normal business operations for the foreseeable future.

59


The following table presents selected data from our condensed consolidated statement of cash flows for the periods presented:
Three Months Ended March 31,
 20212020
Net cash provided by/(used in): (In thousands)
Operating activities$34,294 $27,123 
Investing activities(12,212)(15,542)
Financing activities(103,117)(7,539)
Net (decrease)/increase in cash and cash equivalents(81,035)4,042 
Cash and cash equivalents beginning of period236,562 59,175 
Cash and cash equivalents at end of period$155,527 $63,217 
Operating Activities
Cash provided by operating activities is net income adjusted for certain non-cash items and changes in operating assets and liabilities.
The $7.2 million increase in cash provided by operating activities for the three months ended March 31, 2021 compared to the same period in 2020, was primarily due to higher net income and changes in working capital. Changes in working capital was driven by strong accounts receivable collections and timing of accounts payable, which is partially offset by the timing of accrued wages and related liabilities and prepaid expenses and other assets.
Investing Activities
Investing cash flows consist primarily of capital expenditures, investment activities, insurance proceeds and cash used for acquisitions.
The $3.3 million decrease in cash used in investing activities for the three months ended March 31, 2021 compared to the same period in 2020, was primarily due to an increase in cash from insurance proceeds of $6.3 million which was partially offset by an increase in purchases of investments, net of maturities, of $3.8 million.
Financing Activities
Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, repayment of the Medicare Accelerated and Advance Payment Program funds and sale of shares of common stock through employee equity incentive plans.

The decrease in cash provided by financing activities for the three months ended March 31, 2021 compared to the same period in 2020 of $95.6 million was primarily due to the repayment of the Medicare Accelerated and Advance Payment Program funds of $102.0 million.

Credit Facility with a Lending Consortium Arranged by Truist

We maintain the Credit Facility with a lending consortium arranged by Truist, which includes a revolving line of credit of up to $350.0 million in aggregate principal amount. The maturity date of the Credit Facility is October 1, 2024. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.50% to 1.50% per annum or LIBOR plus a margin range from 1.50% to 2.50% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, we pay a commitment fee on the unused portion of the commitments that ranges from 0.25% to 0.45% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.

60

Mortgage Loans and Promissory Notes

As of March 31, 2021, 19 of our subsidiaries have mortgage loans insured with HUD for an aggregate amount of $113.3 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear fixed interest rates range of 2.6% to 3.5% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. For the majority of the loans, the prepayment fee is 10% during the first three years and is reduced by 3% in the fourth year of the loan, and reduced by 1% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The term of the mortgage loans are 25 to 35 years.

In addition to the HUD mortgage loans above, we have a promissory note in connection with an acquisition. The note bears a fixed interest rate of 5.3% per annum and the term of the note is 12 years. The note is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.
Operating Leases
During the fiscal year of 2020, 164 of our facilities are under long-term lease arrangements, of which 88 of the operations are under nine triple-net Master Leases and one stand-alone lease with CareTrust REIT, Inc. (CareTrust). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%. At our option, we can extend the Master Leases for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 89 facilities leased from CareTrust include an option to purchase that we can exercise starting on December 1, 2024.
We also lease certain affiliated facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases.
Forty of our affiliated facilities, excluding the facilities that are operated under the Master Leases from CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other affiliated facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

U.S. Department of Justice Civil Investigative Demand
On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether we have violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of our Southern California skilled nursing facilities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We have fully cooperated with the U.S. Department of Justice to promptly respond to the requests for information and have been advised that the U.S. Department of Justice has declined to intervene in any subsequent action based on or related to the subject matter of this investigation.

61

Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor and supply expenses make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. We may not be successful in offsetting future cost increases.
Recent Accounting Pronouncements

Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to us. For any new pronouncements announced, we consider whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on our reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12 "Simplifying the Accounting for Income Taxes (Topic 740)", as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. We adopted this standard on January 1, 2021 and determined there was no material impact on our financial position, results of operations and liquidity.

In May 2020, the SEC issued Final Rule Release No. 33-10786, “Amendments to Financial Disclosures about Acquired and Disposed Businesses” (“SEC Rule 33-10786”), which amends the disclosure requirements applicable to acquisitions and dispositions of businesses. Amendments within SEC Rule 33-10786 primarily impact (1) the tests and thresholds used to determine the significance of acquisitions and dispositions; (2) the form and content of pro forma information required to be disclosed in connection with significant acquisitions and dispositions; (3) acquiree financial statement requirements; and (4) thresholds used to determine the significance of acquisitions and dispositions of real estate operations, and related financial statement requirements, among others. We adopted this standard on January 1, 2021 and determined there was no material impact on our condensed consolidated financial statements.

Accounting Standards Recently Issued but Not Yet Adopted by the Company

In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)" which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. We are currently evaluating the impact of ASU. 2020-04 on our financial position, results of operations and liquidity.

62

In November 2020, the SEC issued final rules 33-10890 and 34-90459 “Management’s Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information,” which modernizes and simplifies certain disclosure requirements of Regulation S-K. Certain key rule amendments eliminate the requirement to disclose Selected Financial Data; Selected Quarterly Financial Data, with certain exceptions; the impact of inflation and changing prices, provided the impact is not material; off-balance sheet arrangements in tabular form; and the aggregate amount of contractual obligations in tabular form. The final rules also amended various aspects of Item 303, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” among others. The final rules are effective for all registration statements, annual reports and quarterly reports filed on or after August 9, 2021, with early adoption permitted. We are currently evaluating the impact of the disclosure changes in our annual and quarterly reports.

Off-Balance Sheet Arrangements

As of March 31, 2021, we had approximately $7.6 million on our Credit Facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.

Item 3.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk. We are exposed to risks associated with market changes in interest rates through our borrowing arrangements and investments. In particular, our Credit Facility exposes us to variability in interest payments due to changes in LIBOR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory notes require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.
As of March 31, 2021, there was no outstanding debt under our Credit Facility. We have outstanding indebtedness under mortgage loans insured with Department of Housing and Urban Development (HUD) and one promissory note to a third party of $117.0 million all of which are at fixed interest rates.

Our cash and cash equivalents as of March 31, 2021 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of March 31, 2021, we held debt security investments of approximately $49.0 million which were split between AA, A, and BBB rated securities. We believe our debt security investments that were in an unrealized loss position as of March 31, 2021 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The above only incorporates those exposures that exist as of March 31, 2021 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.

LIBOR Phase Out — LIBOR is expected to be phased out. Currently, our borrowings under our Credit Facility provide us flexibility to choose floating rates, one of which is based on LIBOR. We currently expect that the determination of interest under our credit agreement would be revised as provided under the agreement or amended as necessary to provide for an interest rate that approximates the existing interest rate as calculated in accordance with LIBOR for similar types of loans. Despite our current expectations, we cannot be sure that, if LIBOR is phased out or transitioned, the changes to the determination of interest under our agreement would approximate the current calculation in accordance with LIBOR.
63


Item 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective.
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.

Item 1.        LEGAL PROCEEDINGS
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is HIPAA, which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information.

Cost-Containment MeasuresBoth government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.

IndemnitiesFrom time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and employees, under which we may be required to indemnify such persons for liabilities arising out of their employment or other relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.
In connection with the spin-off transaction, certain landlords required, in exchange for their consent to the transaction, that our lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties.
U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, we received a CID from the U.S. Department of Justice stating that it was investigating to determine whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of our Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We have fully cooperated with the U.S. Department of Justice and promptly responded to their requests for information, and have been advised that the U.S. Department of Justice has declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.

64

LitigationWe and our independent operating entities are party to various legal actions and administrative proceedings, and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by our independent operating entities have resulted in injury or death, and claims related to employment and commercial matters. Although we intend to vigorously defend against these claims, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. In certain states in which we have or have had independent operating entities, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that our independent operating entities will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.

The skilled nursing and post-acute care industry is heavily regulated. As such, we are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which could subject us to civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. We believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows.

Additionally, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which includes the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation, or whether and what other investigations or regulatory responses may result from the investigation and could have a material adverse effect on our reputation, business, financial condition and results of operations.

In addition to the potential lawsuits and claims described above, we are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from Federally funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the qui tam relator is continuing on with the lawsuit and pursuing claims that one or more of the Company's independent operating entities have allegedly violated the False Claims Act and/or the Anti-Kickback Statute.

In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, we could face increased scrutiny, potential liability, and legal expenses and costs based on claims under state false claims acts in markets where our independent operating subsidiaries do business.

In May 2009, Congress passed the FERA which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

65

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent operating entities are routinely subjected to varying types of claims, including class action "staffing" suits. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.
We and our independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment (professional negligence claims) as well as employment related claims. In addition, we and our independent operating subsidiaries, and others in the industry, are subject to claims and lawsuits in connection with COVID-19 and facility preparation for and/or response to the COVID-19 pandemic. While we have been able to settle or otherwise resolve these types of claims without an ongoing material adverse effect on our business, a significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of future claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.
Claims and suits, including class actions, continue to be filed against us and other companies in the post-acute care industry. We and our independent operating entities have been subjected to, and/or are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour law as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and other such similar causes of action. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations.
Medicare Revenue RecoupmentsWe and our independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments resulting from reviews conducted via RAC, Program Safeguard Contractors, and Medicaid Integrity Contractors (collectively referred to as Reviews). For several months during the COVID-19 pandemic, CMS suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. As of March 31, 2021, two of our independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process. Subsequently, during April, one facility review was resolved and closed. We anticipate that these Reviews could increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of March 31, 2021, our independent operating subsidiaries have responded to the requests with respect to the claims currently under review, on appeal or in a dispute resolution process.

66

Item 1A.    RISK FACTORS
We are providing the following summary of the risk factors contained in our Form 10-Q to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors contained in this Form 10-Q in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.

Risks Related to our Business and Industry
We face numerous risks related to the continued COVID-19 public health emergency, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.
Changes to reimbursement rates and rules and other aspects of Medicare and Medicaid could have a material, adverse effect on our revenues, financial condition and results of operations.
Our revenue could be impacted by a shift to value-based reimbursement models, such as PDPM.
Reforms to the U.S. healthcare system, including the ACA, continue to impose new requirements upon us and may lower our reimbursements.
The results of recent U.S. Presidential and Congressional elections may create significant changes to regulatory framework, enforcements, and reimbursements.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.
Failure to comply with applicable laws and regulations, or if these laws and regulations change, could cause us to incur significant expenses and/or change our operations in order to bring our facilities and operations into compliance.
Public and government calls for increased survey and enforcement efforts toward long-term care facilities could result in increased scrutiny by state and federal survey agencies. Potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.
Future cost containment initiatives undertaken by third-party payors may limit our revenue and profitability.
Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals, which could have a negative effect on our business, financial condition or results of operations.
We may be subject to increased investigation and enforcement activities related to HIPAA violations if we fail to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients’ individual health information.
Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.
If we are not fully reimbursed for all services for which each facility bills through consolidated billing, our revenue, financial condition and results of operations could be adversely affected.
Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines resulting from a failure to maintain minimum staffing requirements.
Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.
Increased scrutiny of our billing practices by the Office of the Inspector General or other regulatory authorities may result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.
State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.
Compliance with federal and state fair housing, fire, safety and other regulations may require us to incur unexpected expenses, which could be costly to us.
We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.
We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.
If our regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries detect instances of noncompliance, efforts to correct such non-compliance could materially decrease our revenue.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, or may elect to dispose of underperforming or non-strategic operating subsidiaries, either of which could decrease our revenue.
67

We may not be able to successfully integrate acquired facilities and businesses into our operations, or we may be exposed to costs, liabilities and regulatory issues that may adversely affect our operations.
If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.
If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected, and our self-insurance programs may expose us to significant and unexpected costs and losses.
The geographic concentration of our affiliated facilities could leave us vulnerable to economic downturn, regulatory changes or acts of nature in those areas.
The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.
We lease the majority of our affiliated facilities, and risks associated with leased property, could adversely affect our business, financial position or results of operations.
Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.
Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.
A housing downturn could decrease demand for senior living services.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.
If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.
We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.
The condition of the financial markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments.
Delays in reimbursement may cause liquidity problems.
Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.
Failure to safeguard our patient trust funds may be subject us to citations, fines and penalties.
We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.
We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation of Pennant, including if the Spin-Off and the CareTrust Spin-Off (defined below) are not tax-free for U.S. federal income tax purposes.
We may not achieve some or all of the anticipated benefits of the Spin-Off, which may adversely affect our business.
The Spin-Off and related transactions may expose us to potential liabilities arising out of state and federal fraudulent conveyance laws and legal distribution requirements.
Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.
Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.

Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.


68

Risks Related to Our Business and Industry

We face numerous risks related to the continued COVID-19 public health emergency, which could have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.

The extent to which the COVID-19 public health emergency will continue impacting our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, federal vaccination program efforts, additional or modified government actions, new information which may emerge concerning the severity of the virus and efficacy of vaccinations, and the actions taken to contain the virus or treat its impact, among others. Some of the risks of COVID-19 are being mitigated as a result of the federal vaccination program, including vaccinations of nursing facility staff and residents, but there remains uncertainty as to when the pandemic will officially end.

As discussed in Item 2., under Government Regulation, federal, state and local regulators have implemented new regulations and waived existing regulations to promote care delivery during the COVID-19 public health emergency. While the majority of these changes are beneficial by reducing regulatory burdens, these accommodations may also have an adverse effect through increased legal and operational costs related to compliance and monitoring. Additionally, most of the accommodations are limited in duration and tied to the COVID-19 public health emergency declaration, thus there may be significant operational change requirements on short notice. Also, the reinstatement of waived state and federal regulations may not occur simultaneously, requiring heightened monitoring to ensure compliance.

Other factors from the continuation of the COVID-19 pandemic that could have an adverse effect on our business, financial condition, liquidity, results of operations and prospects, include:

potential for increased government regulations and restrictions to combat COVID-19 as a result of the 2020 Presidential and Congressional elections;
significantly reduced occupancy as a result of government-imposed orders;
lower census due to general decline in all hospital procedures, including elective/non-urgent procedures;
increased costs and staffing requirements related to additional CDC protocols, federal and state workforce protection and related isolation procedures, including obligations to test patients and staff for COVID-19;
limitations on availability of staff due to COVID-19 related illness exposure;
disruptions to supply chains which could negatively impact consistent and reliable delivery of personal protective equipment, sanitizing supplies, food, pharmaceuticals, utilities and other goods to our affiliated facilities, resulting in our inability to obtain on reasonable terms, or at all, personal protective equipment, sanitizing supplies, food, pharmaceuticals, utilities and other goods;
incurrence of additional expenditures to comply with COVID-19 isolation procedures, including temporary construction or purchase of additional equipment;
increased scrutiny by regulators of infection control and prevention measures, including increased reporting requirements related to suspected and confirmed COVID-19 diagnoses of residents and staff, which may result in fines or other sanctions related to non-compliance;
new state requirements or pressure from state officials to accept post-discharge patients from hospitals facing overcrowding, which increases the potential spread of COVID-19 within our facilities;
increased risk of litigation and related liabilities arising in connection with patient or staff illness, hospitalization and/or death; and
negative impacts on our patients' ability or willingness to pay for healthcare services and our third parties' ability or willingness to pay rents.

The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain, our stock price may be more volatile, and our ability to raise capital could be impaired.
Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicare.

We derived 30.5% and 26.6% of our service revenue from the Medicare programs for the three months ended March 31, 2021 and 2020, respectively. In addition, many other payors may use published Medicare rates as a basis for reimbursements. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, if there are changes in the rules governing the Medicare program that are disadvantageous to our business or industry, or if there are delays in Medicare payments, our business and results of operations will be adversely affected.
69


The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), annual caps that limit the amount that can be paid (including deductible and coinsurance amounts) administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins. For example, see Item 2., under Government Regulation, Sequestration of Medicare Rates.

Additionally, Medicare payments can be delayed or declined due to determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.

In addition, CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes to the Medicare program that could adversely affect our business include:
administrative or legislative changes to base rates or the bases of payment;
limits on the services or types of providers for which Medicare will provide reimbursement;
changes in methodology for patient assessment and/or determination of payment levels;
the reduction or elimination of annual rate increases (See also, Item 2., under Government Regulation); or
an increase in co-payments or deductibles payable by beneficiaries.
Among the important statutory changes that are being implemented by CMS are provisions of the IMPACT Act. This law imposes a stringent timeline for implementing benchmark quality measures and data metrics across post-acute care providers (long stay hospitals, IRFs, skilled nursing facilities and home health agencies). The enactment also mandates specific actions to design a unified payment methodology for post-acute providers. CMS continues to promulgate regulations to implement provisions of this enactment. Depending on the final details, the costs of implementation could be significant. The failure to meet implementation requirements could expose providers to fines and payment reductions. 

Reductions in reimbursement rates or the scope of services being reimbursed could have a material, adverse effect on our revenue, financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating costs. Additionally, any delay or default by the government in making Medicare reimbursement payments could materially and adversely affect our business, financial condition and results of operations.
Reductions in Medicaid reimbursement rates or changes in the rules governing the Medicaid program could have a material, adverse effect on our revenue, financial condition and results of operations.
A significant portion of reimbursement for skilled nursing services comes from Medicaid. In fact, Medicaid is our largest source of revenue, accounting for 43.6% and 44.4% of our service revenue for the three months ended March 31, 2021 and 2020, respectively. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets, which has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Since a significant portion of our revenue is generated from our skilled nursing operating subsidiaries in California, Texas and Arizona, any budget reductions or delays in these states could adversely affect our net patient service revenue and profitability. Despite present state budget surpluses in many of the states in which we operate, we can expect continuing cost containment pressures on Medicaid outlays for skilled nursing facilities, and any such decline could adversely affect our financial condition and results of operations.
70

The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans. To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the provider's total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states' Medicaid expenditures, and as a result could have a material and adverse effect on our business, financial condition or results of operations.
Our revenue could be impacted by a shift to value-based reimbursement models, including PDPM.
As discussed in more detail in Item 2., under Government Regulation, CMS implemented a final rule in October 2019 to replace the existing case-mix classification system, Resource Utilization Groups, Version IV, with a new case-mix classification system, PDPM, that focuses more on the clinical condition of the patient and less on the volume of services provided. Payments under PDPM for FY 2021 are estimated to remain largely unchanged from FY 2020, but there remains risk that CMS may make future adjustments to reimbursement levels as it continues to monitor the impact of PDPM on patient outcomes and budget neutrality. With the increased focus on therapy utilization under RUGs IV, there is concern as to the accuracy of the parity adjustment and how closely it will reflect the data that will be captured under PDPM where the focus is on the clinical condition of the patient in lieu of resource utilization. In addition, the entire parity adjustment could be removed by CMS and this would cause a drastic reduction in payments.

Reforms to the U.S. healthcare system continue to impose new requirements upon us and may lower our reimbursements.
The ACA included sweeping changes to how healthcare is paid for and furnished in the U.S. Applicable to our business, as discussed in greater detail in Item 2., under Government Regulation, the ACA has resulted in significant changes to our operations and reimbursement models for services we provide. CMS continues to issue rules to implement the ACA. Courts continue to interpret and apply the ACA’s provisions.

The efficacy of the ACA is the subject of much debate among members of Congress and the public. Additionally, a number of lawsuits have been filed challenging various aspects of the ACA and related regulations with inconsistent outcomes - some expand the ACA while others limit the ACA. The Supreme Court heard oral arguments on November 10, 2020, arising out of a constitutional challenge from the Fifth Circuit, and a decision is not expected until spring 2021. In the event that the ACA is repealed or materially amended, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. Thus, the future impact of the ACA on our business is difficult to predict and its continued uncertain future may negatively impact our business. However, any material changes to the ACA or its implementing regulations may negatively impact our operations.

We cannot predict what effect future reforms to the U.S. healthcare system will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.

The results of recent U.S. Presidential and Congressional elections may create significant changes to regulatory framework, enforcements and reimbursements.

The recent Presidential and Congressional elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation or repeal of laws and rules related to government health programs, including Medicare and Medicaid. Democratic proposals for Medicare for All or significant expansion of Medicare, could significantly impact our business and the healthcare industry if implemented. Further, if proposed policies specific to nursing facilities are implemented, these may result in significant regulatory changes, increased survey frequency and scope, and increased penalties for non-compliance.

71

We continually monitor these developments in order to respond to the changing regulatory environment impacting our business. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

Our business may be materially impacted if certain aspects of the ACA are amended, repealed, or successfully challenged.

A number of lawsuits have been filed challenging various aspects of the ACA and related regulations. In addition, the efficacy of the ACA is the subject of much debate among members of Congress and the public. On December 14, 2018, the U.S. District Court for the Northern District of Texas held the individual mandate provision, and therefore the entirety of the ACA, unconstitutional. This ruling was appealed to the Fifth Circuit Court of Appeals, which issued its decision on December 18, 2019, partially affirming the district court’s decision, finding the individual mandate to be unconstitutional and remanding the case to the district court for additional analysis on whether the individual mandate provision was severable from the remainder of the ACA. The case was appealed to the U.S. Supreme Court, which heard arguments November 10, 2020, and a decision is expected in spring 2021. Other unrelated cases challenging the ACA or related rules have had inconsistent outcomes - some expand the ACA while others limit the ACA. Thus, the future impact of the ACA on our business is difficult to predict. The uncertainty as to the future of the ACA may negatively impact our business, as will any material changes to the ACA.

Presidential and Congressional elections in the United States could result in significant changes to, and uncertainty with respect to, legislation, regulation, implementation or repeal of the ACA, and other federal health program policy that could significantly impact our business and the healthcare industry. In the event that legal challenges are successful or the ACA is repealed or materially amended, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and a new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.

As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. We are subject to regulatory reviews relating to Medicare services, billings and potential overpayments resulting from Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contractors programs, (collectively referred to as Reviews), in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare programs. Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry. We are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:

an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;
state or federal agencies imposing fines, penalties and other sanctions on us;
loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;
an increase in private litigation against us; and
damage to our reputation in various markets.
72

In 2004, our Medicare administrative contractors began to conduct selected reviews of claims previously submitted by and paid to some of our affiliated facilities. While we have always been subject to post-payment audits and reviews, more intensive “probe reviews” appear to be a permanent procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal through the CMS defined continuum. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.

In cases where claim and documentation review by any CMS contractor results in repeated poor performance, an operation can be subjected to protracted oversight. This oversight may include repeat education and re-probe, extended pre-payment review, referral to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement outside of specifically reviewed claims. Sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of March 31, 2021, two of our independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process, either pre or post-payment. Subsequently, during April, one facility review was resolved and closed. We anticipate that these Reviews could increase in frequency in the future.

Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, skilled nursing facilities. The focus of these investigations includes, among other things:
cost reporting and billing practices;
quality of care;
financial relationships with referral sources; and
medical necessity of services provided.
On May 31, 2018, we received a Civil Investigative Demand (CID) from the DOJ stating that it is investigating the Company to determine whether we have violated the FCA or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 through 2018 and was limited in scope to ten of our Southern California skilled nursing facilities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the FCA, the Anti-Kickback Statute, and other applicable regulatory requirements. We are fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information. However, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on the Company.

If we should agree to a settlement of, claims or obligations under federal Medicare statutes, the federal FCA, or similar state and federal statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected, and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement or other arrangement with the government.

If the government or court were to conclude that errors and deficiencies constitute criminal violations, concluded that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or if it were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we or some of the key personnel of our operating subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare.

If any of our affiliated facilities is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our affiliated facilities could harm our reputation for quality care and lead to a reduction in the patient referrals of our operating subsidiaries and ultimately a reduction in occupancy at these facilities. Also, responding to auditing and enforcement efforts diverts material time, resources and attention from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.

73

We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.
 
We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:

licensure and certification;
adequacy and quality of healthcare services;
qualifications of healthcare and support personnel;
quality of medical equipment;
confidentiality, maintenance and security issues associated with medical records and claims processing;
relationships with physicians and other referral sources and recipients;
constraints on protective contractual provisions with patients and third-party payors;
operating policies and procedures;
addition of facilities and services; and
billing for services.
The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we do business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. We believe that such regulations may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. Changes in existing laws or regulations, or the enactment of new laws or regulations, could negatively impact our business. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. Additionally, in the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses.

As discussed in greater detail in Item 2., under Government Regulation, we are subject to federal and state laws intended to prevent healthcare fraud and abuse, including the federal FCA, state false claims acts, the illegal remuneration provisions of the Social Security Act, the Anti-Kickback Statute, state anti-kickback laws, the Civil Monetary Penalties Law and the federal “Stark” law. Among other things, these laws prohibit kickbacks, bribes and rebates, as well as other direct and indirect payments or fee-splitting arrangements that are designed to induce the referral of patients to a particular provider for medical products or services payable by any federal healthcare program and prohibit presenting a false or misleading claim for payment under a federal or state program. They also prohibit some physician self-referrals. Possible sanctions for violation of any of these restrictions or prohibitions include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties.

These anti-fraud and abuse laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. While we do not believe we are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing these prohibitions will not assert that we are violating the provisions of such laws and regulations. The Company is currently aware of another investigation by the DOJ related to allegations some of our California facilities may have violated the FCA or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. While our operating entities maintain policies and procedures to promote compliance with the FCA, the Anti-Kickback Statute, and other applicable regulatory requirements, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on the Company.

74

We are unable to predict the future course of federal, state and local regulation or legislation, including Medicare and Medicaid statutes and regulations related to fraud and abuse, the intensity of federal and state enforcement actions or the extent and size of any potential sanctions, fines or penalties. Changes in the regulatory framework, our failure to obtain or renew required regulatory approvals or licenses or to comply with applicable regulatory requirements, the suspension or revocation of our licenses or our disqualification from participation in federal and state reimbursement programs, or the imposition of other enforcement sanctions, fines or penalties could have a material adverse effect upon our business, financial condition or results of operations. Furthermore, should we lose licenses or certifications for a number of our facilities or other businesses as a result of regulatory action or legal proceedings, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness.

Public and government calls for increased survey and enforcement efforts toward long-term care facilities could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

As CMS turns its attention to enhancing enforcement of long-term care facilities, as discussed in Item 2., under Government Regulation, state survey agencies will have more accountability for their survey and enforcement efforts. As discussed in Item 2., under Government Regulation, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. The focus of these deficiency reports tends to vary from year to year and state to state. Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility, which could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future.

Furthermore, in some states, citations in one Company facility could negatively impact other Company facilities in the same state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. If state or federal regulators were to determine, formally or otherwise, that one facility's regulatory history ought to impact another of our existing or prospective facilities, this could also increase costs, result in increased scrutiny by state and federal survey agencies, and even impact our expansion plans. Therefore, our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and overall of operations results.

For example, in 2016, we elected to voluntarily close one operating subsidiary as a result of multiple regulatory deficiencies in order to avoid continued strain on our staff and other resources and to avoid restrictions on our ability to acquire new facilities or expand or operate existing facilities. In addition, from time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our affiliated facilities. We have had affiliated facilities placed on special focus facility status in the past, continue to have some facilities on this status currently and other operating subsidiaries may be identified for such status in the future. We currently have one facility placed on special focus facility status. Other operating subsidiaries may be identified for such status in the future.

75

Future cost containment initiatives undertaken by private third-party payors may limit our revenue and profitability.

Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates. There can be no assurance that third party payors will make timely payments for our services, or that we will continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.

As discussed in greater detail in Item 2., under Government Regulation, MACRA revised the payment system for physician and non-physician services. Section 1 of that law, the sustainable growth rate repeal and Medicare Provider Payment Modernization will impact payment provisions for medical professional services. That enactment also extended for two years provisions that permit an exceptions process from therapy caps imposed on Medicare Part B outpatient therapy. There was a combined cap for PT and SLP and a separate cap for OT services that apply subject to certain exceptions. On February 9, 2018, the Bipartisan Budget Act of 2018 was signed into law, which provides for the repeal of all therapy caps retroactively to January 1, 2018. The law also reduced the monetary threshold that triggers a manual medical review (MMR), in certain instances (from $3,700 to $3,000). The reduction in the MMR threshold will likely result in increased number of reviews, which could in turn have a negative effect on our business, financial condition or results of operations. 
We may be subject to increased investigation and enforcement activities related to HIPAA violations.

We are required to comply with numerous legislative and regulatory requirements at the federal and state levels addressing patient privacy and security of health information, as discussed in greater detail in Item 2., under Government Regulation. The Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Clinical Health Act of 2009 (HITECH Act), requires us to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients' individual health information. States also have laws that apply to the privacy of healthcare information. We must comply with these state privacy laws to the extent that they are more protective of healthcare information or provide additional protections not afforded by HIPAA. If we fail to comply with these state and federal laws, we could be subject to criminal penalties, civil sanctions, litigation, and be forced to modify our policies and procedures. Additionally, if a breach under HIPAA or other privacy laws were to occur, remediation efforts could be costly and damage to our reputation could occur.

In addition to breaches of protected patient information, under HIPAA and the 21st Century Cures Act (Cures Act), healthcare entities are also required to afford patients with certain rights of access to their health information. Recently, the Office of Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, imposing significant fines for violations largely initiated from patient complaints. If we fail to comply with our obligations under HIPAA, we could face significant fines. Likewise, if we fail to comply with our obligations under the Cures Act, we could face fines from the Office of the National Coordinator for Health Information Technology, the agency responsible for Cures Act enforcement.

Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.

Healthcare businesses are increasingly the target of cyberattacks whereby hackers disrupt business operations or obtain protected health information, often demanding large ransoms. Our business is dependent on the proper functioning and availability of our computer systems and networks. While we have taken steps to protect the safety and security of our information systems and the patient health information and other data maintained within those systems, we cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, we may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our information systems. Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deceiving our employees or contractors.

76

On occasion, we have acquired additional information systems through our business acquisitions, and these acquired systems may expose us to risk. We also license certain third-party software to support our operations and information systems. Our inability, or the inability of third-party software providers, to continue to maintain and upgrade our information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

A cyber security attack or other incident that bypasses our information systems security could cause a security breach which may lead to a material disruption to our information systems infrastructure or business and may involve a significant loss of business or patient health information. If a cyber security attack or other unauthorized attempt to access our systems or facilities were to be successful, it could result in the theft, destructions, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber security attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, Office of Civil Rights, the OIG or state attorneys general), fines, private litigation with those affected by the data breach, loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations and liquidity.

We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

Skilled nursing facilities are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement essentially confers on the skilled nursing facility itself the Medicare billing responsibility for the entire package of care that its patients receive in these situations. The BBA also affected skilled nursing facility payments by requiring that post-hospitalization skilled nursing services be “bundled” into the hospital's diagnostic related group (DRG) payment in certain circumstances. Where this rule applies, the hospital and the skilled nursing facility must, in effect, divide the payment which otherwise would have been paid to the hospital alone for the patient's treatment, and no additional funds are paid by Medicare for skilled nursing care of the patient. Although this provision applies to a limited number of DRGs, it has a negative effect on skilled nursing facility utilization and payments, either because hospitals are finding it difficult to place patients in skilled nursing facilities which will not be paid as before or because hospitals are reluctant to discharge the patients to skilled nursing facilities and lose part of their payment. This bundling requirement could be extended to more DRGs in the future, which would accentuate the negative impact on skilled nursing facility utilization and payments. We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses and other skilled personnel, such as Certified Nurse Assistants, social workers and speech, physical and occupational therapists. Our success also depends upon our ability to retain and attract skilled management personnel who are responsible for the day-to-day operations of each of our affiliated facilities. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff that is directly responsible for day-to-day care of the patients and marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

77

We operate one or more affiliated skilled nursing facilities in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. With the exception of Utah, which follows federal regulations, each of these states has established minimum staffing requirements for facilities operating in that state. Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. In addition, if a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk. Deficiencies (depending on the level) may also result in the suspension of patient admissions and the termination of Medicaid participation, or the suspension, revocation or nonrenewal of the skilled nursing facility's license. If the federal or state governments were to issue regulations which materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly, including the increased scrutiny on staffing at the state and federal levels as a result of the COVID-19 virus.

Increased competition for, or a shortage of, nurses or other trained personnel, or general inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. We may not be able to offset such added costs by increasing the rates we charge to the patients of our operating subsidiaries. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility. An increase in costs associated with, or a shortage of, skilled nurses, could negatively impact our business. In addition, if we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations effectively could be harmed.

Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.

As discussed in detail in Item 2., under Government Regulation, sub-heading Part B Rehabilitation Requirements, several government actions have been taken in recent years to try and contain the costs of rehabilitation therapy services provided under Medicare Part B, including the MPPR, institution of annual caps, mandatory medical reviews for annual claims beyond a certain monetary threshold, and a reduction in reimbursement rates for therapy assistant claim modifiers. Of specific concern is CMS's decision to lower Medicare Part B reimbursement rates for outpatient therapy services by 9%, beginning in January 1, 2021. Such cost-containment measures and ongoing payment changes could have an adverse effect on our revenue.

The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

As discussed in greater detail in Item 2., under Government Regulation, Civil and Criminal Fraud and Abuse Laws and Enforcement, the OIG regularly conducts investigations regarding certain payment or compliance issues within various healthcare sectors. Following, the OIG publishes these reports, in part, to educate involved stakeholders and signal future enforcement focus. Reports published in 2019 and 2020 demonstrate the OIG’s increased scrutiny on post-hospital skilled nursing facility care and billing. This may impact the skilled nursing facility industry by motivating additional reviews and stricter compliance in the areas outlined in the recent reports, expending material time and resources.

Additionally, OIG reports published in 2010 and 2015 show the OIG’s concerns related to the billing practices of skilled nursing facilities based on Medicare Part A claims and financial incentives for facilities to bill for higher levels of therapies, even when not needed by patients. Also, in its fiscal year 2014 work plan, and again in 2017, OIG specifically stated that it will continue to study and report on questionable Part A and Part B billing practices amongst skilled nursing facilities.

Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity and higher-resource utilization patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording activities of daily living services, among other things. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including skilled nursing facilities, to obtain prior approval, known as a certificate of need, for: (i) the purchase, construction or expansion of healthcare facilities; (ii) capital expenditures exceeding a prescribed amount; or (iii) changes in services or bed capacity.

78

In addition, other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds they will certify in certain areas or in the entire state. Other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states the acquisition of a facility being operated by a non-profit organization requires the approval of the state Attorney General.

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Changes to federal and state employment-related laws and regulations could increase our cost of doing business.

Our operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs such matters as minimum wages, overtime and other working conditions, the Americans with Disabilities Act and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the Equal Employment Opportunity Commission, regulations of the Office of Civil Rights, regulations of state Attorneys General, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters. Because labor represents such a large portion of our operating costs, changes in federal and state employment-related laws and regulations could increase our cost of doing business.

The compliance costs associated with these laws and evolving regulations could be substantial. For example, all of our affiliated facilities are required to comply with the ADA. The ADA has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could experience damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.

Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.

The operations of our operating subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third party payors. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our affiliated facilities. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.
79


In addition, we are required to operate our affiliated facilities in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our affiliated skilled nursing facilities are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements.

We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our operating subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us at different rates. For the three months ended March 31, 2021 and 2020, 74.1% and 71.0% of our revenue was provided by government payors that reimburse us at predetermined rates. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. Among other initiatives, these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our operating subsidiaries and the services we provide. The industry has experienced an increased trend in the number and severity of litigation claims, due in part to the number of large verdicts, including large punitive damage awards. These claims are filed based upon a wide variety of claims and theories, including deficiencies under conditions of participation under certain state and federal healthcare programs. Plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers, employing a wide variety of advertising and solicitation activities to generate more claims. The defense of lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome. Additionally, increases to the frequency and/or severity of losses from such claims and suits may result in increased liability insurance premiums or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements. While we have been able to settle these claims without an ongoing material adverse effect on our business, future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been an increase in the number of wage and hour class action claims filed in several of the jurisdictions where we are present. Allegations typically include claimed failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows.

In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

80

Were litigation to be instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.

Congress has repeatedly considered, without passage, a bill that would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. We use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.

We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs. Our compliance program includes, among other things, (i) policies and procedures modeled after applicable laws, regulations, government manuals and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (ii) training about our compliance process for all of the employees of our operating subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (iii) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and would continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our affiliated skilled nursing facilities, which were detected by our internal compliance team in the course of its ongoing reviews.

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have also identified and, at the conclusion of such investigations, assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our affiliated skilled nursing facilities in these areas. We continue to monitor the measures implemented for effectiveness, and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we will accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course. Furthermore, failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability. If future investigations ultimately result in findings of significant billing and reimbursement noncompliance which could require us to record significant additional provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.

We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic operating subsidiaries, which would also decrease our revenue.

To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.

81

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, the purchase price of the facilities, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

We have also historically acquired a few facilities, either because they were included in larger, indivisible groups of facilities or under other circumstances, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities which are more desirable. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenue might decrease.

We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions of facilities and businesses with our existing operating subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.
During the three months ended March 31, 2021, we expanded our operations through long-term leases, with the addition of four stand-alone skilled nursing operations. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our acquisitions, and our business may suffer.

In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved operating subsidiaries and patient care at affiliated facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable.

82

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.

If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.

CMS, as well as certain private organizations engaged in similar monitoring activities, provides comparative public data, rating every skilled nursing facility operating in each state based upon quality-of-care indicators. CMS’s system is the Five-Star Quality Rating System, introduced in 2008, to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each nursing home a rating of between one and five stars in various categories, and the ratings are available on a consumer-facing website, Nursing Home Compare. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating. Over the years, the Five-Star Quality Rating System has been modified, with the most recent changes being implemented in 2018 and 2019. Additionally, as a result of the COVID-19 pandemic and CMS’s suspension of certain inspection and reporting requirements, the data used to calculate the star ratings of facilities was interrupted. CMS temporarily froze certain data on the Nursing Home Compare website through January 2021. Other data related to quality-reporting measures will not be factored into star calculations until 2022 and will not be reflected on the Nursing Home Compare website until April 2022. The temporary adjustments due to COVID-19 could impact facilities that might have less favorable Five-Star Ratings from being able to demonstrate improvements on the public-facing website through mid-2022. For more information on these changes, see Item 2., under Government Regulation.

CMS continues to increase quality measure thresholds, making it more difficult to achieve upward ratings. CMS acknowledges that some facilities may see a decline in their overall five-star rating absent any new inspection information. This change could further affect star ratings across the industry. Additionally, on the Nursing Home Compare website, CMS recently began displaying a consumer alert icon next to nursing homes that have been cited on inspection reports for incidents of abuse, neglect, or exploitation. See Item 2., under Government Regulation.

Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. If we should fail to achieve our internal rating goals or fail to exceed the national average rating on the Five-Star Quality Rating System, or have facilities displaying a consumer alert icon for incidents of abuse, neglect, or exploitation, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.

If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.

It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:

we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;
we receive survey deficiencies or citations of higher-than-normal scope or severity;
83

we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;
insurers tighten underwriting standards applicable to us or our industry; or
insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.

If any of these potential circumstances were to occur, our insurance carriers may require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.

In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, also could inhibit our ability to attract patients or expand our business, and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers' compensation and employee health insurance costs have also increased markedly in recent years. To partially offset these increases, we have increased the amounts of our self-insured retention and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, except Washington, and elected non-subscriber status for workers' compensation in Texas. In Washington, the insurance coverage is financed through premiums paid by the employers and employees. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.

Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers' compensation insurance since 2005 through a wholly owned subsidiary insurance company, Standardbearer Insurance Company, Ltd., to insure our self-insurance reimbursements and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our self-insurance reimbursements under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.

We also self-insure our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.
The frequency and magnitude of claims and legal costs may increase due to the COVID-19 pandemic or our related response efforts.

84

The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 22% of our affiliated facilities are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as fires, earthquakes or mudslides.

In addition, our affiliated facilities in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our operating subsidiaries and our affiliated facilities, which could have an adverse impact on the patients of our operating subsidiaries and our business. In order to provide care for the patients of our operating subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our affiliated facilities, and the availability of employees to provide services at our affiliated facilities. If the delivery of goods or the ability of employees to reach our affiliated facilities were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our affiliated facilities and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our operating subsidiaries, severely damage or destroy one or more of our affiliated facilities, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.

The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our operating subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. With one exception, to our knowledge the staff at our affiliated facilities that have been approached to unionize have uniformly rejected union organizing efforts. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.

Because we lease the majority of our affiliated facilities, we are subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could adversely affect our business, financial position or results of operations.

As of March 31, 2021, we leased 168 of our 232 affiliated facilities. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.

Each lease provides that the landlord may terminate the lease for a variety of reasons, including the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.

85

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

We maintain a revolving credit facility under the Third Amended and Restated Credit Agreement, dated as of October 1, 2019, between the Company and a lending consortium arranged by Truist Financial Corporation (Truist) (formerly known as SunTrust Bank, Inc.) with a revolving line of credit of up to $350.0 million in aggregate principal amount (the Credit Facility). As of March 31, 2021, we have no outstanding debt under our Credit Facility. Nineteen of our subsidiaries have mortgage loans insured with Department of Housing and Urban Development (HUD) for an aggregate amount of $113.3 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The terms of the mortgage loans range from 25- to 35-years. We also have one outstanding promissory note of approximately $3.7 million as of March 31, 2021. The term of the note is 12 years. Because these mortgage loans are insured with HUD, our borrower subsidiaries under these loans are subject to HUD oversight and periodic inspections.

In addition, we had $1.7 billion of future operating lease obligations as of March 31, 2021. We intend to continue financing our operating subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding Credit Facility and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under our existing Credit Facility or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

Because our term loans, promissory notes, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our operating subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.

86

Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.

Occupancy levels at skilled nursing facilities are likely to remain vulnerable to the effects of COVID-19 even after the pandemic is over. Facilities experiencing decreases in move-in rates in the first quarter of 2021 cite resident or family member concerns as the basis for such decreases. These and other similar concerns may continue to impact our ability to attract new residents and our ability to retain existing residents.

A housing downturn could decrease demand for senior living services.
Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.

As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.

As part of, and subsequent to, the Spin-Off, we lease 31 of our properties to Pennant’s senior living operations. In the future, we might expand our leasing property portfolio to additional Pennant operations or other unaffiliated tenants. We have very limited control over the success or failure of our tenants’ and operators’ businesses and, at any time, a tenant or operator may experience a downturn in its business that weakens its financial condition. If that happens, the tenant or operator may fail to make its payments to us when due. Although our lease agreements give us the right to exercise certain remedies in the event of default on the obligations owing to us, we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.

An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy by successfully identifying, securing and consummating beneficial transactions is made more challenging by increased competition and can be affected by many factors, including our relationships with current and prospective tenants, our ability to obtain debt and equity capital at costs comparable to or better than our competitors and our ability to negotiate favorable terms with property owners seeking to sell and other contractual counterparties. Our competitors for these opportunities include healthcare REITs, real estate partnerships, healthcare providers, healthcare lenders and other investors, including developers, banks, insurance companies, pension funds, government-sponsored entities and private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. If we are unsuccessful at identifying and capitalizing on investment or acquisition opportunities, our growth and profitability in our real estate investment portfolio may be adversely affected.

Investments in and acquisitions of healthcare properties entail risks associated with real estate investments generally, including risks that the investment will not achieve expected returns, that the cost estimates for necessary property improvements will prove inaccurate or that the tenant or operator will fail to meet performance expectations. Income from properties and yields from investments in our properties may be affected by many factors, including changes in governmental regulation (such as licensing and government payment), general or local economic conditions (such as fluctuations in interest rates, senior savings, and employment conditions), the available local supply of and demand for improved real estate, a reduction in rental income as the result of an inability to maintain occupancy levels, natural disasters (such as hurricanes, earthquakes and floods) or similar factors. Furthermore, healthcare properties are often highly customized and the development or redevelopment of such properties may require costly tenant-specific improvements. As a result, we cannot assure you that we will achieve the economic benefit we expect from acquisition or investment opportunities.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.

The majority of our affiliated facilities have historically been skilled nursing facilities. As we expand our presence in other relevant healthcare service, our existing overall business model will continue to change and expose our company to risks in markets in which we have limited experience. We expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.

87

If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.

We rely significantly on appropriate referrals from physicians, hospitals and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our affiliated facilities. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.

We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.

Our ability to maintain and enhance our operating subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our affiliated facilities and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, credit and financial market conditions, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, unless and until the current U.S. and global political, credit and financial market crisis has been sufficiently resolved, it may be difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

We may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. U.S. capital markets can be volatile. We cannot assure you that additional capital will be available or available on terms favorable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.

Delays in reimbursement may cause liquidity problems.

If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews.

88

Some states in which we operate are operating with budget deficits or could have budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.

Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.

Nineteen of our affiliated facilities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.

If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our affiliated facilities is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.

We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenue. Each of our affiliated facilities is operated through a separate, wholly owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.

We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation of Pennant.

On October 1, 2019, we distributed all of the outstanding shares of The Pennant Group, Inc. or Pennant, common stock to stockholders in connection with the separation of our home health and hospice business and substantially all of our senior living operations into a separate publicly traded company, or the Spin-Off. In connection with the Spin-Off, we entered into a separation agreement and various other agreements, including a tax matters agreement, an employee matters agreement and transition services agreements. These agreements govern the separation and distribution and the relationship between us and Pennant going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time.

89

The separation agreement provides for indemnification obligations designed to make Pennant financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation, but we cannot guarantee that Pennant will be able to satisfy its indemnification obligations. It is also possible that a court would disregard the allocation agreed to between us and Pennant and require us to assume responsibility for obligations allocated to Pennant. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Pennant, including those related to assets or liabilities allocated to us, may be significant. In addition, certain landlords required, in exchange for their consent to the Spin-Off, that our lease guarantees remain in place for a certain period of time following the Spin-Off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties. These risks could negatively affect our business, financial condition or results of operations.

The separation of Pennant continues to involve a number of additional risks, including, among other things, the potential that management’s and our employees’ attention will be significantly diverted by the provision of transitional services or that we may incur other operational challenges or difficulties as a result of the separation. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If Pennant is unable to satisfy its obligations under these agreements, we could incur losses and may not have sufficient resources available for such services. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the transition activities and related events could adversely affect our business, financial condition or results of operations.

If either of our two Spin-Offs fail to qualify as generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.

In addition to the Spin-Off, in June 2014, we completed the separation of our healthcare business and our real estate business into two separate and independent publicly traded companies through the distribution of all of the outstanding shares of common stock of CareTrust REIT, Inc. (CareTrust) to Ensign stockholders on a pro rata basis (the CareTrust Spin-Off). Both of these transactions were intended to qualify for tax-free treatment to us and our stockholders for U.S. federal income tax purposes. Accordingly, completion of the transactions were conditioned upon, among other things, our receipt of opinions from outside tax advisors that the distributions would qualify as a transaction that is intended to be tax-free to both us and our stockholders for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code. The opinions were based on and relied on, among other things, certain facts and assumptions, as well as certain representations, statements and undertakings, including those relating to the past and future conduct. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if any of the parties breach any of their respective covenants relating to the transactions, the tax opinions may be invalid. Moreover, the opinions are not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the opinion, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.

If either the Spin-Off or the CareTrust Spin-Off fails to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain with respect to the distributed securities and our stockholders who received securities in such distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.

We also have obligations to provide indemnification to a number of parties as a result of these two transactions. Any indemnity obligations for tax issues or other liabilities related to the spin off, could be significant and could adversely impact our business.

Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

Certain of our directors who serve on our Board of Directors also serve on the board of directors of Pennant. This may create, or appear to create, conflicts of interest when our, or Pennant's management and directors face decisions that could have different implications for us and Pennant, including the resolution of any dispute regarding the terms of the agreements governing the Spin-Off and the relationship between us and Pennant after the Spin-Off or any other commercial agreements entered into in the future between us and the spun-off business and the allocation of such directors’ time between us and Pennant.

90

All of our executive officers and some of our non-employee directors own shares of the common stock of Pennant. The continued ownership of such common stock by our directors and executive officers following the Spin-Off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and Pennant.

Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.

Certain of our indebtedness is made at variable interest rates that use the London Interbank Offered Rate, or LIBOR (or metrics derived from or related to LIBOR), as a benchmark for establishing the interest rate. On July 27, 2017, the United Kingdom’s Financial Conduct Authority announced that it intends to stop persuading or compelling banks to submit LIBOR rates after 2021. These reforms may cause LIBOR to cease to exist, new methods of calculating LIBOR to be established, or alternative reference rates to be established. The potential consequences cannot be fully predicted and could have an adverse impact on the market value for or value of LIBOR-linked securities, loans, and other financial obligations or extensions of credit held by or due to us. Changes in market interest rates may influence our financing costs, returns on financial investments and the valuation of derivative contracts and could reduce our earnings and cash flows. In addition, any transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that rely on LIBOR, reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes. This could materially and adversely affect our results of operations, cash flows, and liquidity. We cannot predict the effect of the potential changes to LIBOR or the establishment and use of alternative rates or benchmarks.
Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for our beds, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. The Credit Facility restricts our ability to pay dividends to stockholders if we receive notice that we are in default under this agreement. The failure to pay or maintain dividends could adversely affect our stock price.

Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:

our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;
advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;
our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;
stockholder action by written consent is limited;
special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;
stockholders are not permitted to cumulate their votes for the election of directors;
newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;
91

our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and
stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.
We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.

92

Item 6.        EXHIBITS

EXHIBIT INDEX
ExhibitDescription
Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 2007 (attached as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33757) filed with the SEC on December 21, 2007)
Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on February 4, 2020 (attached as Exhibit 3.2 to the Company’s Annual Report on Form 10-K (File No. 001-33757) filed with the SEC on February 5, 2020)
Amendment to the Amended and Restated Bylaws, dated August 5, 2014 (attached as Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-33757) filed with the SEC on August 8, 2014)
Amended and Restated Bylaws of The Ensign Group, Inc. (attached as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33757) filed with the SEC on December 21, 2007)
Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware on November 7, 2013 (attached as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33757) filed with the SEC on November 7, 2013)
Certificate of Elimination of Series A Junior Participating Preferred Stock (attached as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33757) filed with the SEC on June 5, 2014)
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document

93


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 THE ENSIGN GROUP, INC.
April 29, 2021BY: /s/ SUZANNE D. SNAPPER  
  Suzanne D. Snapper 
  Chief Financial Officer and Executive Vice President (Principal Financial Officer and Accounting Officer and Duly Authorized Officer) 

 


 


 


EX-31.1 2 ensgq12021ex311.htm EX-31.1 Document

EXHIBIT 31.1

I, Barry R. Port, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 29, 2021
     
 /s/ Barry R. Port   
 Name:  Barry R. Port 
 Title:  Chief Executive Officer, President and Director (principal executive officer) 



EX-31.2 3 ensgq12021ex312.htm EX-31.2 Document

EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: April 29, 2021
    
 /s/ Suzanne D. Snapper   
 Name: Suzanne D. Snapper  
 Title:  Chief Financial Officer and Executive Vice President (principal financial officer and accounting officer and duly authorized officer) 


EX-32.1 4 ensgq12021ex321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Barry R. Port 
 Name:  Barry R. Port  
 Title:  
Chief Executive Officer, President and Director (principal executive officer) 
 
 
 
April 29, 2021
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 5 ensgq12021ex322.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Suzanne D. Snapper   
 Name:  Suzanne D. Snapper  
 Title:  Chief Financial Officer and Executive Vice President (principal financial officer and accounting officer and duly authorized officer) 
 
 
April 29, 2021
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-101.SCH 6 ensg-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance General and Professional (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Workers' Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - Summary of Significant Accounting Policies - Self Insurance Recoveries (Details) link:presentationLink link:calculationLink link:definitionLink 2411408 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Health Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 2112103 - Disclosure - COVID-19 UPDATE link:presentationLink link:calculationLink link:definitionLink 2413409 - Disclosure - COVID-19 UPDATE (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - Revenue and Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Revenue and Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details) link:presentationLink link:calculationLink link:definitionLink 2417411 - Disclosure - Revenue and Accounts Receivable - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2418412 - Disclosure - Revenue and Accounts Receivable - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2119105 - Disclosure - Computation of Net Income Per Common Share link:presentationLink link:calculationLink link:definitionLink 2320302 - Disclosure - Computation of Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2421413 - Disclosure - Computation of Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2122106 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2424415 - Disclosure - Fair Value Measurements - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 2326303 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - Business Segments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Business Segments - Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2429418 - Disclosure - Business Segments - Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - Operation Expansions link:presentationLink link:calculationLink link:definitionLink 2431419 - Disclosure - Operation Expansions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2132109 - Disclosure - Property and Equipment — Net link:presentationLink link:calculationLink link:definitionLink 2333304 - Disclosure - Property and Equipment — Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Property and Equipment — Net (Details) link:presentationLink link:calculationLink link:definitionLink 2135110 - Disclosure - Intangible Assets — Net link:presentationLink link:calculationLink link:definitionLink 2336305 - Disclosure - Intangible Assets — Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2437421 - Disclosure - Intangible Assets — Net - Schedule of Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2438422 - Disclosure - Intangible Assets — Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2439423 - Disclosure - Intangible Assets — Net - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2140111 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2341306 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2442424 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2443425 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2144112 - Disclosure - Restricted and Other Assets link:presentationLink link:calculationLink link:definitionLink 2345307 - Disclosure - Restricted and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2446426 - Disclosure - Restricted and Other Assets - Schedule of Restricted and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2447427 - Disclosure - Restricted and Other Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2148113 - Disclosure - Other Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2349308 - Disclosure - Other Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2450428 - Disclosure - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2151114 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2452429 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2153115 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2354309 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2455430 - Disclosure - Debt - Schedule of Long term debt (Details) link:presentationLink link:calculationLink link:definitionLink 2456431 - Disclosure - Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2457432 - Disclosure - Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) link:presentationLink link:calculationLink link:definitionLink 2158116 - Disclosure - Options and Awards link:presentationLink link:calculationLink link:definitionLink 2359310 - Disclosure - Options and Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 2460433 - Disclosure - Options and Awards - Stock Options Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2461434 - Disclosure - Options and Awards - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2462435 - Disclosure - Options and Awards - Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2463436 - Disclosure - Options and Awards - Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2464437 - Disclosure - Options and Awards - Options Outstanding by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 2465438 - Disclosure - Options and Awards - Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 2466439 - Disclosure - Options and Awards - Restricted Stock Awards Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2467440 - Disclosure - Options and Awards - Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2468441 - Disclosure - Options and Awards - Long-Term Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2469442 - Disclosure - Options and Awards - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2170117 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2371311 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2472443 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2473444 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2474445 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2474445 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2475446 - Disclosure - Lessor - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2476447 - Disclosure - Lessor - Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2477448 - Disclosure - Lessor - Future Minimum Lease Payments Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2178118 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2479449 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2180119 - Disclosure - Common Stock Repurchase Program link:presentationLink link:calculationLink link:definitionLink 2481450 - Disclosure - Common Stock Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ensg-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ensg-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ensg-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Options granted to non-employee directors (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Gain on sale of real estate Profit (Loss) from Real Estate Operations Document Type Document Type Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value All States Except Colorado All States Except Colorado [Member] All States Except Colorado [Domain] Other expense, net Other income (expense), net Other Nonoperating Income (Expense) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Options Granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Other third-party Third Party Tenants [Member] Third Party Tenants [Member] Cash held in trust for patients Cash Held in Trust for Residents Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds. Treasury Stock Treasury Stock [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] 2016 Exercise Price Range Five [Member] Exercise Price Range Five [Member] Service revenue Service [Member] Segments [Axis] Segments [Axis] Long-term insurance losses recoverable asset Estimated Insurance Recoveries Capital improvement reserves with landlords and lenders Other Restricted Assets Cash and cash equivalents beginning of period Cash and cash equivalents end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Restricted and other assets Restricted and other assets Other Restricted Assets, Noncurrent Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Number of option plans Number Of Option Plans Number Of Option Plans Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Leases and Leasehold Improvements Lessee, Leases [Policy Text Block] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Year Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and equity Liabilities and Equity [Abstract] 2026 Lessor, Operating Lease, Payment to be Received, Year Five Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Distribution to noncontrolling interest holder Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Total net debt ratio, maximum after increase election Total Net Debt Ratio, Maximum After Increase Election Total Net Debt Ratio, Maximum After Increase Election Health Liability Insurance Health Liability Insurance [Member] Health Liability Insurance [Member] Prepayment penalty reduced rate during the fourth year Prepayment Penalty Reduced Rate During The Fourth Year Percentage that the prepayment penalty percentage is reduced during the fourth year. Reconciliation of Revenue from Segments to Consolidated Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Security Exchange Name Security Exchange Name Number of installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Skilled Nursing Operations Skilled Nursing Operations [Member] Skilled Nursing Operations Income from operations Operating Income (Loss) Total current liabilities Liabilities, Current Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Nonvested at beginning of period (in dollars per share) Nonvested at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] Self insurance reserve Self Insurance Reserve Variable Rate [Axis] Variable Rate [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies (Notes 15, 17 and 18) Commitments and Contingencies Shares of common stock used to satisfy tax withholding obligations Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Issuance of restricted stock, net of forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Repurchase of shares of common stock (Note 19) Payments for Repurchase of Common Stock Assets Assets [Abstract] Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Wholly Owned Properties Wholly Owned Properties [Member] Furniture and fixtures Furniture and Fixtures [Member] Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current OTHER ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Retained earnings Retained Earnings (Accumulated Deficit) 2021 (remainder) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Right-of-use assets Operating Lease, Right-of-Use Asset RESTRICTED AND OTHER ASSETS Other Assets Disclosure [Text Block] Facilities under master lease arrangement Facilities Under Master Lease Arrangement Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Weighted Average Life (Years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Assembled occupancy Assembled occupancy acquired [Member] Assembled occupancy acquired [Member] Skilled nursing, assisted living and independent living facilities Skilled Nursing, Assisted Living and Independent Living Facilities Skilled Nursing, Assisted Living and Independent Living Facilities 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Balance at beginning of period, (in shares) Balance at end of period, (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Payor [Axis] Payor [Axis] Payor [Axis] Customer [Axis] Customer [Axis] Balance at beginning of period (in shares) Balance at end of period (in shares) Shares, Outstanding Lease Arrangement [Axis] Lease Arrangement [Axis] Information by group of related lease arrangements. Exercise price, lower range limit (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Diluted net income from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Promissory Note, 5.3% Promissory Note, 5.3% [Member] Promissory Note, 5.3% Income Taxes Income Tax, Policy [Policy Text Block] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Other Other Liabilities, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Transitional and Skilled Services Transitional and Skilled Services Segment [Member] Transitional and Skilled Services Segment Blanket Aggregate Blanket Aggregate [Member] Blanket Aggregate [Member] Other restricted assets Payments for (Proceeds from) Other Investing Activities Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Transitional and skilled service facilities Transitional And Skilled Service Facilities Transitional And Skilled Service Facilities Employee stock award compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock repurchase program, period in force Stock Repurchase Program, Period in Force Operating Entity [Axis] Operating Entity [Axis] Operating Entity [Axis] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Total revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Lender Name [Axis] Lender Name [Axis] Net income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Concentration risk Concentration Risk, Percentage Business Acquisition [Axis] Business Acquisition [Axis] Number of facilities resolved in period Facilities Under Medicare Probe Reviews, Number Of Facilities Resolved In Period Facilities Under Medicare Probe Reviews, Number Of Facilities Resolved In Period Geographical [Domain] Geographical [Domain] Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Statement [Line Items] Statement [Line Items] Less: Net Income (Loss) Attributable to Noncontrolling Interest [Abstract] Debt instrument, term Debt Instrument, Term Schedule of Aggregate Intrinsic Value of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] Noncontrolling Interest Noncontrolling Interest [Policy Text Block] The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. Statement [Table] Statement [Table] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Statistical Measurement [Axis] Statistical Measurement [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition Credit Facility [Axis] Credit Facility [Axis] The Pennant Group, Inc. The Pennant Group, Inc. [Member] The Pennant Group, Inc. Total Lessor, Operating Lease, Payments to be Received Unusual or Infrequent Items, or Both [Abstract] Cash, uninsured amount Cash, Uninsured Amount Deferred payment of social security taxes, current Liabilities, Deferred Tax Payments Under CARES Act, Current Liabilities, Deferred Tax Payments Under CARES Act, Current Business Combinations [Abstract] Business Combinations [Abstract] Entity Small Business Entity Small Business Health Health Insurance Product Line [Member] Year Lessee, Operating Lease, Liability, Payment, Due [Abstract] Third Amended Credit Facility Third Amended Credit Facility [Member] Third Amended Credit Facility [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Self-Insurance Retention Per Claim Self-insurance retention per claim [Member] Self-insurance retention per claim [Member] Operating lease, variable lease income Operating Lease, Variable Lease Income Cash proceeds from insurance proceeds Proceeds from Insurance Settlement, Investing Activities DEBT Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Accounts receivable Accounts Receivable, before Allowance for Credit Loss Operating Lease, Lease Income Operating Lease, Lease Income [Table Text Block] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Amendment Flag Amendment Flag Weighted average common shares outstanding: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Cost of Sales and General and Administrative Expense Cost of Sales and General and Administrative Expense [Member] Primary financial statement caption encompassing cost of services and general and administrative expense Real Estate Properties [Domain] Real Estate Properties [Domain] Rent - cost of services Rent, Cost Of Services [Member] Rent, Cost Of Servcies[Member] Non-employee directors Share-based Payment Arrangement, Nonemployee [Member] All Other Corporate, Non-Segment [Member] Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other accrued liabilities Other accrued liabilities Other Accrued Liabilities, Current TEXAS TEXAS Forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Accrued self-insurance liabilities—less current portion Self Insurance Reserve, Noncurrent Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Entity Central Index Key Entity Central Index Key General Liability General Liability [Member] Financial Instruments [Domain] Financial Instruments [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Geographical [Axis] Geographical [Axis] Number of real estate properties leased with an option to purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase Accrued self-insurance liabilities Increase (Decrease) in Self Insurance Reserve Segments [Domain] Segments [Domain] (Gain)/loss on sale of asset disposals Gain (Loss) On Other Assets Amount of gain (loss) on sale or disposal of property and equipment assets, gain on sale of business and insurance claims related to damaged property. Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Asset Acquisition Asset Acquisition [Member] These acquisitions were classified as asset acquisitions in accordance with ASC 805. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Non-cash financing and investing activity: Other Noncash Investing and Financing Items [Abstract] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Long-term debt, threshold for EBITDA ratio increase election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Amortization of intangible assets Amortization of Intangible Assets March 13, 2020 Repurchase Program March 13, 2020 Repurchase Program [Member] March 13, 2020 Repurchase Program Lease, Cost Lease, Cost [Table Text Block] Operational skilled nursing beds Operational Skilled Nursing Beds Number of skilled nursing beds available for use at a skilled nursing facility Prepaid income taxes Prepaid Taxes 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Rental revenue Rental [Member] Rental Plan Name [Axis] Plan Name [Axis] BUSINESS SEGMENTS Segment Reporting Disclosure [Text Block] Issuance of common stock to employees and directors resulting from the exercise of stock options Stock Issued During Period, Value, New Issues Cash and cash equivalents, fair value disclosure Cash and Cash Equivalents, Fair Value Disclosure Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Concentration Risk [Table] Concentration Risk [Table] Net income attributable to The Ensign Group, Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Total assets Assets Exercise Price Range [Domain] Exercise Price Range [Domain] Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2017 Plan 2017 Plan [Member] 2017 Plan Title of 12(b) Security Title of 12(b) Security Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Intangible assets, net Net Finite-Lived Intangible Assets, Net Weighted Average Fair Value of Options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] LEASES Lessor, Operating Leases [Text Block] Mortgage loans and promissory notes Collateralized Debt Obligations [Member] 2023 Lessor, Operating Lease, Payment to be Received, Year Two Schedule of Common Stock Outstanding Roll Forward Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Interest expense Interest Expense Depreciation and amortization Depreciation, Depletion and Amortization Variable lease costs Cost of Services [Member] Cost of Services Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program(Note 3) Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Repaid Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds, Repayment Product and Service [Axis] Insurance Policy [Axis] Product and Service [Axis] Total liabilities Liabilities Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2020 Exercise Price Range Nine [Member] Exercise Price Range Nine [Member] Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Third-Party Payor 524292 Third Party Administration of Insurance and Pension Funds [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Rent expense Operating Lease, Expense Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts payable Increase (Decrease) in Accounts Payable Non-Vested Restricted Awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Operating Segments Operating Segments [Member] Medicare Medicare [Member] Revenue from Medicare [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Purchase of property and equipment Payments To Acquire Property And Equipment Payments To Acquire Property And Equipment Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Basic net income from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Deferred compensation liability Increase (Decrease) in Deferred Compensation Variable lease, cost Variable Lease, Cost Revolving credit facility with Truist Revolving Credit Facility [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Stock options vested and exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Per Occurence Per Occurence [Member] Per Occurence [Member] Share-based compensation, restricted awards, exercise price (in dollars per share) Share-based Compensation, Restricted Awards, Exercise Price Share-based Compensation, Restricted Awards, Exercise Price Subsequent Event Subsequent Event [Member] Balance at beginning of period, (in dollars per share) Balance at end of period, (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Notes Payable to Banks Notes Payable to Banks [Member] 8051 Services, Skilled Nursing Care Facilities 8051 Services, Skilled Nursing Care Facilities [Member] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Letters of credit outstanding, pledged amount Letters of Credit Outstanding, Amount Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Property and equipment Property, Plant and Equipment, Gross Plus: incremental shares from assumed conversion (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Issuance of common stock upon exercise of options Proceeds from Stock Options Exercised Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] FMAP payments received Family First Coronavirus Response Act, Payments Received Family First Coronavirus Response Act, Payments Received Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Income Statement [Abstract] Income Statement [Abstract] Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Award requisite service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Long-term lease liabilities—less current portion Long-term operating lease liabilities Operating Lease, Liability, Noncurrent 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Cash surrender value of life insurance policy premiums Life Insurance, Corporate or Bank Owned, Change in Value Workers' Compensation Workers' Compensation Insurance [Member] Total net debt ratio, minimum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Interest and other income Investment Income, Interest Share-based compensation arrangement by share-based payment award, options, expected to vest, number (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan. Dividends declared Dividends General and Professional Liability Professional Malpractice Liability Insurance [Member] Weighted Average Dividend Yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Per Facility Per Facility [Member] Per Facility [Member] Counterparty Name [Domain] Counterparty Name [Domain] City Area Code City Area Code Consolidation Items [Domain] Consolidation Items [Domain] Document Period End Date Document Period End Date GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Segment income (loss) Segment Income (Loss) Segment Income (Loss) Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other long-term liabilities Deferred rent and other long-term liabilities Rental expense in excess of actual rental payments and other long-term liabilities Deposits with landlords Security Deposit Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Schedule of Held-to-maturity Securities [Line Items] Schedule of Held-to-maturity Securities [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Mortgage loans and promissory notes Notes Payable Other Payables Notes Payable, Other Payables [Member] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Repurchase of common stock Repurchase of common stock Stock Repurchased During Period, Value 2011 Exercise Price Range Zero [Member] Exercise Price Range Zero Repurchase of shares of common stock to satisfy tax withholding obligations Payment, Tax Withholding, Share-based Payment Arrangement Nonvested restricted awards, granted (in shares) Granted (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Cover page. Cover [Abstract] Base Rate Base Rate [Member] INTANGIBLE ASSETS — NET Intangible Assets Disclosure [Text Block] Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Goodwill [Line Items] Goodwill [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] LEASES Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Asset Acquisition [Domain] Asset Acquisition [Domain] Asset Acquisition Conversion to reduce shares availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Customer relationships Customer Relationships [Member] Cost of services Cost of Goods and Services Sold Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] California CALIFORNIA Total expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Stock-based compensation expense related to restricted stock awards Restricted Stock [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Real Estate Property Ownership [Axis] Real Estate Property Ownership [Axis] Land Land [Member] Lease liabilities—current Less: current lease liabilities Operating Lease, Liability, Current Malpractice loss contingency, accrual, undiscounted Malpractice Loss Contingency, Accrual, Undiscounted Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Amortization of deferred rent Deferred Rent Adjustment Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period. Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Income tax payable Accrued Income Taxes Entity Interactive Data Current Entity Interactive Data Current Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Escrow deposits Deposits Assets, Noncurrent COMMON STOCK REPURCHASE PROGRAM Stockholders' Equity Note Disclosure [Text Block] Accounts Receivable Accounts Receivable [Member] Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] 2015 Exercise Price Range Four [Member] Exercise Price Range Four [Member] 2021 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Customer [Domain] Customer [Domain] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Health care facilities Number Of Health Care Facilities Number Of Health Care Facilities Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Other accrued liabilities Increase (Decrease) in Other Operating Liabilities Non-cash leasing arrangement Non-Cash Lease Expense Non-Cash Lease Expense Deferred payment of social security taxes, noncurrent Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent Less: debt issuance costs, net Debt Issuance Costs, Net Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of reportable segments Number of Reportable Segments Other income (expense): Other Nonoperating Income (Expense) [Abstract] Exercise Price Range [Axis] Exercise Price Range [Axis] Payments to acquire business and asset acquisitions Payments To Acquire Business And Asset Acquisitions Cash paid to acquire acquisitions. Unapplied state relief funds Accrued Liabilities, State Relief Contract Liabilities Accrued Liabilities, State Relief Contract Liabilities Consolidation Items [Axis] Consolidation Items [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable—less allowance for doubtful accounts of $11,090 and $8,718 at March 31, 2021 and December 31, 2020, respectively Accounts Receivable, after Allowance for Credit Loss, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Cash proceeds from the sale of assets and ancillary business Proceeds from Sales of Assets, Investing Activities Repayment of Medicare Accelerated and Advance Payment Program Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Operating lease, lease income Operating Lease, Lease Income Medicaid Medicaid [Member] Revenue from Medicaid for custodial services [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Employee service share-based compensation, nonvested awards (in shares) Employee Service Share-based Compensation, Nonvested Awards Employee Service Share-based Compensation, Nonvested Awards Restructuring Type [Axis] Restructuring Type [Axis] Goodwill Goodwill Document Transition Report Document Transition Report Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Income taxes payable Increase (Decrease) in Income Taxes Payable Debt Instrument, pre-payment fee reduction, term Debt Instrument, Pre-Payment Fee Reduction, Term Debt Instrument, Pre-Payment Fee Reduction, Term Deferral investment expense Investment Income, Investment Expense Dividends per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Debt issuance costs, net Debt Issuance Costs, Line of Credit Arrangements, Net Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Other long-term liabilities Increase (Decrease) in Other Deferred Liability August 26, 2019 Repurchase Program August 26, 2019 Repurchase Program [Member] August 26, 2019 Repurchase Program [Member] Buildings and improvements Building and Building Improvements [Member] Document Quarterly Report Document Quarterly Report Schedule of Goodwill Schedule of Goodwill [Table Text Block] Non-California Non-California [Member] Non-California [Domain] Total net debt ratio, maximum Total Net Debt Ratio, Maximum Total Net Debt Ratio, Maximum General and administrative expense General and Administrative Expense [Member] Black-Scholes Fair Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range Equity Equity [Abstract] Debt Securities, Held-to-maturity [Table] Debt Securities, Held-to-maturity [Table] Lessee leasing arrangements, operating leases, number of renewal terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Resident advances Contract with Customer, Liability, Current Subsequent Event [Line Items] Subsequent Event [Line Items] Weighted Average Exercise Price (in dollars per share) Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Customer Concentration Risk Customer Concentration Risk [Member] Number of options vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Credit Facility [Domain] Credit Facility [Domain] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Diluted (in shares) Adjusted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Quality assurance fee Quality Assurance Fee Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days Basic income per share attributable to The Ensign Group, Inc. (in dollars per share) Earnings Per Share, Basic Expected Life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Entity File Number Entity File Number Debt Security, Corporate, US Debt Security, Corporate, US [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Private and other Private and other payors Private Pay and Other [Member] Revenue from self-pay and Other payors [Member] Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Master lease agreements Master Lease Agreements Master Lease agreements Amortization of deferred financing fees Amortization of Debt Issuance Costs and Discounts Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] 2025 Lessor, Operating Lease, Payment to be Received, Year Four 2014 Exercise Price Range Three [Member] Exercise Price Range Three [Member] Lease Arrangement [Domain] Lease Arrangement [Domain] Lease Arrangement Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Payments on revolving credit facility and other debt (Note 15) Repayments of Long-term Debt Share-based Payment Arrangement, Option, Exercise Price Range Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Share-based compensation expense Share-based Payment Arrangement, Expense Counterparty Name [Axis] Counterparty Name [Axis] Common stock: $0.001 par value; 100,000 shares authorized; 57,744 and 54,953 shares issued and outstanding at March 31, 2021, respectively, and 57,417 and 54,626 shares issued and outstanding at December 31, 2020, respectively Common Stock, Value, Issued Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Less: net income attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Proceeds from revolving credit facility and other debt (Note 15) Proceeds from Issuance of Secured Debt Advance payment liabilities (Note 3) COVID Liabilities, Current COVID Liabilities, Current Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Current maturities of long-term debt Less: current maturities Amount outstanding, current Long-term Debt, Current Maturities Cash surrender value of life insurance related to deferred compensation plan Deferred Compensation Plan Assets Schedule of Accounts, Notes, Loans and Financing Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Number of operating subsidiaries Number Of Operating Subsidiaries Number Of operating subsidiaries entered into mortgage loans that are insured with HUD. Property, plant and equipment Property, Plant and Equipment, Additions 2021 Exercise Price Range Ten [Member] Exercise Price Range Ten [Member] Subsequent Event [Table] Subsequent Event [Table] Remaining Company Remaining Company [Member] The Ensign Group, Inc. Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Award vesting rights, percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Other States, Except California, Texas and Washington Other states, except California, Texas and Washington [Member] Other states, except California, Texas and Washington Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total Medicare and Medicaid Total Medicaid and Medicare Total Medicaid and Medicare Revenue [Member] Total revenue from Medicaid and Medicare [Member] Number outstanding (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Prepayment penalty reduced rate for the fifth through tenth years Prepayment Penalty Reduced Rate For The Fifth Through Tenth Years Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years. Present value of total lease liabilities Operating Lease, Liability Operational senior living units Operational Senior Living Units Operational Assisted Living and Independent Living Units Long-term debt—less current maturities Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss Share Repurchase Program [Axis] Share Repurchase Program [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Medicaid — skilled Medicaid-skilled [Member] Revenue from Medicaid for skilled services [Member] Self-Insurance Liability Reserve Estimate, Policy [Policy Text Block] Total Ensign Group, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Purchase Option Purchase Option [Member] Purchase Option Proceeds from CARES Act Provider Relief Fund (Note 3) Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and equity Liabilities and Equity Medicare Accelerated and Advance Payment Medicare Accelerated And Advance Payment, CARES ACT Medicare Accelerated And Advance Payment, CARES ACT Number of businesses acquired Number of Businesses Acquired INCOME TAXES Income Tax Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Notes payable Notes Payable Accrued wages and related liabilities (Note 3) Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating lease expense Operating Lease, Cost 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five General and administrative expense General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Operating lease obligations Increase (Decrease) In Operating Lease, Liability Increase (Decrease) In Operating Lease, Liability Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Insurance subsidiary deposits and investments Insurance Subsidiary Deposits And Investments Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity. Colorado COLORADO Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Various Landlords Various Landlords [Member] [Member] Various Landlords[Member] Grantee Status [Domain] Grantee Status [Domain] Dividends paid Payments of Dividends 2013 Exercise Price Range Two [Member] Exercise Price Range Two [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Construction in progress Construction in Progress [Member] Number of real estate properties leased Number of Real Estate Properties Leased Number of Real Estate Properties Leased Entity Tax Identification Number Entity Tax Identification Number Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] OPTIONS AND AWARDS Share-based Payment Arrangement [Text Block] Net income attributable to The Ensign Group, Inc. Net income attributable to the Ensign Group, Inc. Net Income (Loss) Attributable to Parent Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Truist Truist Bank [Member] Truist Bank [Member] 2021 (remainder) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year LIBOR London Interbank Offered Rate (LIBOR) [Member] Facility trade name Trade name Trade Names [Member] Leases [Abstract] Leases [Abstract] Escrow deposits used to fund acquisitions Proceeds from Deposits on Real Estate Sales Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating Entity [Domain] Operating Entity [Domain] [Domain] for Operating Entity [Axis] Accrued self-insurance liabilities—current Self Insurance Reserve, Current Net income per share attributable to The Ensign Group, Inc.: Earnings Per Share [Abstract] Loss-Sensitive Limit Per Claim Loss-Sensitive limit per claim [Member] [Member] Loss-Sensitive limit per claim Transitional and skilled services and senior living campuses Transitional And Skilled Services And Senior Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses Debt securities, held-to-maturity Debt Securities, Held-to-maturity Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Long-term debt—less current maturities Long Term Debt, net of Current Maturities and Debt Discount Long Term Debt, net of Current Maturities and Debt Discount Managed care Managed Care [Member] Revenue from managed care payors [Member] Payor [Domain] Payor [Domain] Payor [Domain] Ensign Group, Inc. stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Number of Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Stop-Loss Insurance Limit Per Claim Stop-Loss Insurance limit per claim [Member] Stop-Loss Insurance limit per claim[Member] Schedule of Other Indefinite-lived Intangible Assets by Major Class Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block] Goodwill and intangible asset impairment Goodwill and Intangible Asset Impairment Parent Company Parent Company [Member] Number of real estate properties Number of Real Estate Properties Aggregate intrinsic value of options that vested in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Senior living facilities Senior Living Facilities Number of Assisted and Independent Living Facilities Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Mortgages Mortgages [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Entity Filer Category Entity Filer Category Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service [Domain] Insurance Policy [Domain] Product and Service [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Operating leases of lessee, contingent rentals, basis spread on variable rate Lessee, Operating Lease, Discount Rate 2019 LTI Plan 2019 LTI Plan [Member] 2019 LTI Plan [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Spinoff Spinoff [Member] Weighted Average Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Lease Contractual Term [Axis] Lease Contractual Term [Axis] 2022 Lessor, Operating Lease, Payment to be Received, Year One Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares) Stock Issued During Period, Shares, New Issues Class of Treasury Stock [Table] Class of Treasury Stock [Table] Non-controlling interest distribution Proceeds from (Payments to) Noncontrolling Interests Leasehold improvements Leasehold Improvements [Member] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Revenue Benchmark Revenue Benchmark [Member] Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Prepaid income taxes Increase (Decrease) in Prepaid Taxes Cash paid during the period for: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Revenue, FMAP payments received Revenue, Family First Coronavirus Response Act, Payments Received Revenue, Family First Coronavirus Response Act, Payments Received Medicare and Medicaid licenses Medicare and Medicaid Licenses [Member] Medicare licenses for home health and hospice segment and all other segment. Net (decrease)/increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Operation Expansions Business Combination Disclosure [Text Block] Senior Living Facilities Senior Living Facilities [Member] Assisted Living Facilities [Member] 2019 Exercise Price Range Eight [Member] Exercise Price Range Eight [Member] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock Options Stock-based compensation expense related to stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Basic (in shares) Weighted average shares outstanding for basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Interest rate margin Debt Instrument, Basis Spread on Variable Rate Expense: Costs and Expenses [Abstract] Weighted Average Risk-Free Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Grantee Status [Axis] Grantee Status [Axis] Ownership [Axis] Ownership [Axis] Common stock in treasury, at cost (in shares) Treasury Stock, Shares Ownership [Domain] Ownership [Domain] Prepayment penalty reduced rate during first three years Prepayment Penalty Reduced Rate During First Three Years Percentage that the prepayment penalty percentage is reduced during the first three years. Plan Name [Domain] Plan Name [Domain] Real Estate Real Estate Segment [Member] Real Estate Segment Rent—cost of services Rent Cost of Services Rent cost of services REVENUE AND ACCOUNTS RECEIVABLE Revenue from Contract with Customer [Text Block] Accrued dividends declared Dividends payable Dividends Payable Interest Interest Paid, Excluding Capitalized Interest, Operating Activities March 4, 2020 Repurchase Program March 4, 2020 Repurchase Program [Member] March 4, 2020 Repurchase Program CareTrust REIT CareTrust REIT [Member] CareTrust REIT [Member] Total equity Balance at beginning of period Balance at end of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Right-of-use assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Provision for income taxes Income Tax Expense (Benefit) Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Total deferred payment of social security taxes Liabilities, Deferred Tax Payments Under CARES Act Liabilities, Deferred Tax Payments Under CARES Act Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Diluted income per share attributable to The Ensign Group, Inc.(in dollars per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Cash payments for asset acquisitions (Note 8) Payments To Acquire Asset Acquisitions Cash paid to acquire acquisitions. Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received Intrinsic value of options exercised in period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 2018 Exercise Price Range Seven [Member] Exercise Price Range Seven [Member] Escrow deposits Payments for Deposits on Real Estate Acquisitions Exercise price, upper range limit (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Refunds payable Resident Refunds Payable Resident refunds payable includes amounts due to residents for overpayments and duplicate payments Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Remaining Contractual Life (Years) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Mortgage loans and promissory notes Long-term debt, gross Long-term Debt, Gross Intercompany Eliminations Consolidation, Eliminations [Member] Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors Stock awards [Member] Stock awards [Member] 2017 Exercise Price Range Six [Member] Exercise Price Range Six [Member] Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Emerging Growth Company Entity Emerging Growth Company Other indefinite-lived intangibles Medicare and Medicaid licenses Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Deferred income taxes Deferred Income Tax Expense (Benefit) Impairment of long-lived assets Impairment of Long-Lived Assets to be Disposed of Property taxes Accrual for Taxes Other than Income Taxes Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Number of stock repurchase programs Number Of Stock Repurchase Programs Number Of Stock Repurchase Programs Lease Contractual Term [Domain] Lease Contractual Term [Domain] Maximum Maximum [Member] Non-Controlling Interest Noncontrolling Interest [Member] Other than options, conversion to reduce shares availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Gain on deferral investment Gain (Loss) on Investments COVID-19 UPDATE Unusual or Infrequent Items, or Both, Disclosure [Text Block] Retained Earnings Retained Earnings [Member] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Facilities under Medicare probe reviews Facilities Under Medicare Probe Reviews Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments Total income tax provision Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Purchases of investments Payments to Acquire Investments Depreciation and amortization Depreciation And Amortization [Member] Depreciation And Amortization [Member] 2024 Lessor, Operating Lease, Payment to be Received, Year Three Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Allowance for doubtful accounts Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Lessor, Operating Lease, Payments to be Received, Maturity Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Award Type [Domain] Award Type [Domain] Owned Properties Owned Properties [Member] Owned Properties Aggregate Deductible Aggregate Deductible [Member] Aggregate Deductible [Member] Schedule of Restricted and Other Assets Schedule of Other Assets [Table Text Block] Trading Symbol Trading Symbol Weighted average exercise price of options vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Grant date intrinsic value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value PROPERTY AND EQUIPMENT— Net Property, Plant and Equipment Disclosure [Text Block] Line of credit facility, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Cash surrender value of life insurance related to deferred compensation plan Cash Surrender Value of Life Insurance Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Third Party Tenants Under Triple Net Lease Arrangements Third Party Tenants Under Triple Net Lease Arrangements [Member] Third Party Tenants Under Triple Net Lease Arrangements Common stock in treasury, at cost, 2,791 shares at both periods ended March 31, 2021 and December 31, 2020 (Note 19) Treasury Stock, Value 2012 Exercise Price Range One [Member] Exercise Price Range One [Member] COMPUTATION OF NET INCOME PER COMMON SHARE Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Equipment Equipment [Member] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Investments—current Short-term Investments EX-101.PRE 10 ensg-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 ensg-20210331_g1.jpg begin 644 ensg-20210331_g1.jpg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ensg-20210331_htm.xml IDEA: XBRL DOCUMENT 0001125376 2021-01-01 2021-03-31 0001125376 2021-04-26 0001125376 2021-03-31 0001125376 2020-12-31 0001125376 us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:RentalMember 2021-01-01 2021-03-31 0001125376 ensg:RentalMember 2020-01-01 2020-03-31 0001125376 2020-01-01 2020-03-31 0001125376 us-gaap:CommonStockMember 2020-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001125376 us-gaap:RetainedEarningsMember 2020-12-31 0001125376 us-gaap:TreasuryStockMember 2020-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-12-31 0001125376 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001125376 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001125376 2020-07-01 2020-09-30 0001125376 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001125376 us-gaap:CommonStockMember 2021-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001125376 us-gaap:RetainedEarningsMember 2021-03-31 0001125376 us-gaap:TreasuryStockMember 2021-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-03-31 0001125376 us-gaap:CommonStockMember 2019-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001125376 us-gaap:RetainedEarningsMember 2019-12-31 0001125376 us-gaap:TreasuryStockMember 2019-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2019-12-31 0001125376 2019-12-31 0001125376 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001125376 2019-07-01 2019-09-30 0001125376 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001125376 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001125376 us-gaap:CommonStockMember 2020-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001125376 us-gaap:RetainedEarningsMember 2020-03-31 0001125376 us-gaap:TreasuryStockMember 2020-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-03-31 0001125376 2020-03-31 0001125376 us-gaap:WhollyOwnedPropertiesMember 2021-03-31 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember ensg:ThePennantGroupInc.Member 2021-03-31 0001125376 ensg:RemainingCompanyMember ensg:SkilledNursingOperationsMember us-gaap:SpinoffMember 2021-03-31 0001125376 srt:MinimumMember 2021-01-01 2021-03-31 0001125376 srt:MaximumMember 2021-01-01 2021-03-31 0001125376 srt:MinimumMember ensg:AssembledOccupancyAcquiredMember 2021-01-01 2021-03-31 0001125376 srt:MaximumMember ensg:AssembledOccupancyAcquiredMember 2021-01-01 2021-03-31 0001125376 us-gaap:TradeNamesMember 2021-01-01 2021-03-31 0001125376 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CA ensg:AggregateDeductibleMember srt:ParentCompanyMember 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerOccurenceMember naics:ZZ524292 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerFacilityMember naics:ZZ524292 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:BlanketAggregateMember naics:ZZ524292 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerOccurenceMember naics:ZZ524292 2021-03-31 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerFacilityMember naics:ZZ524292 2021-03-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2021-03-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2020-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember 2021-03-31 0001125376 us-gaap:WorkersCompensationInsuranceMember stpr:TX 2021-03-31 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember ensg:LossSensitivelimitperclaimMemberMember 2021-03-31 0001125376 us-gaap:WorkersCompensationInsuranceMember 2021-03-31 0001125376 us-gaap:WorkersCompensationInsuranceMember 2020-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember 2021-04-01 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2021-03-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2021-03-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2020-12-31 0001125376 us-gaap:SubsequentEventMember 2021-04-01 2021-04-01 0001125376 2020-07-01 2020-07-31 0001125376 2021-03-01 2021-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 ensg:MedicaidMember 2021-03-31 0001125376 ensg:MedicaidMember 2020-12-31 0001125376 ensg:ManagedCareMember 2021-03-31 0001125376 ensg:ManagedCareMember 2020-12-31 0001125376 ensg:MedicareMember 2021-03-31 0001125376 ensg:MedicareMember 2020-12-31 0001125376 ensg:PrivatePayAndOtherMember 2021-03-31 0001125376 ensg:PrivatePayAndOtherMember 2020-12-31 0001125376 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001125376 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001125376 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2021-03-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0001125376 2020-01-01 2020-09-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:RealEstateSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:RealEstateSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:RentalMember 2021-01-01 2021-03-31 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RealEstateSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0001125376 srt:ConsolidationEliminationsMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:RealEstateSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:RealEstateSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:RentalMember 2020-01-01 2020-03-31 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:RealEstateSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001125376 srt:ConsolidationEliminationsMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2021-01-01 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-01-01 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:TransitionalandSkilledServicesSegmentMember 2020-01-01 2020-03-31 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2020-01-01 2020-03-31 0001125376 ensg:SkilledNursingOperationsMember 2021-01-01 2021-03-31 0001125376 ensg:SkilledNursingOperationsMember 2021-03-31 0001125376 us-gaap:SubsequentEventMember sic:Z8051 2021-04-01 2021-04-01 0001125376 us-gaap:SubsequentEventMember sic:Z8051 2021-04-01 0001125376 ensg:SkilledNursingOperationsMember 2020-01-01 2020-03-31 0001125376 ensg:SeniorLivingFacilitiesMember 2020-01-01 2020-03-31 0001125376 ensg:OwnedPropertiesMember 2020-01-01 2020-03-31 0001125376 ensg:SkilledNursingOperationsMember 2020-03-31 0001125376 ensg:SeniorLivingFacilitiesMember 2020-03-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember ensg:AssetAcquisitionMember 2020-01-01 2020-03-31 0001125376 us-gaap:LandMember ensg:AssetAcquisitionMember 2020-01-01 2020-03-31 0001125376 us-gaap:FurnitureAndFixturesMember ensg:AssetAcquisitionMember 2020-01-01 2020-03-31 0001125376 ensg:AssembledOccupancyAcquiredMember ensg:AssetAcquisitionMember 2020-01-01 2020-03-31 0001125376 ensg:SeniorLivingFacilitiesMember ensg:ThePennantGroupInc.Member 2020-03-31 0001125376 us-gaap:LandMember 2021-03-31 0001125376 us-gaap:LandMember 2020-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2021-03-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001125376 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001125376 us-gaap:EquipmentMember 2021-03-31 0001125376 us-gaap:EquipmentMember 2020-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001125376 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001125376 us-gaap:ConstructionInProgressMember 2021-03-31 0001125376 us-gaap:ConstructionInProgressMember 2020-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2021-01-01 2021-03-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2021-03-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2020-12-31 0001125376 us-gaap:TradeNamesMember 2021-03-31 0001125376 us-gaap:TradeNamesMember 2020-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2021-03-31 0001125376 us-gaap:CustomerRelationshipsMember 2020-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2021-01-01 2021-03-31 0001125376 ensg:DepreciationAndAmortizationMember 2020-01-01 2020-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2021-03-31 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2020-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-03-31 0001125376 us-gaap:CorporateNonSegmentMember 2020-12-31 0001125376 us-gaap:TradeNamesMember 2021-03-31 0001125376 us-gaap:TradeNamesMember 2020-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2021-03-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2020-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2021-03-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2020-12-31 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2021-03-31 0001125376 srt:MinimumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2021-03-31 0001125376 srt:MaximumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2021-03-31 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2021-01-01 2021-03-31 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2021-01-01 2021-03-31 0001125376 ensg:PromissoryNote53Member us-gaap:CollateralizedDebtObligationsMember 2015-05-01 0001125376 srt:MinimumMember ensg:PromissoryNote53Member us-gaap:CollateralizedDebtObligationsMember 2015-05-01 2015-05-01 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:ThirdAmendedCreditFacilityMember ensg:TruistBankMember 2019-10-01 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2019-10-01 2019-10-01 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2019-10-01 2019-10-01 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-10-01 2019-10-01 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-10-01 2019-10-01 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2019-10-01 2019-10-01 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2019-10-01 2019-10-01 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2019-10-01 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:ThirdAmendedCreditFacilityMember ensg:TruistBankMember 2021-03-31 0001125376 ensg:A2017PlanMember 2017-05-25 0001125376 ensg:A2017PlanMember us-gaap:SpinoffMember 2019-10-01 0001125376 ensg:A2017PlanMember 2017-05-25 2017-05-25 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember ensg:A2017PlanMember 2017-05-25 2017-05-25 0001125376 ensg:A2017PlanMember 2021-03-31 0001125376 ensg:ExercisePriceRangeZeroMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeZeroMember 2021-03-31 0001125376 ensg:ExercisePriceRangeOneMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeOneMember 2021-03-31 0001125376 ensg:ExercisePriceRangeTwoMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeTwoMember 2021-03-31 0001125376 ensg:ExercisePriceRangeThreeMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeThreeMember 2021-03-31 0001125376 ensg:ExercisePriceRangeFourMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeFourMember 2021-03-31 0001125376 ensg:ExercisePriceRangeFiveMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeFiveMember 2021-03-31 0001125376 ensg:ExercisePriceRangeSixMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeSixMember 2021-03-31 0001125376 ensg:ExercisePriceRangeSevenMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeSevenMember 2021-03-31 0001125376 ensg:ExercisePriceRangeEightMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeEightMember 2021-03-31 0001125376 ensg:ExercisePriceRangeNineMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeNineMember 2021-03-31 0001125376 ensg:ExercisePriceRangeTenMember 2021-01-01 2021-03-31 0001125376 ensg:ExercisePriceRangeTenMember 2021-03-31 0001125376 us-gaap:EmployeeStockOptionMember 2021-03-31 0001125376 us-gaap:EmployeeStockOptionMember 2020-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001125376 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001125376 srt:MinimumMember 2020-01-01 2020-03-31 0001125376 srt:MaximumMember 2020-01-01 2020-03-31 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-03-31 0001125376 srt:MinimumMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-03-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2021-01-01 2021-03-31 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2020-01-01 2020-03-31 0001125376 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001125376 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001125376 ensg:StockAwardsMember 2021-01-01 2021-03-31 0001125376 ensg:StockAwardsMember 2020-01-01 2020-03-31 0001125376 us-gaap:RestrictedStockMember 2021-03-31 0001125376 ensg:CareTrustREITMember 2021-03-31 0001125376 ensg:CareTrustREITMember ensg:ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember 2021-03-31 0001125376 ensg:CareTrustREITMember srt:MinimumMember 2021-03-31 0001125376 ensg:CareTrustREITMember srt:MaximumMember 2021-03-31 0001125376 ensg:CareTrustREITMember ensg:PurchaseOptionMember 2021-03-31 0001125376 ensg:CareTrustREITMember 2021-01-01 2021-03-31 0001125376 ensg:CareTrustREITMember 2020-01-01 2020-03-31 0001125376 ensg:VariousLandlordsMemberMember srt:MinimumMember 2021-03-31 0001125376 ensg:VariousLandlordsMemberMember srt:MaximumMember 2021-03-31 0001125376 ensg:VariousLandlordsMemberMember 2021-03-31 0001125376 ensg:VariousLandlordsMemberMember srt:MinimumMember us-gaap:EquipmentMember 2021-03-31 0001125376 ensg:VariousLandlordsMemberMember srt:MaximumMember us-gaap:EquipmentMember 2021-03-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2021-01-01 2021-03-31 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2020-01-01 2020-03-31 0001125376 ensg:RentCostOfServicesMember 2021-01-01 2021-03-31 0001125376 ensg:RentCostOfServicesMember 2020-01-01 2020-03-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001125376 ensg:CostOfServicesMember 2021-01-01 2021-03-31 0001125376 ensg:CostOfServicesMember 2020-01-01 2020-03-31 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember ensg:ThePennantGroupInc.Member 2019-10-01 0001125376 srt:MinimumMember us-gaap:SpinoffMember 2019-10-01 0001125376 srt:MaximumMember us-gaap:SpinoffMember 2019-10-01 0001125376 ensg:ThePennantGroupInc.Member 2021-01-01 2021-03-31 0001125376 ensg:ThePennantGroupInc.Member 2020-01-01 2020-03-31 0001125376 ensg:ThirdPartyTenantsMember 2021-01-01 2021-03-31 0001125376 ensg:ThirdPartyTenantsMember 2020-01-01 2020-03-31 0001125376 ensg:ThePennantGroupInc.Member 2021-01-01 2021-03-31 0001125376 ensg:ThePennantGroupInc.Member 2020-01-01 2020-03-31 0001125376 us-gaap:SubsequentEventMember 2021-04-01 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001125376 us-gaap:SubsequentEventMember 2021-04-26 0001125376 2020-03-13 0001125376 ensg:March42020RepurchaseProgramMember 2020-03-04 0001125376 ensg:March132020RepurchaseProgramMember 2020-03-13 0001125376 ensg:March132020RepurchaseProgramMember 2020-03-13 2020-03-13 0001125376 ensg:March42020RepurchaseProgramMember 2020-03-04 2020-03-04 0001125376 ensg:March42020RepurchaseProgramMember 2020-01-01 2020-03-31 0001125376 ensg:March132020RepurchaseProgramMember 2020-01-01 2020-03-31 0001125376 ensg:August262019RepurchaseProgramMember 2019-08-26 0001125376 ensg:August262019RepurchaseProgramMember 2019-08-26 2019-08-26 0001125376 ensg:August262019RepurchaseProgramMember 2019-01-01 2019-12-31 shares iso4217:USD iso4217:USD shares ensg:facility ensg:bed ensg:segment pure ensg:operation ensg:plan ensg:installment ensg:agreement ensg:renewal ensg:numberOfRepurchasePrograms 0001125376 --12-31 2021 Q1 false P3Y0M0D P4M0D P5Y0M P10Y0M P10Y0M P5Y0M P3Y0M 10-Q true 2021-03-31 false 001-33757 ENSIGN GROUP, INC DE 33-0861263 29222 Rancho Viejo Road, Suite 127 San Juan Capistrano CA 92675 949 487-9500 Common Stock, par value $0.001 per share ENSG NASDAQ Yes Yes Large Accelerated Filer false false false 54977473 155527000 236562000 11090000 8718000 312578000 305062000 14623000 13449000 0 1224000 30588000 26659000 513316000 582956000 779269000 778244000 1050506000 1025510000 34370000 32105000 350000 100000 32424000 32424000 41422000 33155000 2828000 2899000 54469000 54469000 3546000 3716000 2512500000 2545578000 53942000 50901000 203420000 236614000 50056000 48187000 35135000 34396000 0 102023000 97639000 87318000 2828000 2960000 443020000 562399000 111859000 112544000 973679000 950320000 66742000 62402000 41620000 39686000 1636920000 1727351000 0.001 0.001 100000000 100000000 57744000 54953000 57417000 54626000 58000 58000 349836000 338177000 597375000 551055000 2791000 2791000 71222000 71213000 876047000 818077000 -467000 150000 875580000 818227000 2512500000 2545578000 623276000 585951000 3977000 3662000 627253000 589613000 482186000 454521000 33456000 32330000 34273000 32249000 13659000 13720000 563574000 532820000 63679000 56793000 1641000 3665000 748000 698000 -893000 -2967000 62786000 53826000 12949000 12625000 49837000 41201000 631000 352000 49206000 40849000 0.91 0.76 0.86 0.73 54192000 53475000 56891000 55796000 54626000 58000 338177000 551055000 2791000 -71213000 150000 818227000 246000 3880000 3880000 81000 0 3725000 3725000 9000 9000 0.0525 2886000 2886000 4054000 4054000 631000 631000 1248000 1248000 49206000 49206000 54953000 58000 349836000 597375000 2791000 -71222000 -467000 875580000 53487000 56000 307914000 391523000 2079000 -45296000 1947000 656144000 148000 1552000 1552000 723000 1000 3085000 3086000 0.0500 2683000 2683000 3235000 3235000 692000 -692000 25000000 25000000 352000 352000 720000 720000 40849000 40849000 53666000 57000 315786000 429689000 2771000 -70296000 1579000 676815000 49837000 41201000 13659000 13720000 210000 210000 112000 125000 0 1003000 2560000 1312000 4054000 3235000 236000 -101000 15449000 21845000 -1224000 -739000 4271000 1589000 7440000 3712000 -133000 -181000 7459000 3660000 2768000 -3257000 -34562000 -16381000 11791000 10882000 -1737000 -4040000 4615000 1985000 -167000 -45000 34294000 27123000 15334000 15810000 0 14054000 250000 0 0 14050000 6250000 0 840000 121000 6869000 1008000 3430000 1396000 279000 237000 -12212000 -15542000 0 260000000 849000 240666000 3880000 1552000 9000 0 0 25000000 2868000 2705000 -1248000 -720000 9139000 0 111162000 0 -103117000 -7539000 -81035000 4042000 236562000 59175000 155527000 63217000 1427000 4835000 33339000 32481000 3800000 3300000 2886000 2683000 37471000 8370000 DESCRIPTION OF BUSINESS<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties, and other ancillary businesses. As of March 31, 2021, the Company operated 232 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 23,600 operational skilled nursing beds and 2,200 senior living units. As of March 31, 2021, the Company operated 168 facilities under long-term lease arrangements, and had options to purchase 11 of those 168 facilities. The Company's real estate portfolio includes 94 owned real estate properties, which included 64 facilities operated and managed by the Company, 31 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019, and the Service Center location. Of those 31 senior living operations, two are located on the same real estate properties as skilled nursing facilities that the Company owns and operates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Updates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the fourth quarter of 2020, the Company began reporting the results of its real estate portfolio as a new segment. The Company has two reportable segments: (1) transitional and skilled services and (2) real estate. Refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information. Corresponding items of segment information for prior periods have been recast to reflect the change of the Company’s segment structure. This structure reflects its current operational and financial management, and provides the best structure for the Company to focus on growth and investing opportunities while maintaining financial discipline. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying condensed consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2021 and 2020 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2020 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.</span></div> 232 23600 2200 168 11 168 94 64 31 31 2 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period results have been reclassified to be consistent with the current period presentation. Prior period results also reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure. Refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to segments. Prior to the fourth quarter of 2020, the Company only presented total revenue for all revenue services. As a result of the change in segments, the presentation of the Company's service revenue and rental revenue are presented separately on the Company's Condensed Consolidated Statements of Income. The reclassifications had no effect on the reported condensed consolidated results of operations. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use-assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The fair value of the pooled investment funds is derived using Level 2 inputs.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ee Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue and Accounts Receivable.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable (ASC 842). See Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue and Accounts Receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8xODQvZnJhZzplZjcwNWFmMTYwZGI0MzVkOTZhNWVlNjQ5ZGQ2MzNhZC90ZXh0cmVnaW9uOmVmNzA1YWYxNjBkYjQzNWQ5NmE1ZWU2NDlkZDYzM2FkXzc0NDM_c1a9ee9f-f4cb-4506-87f6-2513b2466179">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases and Leasehold Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. As of March 31, 2021, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8xODQvZnJhZzplZjcwNWFmMTYwZGI0MzVkOTZhNWVlNjQ5ZGQ2MzNhZC90ZXh0cmVnaW9uOmVmNzA1YWYxNjBkYjQzNWQ5NmE1ZWU2NDlkZDYzM2FkXzExMjIw_6e56854b-3028-4335-9fd4-ca698077988d">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $60,761 and $57,628 as of March 31, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per occurrence. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,078 and $24,499 as of March 31, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2021, the Company's operating subsidiaries in Washington are covered under the Company's self-insured program and the Company purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has recorded an asset and equal liability of $7,602 and $7,138 as of March 31, 2021 and December 31, 2020, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $500 for each covered person for fiscal year 2021. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $8,436 and $7,533 as of March 31, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div><span><br/></span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Simplifying the Accounting for Income Taxes (Topic 740)" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's financial position, results of operations and liquidity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the SEC issued Final Rule Release No. 33-10786 “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendments to Financial Disclosures about Acquired and Disposed Businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” (“SEC Rule 33-10786”), which amends the disclosure requirements applicable to acquisitions and dispositions of businesses. Amendments within SEC Rule 33-10786 primarily impact (1) the tests and thresholds used to determine the significance of acquisitions and dispositions; (2) the form and content of pro forma information required to be disclosed in connection with significant acquisitions and dispositions; (3) acquiree financial statement requirements; and (4) thresholds used to determine the significance of acquisitions and dispositions of real estate operations, and related financial statement requirements, among others. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's condensed consolidated financial statements.</span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Recently Issued but Not Yet Adopted by the Company</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the FASB issued ASU 2020-04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Reference Rate Reform (Topic 848),"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on its financial position, results of operations and liquidity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the SEC issued final rules 33-10890 and 34-90459 “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management’s Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,” which modernizes and simplifies certain disclosure requirements of Regulation S-K. Certain key rule amendments eliminate the requirement to disclose Selected Financial Data; Selected Quarterly Financial Data, with certain exceptions; the impact of inflation and changing prices, provided the impact is not material; off-balance sheet arrangements in tabular form; and the aggregate amount of contractual obligations in tabular form. The final rules also amended various aspects of Item 303, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,” among others. The final rules are effective for all registration statements, annual reports and quarterly reports filed on or after August 9, 2021, with early adoption permitted. The Company is currently evaluating the impact of the disclosure changes in its annual and quarterly report.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three months ended March 31, 2021 and 2020.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period results have been reclassified to be consistent with the current period presentation. Prior period results also reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure. Refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span>, for additional information related to segments. Prior to the fourth quarter of 2020, the Company only presented total revenue for all revenue services. As a result of the change in segments, the presentation of the Company's service revenue and rental revenue are presented separately on the Company's Condensed Consolidated Statements of Income. The reclassifications had no effect on the reported condensed consolidated results of operations. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use-assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The fair value of the pooled investment funds is derived using Level 2 inputs.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span>(ASC 606).<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable (ASC 842). <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8xODQvZnJhZzplZjcwNWFmMTYwZGI0MzVkOTZhNWVlNjQ5ZGQ2MzNhZC90ZXh0cmVnaW9uOmVmNzA1YWYxNjBkYjQzNWQ5NmE1ZWU2NDlkZDYzM2FkXzc0NDM_c1a9ee9f-f4cb-4506-87f6-2513b2466179">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. P59Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases and Leasehold Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. As of March 31, 2021, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div>The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. 0 0 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8xODQvZnJhZzplZjcwNWFmMTYwZGI0MzVkOTZhNWVlNjQ5ZGQ2MzNhZC90ZXh0cmVnaW9uOmVmNzA1YWYxNjBkYjQzNWQ5NmE1ZWU2NDlkZDYzM2FkXzExMjIw_6e56854b-3028-4335-9fd4-ca698077988d">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div>Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. P8M P30Y P20Y 0 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $60,761 and $57,628 as of March 31, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per occurrence. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,078 and $24,499 as of March 31, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2021, the Company's operating subsidiaries in Washington are covered under the Company's self-insured program and the Company purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has recorded an asset and equal liability of $7,602 and $7,138 as of March 31, 2021 and December 31, 2020, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $500 for each covered person for fiscal year 2021. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $8,436 and $7,533 as of March 31, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div> 500000 750000 1000000 1000000 3000000 5000000 1000000 3000000 60761000 57628000 625000 750000 350000 350000 25078000 24499000 500000 7602000 7138000 500000 8436000 7533000 <div style="margin-bottom:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span> <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div><span><br/></span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Simplifying the Accounting for Income Taxes (Topic 740)" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's financial position, results of operations and liquidity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the SEC issued Final Rule Release No. 33-10786 “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendments to Financial Disclosures about Acquired and Disposed Businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” (“SEC Rule 33-10786”), which amends the disclosure requirements applicable to acquisitions and dispositions of businesses. Amendments within SEC Rule 33-10786 primarily impact (1) the tests and thresholds used to determine the significance of acquisitions and dispositions; (2) the form and content of pro forma information required to be disclosed in connection with significant acquisitions and dispositions; (3) acquiree financial statement requirements; and (4) thresholds used to determine the significance of acquisitions and dispositions of real estate operations, and related financial statement requirements, among others. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's condensed consolidated financial statements.</span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Recently Issued but Not Yet Adopted by the Company</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the FASB issued ASU 2020-04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Reference Rate Reform (Topic 848),"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on its financial position, results of operations and liquidity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the SEC issued final rules 33-10890 and 34-90459 “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management’s Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,” which modernizes and simplifies certain disclosure requirements of Regulation S-K. Certain key rule amendments eliminate the requirement to disclose Selected Financial Data; Selected Quarterly Financial Data, with certain exceptions; the impact of inflation and changing prices, provided the impact is not material; off-balance sheet arrangements in tabular form; and the aggregate amount of contractual obligations in tabular form. The final rules also amended various aspects of Item 303, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,” among others. The final rules are effective for all registration statements, annual reports and quarterly reports filed on or after August 9, 2021, with early adoption permitted. The Company is currently evaluating the impact of the disclosure changes in its annual and quarterly report.</span></div> COVID-19 UPDATE<div style="margin-bottom:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's affiliated operations continued to be impacted by the worldwide outbreak of the 2019 coronavirus disease (COVID-19). The Company received cash distribution of relief fund payments (Provider Relief Funds) from the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act) and funds authorized by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. Department of Health and Human Services (HHS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to be used to protect residents of nursing homes and long-term care facilities from the impact of COVID-19 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">throughout 2020 and continued into 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the first quarter of 2021, the Company received $9,139 in Provider Relief Funds and as of March 31, 2021 had returned all of the funds. The Company may continue to receive additional funding in future periods. Subsequent to March 31, 2021, the Company received and returned another $2,083 in Provider Relief Funds. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act during fiscal year 2020. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in July 2020. In March 2021, the Company repaid the remaining funds of $102,023. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Family First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of December 31, 2020, the Company had $6,520 in unapplied state relief funds. During the three months ended March 31, 2021, the Company received an additional $15,645 in state relief funding and recognized $16,465 as revenue. For the three months ended March 31, 2020, the Company received and recognized $730 in state relief funding.</span></div>The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020. The total short-term balance of $24,155 is included in accrued wages and related liabilities and the remaining $24,154 is included in other long-term liabilities within the condensed consolidated balance sheets as of March 31, 2021 and December 31, 2020. 9139000 2083000 105255000 3232000 102023000 6520000 15645000 16465000 730000 48309000 24155000 24154000 REVENUE AND ACCOUNTS RECEIVABLE<div style="text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in transitional and skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 74.1% and 71.0% of all service revenue for the three months ended March 31, 2021 and 2020, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue for the three months ended March 31, 2021 and 2020.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. This single component practical expedient requires the Company to account for the lease component and non-lease component(s) associated with that lease as a single component if (1) the timing and pattern of transfer of the lease component and the non-lease component(s) associated with it are the same and (2) the lease component would be classified as an operating lease if it were accounted for separately. If the Company determines that the lease component is the predominant component, it accounts for the single component as an operating lease in accordance with the new lease standards. Conversely, the Company is required to account for the combined component under the revenue recognition standard if it determines that the non-lease component is the predominant component. As a result of this assessment, rental revenues from the lease of real estate assets that qualify for this expedient are accounted for as a single component under the new lease standards. The components of the Company's operating leases qualify for the single component presentation.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.</span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Payor</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the three months ended March 31, 2021 and 2020 is summarized in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">231,358</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,195 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,303</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,993</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461,654</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,788 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,345</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.4</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,277</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623,276</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,951 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.148%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662, respectively for the three months ended March 31, 2021 and 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of March 31, 2021 and December 31, 2020, or activity during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of March 31, 2021 and 2020, is summarized in the following table:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121,942</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,077 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71,830</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,095</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,904 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66,801</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323,668</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,780 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,090)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,718)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312,578</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,062 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span>, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less. 0.741 0.710 <div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the three months ended March 31, 2021 and 2020 is summarized in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">231,358</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,195 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,303</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,993</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461,654</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,788 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,345</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.4</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,277</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623,276</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,951 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div> 231358000 0.371 224195000 0.383 190303000 0.305 155584000 0.266 39993000 0.065 36009000 0.061 461654000 0.741 415788000 0.710 108345000 0.174 102029000 0.174 53277000 0.085 68134000 0.116 623276000 1.000 585951000 1.000 3977000 3662000 <div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of March 31, 2021 and 2020, is summarized in the following table:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121,942</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,077 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71,830</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,095</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,904 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66,801</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323,668</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,780 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,090)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,718)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312,578</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,062 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 121942000 102077000 71830000 61743000 63095000 80904000 66801000 69056000 323668000 313780000 11090000 8718000 312578000 305062000 COMPUTATION OF NET INCOME PER COMMON SHARE<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,837</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interests </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">631</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,206</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,849 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,192</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,475 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.91</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,837</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">631</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,206</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,849 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,192</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,699</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,321 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56,891</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,796 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.86</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.73 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and 787 for the three months ended March 31, 2021 and 2020, respectivel</span>y. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,837</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interests </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">631</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,206</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,849 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,192</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,475 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.91</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 49837000 41201000 631000 352000 49206000 40849000 54192000 53475000 0.91 0.76 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,837</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">631</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,206</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,849 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,192</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,475 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,699</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,321 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56,891</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,796 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.86</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.73 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and 787 for the three months ended March 31, 2021 and 2020, respectivel</span>y. 49837000 41201000 631000 352000 49206000 40849000 54192000 53475000 2699000 2321000 56891000 55796000 0.86 0.73 28000 787000 FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents of $155,527 and $236,562 as of March 31, 2021 and December 31, 2020, respectively, is derived using Level 1 inputs. The Company's other financial assets include contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. As of March 31, 2021, and December 31, 2020, the fair value of the pooled investment funds of $14,017 and $6,577, respectively, is derived using Level 2 inputs. The pooled investment funds are included in restricted and other assets in the Condensed Consolidated Balance Sheets. See Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. </span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Security Investments - Held to Maturity</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had approximately $48,993 and $45,554, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of March 31, 2021, the debt security investments were held in AA, A and BBB r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ated de</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bt securities. The Company believes its debt security investments that were in an unrealized loss position as of March 31, 2021 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.</span></div> 155527000 236562000 14017000 6577000 48993000 45554000 BUSINESS SEGMENTS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of the Company's real estate portfolio. Accordingly, the Company began reporting a new segment as it continues to expand its real estate investment strategy. The Company has two reportable segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) real estate, which is comprised of properties owned by the Company and leased to skilled nursing and assisted living operations where the properties are subject to triple-net long-term leases, including operations that are owned and operated by the Company. Prior to this new segment structure, the Company had one reportable segment, transitional and skilled services. Corresponding items of segment information for prior periods have been recast to reflect the change of the Company’s segment structure.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the transitional and skilled services segment includes 200 skilled nursing operations and 23 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's real estate segment includes 94 owned real estate properties. These properties include 64</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations the Company operated and managed, real estate properties of 31 senior living operations that are leased to and operated by Pennant and the Service Center location, which continues to lease office space to various third parties. Of the 31 real estate operations leased to Pennant, two senior living operations are located on the same real estate properties as skilled nursing facilities that the Company owns and operates. The Company also reports an “All Other” category that includes results from its senior living operations, which includes nine stand-alone senior living operations and 23 campus operations that provide both skilled nursing and rehabilitative care services and senior living services, mobile diagnostics, medical transportation and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2020, segment income and loss was changed from profit or loss from operations before interest and provision for income taxes to profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment charges from operations. Prior period presentation has been revised to reflect the new measurement. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With the exception of intercompany rental revenue, the accounting policies of the reportable segments are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Rental revenue from Ensign-affiliated operations are based on mutually agreed-upon base rent that are subject to change from time to time. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of the related healthcare facilities. Included in the real estate segment income is interest expense related to the borrowings to fund real estate acquisitions. Interest revenue is related to the investment accounts that the Service Center manages on behalf of the Company and is included in the "All Other" category. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Real Estate</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601,036</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,240</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623,276</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,879</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,977</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601,036</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,879</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,240</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,902)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">627,253</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,931</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,821</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,406)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,346</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">440</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,786</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,475</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,693</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,491</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,659</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,641</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(748)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">893</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) General and administrative expense are included in the "all other" category. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Other expense (income), net includes interest expense and interest revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Real Estate</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,304 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,647 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,951 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,944 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,282)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,304 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,944 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,647 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,282)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,613 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,591 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,090)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,826 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,515 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720 </span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(698)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) General and administrative expense is included in the "all other" category </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Other expense (income), net includes interest expense and interest revenue. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227,741</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">231,358</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,303</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,303</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,993</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,993</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458,037</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461,654</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,345</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,345</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.4</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,654</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,623</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,277</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601,036</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,240</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623,276</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,969 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,195 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,562 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,788 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,713 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,304 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,647 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,951 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2020.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662 for the three months ended March 31, 2021 and 2020, respectively. This revenue is included in our real estate segment.</span></div> 2 1 200 23 94 64 31 31 2 9 23 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Real Estate</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601,036</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,240</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623,276</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,879</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,902)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,977</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601,036</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,879</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,240</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,902)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">627,253</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,931</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,821</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,406)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,346</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">440</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,786</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,475</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,693</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,491</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,659</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,641</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(748)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">893</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) General and administrative expense are included in the "all other" category. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Other expense (income), net includes interest expense and interest revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Real Estate</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,304 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,647 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,951 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,944 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,282)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,304 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,944 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,647 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,282)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,613 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,591 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,325 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,090)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,826 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,515 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720 </span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(698)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) General and administrative expense is included in the "all other" category </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.</span></div>(3) Other expense (income), net includes interest expense and interest revenue. 601036000 0 22240000 0 623276000 0 15879000 0 -11902000 3977000 601036000 15879000 22240000 -11902000 627253000 88931000 8821000 -35406000 0 62346000 440000 62786000 7475000 4693000 1491000 0 13659000 0 -1641000 748000 0 -893000 558304000 0 27647000 0 585951000 0 14944000 0 -11282000 3662000 558304000 14944000 27647000 -11282000 589613000 80591000 6325000 -33090000 0 53826000 53826000 7148000 4515000 2057000 0 13720000 0 -3665000 698000 0 -2967000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227,741</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">231,358</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,303</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,303</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,993</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,993</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458,037</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461,654</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.1</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,345</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,345</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.4</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,654</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,623</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,277</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601,036</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,240</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623,276</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,969 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,195 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,009 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,562 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,788 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,029 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,713 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total service revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,304 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,647 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,951 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2020. </span></div>(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2020. 227741000 3617000 231358000 0.371 190303000 0 190303000 0.305 39993000 0 39993000 0.065 458037000 3617000 461654000 0.741 108345000 0 108345000 0.174 34654000 18623000 53277000 0.085 601036000 22240000 623276000 1.000 220969000 3226000 224195000 0.383 155584000 0 155584000 0.266 36009000 0 36009000 0.061 412562000 3226000 415788000 0.710 102029000 0 102029000 0.174 43713000 24421000 68134000 0.116 558304000 27647000 585951000 1.000 3977000 3662000 OPERATION EXPANSIONS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the accompanying Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company expanded its operations through long-term leases, with the addition of four stand-alone skilled nursing operations. These new operations added a total of 447 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, the Company expanded its operations through long-term leases with the addition of three stand-alone skilled nursing operations. These new operations added 322 operational skilled nursing beds to be operated by the Company's affiliated operating subsidiaries. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of a long-term lease and real estate purchases,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of three stand-alone skilled nursing operations and one stand-alone senior living operation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these additions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are related to purchases of owned properties, further expanding our real estate portfolio. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new operations added a total of 247 operational skilled nursing beds and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 162 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operational senior living units to be operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the three months ended March 31, 2020 was $14,054.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of assets</span><span style="background-color:#ffffff;color:#ff0090;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our purchases of these properties</span><span style="background-color:#ffffff;color:#ff0090;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. The purchase price for the asset acquisitions consists of building and improvements of $9,669; land of $4,080; equipment, furniture and fixtures of $236; and assembled occupancy of $69.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of 2020, the Company entered into a long-term lease agreement to transfer two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these two senior living communities.    </span></div>The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the three months ended March 31, 2021 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the March 31, 2021 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control. 4 447 3 322 3 1 2 247 162 14054000 9669000 4080000 236000 69000 2 2 PROPERTY AND EQUIPMENT - NET<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,236</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">557,616</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131,911</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">239,867</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,498</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,657</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,040,785</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027,249 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(261,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">779,269</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information on acquisitions during the three months ended March 31, 2021 and 2020.</span></div> <div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,236</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">557,616</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131,911</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">239,867</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,498</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,657</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,040,785</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027,249 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(261,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">779,269</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,244 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 101236000 101236000 557616000 555416000 131911000 129727000 239867000 233453000 4498000 4409000 5657000 3008000 1040785000 1027249000 261516000 249005000 779269000 778244000 INTANGIBLE ASSETS - NET<div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">733</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,582</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,115)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,467</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,519 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,354</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,526)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,828</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,412</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,513)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,899</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, amortization expense was $361 and $674, respectively, of which $290 and $354 was related to the amortization of right-of-use assets, respectively. Additionally, the Company identified intangible assets which became fully amortized during the prior year and removed these fully amortized balances from the gross asset and accumulated amortization amounts. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">733</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">361</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,582</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,115)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,467</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,519 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,354</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,526)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,828</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,412</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,513)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,899</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P0Y4M24D 39000 39000 0 39000 26000 13000 P30Y 733000 372000 361000 733000 366000 367000 P18Y4M24D 4582000 2115000 2467000 4640000 2121000 2519000 5354000 2526000 2828000 5412000 2513000 2899000 361000 674000 290000 354000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 176000 234000 234000 234000 234000 234000 1482000 2828000 GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of March 31, 2021. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's expansions during the three months ended March 31, 2021 were all through long-term leases and accordingly, no goodwill was recognized for these acquisitions. There were no activities in goodwill during the three months ended March 31, 2021. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's real estate segment appropriately does not carry a goodwill balance. The following table represents the goodwill value by transitional and skilled service segment and "all other" category, which includes other ancillary services, as of March 31, 2021 and December 31, 2020:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">889</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,657</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,546</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The following table represents the goodwill value by transitional and skilled service segment and "all other" category, which includes other ancillary services, as of March 31, 2021 and December 31, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitional and Skilled Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 45486000 45486000 8983000 8983000 54469000 54469000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">889</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,657</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,546</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 889000 889000 2657000 2827000 3546000 3716000 RESTRICTED AND OTHER ASSETS<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,486</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,602</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,637</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,680</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance related to deferred compensation plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,017</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted and other assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,422</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,155 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in restricted and other assets as of March 31, 2021 and December 31, 2020 are anticipated insurance recoveries related to the Company's workers' compensation liabilities and general and professional liability claims that are recorded on a gross rather than net basis in accordance with ASU issued by the FASB. </span></div>The Company implemented a non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain executives and was expanded to other highly compensated employees on January 1, 2020. The plan allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to informally fund savings plans of this nature. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The Company recorded a gain on the deferral investment of $306, which is included in interest and other income, and an offsetting expense of $351 between cost of services and general and administrative expenses in the accompanying consolidated statements of income for the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company had an expense of $87, which was recorded between cost of services and general and administrative expenses. <div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,486</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,602</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,637</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,680</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance related to deferred compensation plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,017</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted and other assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,422</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,155 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2486000 2664000 7602000 7138000 12637000 12400000 4680000 4376000 14017000 6577000 41422000 33155000 306000 351000 87000 OTHER ACCRUED LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,103</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,631 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,590</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,049</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,558 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,700</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,611</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,052 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,886</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,656</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,222 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,927</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,117</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,639</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,318 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheets.</span></div> <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,103</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,631 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,590</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,049</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,558 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,700</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,611</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,052 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,886</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,656</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,222 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,927</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,117</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,639</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,318 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7103000 6631000 39590000 36323000 6049000 8558000 5700000 6520000 5611000 6052000 2886000 2868000 7656000 9222000 11927000 136000 11117000 11008000 97639000 87318000 INCOME TAXES<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $12,949 and $12,625 during the three months ended March 31, 2021 and 2020, respectively, or 20.6% of earnings before income taxes for the three months ended March 31, 2021, compared to 23.5% for the three months ended March 31, 2020. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 Federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the three months ended March 31, 2021 and 2020.</span></div> 12949000 12625000 0.206 0.235 DEBT<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory notes</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,957</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,806 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,960)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,302)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt less current maturities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111,859</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,544 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Notes</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company's operating subsidiaries had $116,957 outstanding under the mortgage loans and notes, of which $2,828 is classified as short-term and the remaining $114,129 is classified as long-term. The Company was in compliance with all loan covenants as of March 31, 2021. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, 19 of the Company's subsidiaries have mortgage loans insured with the Department of Housing and Urban Development (HUD) in the aggregate amount of $113,304, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear fixed interest rates ranging from 2.6% to 3.5% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0%</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yNjUvZnJhZzo5NzkxMTc3MGI0MmU0MGY5YTRlNDVjMmQ0OWZlZmYzYi90ZXh0cmVnaW9uOjk3OTExNzcwYjQyZTQwZjlhNGU0NWMyZDQ5ZmVmZjNiXzM1NTI_47d5dbd5-2255-467e-8507-b1ca0243711f">five</span> through <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yNjUvZnJhZzo5NzkxMTc3MGI0MmU0MGY5YTRlNDVjMmQ0OWZlZmYzYi90ZXh0cmVnaW9uOjk3OTExNzcwYjQyZTQwZjlhNGU0NWMyZDQ5ZmVmZjNiXzM1NjM_ae7b1e95-837c-4ca5-9211-c21059514fcd">ten</span> of the loan. There is no prepayment penalty after year <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yNjUvZnJhZzo5NzkxMTc3MGI0MmU0MGY5YTRlNDVjMmQ0OWZlZmYzYi90ZXh0cmVnaW9uOjk3OTExNzcwYjQyZTQwZjlhNGU0NWMyZDQ5ZmVmZjNiXzM2MjE_3bfe7b87-4132-4dbd-9bcb-08ffb33fb141">ten</span>. The terms for all the mortgage loans are 25 to 35 years. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, renovate and upgrade existing and future facilities, cover working capital needs and other business purposes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans above, the Company has a promissory note in connection with an acquisition. The note bears a fixed interest rate of 5.3% per annum and the term of the note is 12 years. The note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a revolving credit facility under the Third Amended and Restated Credit Agreements, dated as of October 1, 2019, between the Company and Truist Financial Corporation (Truist) (formerly known as SunTrust Bank, Inc.) (the Credit Facility). The Credit Facility includes a revolving line of credit of up to $350,000 in aggregate principal amount. The maturity date of the Credit Facility is October 1, 2024. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.50% to 1.50% per annum or LIBOR plus a margin range from 1.50% to 2.50% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company pays a commitment fee on the unused portion of the commitments that ranges from 0.25% to 0.45% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of March 31, 2021, and April 26, 2021, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of March 31, 2021. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7,580</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> o</span>n the Credit Facility of borrowing capacity pledged as collateral to secure outstanding letters of credit. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory notes</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,957</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,806 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,960)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,302)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt less current maturities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111,859</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,544 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 116957000 117806000 2828000 2960000 2270000 2302000 111859000 112544000 116957000 2828000 114129000 19 113304000 0.026 0.035 0.10 0.03 0.010 P25Y P35Y 0.053 P12Y 350000000 0.0050 0.0150 0.0150 0.0250 0.0025 0.0045 3.00 50000000 3.50 1.50 0 7580000 OPTIONS AND AWARDS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three months ended March 31, 2021 and 2020 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Omnibus Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company has one active stock incentive plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The 2017 Plan provided for the issuance of 6,881 shares of common stock which are to be proportionally adjusted in the event of any Equity Restructuring. The number of shares available to be issued under the 2017 Plan were adjusted to 8,118 shares of common stock in order to reflect the proportional adjustments as part of the spin-off transaction that occurred in October 2019. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. As of March 31, 2021, there were approximately 2,839 unissued shares of common stock available for issuance under this plan. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 136 stock options during the three months ended March 31, 2021. The Company used the following assumptions for stock options granted during the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.2%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.64</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.99</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended March 31, 2021 and 2020 and therefore, the intrinsic value was $0 at the date of grant. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the three months ended March 31, 2021:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.71</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,148</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.66</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.64</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.27</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.78</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,895</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.30</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,034</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.73</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following summary information reflects stock options outstanding, vested and related details as of March 31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.00</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.77</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,955 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83.64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,625 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,151 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of March 31, 2021 and December 31, 2020 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.856%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247,457</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,552 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,841</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,867 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,008</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The aggregate intrinsic value of options that vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2021 and 2020 was</span><span style="color:#ff0090;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8,545 and $2,084, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2021 and 2020 was $17,241 and $5,621, respectively. </span><span style="color:#ff0090;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 90 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restricted stock awards during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranged from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $83.64 to $84.70</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $42.02 to $51.20, respectively. The fair value per share includes quarterly stock awards to non-employee directors. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">591</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.90</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.71</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.35</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.18</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">592</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.16</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 6</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$84.70 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the market price on the grant date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off transaction that occurred in October 2019 are granted shares of restricted stock upon the successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $201 and $194 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three months ended March 31, 2021 and 2020 was as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,733</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,838</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">483</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,054</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company expects to recognize approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $27,178 and $26,072 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of March 31, 2021. Future stock-based compensation expense will be recognized over 3.8 and 3.5 weighted average years for unvested options and restricted stock awards, respectively. There were 1,861 unvested and outstanding options as of March 31, 2021, of which 1,726 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of March 31, 2021 was 6.1 years.</span></div> 1 6881000 8118000 1 2.5 3 P3Y P5Y 0.20 P10Y 2839000 136000 The Company used the following assumptions for stock options granted during the three months ended March 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.2%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 136000 0.008 P6Y3M18D 0.422 0.002 145000 0.013 P6Y2M12D 0.321 0.004 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.64</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.99</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 136000 83.64 33.99 145000 51.20 16.60 0 0 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the three months ended March 31, 2021:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,038</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.71</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,148</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.66</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.64</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.27</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.78</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,895</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.30</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,034</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.73</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4038000 27.71 2148000 16.66 136000 83.64 33000 41.27 246000 15.78 3895000 30.30 2034000 17.73 The following summary information reflects stock options outstanding, vested and related details as of March 31, 2021:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.00</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.77</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,955 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83.64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,625 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,151 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5.00 6.77 14000 38000 P0Y 14000 5.56 6.75 88000 267000 P1Y 88000 6.76 9.74 165000 712000 P2Y 165000 8.94 16.05 676000 3231000 P3Y 676000 18.20 21.39 303000 2362000 P4Y 303000 15.93 16.86 275000 1618000 P5Y 219000 15.80 19.41 336000 1977000 P6Y 184000 22.49 32.71 566000 5855000 P7Y 214000 41.07 45.76 698000 10955000 P8Y 147000 44.84 59.49 638000 12511000 P9Y 24000 83.64 136000 4625000 P10Y 0 3895000 44151000 2034000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of March 31, 2021 and December 31, 2020 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.856%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247,457</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,552 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,841</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,867 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,008</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 247457000 182552000 154841000 120867000 80008000 53366000 8545000 2084000 17241000 5621000 90000 113000 0 P5Y 83.64 84.70 42.02 51.20 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">591</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.90</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.71</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.35</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.18</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">592</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.16</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 591000 38.90 90000 83.71 80000 64.35 9000 45.18 592000 42.16 6000 84.70 500000 P5Y 0.20 201000 194000 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three months ended March 31, 2021 and 2020 was as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,733</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,838</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">483</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,054</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1733000 1419000 1838000 1598000 483000 218000 4054000 3235000 27178000 26072000 P3Y9M18D P3Y6M 1861000 1726000 P6Y1M6D LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 89 affiliated skilled nursing and senior living facilities used in the Company’s operations, 88 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 89 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.</span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $14,080 and $13,125 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of March 31, 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction that occurred in October 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yODMvZnJhZzowNjQ0NzE3YzczMTk0YmI0OGQyNDkzODM4N2JlZTYwMS90ZXh0cmVnaW9uOjA2NDQ3MTdjNzMxOTRiYjQ4ZDI0OTM4Mzg3YmVlNjAxXzQ3OTE_a8d590a4-b191-4391-8cb1-51df776e0ff4">five</span> to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yODMvZnJhZzowNjQ0NzE3YzczMTk0YmI0OGQyNDkzODM4N2JlZTYwMS90ZXh0cmVnaW9uOjA2NDQ3MTdjNzMxOTRiYjQ4ZDI0OTM4Mzg3YmVlNjAxXzUyNzI_241d63f6-e36e-47d2-b103-ed9cf28966f4">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $33,476 and $32,347 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,456</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,330 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,443</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,209</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,912 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of March 31, 2021 are as follows: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,448 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,506 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,383 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,340 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,009 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(678,274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,735 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973,679 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of March 31, 2021, the weighted average remaining lease term is 13.7 years and the weighted average discount rate used to determine the operating lease liabilities is 8.2%.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, the Company expanded its operations through long-term lease arrangements with the addition of three stand-alone skilled nursing facilities under a new triple-net master lease, adding a total of 322 operational skilled nursing beds operated by the Company’s affiliated operating subsidiaries. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to new master lease is estimated to be approximately $20,005.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction that occurred in October 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. During the first quarter of 2020, the Company transferred the operations of an additional two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these 31 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,488</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">489</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,977</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of March 31, 2021 were as follows:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,170 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,952 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,689 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021. LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 89 affiliated skilled nursing and senior living facilities used in the Company’s operations, 88 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 89 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.</span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $14,080 and $13,125 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of March 31, 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction that occurred in October 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yODMvZnJhZzowNjQ0NzE3YzczMTk0YmI0OGQyNDkzODM4N2JlZTYwMS90ZXh0cmVnaW9uOjA2NDQ3MTdjNzMxOTRiYjQ4ZDI0OTM4Mzg3YmVlNjAxXzQ3OTE_a8d590a4-b191-4391-8cb1-51df776e0ff4">five</span> to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEyNTQ0YzE1ZTFhNDQ0YTJhN2RmN2IxNTNiZjg2YzFmL3NlYzoxMjU0NGMxNWUxYTQ0NGEyYTdkZjdiMTUzYmY4NmMxZl8yODMvZnJhZzowNjQ0NzE3YzczMTk0YmI0OGQyNDkzODM4N2JlZTYwMS90ZXh0cmVnaW9uOjA2NDQ3MTdjNzMxOTRiYjQ4ZDI0OTM4Mzg3YmVlNjAxXzUyNzI_241d63f6-e36e-47d2-b103-ed9cf28966f4">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $33,476 and $32,347 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,456</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,330 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,443</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,209</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,912 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of March 31, 2021 are as follows: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,448 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,506 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,383 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,340 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,009 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(678,274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,735 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973,679 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of March 31, 2021, the weighted average remaining lease term is 13.7 years and the weighted average discount rate used to determine the operating lease liabilities is 8.2%.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021, the Company expanded its operations through long-term lease arrangements with the addition of three stand-alone skilled nursing facilities under a new triple-net master lease, adding a total of 322 operational skilled nursing beds operated by the Company’s affiliated operating subsidiaries. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to new master lease is estimated to be approximately $20,005.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction that occurred in October 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. During the first quarter of 2020, the Company transferred the operations of an additional two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these 31 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,488</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">489</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,977</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of March 31, 2021 were as follows:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,170 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,952 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,689 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021. 89 88 9 P12Y P20Y 2 3 P5Y 4 89 0.025 14080000 13125000 P20Y P15Y 2 P5Y P5Y 33476000 32347000 40 7 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,456</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,330 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,443</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,209</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,912 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</span></div> 33456000 32330000 20000 17000 290000 354000 3443000 3211000 37209000 35912000 112000 125000 584000 594000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of March 31, 2021 are as follows: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,448 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,506 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,383 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,340 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,009 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(678,274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,735 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973,679 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 98448000 131211000 129521000 128600000 128506000 128383000 957340000 1702009000 678274000 1023735000 50056000 973679000 P13Y8M12D 0.082 3 322 20005000 29 2 31 P14Y P16Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,488</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">489</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,977</span><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020. 3488000 3101000 489000 561000 3977000 3662000 314000 466000 <div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of March 31, 2021 were as follows:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,790 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,170 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,952 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,689 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021. 11671000 15053000 14790000 14170000 13952000 13772000 85281000 168689000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations can likewise be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996, which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-Containment Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment or other relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheets for any of the periods presented.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction that occurred in October 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Department of Justice Civil Investigative Demand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company has fully cooperated with the U.S. Department of Justice and promptly responded to the requests for information, and has been advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation. </span></div><div style="margin-top:1pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:1pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. House of Representatives Select Subcommittee Request</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis has launched a nation-wide investigation into the COVID-19 pandemic, which includes the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation or whether and what other investigations or regulatory responses may result from the investigation and could have a material adverse effect on our reputation, business, financial condition, and results of operations.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relator has continued on with the lawsuit and is pursuing claims that the Company has allegedly violated the False Claims Act and/or the Anti-Kickback Statute.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and au</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thorize meal and rest breaks, and related causes action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims filed by residents and responsible parties related to patient care and treatment (professional negligence claims), as well as employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its operating subsidiaries going forward under a corporate integrity agreement and/or other such arrangement.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. As of March 31, 2021, two of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process. Subsequently, during April, one facility review was resolved and closed. The Company anticipates that these Reviews could increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of March 31, 2021, the Company's independent operating subsidiaries have responded to the requests with respect to the claims currently under review, on appeal or in a dispute resolution process.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 57.2% and 58.3% of its total accounts receivable as of March 31, 2021 and December 31, 2020, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 74.1% and 71.0% of the Company's service revenue for the three months ended March 31, 2021 and 2020, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash in Excess of FDIC Limits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of April 26, 2021, the Company had approximately $424 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.</span> 2 1 0.572 0.583 0.741 0.710 424000 COMMON STOCK REPURCHASE PROGRAMAs approved by the Board of Directors on March 4, 2020 and March 13, 2020, the Company entered into two stock repurchase programs pursuant to which the Company was authorized to repurchase up to $20,000 and $5,000, respectively, of its common stock under the programs for a period of approximately 12 months. Under these programs, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2020, the Company repurchased 503 and 189 shares of its common stock for $20,000 and $5,000, respectively. These repurchase programs expired upon the repurchase of the full authorized amount under the two plans.As approved by the Board of Directors on August 26, 2019, the Company entered into a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company repurchased 138 shares of its common stock for a total of $6,406 in fiscal year 2019 before the repurchase program was cancelled in the first quarter of 2020. 2 20000000 5000000 P12M P12M 503000 189000 20000000 5000000 2 20000000 P12M 138000 6406000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
3 Months Ended
Mar. 31, 2021
Apr. 26, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-33757  
Entity Registrant Name ENSIGN GROUP, INC  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 33-0861263  
Entity Address, Address Line One 29222 Rancho Viejo Road, Suite 127  
Entity Address, City or Town San Juan Capistrano  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92675  
City Area Code 949  
Local Phone Number 487-9500  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol ENSG  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   54,977,473
Entity Central Index Key 0001125376  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 155,527 $ 236,562
Accounts receivable—less allowance for doubtful accounts of $11,090 and $8,718 at March 31, 2021 and December 31, 2020, respectively 312,578 305,062
Investments—current 14,623 13,449
Prepaid income taxes 0 1,224
Prepaid expenses and other current assets 30,588 26,659
Total current assets 513,316 582,956
Property and equipment, net 779,269 778,244
Right-of-use assets 1,050,506 1,025,510
Insurance subsidiary deposits and investments 34,370 32,105
Escrow deposits 350 100
Deferred tax assets 32,424 32,424
Restricted and other assets 41,422 33,155
Intangible assets, net 2,828 2,899
Goodwill 54,469 54,469
Other indefinite-lived intangibles 3,546 3,716
Total assets 2,512,500 2,545,578
Current liabilities:    
Accounts payable 53,942 50,901
Accrued wages and related liabilities (Note 3) 203,420 236,614
Lease liabilities—current 50,056 48,187
Accrued self-insurance liabilities—current 35,135 34,396
Advance payment liabilities (Note 3) 0 102,023
Other accrued liabilities 97,639 87,318
Current maturities of long-term debt 2,828 2,960
Total current liabilities 443,020 562,399
Long-term debt—less current maturities 111,859 112,544
Long-term lease liabilities—less current portion 973,679 950,320
Accrued self-insurance liabilities—less current portion 66,742 62,402
Other long-term liabilities 41,620 39,686
Total liabilities 1,636,920 1,727,351
Commitments and contingencies (Notes 15, 17 and 18)
Ensign Group, Inc. stockholders' equity:    
Common stock: $0.001 par value; 100,000 shares authorized; 57,744 and 54,953 shares issued and outstanding at March 31, 2021, respectively, and 57,417 and 54,626 shares issued and outstanding at December 31, 2020, respectively 58 58
Additional paid-in capital 349,836 338,177
Retained earnings 597,375 551,055
Common stock in treasury, at cost, 2,791 shares at both periods ended March 31, 2021 and December 31, 2020 (Note 19) (71,222) (71,213)
Total Ensign Group, Inc. stockholders' equity 876,047 818,077
Non-controlling interest (467) 150
Total equity 875,580 818,227
Total liabilities and equity $ 2,512,500 $ 2,545,578
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 11,090 $ 8,718
Common stock, par value (usd per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 57,744,000 57,417,000
Common stock, shares outstanding (in shares) 54,953,000 54,626,000
Common stock in treasury, at cost (in shares) 2,791,000 2,791,000
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Total revenue $ 627,253 $ 589,613
Expense:    
Cost of services 482,186 454,521
Rent—cost of services 33,456 32,330
General and administrative expense 34,273 32,249
Depreciation and amortization 13,659 13,720
Total expenses 563,574 532,820
Income from operations 63,679 56,793
Other income (expense):    
Interest expense (1,641) (3,665)
Interest and other income 748 698
Other expense, net (893) (2,967)
Income before provision for income taxes 62,786 53,826
Provision for income taxes 12,949 12,625
Net income 49,837 41,201
Less:    
Net income attributable to noncontrolling interests 631 352
Net income attributable to The Ensign Group, Inc. $ 49,206 $ 40,849
Net income per share attributable to The Ensign Group, Inc.:    
Basic income per share attributable to The Ensign Group, Inc. (in dollars per share) $ 0.91 $ 0.76
Diluted income per share attributable to The Ensign Group, Inc.(in dollars per share) $ 0.86 $ 0.73
Weighted average common shares outstanding:    
Basic (in shares) 54,192 53,475
Diluted (in shares) 56,891 55,796
Service revenue    
Total revenue $ 623,276 $ 585,951
Rental revenue    
Total revenue $ 3,977 $ 3,662
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Treasury Stock
Non-Controlling Interest
Balance at beginning of period (in shares) at Dec. 31, 2019   53,487     2,079  
Balance at beginning of period at Dec. 31, 2019 $ 656,144 $ 56 $ 307,914 $ 391,523 $ (45,296) $ 1,947
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   148        
Issuance of common stock to employees and directors resulting from the exercise of stock options 1,552   1,552      
Issuance of restricted stock (in shares)   723        
Issuance of restricted stock, net of forfeitures 3,086 $ 1 3,085      
Dividends declared (2,683)     (2,683)    
Employee stock award compensation 3,235   3,235      
Repurchase of common stock (in shares)   (692)     692  
Repurchase of common stock (25,000)       $ (25,000)  
Net income attributable to noncontrolling interests 352         352
Distribution to noncontrolling interest holder (720)         (720)
Net income attributable to the Ensign Group, Inc. 40,849     40,849    
Balance at end of period (in shares) at Mar. 31, 2020   53,666     2,771  
Balance at end of period at Mar. 31, 2020 676,815 $ 57 315,786 429,689 $ (70,296) 1,579
Balance at beginning of period (in shares) at Dec. 31, 2020   54,626     2,791  
Balance at beginning of period at Dec. 31, 2020 818,227 $ 58 338,177 551,055 $ (71,213) 150
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   246        
Issuance of common stock to employees and directors resulting from the exercise of stock options 3,880   3,880      
Issuance of restricted stock (in shares)   81        
Issuance of restricted stock, net of forfeitures 3,725 $ 0 3,725      
Shares of common stock used to satisfy tax withholding obligations (9)       $ (9)  
Dividends declared (2,886)     (2,886)    
Employee stock award compensation 4,054   4,054      
Net income attributable to noncontrolling interests 631         631
Distribution to noncontrolling interest holder (1,248)         (1,248)
Net income attributable to the Ensign Group, Inc. 49,206     49,206    
Balance at end of period (in shares) at Mar. 31, 2021   54,953     2,791  
Balance at end of period at Mar. 31, 2021 $ 875,580 $ 58 $ 349,836 $ 597,375 $ (71,222) $ (467)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Statement of Stockholders' Equity [Abstract]    
Dividends per share (in dollars per share) $ 0.0525 $ 0.0500
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 49,837 $ 41,201
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 13,659 13,720
Amortization of deferred financing fees 210 210
Non-cash leasing arrangement 112 125
Deferred income taxes 0 1,003
Provision for doubtful accounts 2,560 1,312
Stock-based compensation 4,054 3,235
(Gain)/loss on sale of asset disposals (236) 101
Change in operating assets and liabilities    
Accounts receivable (15,449) (21,845)
Prepaid income taxes 1,224 739
Prepaid expenses and other assets (4,271) (1,589)
Cash surrender value of life insurance policy premiums (7,440) (3,712)
Operating lease obligations (133) (181)
Deferred compensation liability 7,459 3,660
Accounts payable 2,768 (3,257)
Accrued wages and related liabilities (34,562) (16,381)
Income taxes payable 11,791 10,882
Other accrued liabilities (1,737) (4,040)
Accrued self-insurance liabilities 4,615 1,985
Other long-term liabilities (167) (45)
Net cash provided by operating activities 34,294 27,123
Cash flows from investing activities:    
Purchase of property and equipment (15,334) (15,810)
Cash payments for asset acquisitions (Note 8) 0 (14,054)
Escrow deposits (250) 0
Escrow deposits used to fund acquisitions 0 14,050
Cash proceeds from insurance proceeds 6,250 0
Cash proceeds from the sale of assets and ancillary business 840 121
Purchases of investments (6,869) (1,008)
Maturities of investments 3,430 1,396
Other restricted assets (279) (237)
Net cash used in investing activities (12,212) (15,542)
Cash flows from financing activities:    
Proceeds from revolving credit facility and other debt (Note 15) 0 260,000
Payments on revolving credit facility and other debt (Note 15) (849) (240,666)
Issuance of common stock upon exercise of options 3,880 1,552
Repurchase of shares of common stock to satisfy tax withholding obligations (9) 0
Repurchase of shares of common stock (Note 19) 0 (25,000)
Dividends paid (2,868) (2,705)
Non-controlling interest distribution (1,248) (720)
Proceeds from CARES Act Provider Relief Fund (Note 3) 9,139 0
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program(Note 3) (111,162) 0
Net cash used in financing activities (103,117) (7,539)
Net (decrease)/increase in cash and cash equivalents (81,035) 4,042
Cash and cash equivalents beginning of period 236,562 59,175
Cash and cash equivalents end of period 155,527 63,217
Cash paid during the period for:    
Interest 1,427 4,835
Lease liabilities 33,339 32,481
Non-cash financing and investing activity:    
Accrued capital expenditures 3,800 3,300
Accrued dividends declared 2,886 2,683
Right-of-use assets obtained in exchange for new operating lease obligations $ 37,471 $ 8,370
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Description of Business
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties, and other ancillary businesses. As of March 31, 2021, the Company operated 232 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 23,600 operational skilled nursing beds and 2,200 senior living units. As of March 31, 2021, the Company operated 168 facilities under long-term lease arrangements, and had options to purchase 11 of those 168 facilities. The Company's real estate portfolio includes 94 owned real estate properties, which included 64 facilities operated and managed by the Company, 31 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019, and the Service Center location. Of those 31 senior living operations, two are located on the same real estate properties as skilled nursing facilities that the Company owns and operates.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

Segment Updates In the fourth quarter of 2020, the Company began reporting the results of its real estate portfolio as a new segment. The Company has two reportable segments: (1) transitional and skilled services and (2) real estate. Refer to Note 7, Business Segments, for additional information. Corresponding items of segment information for prior periods have been recast to reflect the change of the Company’s segment structure. This structure reflects its current operational and financial management, and provides the best structure for the Company to focus on growth and investing opportunities while maintaining financial discipline.

Other Information The accompanying condensed consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2021 and 2020 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2020 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three months ended March 31, 2021 and 2020.
ReclassificationsCertain prior period results have been reclassified to be consistent with the current period presentation. Prior period results also reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure. Refer to Note 7, Business Segments, for additional information related to segments. Prior to the fourth quarter of 2020, the Company only presented total revenue for all revenue services. As a result of the change in segments, the presentation of the Company's service revenue and rental revenue are presented separately on the Company's Condensed Consolidated Statements of Income. The reclassifications had no effect on the reported condensed consolidated results of operations.
Estimates and Assumptions The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use-assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.

Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The fair value of the pooled investment funds is derived using Level 2 inputs.

Service Revenue RecognitionThe Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 4, Revenue and Accounts Receivable.

Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable (ASC 842). See Note 4, Revenue and Accounts Receivable.
Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence.
Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. As of March 31, 2021, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.

The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.

The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.

Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three months ended March 31, 2021 and 2020.
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the three months ended March 31, 2021 and 2020.
Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $60,761 and $57,628 as of March 31, 2021 and December 31, 2020, respectively.
 The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per occurrence. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,078 and $24,499 as of March 31, 2021 and December 31, 2020, respectively.
Effective April 1, 2021, the Company's operating subsidiaries in Washington are covered under the Company's self-insured program and the Company purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence.
In addition, the Company has recorded an asset and equal liability of $7,602 and $7,138 as of March 31, 2021 and December 31, 2020, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12 Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $500 for each covered person for fiscal year 2021. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $8,436 and $7,533 as of March 31, 2021 and December 31, 2020, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12 "Simplifying the Accounting for Income Taxes (Topic 740)" as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's financial position, results of operations and liquidity.

In May 2020, the SEC issued Final Rule Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses” (“SEC Rule 33-10786”), which amends the disclosure requirements applicable to acquisitions and dispositions of businesses. Amendments within SEC Rule 33-10786 primarily impact (1) the tests and thresholds used to determine the significance of acquisitions and dispositions; (2) the form and content of pro forma information required to be disclosed in connection with significant acquisitions and dispositions; (3) acquiree financial statement requirements; and (4) thresholds used to determine the significance of acquisitions and dispositions of real estate operations, and related financial statement requirements, among others. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's condensed consolidated financial statements.
Accounting Standards Recently Issued but Not Yet Adopted by the Company

In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on its financial position, results of operations and liquidity.

In November 2020, the SEC issued final rules 33-10890 and 34-90459 “Management’s Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information,” which modernizes and simplifies certain disclosure requirements of Regulation S-K. Certain key rule amendments eliminate the requirement to disclose Selected Financial Data; Selected Quarterly Financial Data, with certain exceptions; the impact of inflation and changing prices, provided the impact is not material; off-balance sheet arrangements in tabular form; and the aggregate amount of contractual obligations in tabular form. The final rules also amended various aspects of Item 303, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” among others. The final rules are effective for all registration statements, annual reports and quarterly reports filed on or after August 9, 2021, with early adoption permitted. The Company is currently evaluating the impact of the disclosure changes in its annual and quarterly report.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
COVID-19 UPDATE
3 Months Ended
Mar. 31, 2021
Unusual or Infrequent Items, or Both [Abstract]  
COVID-19 UPDATE COVID-19 UPDATE
The Company's affiliated operations continued to be impacted by the worldwide outbreak of the 2019 coronavirus disease (COVID-19). The Company received cash distribution of relief fund payments (Provider Relief Funds) from the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care facilities from the impact of COVID-19 throughout 2020 and continued into 2021. During the first quarter of 2021, the Company received $9,139 in Provider Relief Funds and as of March 31, 2021 had returned all of the funds. The Company may continue to receive additional funding in future periods. Subsequent to March 31, 2021, the Company received and returned another $2,083 in Provider Relief Funds.
Additionally, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act during fiscal year 2020. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in July 2020. In March 2021, the Company repaid the remaining funds of $102,023.

The Family First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of December 31, 2020, the Company had $6,520 in unapplied state relief funds. During the three months ended March 31, 2021, the Company received an additional $15,645 in state relief funding and recognized $16,465 as revenue. For the three months ended March 31, 2020, the Company received and recognized $730 in state relief funding.
The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020. The total short-term balance of $24,155 is included in accrued wages and related liabilities and the remaining $24,154 is included in other long-term liabilities within the condensed consolidated balance sheets as of March 31, 2021 and December 31, 2020.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and Accounts Receivable
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
REVENUE AND ACCOUNTS RECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE
Service Revenue

The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in transitional and skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 74.1% and 71.0% of all service revenue for the three months ended March 31, 2021 and 2020, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue for the three months ended March 31, 2021 and 2020.

Rental Revenue
The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. This single component practical expedient requires the Company to account for the lease component and non-lease component(s) associated with that lease as a single component if (1) the timing and pattern of transfer of the lease component and the non-lease component(s) associated with it are the same and (2) the lease component would be classified as an operating lease if it were accounted for separately. If the Company determines that the lease component is the predominant component, it accounts for the single component as an operating lease in accordance with the new lease standards. Conversely, the Company is required to account for the combined component under the revenue recognition standard if it determines that the non-lease component is the predominant component. As a result of this assessment, rental revenues from the lease of real estate assets that qualify for this expedient are accounted for as a single component under the new lease standards. The components of the Company's operating leases qualify for the single component presentation.
Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenue by Payor
The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
Service revenue for the three months ended March 31, 2021 and 2020 is summarized in the following tables:
 Three Months Ended March 31,
20212020
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$231,358 37.1 %$224,195 38.3 %
Medicare190,303 30.5 155,584 26.6 
Medicaid — skilled39,993 6.5 36,009 6.1 
Total Medicaid and Medicare461,654 74.1 415,788 71.0 
Managed care108,345 17.4 102,029 17.4 
Private and other(2)
53,277 8.5 68,134 11.6 
Service revenue$623,276 100.0 %$585,951 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2021 and 2020.
(2) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended March 31, 2021 and 2020.
In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662, respectively for the three months ended March 31, 2021 and 2020.

Balance Sheet Impact
Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of March 31, 2021 and December 31, 2020, or activity during the three months ended March 31, 2021 and 2020.
Accounts receivable as of March 31, 2021 and 2020, is summarized in the following table:
March 31, 2021December 31, 2020
Medicaid$121,942 $102,077 
Managed care71,830 61,743 
Medicare63,095 80,904 
Private and other payors66,801 69,056 
 323,668 313,780 
Less: allowance for doubtful accounts(11,090)(8,718)
Accounts receivable, net$312,578 $305,062 
Practical Expedients and Exemptions
As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Computation of Net Income Per Common Share
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
COMPUTATION OF NET INCOME PER COMMON SHARE COMPUTATION OF NET INCOME PER COMMON SHARE
Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
Three Months Ended March 31,
 20212020
Numerator:  
Net income$49,837 $41,201 
Less: net income attributable to noncontrolling interests 631 352 
Net income attributable to The Ensign Group, Inc. $49,206 $40,849 
Denominator: 
Weighted average shares outstanding for basic net income per share54,192 53,475 
Basic net income per common share:$0.91 $0.76 

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:
Three Months Ended March 31,
 20212020
Numerator:  
Net income $49,837 $41,201 
Less: net income attributable to noncontrolling interests631 352 
Net income attributable to The Ensign Group, Inc. $49,206 $40,849 
Denominator:  
Weighted average common shares outstanding54,192 53,475 
Plus: incremental shares from assumed conversion (1)
2,699 2,321 
Adjusted weighted average common shares outstanding56,891 55,796 
Diluted net income per common share:$0.86 $0.73 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 28 and 787 for the three months ended March 31, 2021 and 2020, respectively.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The fair value of cash and cash equivalents of $155,527 and $236,562 as of March 31, 2021 and December 31, 2020, respectively, is derived using Level 1 inputs. The Company's other financial assets include contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. As of March 31, 2021, and December 31, 2020, the fair value of the pooled investment funds of $14,017 and $6,577, respectively, is derived using Level 2 inputs. The pooled investment funds are included in restricted and other assets in the Condensed Consolidated Balance Sheets. See Note 12 Restricted and Other Assets.

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
Debt Security Investments - Held to Maturity

As of March 31, 2021 and December 31, 2020, the Company had approximately $48,993 and $45,554, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of March 31, 2021, the debt security investments were held in AA, A and BBB rated debt securities. The Company believes its debt security investments that were in an unrealized loss position as of March 31, 2021 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Business Segments
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
BUSINESS SEGMENTS BUSINESS SEGMENTS
In the fourth quarter of 2020, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of the Company's real estate portfolio. Accordingly, the Company began reporting a new segment as it continues to expand its real estate investment strategy. The Company has two reportable segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) real estate, which is comprised of properties owned by the Company and leased to skilled nursing and assisted living operations where the properties are subject to triple-net long-term leases, including operations that are owned and operated by the Company. Prior to this new segment structure, the Company had one reportable segment, transitional and skilled services. Corresponding items of segment information for prior periods have been recast to reflect the change of the Company’s segment structure.

As of March 31, 2021, the transitional and skilled services segment includes 200 skilled nursing operations and 23 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's real estate segment includes 94 owned real estate properties. These properties include 64 operations the Company operated and managed, real estate properties of 31 senior living operations that are leased to and operated by Pennant and the Service Center location, which continues to lease office space to various third parties. Of the 31 real estate operations leased to Pennant, two senior living operations are located on the same real estate properties as skilled nursing facilities that the Company owns and operates. The Company also reports an “All Other” category that includes results from its senior living operations, which includes nine stand-alone senior living operations and 23 campus operations that provide both skilled nursing and rehabilitative care services and senior living services, mobile diagnostics, medical transportation and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

Beginning in the fourth quarter of 2020, segment income and loss was changed from profit or loss from operations before interest and provision for income taxes to profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment charges from operations. Prior period presentation has been revised to reflect the new measurement.

With the exception of intercompany rental revenue, the accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Rental revenue from Ensign-affiliated operations are based on mutually agreed-upon base rent that are subject to change from time to time. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of the related healthcare facilities. Included in the real estate segment income is interest expense related to the borrowings to fund real estate acquisitions. Interest revenue is related to the investment accounts that the Service Center manages on behalf of the Company and is included in the "All Other" category.
The following tables set forth financial information for the segments:

 Three Months Ended March 31, 2021
 Transitional and Skilled ServicesReal Estate
All Other(1)
Intercompany Elimination(2)
Total
Service revenue$601,036 $ $22,240 $ $623,276 
Rental revenue  15,879  (11,902)3,977 
Total revenue$601,036 $15,879 $22,240 $(11,902)$627,253 
Segment income (loss)88,931 8,821 (35,406) 62,346 
Gain on sale of real estate440 
Income before provision for income taxes $62,786 
Depreciation and amortization7,475 4,693 1,491  13,659 
Other expense (income), net(3)
$ $1,641 $(748)$ $893 
(1) General and administrative expense are included in the "all other" category.
(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.
(3) Other expense (income), net includes interest expense and interest revenue.

 Three Months Ended March 31, 2020
 Transitional and Skilled ServicesReal Estate
All Other(1)
Intercompany Elimination(2)
Total
Service revenue$558,304 $— $27,647 $— $585,951 
Rental revenue— 14,944 — (11,282)3,662 
Total revenue$558,304 $14,944 $27,647 $(11,282)$589,613 
Segment income (loss)80,591 6,325 (33,090)— 53,826 
Income before provision for income taxes $53,826 
Depreciation and amortization7,148 4,515 2,057 — 13,720 
Other expense (income), net(3)
$— $3,665 $(698)$— $2,967 
(1) General and administrative expense is included in the "all other" category
(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.
(3) Other expense (income), net includes interest expense and interest revenue.

Service revenue by major payor source were as follows:

 Three Months Ended March 31, 2021
 Transitional and Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid$227,741 $3,617 (1)$231,358 37.1 %
Medicare190,303  190,303 30.5 
Medicaid-skilled39,993  39,993 6.5 
Subtotal458,037 3,617 461,654 74.1 
Managed care108,345  108,345 17.4 
Private and other34,654 18,623 (2)53,277 8.5 
Total service revenue$601,036 $22,240 $623,276 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2021.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2021.
 Three Months Ended March 31, 2020
 Transitional and Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid$220,969 $3,226 (1)$224,195 38.3 %
Medicare155,584 — 155,584 26.6 
Medicaid-skilled36,009 — 36,009 6.1 
Subtotal412,562 3,226 415,788 71.0 
Managed care102,029 — 102,029 17.4 
Private and other43,713 24,421 (2)68,134 11.6 
Total service revenue$558,304 $27,647 $585,951 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2020.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2020.

In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $3,977 and $3,662 for the three months ended March 31, 2021 and 2020, respectively. This revenue is included in our real estate segment.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Operation Expansions
3 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
Operation Expansions OPERATION EXPANSIONS
The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the accompanying Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.

2021 Expansions
During the three months ended March 31, 2021, the Company expanded its operations through long-term leases, with the addition of four stand-alone skilled nursing operations. These new operations added a total of 447 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
Subsequent to March 31, 2021, the Company expanded its operations through long-term leases with the addition of three stand-alone skilled nursing operations. These new operations added 322 operational skilled nursing beds to be operated by the Company's affiliated operating subsidiaries.
2020 Expansions
During the three months ended March 31, 2020, the Company expanded its operations through a combination of a long-term lease and real estate purchases, with the addition of three stand-alone skilled nursing operations and one stand-alone senior living operation. Of these additions, two are related to purchases of owned properties, further expanding our real estate portfolio. These new operations added a total of 247 operational skilled nursing beds and 162 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the three months ended March 31, 2020 was $14,054.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The fair value of assets for our purchases of these properties was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. The purchase price for the asset acquisitions consists of building and improvements of $9,669; land of $4,080; equipment, furniture and fixtures of $236; and assembled occupancy of $69.
During the first quarter of 2020, the Company entered into a long-term lease agreement to transfer two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these two senior living communities.    
The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the three months ended March 31, 2021 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the March 31, 2021 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment — Net
3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT— Net PROPERTY AND EQUIPMENT - NET
Property and equipment, net consists of the following:
March 31, 2021December 31, 2020
Land$101,236 $101,236 
Buildings and improvements557,616 555,416 
Leasehold improvements131,911 129,727 
Equipment239,867 233,453 
Furniture and fixtures4,498 4,409 
Construction in progress5,657 3,008 
 1,040,785 1,027,249 
Less: accumulated depreciation(261,516)(249,005)
Property and equipment, net$779,269 $778,244 
See also Note 8, Operation Expansions for information on acquisitions during the three months ended March 31, 2021 and 2020.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets — Net
3 Months Ended
Mar. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
INTANGIBLE ASSETS — NET INTANGIBLE ASSETS - NET
 March 31, 2021December 31, 2020
Weighted Average Life (Years)
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.4$39 $(39)$ $39 $(26)$13 
Facility trade name30.0733 (372)361 733 (366)367 
Customer relationships18.44,582 (2,115)2,467 4,640 (2,121)2,519 
Total $5,354 $(2,526)$2,828 $5,412 $(2,513)$2,899 

During the three months ended March 31, 2021 and 2020, amortization expense was $361 and $674, respectively, of which $290 and $354 was related to the amortization of right-of-use assets, respectively. Additionally, the Company identified intangible assets which became fully amortized during the prior year and removed these fully amortized balances from the gross asset and accumulated amortization amounts.
Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2021 (remainder)$176 
2022234 
2023234 
2024234 
2025234 
2026234 
Thereafter1,482 
 $2,828 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Other Indefinite-Lived Intangible Assets
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS
The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of March 31, 2021.

The Company's expansions during the three months ended March 31, 2021 were all through long-term leases and accordingly, no goodwill was recognized for these acquisitions. There were no activities in goodwill during the three months ended March 31, 2021. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's real estate segment appropriately does not carry a goodwill balance. The following table represents the goodwill value by transitional and skilled service segment and "all other" category, which includes other ancillary services, as of March 31, 2021 and December 31, 2020:

 Transitional and Skilled ServicesAll OtherTotal
Goodwill$45,486 $8,983 $54,469 

Other indefinite-lived intangible assets consist of the following:
March 31, 2021December 31, 2020
Trade name$889 $889 
Medicare and Medicaid licenses2,657 2,827 
 $3,546 $3,716 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Restricted and Other Assets
3 Months Ended
Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
RESTRICTED AND OTHER ASSETS RESTRICTED AND OTHER ASSETS
Restricted and other assets consist of the following:
March 31, 2021December 31, 2020
Debt issuance costs, net$2,486 $2,664 
Long-term insurance losses recoverable asset7,602 7,138 
Deposits with landlords12,637 12,400 
Capital improvement reserves with landlords and lenders4,680 4,376 
Cash surrender value of life insurance related to deferred compensation plan14,017 6,577 
Restricted and other assets$41,422 $33,155 

Included in restricted and other assets as of March 31, 2021 and December 31, 2020 are anticipated insurance recoveries related to the Company's workers' compensation liabilities and general and professional liability claims that are recorded on a gross rather than net basis in accordance with ASU issued by the FASB.
The Company implemented a non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain executives and was expanded to other highly compensated employees on January 1, 2020. The plan allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to informally fund savings plans of this nature. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The Company recorded a gain on the deferral investment of $306, which is included in interest and other income, and an offsetting expense of $351 between cost of services and general and administrative expenses in the accompanying consolidated statements of income for the three months ended March 31, 2021. During the three months ended March 31, 2020, the Company had an expense of $87, which was recorded between cost of services and general and administrative expenses.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Other Accrued Liabilities
3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
OTHER ACCRUED LIABILITIES OTHER ACCRUED LIABILITIES
Other accrued liabilities consists of the following:
March 31, 2021December 31, 2020
Quality assurance fee$7,103 $6,631 
Refunds payable39,590 36,323 
Resident advances6,049 8,558 
Unapplied state relief funds5,700 6,520 
Cash held in trust for patients5,611 6,052 
Dividends payable2,886 2,868 
Property taxes7,656 9,222 
Income tax payable11,927 136 
Other11,117 11,008 
Other accrued liabilities$97,639 $87,318 

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying condensed consolidated balance sheets.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
3 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company recorded income tax expense of $12,949 and $12,625 during the three months ended March 31, 2021 and 2020, respectively, or 20.6% of earnings before income taxes for the three months ended March 31, 2021, compared to 23.5% for the three months ended March 31, 2020. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 Federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the three months ended March 31, 2021 and 2020.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Debt
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
DEBT DEBT
Debt consists of the following:
March 31, 2021December 31, 2020
Mortgage loans and promissory notes$116,957 $117,806 
Less: current maturities(2,828)(2,960)
Less: debt issuance costs, net(2,270)(2,302)
Long term debt less current maturities$111,859 $112,544 

Mortgage Loans and Promissory Notes
As of March 31, 2021, the Company's operating subsidiaries had $116,957 outstanding under the mortgage loans and notes, of which $2,828 is classified as short-term and the remaining $114,129 is classified as long-term. The Company was in compliance with all loan covenants as of March 31, 2021.

As of March 31, 2021, 19 of the Company's subsidiaries have mortgage loans insured with the Department of Housing and Urban Development (HUD) in the aggregate amount of $113,304, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear fixed interest rates ranging from 2.6% to 3.5% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, renovate and upgrade existing and future facilities, cover working capital needs and other business purposes.

In addition to the HUD mortgage loans above, the Company has a promissory note in connection with an acquisition. The note bears a fixed interest rate of 5.3% per annum and the term of the note is 12 years. The note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.

Credit Facility with a Lending Consortium Arranged by Truist
The Company maintains a revolving credit facility under the Third Amended and Restated Credit Agreements, dated as of October 1, 2019, between the Company and Truist Financial Corporation (Truist) (formerly known as SunTrust Bank, Inc.) (the Credit Facility). The Credit Facility includes a revolving line of credit of up to $350,000 in aggregate principal amount. The maturity date of the Credit Facility is October 1, 2024. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.50% to 1.50% per annum or LIBOR plus a margin range from 1.50% to 2.50% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company pays a commitment fee on the unused portion of the commitments that ranges from 0.25% to 0.45% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.
The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of March 31, 2021, and April 26, 2021, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of March 31, 2021.

Off-Balance Sheet Arrangements
As of March 31, 2021, the Company had approximately $7,580 on the Credit Facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
OPTIONS AND AWARDS OPTIONS AND AWARDS
Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three months ended March 31, 2021 and 2020 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
2017 Omnibus Incentive Plan - The Company has one active stock incentive plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The 2017 Plan provided for the issuance of 6,881 shares of common stock which are to be proportionally adjusted in the event of any Equity Restructuring. The number of shares available to be issued under the 2017 Plan were adjusted to 8,118 shares of common stock in order to reflect the proportional adjustments as part of the spin-off transaction that occurred in October 2019. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. As of March 31, 2021, there were approximately 2,839 unissued shares of common stock available for issuance under this plan.
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time.

Stock Options
The Company granted 136 stock options during the three months ended March 31, 2021. The Company used the following assumptions for stock options granted during the three months ended March 31, 2021 and 2020:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20211360.8%6.3 years42.2%0.2%
20201451.3%6.2 years32.1%0.4%
For the three months ended March 31, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2021136$83.64 $33.99 
2020145$51.20 $16.60 
The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended March 31, 2021 and 2020 and therefore, the intrinsic value was $0 at the date of grant.


The following table represents the employee stock option activity during the three months ended March 31, 2021:

Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20214,038 $27.71 2,148 $16.66 
Granted136 83.64 
Forfeited(33)41.27 
Exercised(246)15.78 
March 31, 20213,895 $30.30 2,034 $17.73 

The following summary information reflects stock options outstanding, vested and related details as of March 31, 2021:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
2011$5.00-$6.7714 $38 014 
20125.56-6.7588 267 188 
20136.76-9.74165 712 2165 
20148.94-16.05676 3,231 3676 
201518.20-21.39303 2,362 4303 
201615.93-16.86275 1,618 5219 
201715.80-19.41336 1,977 6184 
201822.49-32.71566 5,855 7214 
201941.07-45.76698 10,955 8147 
202044.84-59.49638 12,511 924 
2021$83.64136 4,625 10— 
Total 3,895 $44,151  2,034 
The aggregate intrinsic value of options outstanding, vested and expected to vest as of March 31, 2021 and December 31, 2020 is as follows:
OptionsMarch 31, 2021December 31, 2020
Outstanding$247,457 $182,552 
Vested154,841 120,867 
Expected to vest80,008 53,366 

The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the three months ended March 31, 2021 and 2020 was $8,545 and $2,084, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2021 and 2020 was $17,241 and $5,621, respectively.
Restricted Stock Awards
The Company granted 90 and 113 restricted stock awards during the three months ended March 31, 2021 and 2020, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the three months ended March 31, 2021 and 2020 ranged from $83.64 to $84.70 and $42.02 to $51.20, respectively. The fair value per share includes quarterly stock awards to non-employee directors.

A summary of the status of the Company's non-vested restricted stock awards as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Nonvested at January 1, 2021591 $38.90 
Granted90 83.71 
Vested(80)64.35 
Forfeited(9)45.18 
Nonvested at March 31, 2021592 $42.16 
During the three months ended March 31, 2021, the Company granted 6 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards was $84.70 based on the market price on the grant date.
Long-Term Incentive Plan
On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off transaction that occurred in October 2019 are granted shares of restricted stock upon the successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $201 and $194 for the three months ended March 31, 2021 and 2020, respectively.
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three months ended March 31, 2021 and 2020 was as follows:
Three Months Ended March 31,
 20212020
Stock-based compensation expense related to stock options$1,733 $1,419 
Stock-based compensation expense related to restricted stock awards1,838 1,598 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors483 218 
Total$4,054 $3,235 

In future periods, the Company expects to recognize approximately $27,178 and $26,072 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of March 31, 2021. Future stock-based compensation expense will be recognized over 3.8 and 3.5 weighted average years for unvested options and restricted stock awards, respectively. There were 1,861 unvested and outstanding options as of March 31, 2021, of which 1,726 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of March 31, 2021 was 6.1 years.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Leases
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
LEASES LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 89 affiliated skilled nursing and senior living facilities used in the Company’s operations, 88 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 89 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $14,080 and $13,125 for the three months ended March 31, 2021 and 2020, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of March 31, 2021.
In connection with the spin-off transaction that occurred in October 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $33,476 and $32,347 for the three months ended March 31, 2021 and 2020, respectively.
Forty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
The components of operating lease expense are as follows:
Three Months Ended March 31,
20212020
Rent - cost of services(1)
$33,456 $32,330 
General and administrative expense20 17 
Depreciation and amortization(2)
290 354 
Variable lease costs(3)
3,443 3,211 
$37,209 $35,912 
(1)Rent- cost of services includes deferred rent expense adjustments of $112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of March 31, 2021 are as follows:
YearAmount
2021 (remainder)$98,448 
2022131,211 
2023129,521 
2024128,600 
2025128,506 
2026128,383 
Thereafter957,340 
Total lease payments1,702,009 
Less: present value adjustment (678,274)
Present value of total lease liabilities1,023,735 
Less: current lease liabilities(50,056)
Long-term operating lease liabilities$973,679 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of March 31, 2021, the weighted average remaining lease term is 13.7 years and the weighted average discount rate used to determine the operating lease liabilities is 8.2%.

Subsequent to March 31, 2021, the Company expanded its operations through long-term lease arrangements with the addition of three stand-alone skilled nursing facilities under a new triple-net master lease, adding a total of 322 operational skilled nursing beds operated by the Company’s affiliated operating subsidiaries. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to new master lease is estimated to be approximately $20,005.

Lessor Activities

In connection with the spin-off transaction that occurred in October 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. During the first quarter of 2020, the Company transferred the operations of an additional two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these 31 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.
Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:

Three Months Ended March 31,
20212020
Pennant(1)
$3,488 $3,101 
Other third-party489 561 
$3,977 $3,662 
(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020.


Future annual rental income for all leases as of March 31, 2021 were as follows:

Year
Amount(1)
2021 (remainder)$11,671 
202215,053 
202314,790 
202414,170 
202513,952 
202613,772 
Thereafter85,281 
Total$168,689 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021.
LEASES LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 89 affiliated skilled nursing and senior living facilities used in the Company’s operations, 88 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 89 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $14,080 and $13,125 for the three months ended March 31, 2021 and 2020, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of March 31, 2021.
In connection with the spin-off transaction that occurred in October 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $33,476 and $32,347 for the three months ended March 31, 2021 and 2020, respectively.
Forty of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
The components of operating lease expense are as follows:
Three Months Ended March 31,
20212020
Rent - cost of services(1)
$33,456 $32,330 
General and administrative expense20 17 
Depreciation and amortization(2)
290 354 
Variable lease costs(3)
3,443 3,211 
$37,209 $35,912 
(1)Rent- cost of services includes deferred rent expense adjustments of $112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of March 31, 2021 are as follows:
YearAmount
2021 (remainder)$98,448 
2022131,211 
2023129,521 
2024128,600 
2025128,506 
2026128,383 
Thereafter957,340 
Total lease payments1,702,009 
Less: present value adjustment (678,274)
Present value of total lease liabilities1,023,735 
Less: current lease liabilities(50,056)
Long-term operating lease liabilities$973,679 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of March 31, 2021, the weighted average remaining lease term is 13.7 years and the weighted average discount rate used to determine the operating lease liabilities is 8.2%.

Subsequent to March 31, 2021, the Company expanded its operations through long-term lease arrangements with the addition of three stand-alone skilled nursing facilities under a new triple-net master lease, adding a total of 322 operational skilled nursing beds operated by the Company’s affiliated operating subsidiaries. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to new master lease is estimated to be approximately $20,005.

Lessor Activities

In connection with the spin-off transaction that occurred in October 2019, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. During the first quarter of 2020, the Company transferred the operations of an additional two senior living operations to Pennant. Ensign affiliates retained ownership of the real estate for these 31 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.
Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:

Three Months Ended March 31,
20212020
Pennant(1)
$3,488 $3,101 
Other third-party489 561 
$3,977 $3,662 
(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020.


Future annual rental income for all leases as of March 31, 2021 were as follows:

Year
Amount(1)
2021 (remainder)$11,671 
202215,053 
202314,790 
202414,170 
202513,952 
202613,772 
Thereafter85,281 
Total$168,689 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations can likewise be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996, which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information.
Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment or other relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.

In connection with the spin-off transaction that occurred in October 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.
U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company has fully cooperated with the U.S. Department of Justice and promptly responded to the requests for information, and has been advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.

U.S. House of Representatives Select Subcommittee Request The U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis has launched a nation-wide investigation into the COVID-19 pandemic, which includes the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation or whether and what other investigations or regulatory responses may result from the investigation and could have a material adverse effect on our reputation, business, financial condition, and results of operations.

Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.
In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the qui tam relator has continued on with the lawsuit and is pursuing claims that the Company has allegedly violated the False Claims Act and/or the Anti-Kickback Statute.
In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.
The Company and its independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims filed by residents and responsible parties related to patient care and treatment (professional negligence claims), as well as employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.

The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its operating subsidiaries going forward under a corporate integrity agreement and/or other such arrangement.

Medicare Revenue Recoupments The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. As of March 31, 2021, two of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process. Subsequently, during April, one facility review was resolved and closed. The Company anticipates that these Reviews could increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of March 31, 2021, the Company's independent operating subsidiaries have responded to the requests with respect to the claims currently under review, on appeal or in a dispute resolution process.

Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 57.2% and 58.3% of its total accounts receivable as of March 31, 2021 and December 31, 2020, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 74.1% and 71.0% of the Company's service revenue for the three months ended March 31, 2021 and 2020, respectively.
Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of April 26, 2021, the Company had approximately $424 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock Repurchase Program
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
COMMON STOCK REPURCHASE PROGRAM COMMON STOCK REPURCHASE PROGRAMAs approved by the Board of Directors on March 4, 2020 and March 13, 2020, the Company entered into two stock repurchase programs pursuant to which the Company was authorized to repurchase up to $20,000 and $5,000, respectively, of its common stock under the programs for a period of approximately 12 months. Under these programs, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the first quarter of 2020, the Company repurchased 503 and 189 shares of its common stock for $20,000 and $5,000, respectively. These repurchase programs expired upon the repurchase of the full authorized amount under the two plans.As approved by the Board of Directors on August 26, 2019, the Company entered into a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The Company repurchased 138 shares of its common stock for a total of $6,406 in fiscal year 2019 before the repurchase program was cancelled in the first quarter of 2020.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three months ended March 31, 2021 and 2020.
Reclassifications ReclassificationsCertain prior period results have been reclassified to be consistent with the current period presentation. Prior period results also reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure. Refer to Note 7, Business Segments, for additional information related to segments. Prior to the fourth quarter of 2020, the Company only presented total revenue for all revenue services. As a result of the change in segments, the presentation of the Company's service revenue and rental revenue are presented separately on the Company's Condensed Consolidated Statements of Income. The reclassifications had no effect on the reported condensed consolidated results of operations.
Estimates and Assumptions Estimates and Assumptions The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use-assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on performance measurement funds that shadow the deferral investment allocations made by participants in the deferred compensation plan. The fair value of the pooled investment funds is derived using Level 2 inputs.
Revenue Recognition Service Revenue RecognitionThe Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606).Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable (ASC 842).
Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence.
Property and Equipment Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases and Leasehold Improvements
Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. As of March 31, 2021, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.

The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
Intangible Assets and Goodwill
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year.
Self-Insurance Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $60,761 and $57,628 as of March 31, 2021 and December 31, 2020, respectively.
 The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per occurrence. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,078 and $24,499 as of March 31, 2021 and December 31, 2020, respectively.
Effective April 1, 2021, the Company's operating subsidiaries in Washington are covered under the Company's self-insured program and the Company purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence.
In addition, the Company has recorded an asset and equal liability of $7,602 and $7,138 as of March 31, 2021 and December 31, 2020, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12 Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $500 for each covered person for fiscal year 2021. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $8,436 and $7,533 as of March 31, 2021 and December 31, 2020, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
Noncontrolling Interest Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based Compensation Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Recent Accounting Pronouncements
Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12 "Simplifying the Accounting for Income Taxes (Topic 740)" as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's financial position, results of operations and liquidity.

In May 2020, the SEC issued Final Rule Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses” (“SEC Rule 33-10786”), which amends the disclosure requirements applicable to acquisitions and dispositions of businesses. Amendments within SEC Rule 33-10786 primarily impact (1) the tests and thresholds used to determine the significance of acquisitions and dispositions; (2) the form and content of pro forma information required to be disclosed in connection with significant acquisitions and dispositions; (3) acquiree financial statement requirements; and (4) thresholds used to determine the significance of acquisitions and dispositions of real estate operations, and related financial statement requirements, among others. The Company adopted this standard on January 1, 2021 and determined there was no material impact on the Company's condensed consolidated financial statements.
Accounting Standards Recently Issued but Not Yet Adopted by the Company

In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-04 on its financial position, results of operations and liquidity.

In November 2020, the SEC issued final rules 33-10890 and 34-90459 “Management’s Discussion and Analysis, Selected Financial Data, and Supplementary Financial Information,” which modernizes and simplifies certain disclosure requirements of Regulation S-K. Certain key rule amendments eliminate the requirement to disclose Selected Financial Data; Selected Quarterly Financial Data, with certain exceptions; the impact of inflation and changing prices, provided the impact is not material; off-balance sheet arrangements in tabular form; and the aggregate amount of contractual obligations in tabular form. The final rules also amended various aspects of Item 303, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” among others. The final rules are effective for all registration statements, annual reports and quarterly reports filed on or after August 9, 2021, with early adoption permitted. The Company is currently evaluating the impact of the disclosure changes in its annual and quarterly report.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and Accounts Receivable (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
Service revenue for the three months ended March 31, 2021 and 2020 is summarized in the following tables:
 Three Months Ended March 31,
20212020
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$231,358 37.1 %$224,195 38.3 %
Medicare190,303 30.5 155,584 26.6 
Medicaid — skilled39,993 6.5 36,009 6.1 
Total Medicaid and Medicare461,654 74.1 415,788 71.0 
Managed care108,345 17.4 102,029 17.4 
Private and other(2)
53,277 8.5 68,134 11.6 
Service revenue$623,276 100.0 %$585,951 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2021 and 2020.
(2) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended March 31, 2021 and 2020.
Schedule of Accounts, Notes, Loans and Financing Receivable
Accounts receivable as of March 31, 2021 and 2020, is summarized in the following table:
March 31, 2021December 31, 2020
Medicaid$121,942 $102,077 
Managed care71,830 61,743 
Medicare63,095 80,904 
Private and other payors66,801 69,056 
 323,668 313,780 
Less: allowance for doubtful accounts(11,090)(8,718)
Accounts receivable, net$312,578 $305,062 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Computation of Net Income Per Common Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method
A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
Three Months Ended March 31,
 20212020
Numerator:  
Net income$49,837 $41,201 
Less: net income attributable to noncontrolling interests 631 352 
Net income attributable to The Ensign Group, Inc. $49,206 $40,849 
Denominator: 
Weighted average shares outstanding for basic net income per share54,192 53,475 
Basic net income per common share:$0.91 $0.76 
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method
A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:
Three Months Ended March 31,
 20212020
Numerator:  
Net income $49,837 $41,201 
Less: net income attributable to noncontrolling interests631 352 
Net income attributable to The Ensign Group, Inc. $49,206 $40,849 
Denominator:  
Weighted average common shares outstanding54,192 53,475 
Plus: incremental shares from assumed conversion (1)
2,699 2,321 
Adjusted weighted average common shares outstanding56,891 55,796 
Diluted net income per common share:$0.86 $0.73 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 28 and 787 for the three months ended March 31, 2021 and 2020, respectively.
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Business Segments (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables set forth financial information for the segments:

 Three Months Ended March 31, 2021
 Transitional and Skilled ServicesReal Estate
All Other(1)
Intercompany Elimination(2)
Total
Service revenue$601,036 $ $22,240 $ $623,276 
Rental revenue  15,879  (11,902)3,977 
Total revenue$601,036 $15,879 $22,240 $(11,902)$627,253 
Segment income (loss)88,931 8,821 (35,406) 62,346 
Gain on sale of real estate440 
Income before provision for income taxes $62,786 
Depreciation and amortization7,475 4,693 1,491  13,659 
Other expense (income), net(3)
$ $1,641 $(748)$ $893 
(1) General and administrative expense are included in the "all other" category.
(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.
(3) Other expense (income), net includes interest expense and interest revenue.

 Three Months Ended March 31, 2020
 Transitional and Skilled ServicesReal Estate
All Other(1)
Intercompany Elimination(2)
Total
Service revenue$558,304 $— $27,647 $— $585,951 
Rental revenue— 14,944 — (11,282)3,662 
Total revenue$558,304 $14,944 $27,647 $(11,282)$589,613 
Segment income (loss)80,591 6,325 (33,090)— 53,826 
Income before provision for income taxes $53,826 
Depreciation and amortization7,148 4,515 2,057 — 13,720 
Other expense (income), net(3)
$— $3,665 $(698)$— $2,967 
(1) General and administrative expense is included in the "all other" category
(2) Intercompany elimination represents rental income at the real estate segment generated from triple-net lease arrangements with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation, along with corresponding intercompany rent expenses of related healthcare facilities.
(3) Other expense (income), net includes interest expense and interest revenue.
Reconciliation of Revenue from Segments to Consolidated
Service revenue by major payor source were as follows:

 Three Months Ended March 31, 2021
 Transitional and Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid$227,741 $3,617 (1)$231,358 37.1 %
Medicare190,303  190,303 30.5 
Medicaid-skilled39,993  39,993 6.5 
Subtotal458,037 3,617 461,654 74.1 
Managed care108,345  108,345 17.4 
Private and other34,654 18,623 (2)53,277 8.5 
Total service revenue$601,036 $22,240 $623,276 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2021.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2021.
 Three Months Ended March 31, 2020
 Transitional and Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid$220,969 $3,226 (1)$224,195 38.3 %
Medicare155,584 — 155,584 26.6 
Medicaid-skilled36,009 — 36,009 6.1 
Subtotal412,562 3,226 415,788 71.0 
Managed care102,029 — 102,029 17.4 
Private and other43,713 24,421 (2)68,134 11.6 
Total service revenue$558,304 $27,647 $585,951 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP for the three months ended March 31, 2020.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services for the three months ended March 31, 2020.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment — Net (Tables)
3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment, net consists of the following:
March 31, 2021December 31, 2020
Land$101,236 $101,236 
Buildings and improvements557,616 555,416 
Leasehold improvements131,911 129,727 
Equipment239,867 233,453 
Furniture and fixtures4,498 4,409 
Construction in progress5,657 3,008 
 1,040,785 1,027,249 
Less: accumulated depreciation(261,516)(249,005)
Property and equipment, net$779,269 $778,244 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets — Net (Tables)
3 Months Ended
Mar. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Finite-Lived Intangible Assets
 March 31, 2021December 31, 2020
Weighted Average Life (Years)
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.4$39 $(39)$ $39 $(26)$13 
Facility trade name30.0733 (372)361 733 (366)367 
Customer relationships18.44,582 (2,115)2,467 4,640 (2,121)2,519 
Total $5,354 $(2,526)$2,828 $5,412 $(2,513)$2,899 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2021 (remainder)$176 
2022234 
2023234 
2024234 
2025234 
2026234 
Thereafter1,482 
 $2,828 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Other Indefinite-Lived Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill The following table represents the goodwill value by transitional and skilled service segment and "all other" category, which includes other ancillary services, as of March 31, 2021 and December 31, 2020:
 Transitional and Skilled ServicesAll OtherTotal
Goodwill$45,486 $8,983 $54,469 
Schedule of Other Indefinite-lived Intangible Assets by Major Class
Other indefinite-lived intangible assets consist of the following:
March 31, 2021December 31, 2020
Trade name$889 $889 
Medicare and Medicaid licenses2,657 2,827 
 $3,546 $3,716 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Restricted and Other Assets (Tables)
3 Months Ended
Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Restricted and Other Assets
Restricted and other assets consist of the following:
March 31, 2021December 31, 2020
Debt issuance costs, net$2,486 $2,664 
Long-term insurance losses recoverable asset7,602 7,138 
Deposits with landlords12,637 12,400 
Capital improvement reserves with landlords and lenders4,680 4,376 
Cash surrender value of life insurance related to deferred compensation plan14,017 6,577 
Restricted and other assets$41,422 $33,155 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Other Accrued Liabilities (Tables)
3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Other Accrued Liabilities
Other accrued liabilities consists of the following:
March 31, 2021December 31, 2020
Quality assurance fee$7,103 $6,631 
Refunds payable39,590 36,323 
Resident advances6,049 8,558 
Unapplied state relief funds5,700 6,520 
Cash held in trust for patients5,611 6,052 
Dividends payable2,886 2,868 
Property taxes7,656 9,222 
Income tax payable11,927 136 
Other11,117 11,008 
Other accrued liabilities$97,639 $87,318 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Tables)
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Debt consists of the following:
March 31, 2021December 31, 2020
Mortgage loans and promissory notes$116,957 $117,806 
Less: current maturities(2,828)(2,960)
Less: debt issuance costs, net(2,270)(2,302)
Long term debt less current maturities$111,859 $112,544 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions The Company used the following assumptions for stock options granted during the three months ended March 31, 2021 and 2020:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20211360.8%6.3 years42.2%0.2%
20201451.3%6.2 years32.1%0.4%
Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options
For the three months ended March 31, 2021 and 2020, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2021136$83.64 $33.99 
2020145$51.20 $16.60 
Schedule of Common Stock Outstanding Roll Forward
The following table represents the employee stock option activity during the three months ended March 31, 2021:

Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20214,038 $27.71 2,148 $16.66 
Granted136 83.64 
Forfeited(33)41.27 
Exercised(246)15.78 
March 31, 20213,895 $30.30 2,034 $17.73 
Share-based Payment Arrangement, Option, Exercise Price Range The following summary information reflects stock options outstanding, vested and related details as of March 31, 2021:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
2011$5.00-$6.7714 $38 014 
20125.56-6.7588 267 188 
20136.76-9.74165 712 2165 
20148.94-16.05676 3,231 3676 
201518.20-21.39303 2,362 4303 
201615.93-16.86275 1,618 5219 
201715.80-19.41336 1,977 6184 
201822.49-32.71566 5,855 7214 
201941.07-45.76698 10,955 8147 
202044.84-59.49638 12,511 924 
2021$83.64136 4,625 10— 
Total 3,895 $44,151  2,034 
Schedule of Aggregate Intrinsic Value of Options
The aggregate intrinsic value of options outstanding, vested and expected to vest as of March 31, 2021 and December 31, 2020 is as follows:
OptionsMarch 31, 2021December 31, 2020
Outstanding$247,457 $182,552 
Vested154,841 120,867 
Expected to vest80,008 53,366 
Schedule of Nonvested Restricted Stock Units Activity
A summary of the status of the Company's non-vested restricted stock awards as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Nonvested at January 1, 2021591 $38.90 
Granted90 83.71 
Vested(80)64.35 
Forfeited(9)45.18 
Nonvested at March 31, 2021592 $42.16 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three months ended March 31, 2021 and 2020 was as follows:
Three Months Ended March 31,
 20212020
Stock-based compensation expense related to stock options$1,733 $1,419 
Stock-based compensation expense related to restricted stock awards1,838 1,598 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors483 218 
Total$4,054 $3,235 
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Leases (Tables)
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Lease, Cost
The components of operating lease expense are as follows:
Three Months Ended March 31,
20212020
Rent - cost of services(1)
$33,456 $32,330 
General and administrative expense20 17 
Depreciation and amortization(2)
290 354 
Variable lease costs(3)
3,443 3,211 
$37,209 $35,912 
(1)Rent- cost of services includes deferred rent expense adjustments of $112 and $125 for the three months ended March 31, 2021 and 2020, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $584 and $594 for the three months ended March 31, 2021 and 2020, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.
Lessee, Operating Lease, Liability, Maturity
Future minimum lease payments for all leases as of March 31, 2021 are as follows:
YearAmount
2021 (remainder)$98,448 
2022131,211 
2023129,521 
2024128,600 
2025128,506 
2026128,383 
Thereafter957,340 
Total lease payments1,702,009 
Less: present value adjustment (678,274)
Present value of total lease liabilities1,023,735 
Less: current lease liabilities(50,056)
Long-term operating lease liabilities$973,679 
Operating Lease, Lease Income
Total rental income from all third-party sources for the three months ended March 31, 2021 and 2020 is as follows:

Three Months Ended March 31,
20212020
Pennant(1)
$3,488 $3,101 
Other third-party489 561 
$3,977 $3,662 
(1) Pennant rental income includes variable rent such as property taxes of $314 and $466 during the three months ended March 31, 2021 and 2020.
Lessor, Operating Lease, Payments to be Received, Maturity
Future annual rental income for all leases as of March 31, 2021 were as follows:

Year
Amount(1)
2021 (remainder)$11,671 
202215,053 
202314,790 
202414,170 
202513,952 
202613,772 
Thereafter85,281 
Total$168,689 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of March 31, 2021.
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Description of Business (Details)
3 Months Ended 9 Months Ended
Mar. 31, 2021
bed
facility
segment
Sep. 30, 2020
segment
Mar. 31, 2020
bed
facility
Oct. 01, 2019
facility
Restructuring Cost and Reserve [Line Items]        
Health care facilities 232      
Operational skilled nursing beds | bed 23,600      
Operational senior living units | bed 2,200      
Number of real estate properties leased 168      
Number of real estate properties leased with an option to purchase 11      
Number of real estate properties 94      
Number of reportable segments | segment 2 1    
Wholly Owned Properties        
Restructuring Cost and Reserve [Line Items]        
Number of real estate properties 64      
Senior Living Facilities | The Pennant Group, Inc.        
Restructuring Cost and Reserve [Line Items]        
Number of real estate properties     2  
Spinoff | Senior Living Facilities | The Pennant Group, Inc.        
Restructuring Cost and Reserve [Line Items]        
Number of real estate properties 31     29
Skilled Nursing Operations        
Restructuring Cost and Reserve [Line Items]        
Operational skilled nursing beds | bed 447   247  
Remaining Company | Skilled Nursing Operations | Spinoff        
Restructuring Cost and Reserve [Line Items]        
Number of real estate properties 2      
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Property and Equipment (Details)
3 Months Ended
Mar. 31, 2021
Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 3 years
Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 59 years
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Accounting Policies [Abstract]    
Impairment of long-lived assets $ 0 $ 0
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Goodwill and intangible asset impairment $ 0 $ 0
Facility trade name    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 30 years  
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 20 years  
Minimum | Assembled occupancy    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 4 months  
Maximum | Assembled occupancy    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 8 months  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Self-Insurance General and Professional (Details) - USD ($)
$ in Thousands
Apr. 01, 2021
Mar. 31, 2021
Dec. 31, 2020
Liability for Claims and Claims Adjustment Expense [Line Items]      
Long-term insurance losses recoverable asset   $ 7,602 $ 7,138
General and Professional Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Malpractice loss contingency, accrual, undiscounted   60,761 57,628
Health      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   8,436 $ 7,533
Self-Insurance Retention Per Claim | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve $ 500    
Self-Insurance Retention Per Claim | Parent Company | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   500  
Aggregate Deductible | Parent Company | California | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   750  
Aggregate Deductible | Parent Company | Non-California | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   1,000  
Blanket Aggregate | Third-Party Payor | All States Except Colorado | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   5,000  
Per Occurence | Third-Party Payor | All States Except Colorado | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   1,000  
Per Occurence | Third-Party Payor | Colorado | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   1,000  
Per Facility | Third-Party Payor | All States Except Colorado | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   3,000  
Per Facility | Third-Party Payor | Colorado | General Liability      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   $ 3,000  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Self-Insurance Workers' Compensation (Details) - USD ($)
$ in Thousands
Apr. 01, 2021
Mar. 31, 2021
Dec. 31, 2020
Workers' Compensation      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   $ 25,078 $ 24,499
Workers' Compensation      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   625  
Workers' Compensation | TEXAS      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   750  
Workers' Compensation | Loss-Sensitive Limit Per Claim | Other States, Except California, Texas and Washington      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   350  
General Liability | Self-Insurance Retention Per Claim      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve $ 500    
General Liability | Self-Insurance Retention Per Claim | Parent Company      
Liability for Claims and Claims Adjustment Expense [Line Items]      
Self insurance reserve   $ 500  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Self Insurance Recoveries (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Long-term insurance losses recoverable asset $ 7,602 $ 7,138
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Self-Insurance Health Insurance (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Health Liability Insurance | Stop-Loss Insurance Limit Per Claim  
Liability for Claims and Claims Adjustment Expense [Line Items]  
Self insurance reserve $ 500
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.1
COVID-19 UPDATE (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Apr. 01, 2021
Mar. 31, 2021
Jul. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Subsequent Event [Line Items]            
Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received       $ 9,139    
Medicare Accelerated and Advance Payment       105,255    
Repayment of Medicare Accelerated and Advance Payment Program   $ 102,023 $ 3,232      
Unapplied state relief funds   5,700   5,700   $ 6,520
FMAP payments received       15,645 $ 730  
Revenue, FMAP payments received       16,465    
Total deferred payment of social security taxes   48,309   48,309    
Deferred payment of social security taxes, current   24,155   24,155    
Deferred payment of social security taxes, noncurrent   $ 24,154   $ 24,154    
Subsequent Event            
Subsequent Event [Line Items]            
Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received $ 2,083          
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Customer Concentration Risk | Revenue Benchmark | Total Medicare and Medicaid    
Disaggregation of Revenue [Line Items]    
Concentration risk 74.10% 71.00%
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and Accounts Receivable - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Total revenue $ 627,253 $ 589,613
Rental revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 3,977 3,662
Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 623,276 $ 585,951
Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 100.00% 100.00%
Medicaid | Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 231,358 $ 224,195
Medicaid | Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 37.10% 38.30%
Medicare | Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 190,303 $ 155,584
Medicare | Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 30.50% 26.60%
Medicaid — skilled | Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 39,993 $ 36,009
Medicaid — skilled | Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 6.50% 6.10%
Total Medicaid and Medicare | Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 461,654 $ 415,788
Total Medicaid and Medicare | Customer Concentration Risk | Revenue Benchmark    
Disaggregation of Revenue [Line Items]    
Concentration risk 74.10% 71.00%
Total Medicaid and Medicare | Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 74.10% 71.00%
Managed care | Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 108,345 $ 102,029
Managed care | Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 17.40% 17.40%
Private and other | Service revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 53,277 $ 68,134
Private and other | Customer Concentration Risk | Revenue Benchmark | Service revenue    
Disaggregation of Revenue [Line Items]    
Concentration risk 8.50% 11.60%
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue and Accounts Receivable - Accounts Receivable (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable $ 323,668 $ 313,780
Less: allowance for doubtful accounts (11,090) (8,718)
Accounts receivable, net 312,578 305,062
Medicaid    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 121,942 102,077
Managed care    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 71,830 61,743
Medicare    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 63,095 80,904
Private and other payors    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable $ 66,801 $ 69,056
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Computation of Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator:    
Net income from continuing operations $ 49,837 $ 41,201
Less: net income attributable to noncontrolling interests 631 352
Net income attributable to The Ensign Group, Inc. $ 49,206 $ 40,849
Denominator:    
Weighted average shares outstanding for basic net income per share (in shares) 54,192 53,475
Plus: incremental shares from assumed conversion (in shares) 2,699 2,321
Adjusted weighted average common shares outstanding (in shares) 56,891 55,796
Basic net income from continuing operations (in dollars per share) $ 0.91 $ 0.76
Diluted net income from continuing operations (in dollars per share) $ 0.86 $ 0.73
Antidilutive securities excluded from computation of earnings per share, amount (in shares) 28 787
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Inputs, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cash and cash equivalents, fair value disclosure $ 155,527 $ 236,562
Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cash surrender value of life insurance related to deferred compensation plan $ 14,017 $ 6,577
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Debt Security, Corporate, US    
Schedule of Held-to-maturity Securities [Line Items]    
Debt securities, held-to-maturity $ 48,993 $ 45,554
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Business Segments - Narrative (Details)
3 Months Ended 9 Months Ended
Mar. 31, 2021
facility
segment
Sep. 30, 2020
segment
Mar. 31, 2020
facility
Oct. 01, 2019
facility
Segment Reporting Information [Line Items]        
Number of reportable segments | segment 2 1    
Transitional and skilled service facilities 200      
Transitional and skilled services and senior living campuses 23      
Number of real estate properties 94      
Senior living facilities 9      
Spinoff | Remaining Company | Skilled Nursing Operations        
Segment Reporting Information [Line Items]        
Number of real estate properties 2      
The Pennant Group, Inc. | Senior Living Facilities        
Segment Reporting Information [Line Items]        
Number of real estate properties     2  
The Pennant Group, Inc. | Senior Living Facilities | Spinoff        
Segment Reporting Information [Line Items]        
Number of real estate properties 31     29
Wholly Owned Properties        
Segment Reporting Information [Line Items]        
Number of real estate properties 64      
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Business Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]    
Total revenue $ 627,253 $ 589,613
Segment income (loss) 62,346 53,826
Gain on sale of real estate 440  
Income before provision for income taxes 62,786 53,826
Depreciation and amortization 13,659 13,720
Other income (expense), net 893 2,967
Service revenue    
Segment Reporting Information [Line Items]    
Total revenue 623,276 585,951
Rental revenue    
Segment Reporting Information [Line Items]    
Total revenue 3,977 3,662
Operating Segments | Transitional and Skilled Services    
Segment Reporting Information [Line Items]    
Total revenue 601,036 558,304
Segment income (loss) 88,931 80,591
Depreciation and amortization 7,475 7,148
Other income (expense), net 0 0
Operating Segments | Transitional and Skilled Services | Service revenue    
Segment Reporting Information [Line Items]    
Total revenue 601,036 558,304
Operating Segments | Transitional and Skilled Services | Rental revenue    
Segment Reporting Information [Line Items]    
Total revenue 0 0
Operating Segments | Real Estate    
Segment Reporting Information [Line Items]    
Total revenue 15,879 14,944
Segment income (loss) 8,821 6,325
Depreciation and amortization 4,693 4,515
Other income (expense), net 1,641 3,665
Operating Segments | Real Estate | Service revenue    
Segment Reporting Information [Line Items]    
Total revenue 0 0
Operating Segments | Real Estate | Rental revenue    
Segment Reporting Information [Line Items]    
Total revenue 15,879 14,944
All Other    
Segment Reporting Information [Line Items]    
Total revenue 22,240 27,647
Segment income (loss) (35,406) (33,090)
Depreciation and amortization 1,491 2,057
Other income (expense), net (748) (698)
All Other | Service revenue    
Segment Reporting Information [Line Items]    
Total revenue 22,240 27,647
All Other | Rental revenue    
Segment Reporting Information [Line Items]    
Total revenue 0 0
Intercompany Eliminations    
Segment Reporting Information [Line Items]    
Total revenue (11,902) (11,282)
Segment income (loss) 0 0
Depreciation and amortization 0 0
Other income (expense), net 0 0
Intercompany Eliminations | Service revenue    
Segment Reporting Information [Line Items]    
Total revenue 0 0
Intercompany Eliminations | Rental revenue    
Segment Reporting Information [Line Items]    
Total revenue $ (11,902) $ (11,282)
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Business Segments - Revenue by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 627,253 $ 589,613
Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 623,276 $ 585,951
Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 100.00% 100.00%
Medicaid | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 231,358 $ 224,195
Medicaid | Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 37.10% 38.30%
Medicare | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 190,303 $ 155,584
Medicare | Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 30.50% 26.60%
Medicaid — skilled | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 39,993 $ 36,009
Medicaid — skilled | Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 6.50% 6.10%
Total Medicaid and Medicare | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 461,654 $ 415,788
Total Medicaid and Medicare | Revenue Benchmark | Customer Concentration Risk    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 74.10% 71.00%
Total Medicaid and Medicare | Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 74.10% 71.00%
Managed care | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 108,345 $ 102,029
Managed care | Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 17.40% 17.40%
Private and other | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 53,277 $ 68,134
Private and other | Revenue Benchmark | Customer Concentration Risk | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Concentration risk 8.50% 11.60%
Operating Segments | Transitional and Skilled Services    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 601,036 $ 558,304
Operating Segments | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 601,036 558,304
Operating Segments | Medicaid | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 227,741 220,969
Operating Segments | Medicare | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 190,303 155,584
Operating Segments | Medicaid — skilled | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 39,993 36,009
Operating Segments | Total Medicaid and Medicare | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 458,037 412,562
Operating Segments | Managed care | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 108,345 102,029
Operating Segments | Private and other | Transitional and Skilled Services | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 34,654 43,713
All Other    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 22,240 27,647
All Other | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 22,240 27,647
All Other | Medicaid | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 3,617 3,226
All Other | Medicare | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 0 0
All Other | Medicaid — skilled | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 0 0
All Other | Total Medicaid and Medicare | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 3,617 3,226
All Other | Managed care | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue 0 0
All Other | Private and other | Service revenue    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Total revenue $ 18,623 $ 24,421
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Operation Expansions - Narrative (Details)
$ in Thousands
3 Months Ended
Apr. 01, 2021
operation
bed
Mar. 31, 2021
bed
facility
operation
Mar. 31, 2020
USD ($)
operation
facility
bed
Business Acquisition [Line Items]      
Operational skilled nursing beds | bed   23,600  
Operational senior living units | bed   2,200  
Payments to acquire business and asset acquisitions     $ 14,054
Number of real estate properties | facility   94  
8051 Services, Skilled Nursing Care Facilities | Subsequent Event      
Business Acquisition [Line Items]      
Number of businesses acquired | operation 3    
Operational skilled nursing beds | bed 322    
Asset Acquisition | Buildings and improvements      
Business Acquisition [Line Items]      
Property, plant and equipment     9,669
Asset Acquisition | Land      
Business Acquisition [Line Items]      
Property, plant and equipment     4,080
Asset Acquisition | Furniture and fixtures      
Business Acquisition [Line Items]      
Property, plant and equipment     236
Asset Acquisition | Assembled occupancy      
Business Acquisition [Line Items]      
Property, plant and equipment     $ 69
The Pennant Group, Inc. | Senior Living Facilities      
Business Acquisition [Line Items]      
Number of real estate properties | facility     2
Skilled Nursing Operations      
Business Acquisition [Line Items]      
Number of businesses acquired | operation   4 3
Operational skilled nursing beds | bed   447 247
Owned Properties      
Business Acquisition [Line Items]      
Number of businesses acquired | facility     2
Senior Living Facilities      
Business Acquisition [Line Items]      
Number of businesses acquired | operation     1
Operational senior living units | facility     162
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment — Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property and equipment $ 1,040,785 $ 1,027,249
Less: accumulated depreciation (261,516) (249,005)
Property and equipment, net 779,269 778,244
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment 101,236 101,236
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 557,616 555,416
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 131,911 129,727
Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 239,867 233,453
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment 4,498 4,409
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment $ 5,657 $ 3,008
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets — Net - Schedule of Finite Lived Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 5,354 $ 5,412
Accumulated Amortization (2,526) (2,513)
Net $ 2,828 2,899
Assembled occupancy    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 4 months 24 days  
Gross Carrying Amount $ 39 39
Accumulated Amortization (39) (26)
Net $ 0 13
Facility trade name    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 30 years  
Gross Carrying Amount $ 733 733
Accumulated Amortization (372) (366)
Net $ 361 367
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 18 years 4 months 24 days  
Gross Carrying Amount $ 4,582 4,640
Accumulated Amortization (2,115) (2,121)
Net $ 2,467 $ 2,519
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets — Net - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Amortization of intangible assets $ 361 $ 674
Operating lease expense 37,209 35,912
Depreciation and amortization    
Finite-Lived Intangible Assets [Line Items]    
Operating lease expense $ 290 $ 354
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets — Net - Future Amortization (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Year    
2021 (remainder) $ 176  
2022 234  
2023 234  
2024 234  
2025 234  
2026 234  
Thereafter 1,482  
Net $ 2,828 $ 2,899
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Goodwill [Line Items]    
Goodwill $ 54,469 $ 54,469
Operating Segments | Transitional and Skilled Services    
Goodwill [Line Items]    
Goodwill 45,486 45,486
All Other    
Goodwill [Line Items]    
Goodwill $ 8,983 $ 8,983
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Indefinite-lived Intangible Assets [Line Items]    
Medicare and Medicaid licenses $ 3,546 $ 3,716
Trade name    
Indefinite-lived Intangible Assets [Line Items]    
Medicare and Medicaid licenses 889 889
Medicare and Medicaid licenses    
Indefinite-lived Intangible Assets [Line Items]    
Medicare and Medicaid licenses $ 2,657 $ 2,827
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Restricted and Other Assets - Schedule of Restricted and Other Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Debt issuance costs, net $ 2,486 $ 2,664
Long-term insurance losses recoverable asset 7,602 7,138
Deposits with landlords 12,637 12,400
Capital improvement reserves with landlords and lenders 4,680 4,376
Cash surrender value of life insurance related to deferred compensation plan 14,017 6,577
Restricted and other assets $ 41,422 $ 33,155
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Restricted and Other Assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Gain on deferral investment $ 306  
Deferral investment expense $ 351 $ 87
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Payables and Accruals [Abstract]      
Quality assurance fee $ 7,103 $ 6,631  
Refunds payable 39,590 36,323  
Resident advances 6,049 8,558  
Unapplied state relief funds 5,700 6,520  
Cash held in trust for patients 5,611 6,052  
Dividends payable 2,886 2,868 $ 2,683
Property taxes 7,656 9,222  
Income tax payable 11,927 136  
Other 11,117 11,008  
Other accrued liabilities $ 97,639 $ 87,318  
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Tax Disclosure [Abstract]    
Provision for income taxes $ 12,949 $ 12,625
Total income tax provision 20.60% 23.50%
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Schedule of Long term debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Less: current maturities $ (2,828) $ (2,960)
Less: debt issuance costs, net (2,270) (2,302)
Long-term debt—less current maturities 111,859 112,544
Mortgage loans and promissory notes | Mortgage loans and promissory notes    
Debt Instrument [Line Items]    
Mortgage loans and promissory notes 116,957 $ 117,806
Less: current maturities $ (2,828)  
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)
$ in Thousands
3 Months Ended
May 01, 2015
Mar. 31, 2021
USD ($)
facility
Dec. 31, 2020
USD ($)
Debt Instrument [Line Items]      
Amount outstanding, current   $ 2,828 $ 2,960
Letters of credit outstanding, pledged amount   7,580  
Mortgage loans and promissory notes | Notes Payable Other Payables      
Debt Instrument [Line Items]      
Long-term debt, gross   116,957 $ 117,806
Amount outstanding, current   2,828  
Long-term debt—less current maturities   $ 114,129  
Mortgage loans and promissory notes | Mortgages      
Debt Instrument [Line Items]      
Number of operating subsidiaries | facility   19  
Notes payable   $ 113,304  
Prepayment penalty reduced rate during first three years   10.00%  
Prepayment penalty reduced rate during the fourth year   3.00%  
Prepayment penalty reduced rate for the fifth through tenth years   1.00%  
Mortgage loans and promissory notes | Mortgages | Minimum      
Debt Instrument [Line Items]      
Debt Instrument, pre-payment fee reduction, term   5 years  
Debt instrument, term   25 years  
Mortgage loans and promissory notes | Mortgages | Maximum      
Debt Instrument [Line Items]      
Debt Instrument, pre-payment fee reduction, term   10 years  
Debt instrument, term   35 years  
Mortgage loans and promissory notes | Notes Payable to Banks | Minimum      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   2.60%  
Mortgage loans and promissory notes | Notes Payable to Banks | Maximum      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   3.50%  
Mortgage loans and promissory notes | Promissory Note, 5.3%      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage 5.30%    
Mortgage loans and promissory notes | Promissory Note, 5.3% | Minimum      
Debt Instrument [Line Items]      
Debt instrument, term 12 years    
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) - Truist - Revolving credit facility with Truist
Oct. 01, 2019
USD ($)
Mar. 31, 2021
USD ($)
Debt Instrument [Line Items]    
Total net debt ratio, maximum 3.00  
Long-term debt, threshold for EBITDA ratio increase election $ 50,000,000  
Total net debt ratio, maximum after increase election 3.50  
Total net debt ratio, minimum 1.50  
Minimum    
Debt Instrument [Line Items]    
Line of credit facility, unused capacity, commitment fee percentage 0.25%  
Maximum    
Debt Instrument [Line Items]    
Line of credit facility, unused capacity, commitment fee percentage 0.45%  
Third Amended Credit Facility    
Debt Instrument [Line Items]    
Line of credit facility, maximum borrowing capacity $ 350,000,000  
Long-term debt, gross   $ 0
Base Rate | Minimum    
Debt Instrument [Line Items]    
Interest rate margin 0.50%  
Base Rate | Maximum    
Debt Instrument [Line Items]    
Interest rate margin 1.50%  
LIBOR | Minimum    
Debt Instrument [Line Items]    
Interest rate margin 1.50%  
LIBOR | Maximum    
Debt Instrument [Line Items]    
Interest rate margin 2.50%  
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Stock Options Narrative (Details)
shares in Thousands
3 Months Ended
May 25, 2017
installment
shares
Mar. 31, 2021
plan
$ / shares
shares
Mar. 31, 2020
$ / shares
Oct. 01, 2019
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of option plans | plan   1    
Award vesting period   5 years    
Grant date intrinsic value (in dollars per share) | $ / shares   $ 0 $ 0  
2017 Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares authorized (in shares) 6,881      
Conversion to reduce shares availability 1      
Other than options, conversion to reduce shares availability 2.5      
Award vesting period 5 years      
Award vesting rights, percentage 20.00%      
Expiration period 10 years      
Number of shares available for grant (in shares)   2,839    
2017 Plan | Non-employee directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of installments | installment 3      
Award requisite service period 3 years      
Spinoff | 2017 Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares authorized (in shares)       8,118
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Valuation Assumptions (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]    
Options Granted (in shares) 136 145
Weighted Average Risk-Free Rate 0.80% 1.30%
Expected Life 6 years 3 months 18 days 6 years 2 months 12 days
Weighted Average Volatility 42.20% 32.10%
Weighted Average Dividend Yield 0.20% 0.40%
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Exercise Price and Fair Value (Details) - $ / shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]    
Granted (in shares) 136 145
Weighted Average Exercise Price (in dollars per share) $ 83.64 $ 51.20
Weighted Average Fair Value of Options (in dollars per share) $ 33.99 $ 16.60
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Options Outstanding Rollforward (Details) - $ / shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Number of Options Outstanding      
Balance at beginning of period, (in shares) 4,038    
Granted (in shares) 136 145  
Forfeited (in shares) (33)    
Exercised (in shares) (246)    
Balance at end of period, (in shares) 3,895    
Weighted Average Exercise Price      
Balance at beginning of period, (in dollars per share) $ 27.71    
Granted (in dollars per share) 83.64 $ 51.20  
Forfeited (in dollars per share) 41.27    
Exercised (in dollars per share) 15.78    
Balance at end of period, (in dollars per share) $ 30.30    
Number of options vested (in shares) 2,034   2,148
Weighted average exercise price of options vested (in dollars per share) $ 17.73   $ 16.66
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Options Outstanding by Exercise Price (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number outstanding (in shares) 3,895
Black-Scholes Fair Value | $ $ 44,151
Stock options vested and exercisable (in shares) 2,034
2011  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 5.00
Exercise price, upper range limit (in dollars per share) | $ / shares $ 6.77
Number outstanding (in shares) 14
Black-Scholes Fair Value | $ $ 38
Remaining Contractual Life (Years) 0 years
Stock options vested and exercisable (in shares) 14
2012  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 5.56
Exercise price, upper range limit (in dollars per share) | $ / shares $ 6.75
Number outstanding (in shares) 88
Black-Scholes Fair Value | $ $ 267
Remaining Contractual Life (Years) 1 year
Stock options vested and exercisable (in shares) 88
2013  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 6.76
Exercise price, upper range limit (in dollars per share) | $ / shares $ 9.74
Number outstanding (in shares) 165
Black-Scholes Fair Value | $ $ 712
Remaining Contractual Life (Years) 2 years
Stock options vested and exercisable (in shares) 165
2014  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 8.94
Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.05
Number outstanding (in shares) 676
Black-Scholes Fair Value | $ $ 3,231
Remaining Contractual Life (Years) 3 years
Stock options vested and exercisable (in shares) 676
2015  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 18.20
Exercise price, upper range limit (in dollars per share) | $ / shares $ 21.39
Number outstanding (in shares) 303
Black-Scholes Fair Value | $ $ 2,362
Remaining Contractual Life (Years) 4 years
Stock options vested and exercisable (in shares) 303
2016  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.93
Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.86
Number outstanding (in shares) 275
Black-Scholes Fair Value | $ $ 1,618
Remaining Contractual Life (Years) 5 years
Stock options vested and exercisable (in shares) 219
2017  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.80
Exercise price, upper range limit (in dollars per share) | $ / shares $ 19.41
Number outstanding (in shares) 336
Black-Scholes Fair Value | $ $ 1,977
Remaining Contractual Life (Years) 6 years
Stock options vested and exercisable (in shares) 184
2018  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 22.49
Exercise price, upper range limit (in dollars per share) | $ / shares $ 32.71
Number outstanding (in shares) 566
Black-Scholes Fair Value | $ $ 5,855
Remaining Contractual Life (Years) 7 years
Stock options vested and exercisable (in shares) 214
2019  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 41.07
Exercise price, upper range limit (in dollars per share) | $ / shares $ 45.76
Number outstanding (in shares) 698
Black-Scholes Fair Value | $ $ 10,955
Remaining Contractual Life (Years) 8 years
Stock options vested and exercisable (in shares) 147
2020  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 44.84
Exercise price, upper range limit (in dollars per share) | $ / shares $ 59.49
Number outstanding (in shares) 638
Black-Scholes Fair Value | $ $ 12,511
Remaining Contractual Life (Years) 9 years
Stock options vested and exercisable (in shares) 24
2021  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 83.64
Number outstanding (in shares) 136
Black-Scholes Fair Value | $ $ 4,625
Remaining Contractual Life (Years) 10 years
Stock options vested and exercisable (in shares) 0
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Intrinsic Values (Details) - Stock Options - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Outstanding $ 247,457   $ 182,552
Vested 154,841   120,867
Expected to vest 80,008   $ 53,366
Aggregate intrinsic value of options that vested in period 8,545 $ 2,084  
Intrinsic value of options exercised in period $ 17,241 $ 5,621  
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Restricted Stock Awards Narrative (Details) - $ / shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Nonvested restricted awards, granted (in shares) 90 113
Share-based compensation, restricted awards, exercise price (in dollars per share) $ 0  
Award vesting period 5 years  
Granted (in dollars per share) $ 83.71  
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in dollars per share) 83.64 $ 42.02
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in dollars per share) $ 84.70 $ 51.20
Non-employee directors    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted to non-employee directors (in shares) 6  
Non-employee directors | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in dollars per share) $ 84.70  
XML 90 R78.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Restricted Award Rollforward (Details) - $ / shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Non-Vested Restricted Awards    
Nonvested at beginning of period (in shares) 591  
Granted (in shares) 90 113
Vested (in shares) (80)  
Forfeited (in shares) (9)  
Nonvested at end of period (in shares) 592  
Weighted Average Grant Date Fair Value    
Nonvested at beginning of period (in dollars per share) $ 38.90  
Granted (in dollars per share) 83.71  
Vested (in dollars per share) 64.35  
Forfeited (in dollars per share) 45.18  
Nonvested at end of period (in dollars per share) $ 42.16  
XML 91 R79.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Long-Term Incentive Plan (Details) - USD ($)
$ in Thousands
3 Months Ended
Aug. 27, 2019
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting period   5 years  
Share-based compensation expense   $ 4,054 $ 3,235
Spinoff | 2019 LTI Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares authorized (in shares) 500,000    
Award vesting period 5 years    
Award vesting rights, percentage 20.00%    
Share-based compensation expense   $ 201 $ 194
XML 92 R80.htm IDEA: XBRL DOCUMENT v3.21.1
Options and Awards - Compensation Expense (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation expense $ 4,054 $ 3,235
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term 6 years 1 month 6 days  
Stock-based compensation expense related to stock options    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation expense $ 1,733 1,419
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized $ 27,178  
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition 3 years 9 months 18 days  
Employee service share-based compensation, nonvested awards (in shares) 1,861  
Share-based compensation arrangement by share-based payment award, options, expected to vest, number (in shares) 1,726  
Stock-based compensation expense related to restricted stock awards    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation expense $ 1,838 1,598
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized $ 26,072  
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition 3 years 6 months  
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation expense $ 483 $ 218
XML 93 R81.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Narrative (Details)
$ in Thousands
3 Months Ended
Apr. 01, 2021
USD ($)
operation
bed
Mar. 31, 2021
USD ($)
bed
renewal
agreement
facility
Mar. 31, 2020
USD ($)
Lessee, Lease, Description [Line Items]      
Master lease agreements | agreement   7  
Facilities under master lease arrangement | facility   40  
Operating lease, weighted average remaining lease term   13 years 8 months 12 days  
Operating lease, weighted average discount rate, percent   8.20%  
Operational skilled nursing beds | bed   23,600  
Right-of-use assets obtained in exchange for new operating lease obligations | $   $ 37,471 $ 8,370
Subsequent Event      
Lessee, Lease, Description [Line Items]      
Right-of-use assets obtained in exchange for new operating lease obligations | $ $ 20,005    
Subsequent Event | 8051 Services, Skilled Nursing Care Facilities      
Lessee, Lease, Description [Line Items]      
Number of businesses acquired | operation 3    
Operational skilled nursing beds | bed 322    
Cost of Sales and General and Administrative Expense      
Lessee, Lease, Description [Line Items]      
Rent expense | $   $ 33,476 32,347
CareTrust REIT      
Lessee, Lease, Description [Line Items]      
Skilled nursing, assisted living and independent living facilities | facility   89  
Master lease agreements | agreement   9  
Lessee, operating lease, renewal term   5 years  
Operating leases of lessee, contingent rentals, basis spread on variable rate   2.50%  
Rent expense | $   $ 14,080 $ 13,125
CareTrust REIT | Third Party Tenants Under Triple Net Lease Arrangements      
Lessee, Lease, Description [Line Items]      
Skilled nursing, assisted living and independent living facilities | facility   88  
CareTrust REIT | Purchase Option      
Lessee, Lease, Description [Line Items]      
Skilled nursing, assisted living and independent living facilities | facility   4  
CareTrust REIT | Minimum      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   12 years  
Lessee leasing arrangements, operating leases, number of renewal terms | renewal   2  
CareTrust REIT | Maximum      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   20 years  
Lessee leasing arrangements, operating leases, number of renewal terms | renewal   3  
Various Landlords      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   15 years  
Lessee leasing arrangements, operating leases, number of renewal terms | renewal   2  
Lessee, operating lease, renewal term   5 years  
Various Landlords | Minimum      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   5 years  
Various Landlords | Minimum | Equipment      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   3 years  
Various Landlords | Maximum      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   20 years  
Various Landlords | Maximum | Equipment      
Lessee, Lease, Description [Line Items]      
Lessee, operating lease, term of contract   5 years  
XML 94 R82.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Lessee, Lease, Description [Line Items]    
Operating lease expense $ 37,209 $ 35,912
Amortization of deferred rent 112 125
Rent - cost of services    
Lessee, Lease, Description [Line Items]    
Operating lease expense 33,456 32,330
Variable lease, cost 584 594
General and administrative expense    
Lessee, Lease, Description [Line Items]    
Operating lease expense 20 17
Depreciation and amortization    
Lessee, Lease, Description [Line Items]    
Operating lease expense 290 354
Variable lease costs    
Lessee, Lease, Description [Line Items]    
Variable lease, cost $ 3,443 $ 3,211
XML 95 R83.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Year    
2021 (remainder) $ 98,448  
2022 131,211  
2023 129,521  
2024 128,600  
2025 128,506  
2026 128,383  
Thereafter 957,340  
Total lease payments 1,702,009  
Less: present value adjustment (678,274)  
Present value of total lease liabilities 1,023,735  
Less: current lease liabilities (50,056) $ (48,187)
Long-term operating lease liabilities $ 973,679 $ 950,320
XML 96 R84.htm IDEA: XBRL DOCUMENT v3.21.1
Lessor - Narrative (Details) - facility
Mar. 31, 2021
Mar. 31, 2020
Oct. 01, 2019
Lessor, Lease, Description [Line Items]      
Number of real estate properties 94    
Spinoff | Minimum      
Lessor, Lease, Description [Line Items]      
Lessee, operating lease, term of contract     14 years
Spinoff | Maximum      
Lessor, Lease, Description [Line Items]      
Lessee, operating lease, term of contract     16 years
The Pennant Group, Inc. | Senior Living Facilities      
Lessor, Lease, Description [Line Items]      
Number of real estate properties   2  
The Pennant Group, Inc. | Spinoff | Senior Living Facilities      
Lessor, Lease, Description [Line Items]      
Number of real estate properties 31   29
XML 97 R85.htm IDEA: XBRL DOCUMENT v3.21.1
Lessor - Rental Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Lessor, Lease, Description [Line Items]    
Operating lease, lease income $ 3,977 $ 3,662
The Pennant Group, Inc.    
Lessor, Lease, Description [Line Items]    
Operating lease, variable lease income 314 466
The Pennant Group, Inc.    
Lessor, Lease, Description [Line Items]    
Operating lease, lease income 3,488 3,101
Other third-party    
Lessor, Lease, Description [Line Items]    
Operating lease, lease income $ 489 $ 561
XML 98 R86.htm IDEA: XBRL DOCUMENT v3.21.1
Lessor - Future Minimum Lease Payments Receivable (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Leases [Abstract]  
2021 (remainder) $ 11,671
2022 15,053
2023 14,790
2024 14,170
2025 13,952
2026 13,772
Thereafter 85,281
Total $ 168,689
XML 99 R87.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
facility
Mar. 31, 2020
Dec. 31, 2020
Apr. 26, 2021
USD ($)
Apr. 01, 2021
facility
Concentration Risk [Line Items]          
Facilities under Medicare probe reviews 2        
Subsequent Event          
Concentration Risk [Line Items]          
Number of facilities resolved in period         1
Cash, uninsured amount | $       $ 424  
Customer Concentration Risk | Total Medicaid and Medicare | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk 57.20%   58.30%    
Customer Concentration Risk | Total Medicaid and Medicare | Revenue Benchmark          
Concentration Risk [Line Items]          
Concentration risk 74.10% 71.00%      
XML 100 R88.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock Repurchase Program (Details)
shares in Thousands
3 Months Ended 12 Months Ended
Mar. 13, 2020
USD ($)
numberOfRepurchasePrograms
Mar. 04, 2020
USD ($)
Aug. 26, 2019
USD ($)
Mar. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Equity, Class of Treasury Stock [Line Items]          
Number of stock repurchase programs | numberOfRepurchasePrograms 2        
Repurchase of common stock       $ 25,000,000  
March 4, 2020 Repurchase Program          
Equity, Class of Treasury Stock [Line Items]          
Stock repurchase program, authorized amount   $ 20,000,000      
Stock repurchase program, period in force   12 months      
Repurchase of common stock (in shares) | shares       503  
Repurchase of common stock       $ 20,000,000  
March 13, 2020 Repurchase Program          
Equity, Class of Treasury Stock [Line Items]          
Stock repurchase program, authorized amount $ 5,000,000        
Stock repurchase program, period in force 12 months        
Repurchase of common stock (in shares) | shares       189  
Repurchase of common stock       $ 5,000,000  
August 26, 2019 Repurchase Program          
Equity, Class of Treasury Stock [Line Items]          
Stock repurchase program, authorized amount     $ 20,000,000    
Stock repurchase program, period in force     12 months    
Repurchase of common stock (in shares) | shares         138
Repurchase of common stock         $ 6,406,000
EXCEL 101 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 102 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 103 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 313 459 1 false 112 0 false 13 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.ensigngroup.net/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Statements 4 false false R5.htm 1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Description of Business Sheet http://www.ensigngroup.net/role/DescriptionofBusiness Description of Business Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2112103 - Disclosure - COVID-19 UPDATE Sheet http://www.ensigngroup.net/role/COVID19UPDATE COVID-19 UPDATE Notes 10 false false R11.htm 2114104 - Disclosure - Revenue and Accounts Receivable Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivable Revenue and Accounts Receivable Notes 11 false false R12.htm 2119105 - Disclosure - Computation of Net Income Per Common Share Sheet http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare Computation of Net Income Per Common Share Notes 12 false false R13.htm 2122106 - Disclosure - Fair Value Measurements Sheet http://www.ensigngroup.net/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2125107 - Disclosure - Business Segments Sheet http://www.ensigngroup.net/role/BusinessSegments Business Segments Notes 14 false false R15.htm 2130108 - Disclosure - Operation Expansions Sheet http://www.ensigngroup.net/role/OperationExpansions Operation Expansions Notes 15 false false R16.htm 2132109 - Disclosure - Property and Equipment ??? Net Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNet Property and Equipment ??? Net Notes 16 false false R17.htm 2135110 - Disclosure - Intangible Assets ??? Net Sheet http://www.ensigngroup.net/role/IntangibleAssetsNet Intangible Assets ??? Net Notes 17 false false R18.htm 2140111 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets Goodwill and Other Indefinite-Lived Intangible Assets Notes 18 false false R19.htm 2144112 - Disclosure - Restricted and Other Assets Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssets Restricted and Other Assets Notes 19 false false R20.htm 2148113 - Disclosure - Other Accrued Liabilities Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilities Other Accrued Liabilities Notes 20 false false R21.htm 2151114 - Disclosure - Income Taxes Sheet http://www.ensigngroup.net/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2153115 - Disclosure - Debt Sheet http://www.ensigngroup.net/role/Debt Debt Notes 22 false false R23.htm 2158116 - Disclosure - Options and Awards Sheet http://www.ensigngroup.net/role/OptionsandAwards Options and Awards Notes 23 false false R24.htm 2170117 - Disclosure - Leases Sheet http://www.ensigngroup.net/role/Leases Leases Notes 24 false false R25.htm 2178118 - Disclosure - Commitments and Contingencies Sheet http://www.ensigngroup.net/role/CommitmentsandContingencies Commitments and Contingencies Notes 25 false false R26.htm 2180119 - Disclosure - Common Stock Repurchase Program Sheet http://www.ensigngroup.net/role/CommonStockRepurchaseProgram Common Stock Repurchase Program Notes 26 false false R27.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 2315301 - Disclosure - Revenue and Accounts Receivable (Tables) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables Revenue and Accounts Receivable (Tables) Tables http://www.ensigngroup.net/role/RevenueandAccountsReceivable 28 false false R29.htm 2320302 - Disclosure - Computation of Net Income Per Common Share (Tables) Sheet http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables Computation of Net Income Per Common Share (Tables) Tables http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare 29 false false R30.htm 2326303 - Disclosure - Business Segments (Tables) Sheet http://www.ensigngroup.net/role/BusinessSegmentsTables Business Segments (Tables) Tables http://www.ensigngroup.net/role/BusinessSegments 30 false false R31.htm 2333304 - Disclosure - Property and Equipment ??? Net (Tables) Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNetTables Property and Equipment ??? Net (Tables) Tables http://www.ensigngroup.net/role/PropertyandEquipmentNet 31 false false R32.htm 2336305 - Disclosure - Intangible Assets ??? Net (Tables) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetTables Intangible Assets ??? Net (Tables) Tables http://www.ensigngroup.net/role/IntangibleAssetsNet 32 false false R33.htm 2341306 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Tables http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets 33 false false R34.htm 2345307 - Disclosure - Restricted and Other Assets (Tables) Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables Restricted and Other Assets (Tables) Tables http://www.ensigngroup.net/role/RestrictedandOtherAssets 34 false false R35.htm 2349308 - Disclosure - Other Accrued Liabilities (Tables) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables Other Accrued Liabilities (Tables) Tables http://www.ensigngroup.net/role/OtherAccruedLiabilities 35 false false R36.htm 2354309 - Disclosure - Debt (Tables) Sheet http://www.ensigngroup.net/role/DebtTables Debt (Tables) Tables http://www.ensigngroup.net/role/Debt 36 false false R37.htm 2359310 - Disclosure - Options and Awards (Tables) Sheet http://www.ensigngroup.net/role/OptionsandAwardsTables Options and Awards (Tables) Tables http://www.ensigngroup.net/role/OptionsandAwards 37 false false R38.htm 2371311 - Disclosure - Leases (Tables) Sheet http://www.ensigngroup.net/role/LeasesTables Leases (Tables) Tables http://www.ensigngroup.net/role/Leases 38 false false R39.htm 2402401 - Disclosure - Description of Business (Details) Sheet http://www.ensigngroup.net/role/DescriptionofBusinessDetails Description of Business (Details) Details http://www.ensigngroup.net/role/DescriptionofBusiness 39 false false R40.htm 2405402 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 40 false false R41.htm 2406403 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) Details 41 false false R42.htm 2407404 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) Details 42 false false R43.htm 2408405 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance General and Professional (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails Summary of Significant Accounting Policies - Self-Insurance General and Professional (Details) Details 43 false false R44.htm 2409406 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Workers' Compensation (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails Summary of Significant Accounting Policies - Self-Insurance Workers' Compensation (Details) Details 44 false false R45.htm 2410407 - Disclosure - Summary of Significant Accounting Policies - Self Insurance Recoveries (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceRecoveriesDetails Summary of Significant Accounting Policies - Self Insurance Recoveries (Details) Details 45 false false R46.htm 2411408 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Health Insurance (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails Summary of Significant Accounting Policies - Self-Insurance Health Insurance (Details) Details 46 false false R47.htm 2413409 - Disclosure - COVID-19 UPDATE (Details) Sheet http://www.ensigngroup.net/role/COVID19UPDATEDetails COVID-19 UPDATE (Details) Details http://www.ensigngroup.net/role/COVID19UPDATE 47 false false R48.htm 2416410 - Disclosure - Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details) Details 48 false false R49.htm 2417411 - Disclosure - Revenue and Accounts Receivable - Disaggregation of Revenue (Details) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails Revenue and Accounts Receivable - Disaggregation of Revenue (Details) Details 49 false false R50.htm 2418412 - Disclosure - Revenue and Accounts Receivable - Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails Revenue and Accounts Receivable - Accounts Receivable (Details) Details 50 false false R51.htm 2421413 - Disclosure - Computation of Net Income Per Common Share (Details) Sheet http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails Computation of Net Income Per Common Share (Details) Details http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables 51 false false R52.htm 2423414 - Disclosure - Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) Details 52 false false R53.htm 2424415 - Disclosure - Fair Value Measurements - Investments (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails Fair Value Measurements - Investments (Details) Details 53 false false R54.htm 2427416 - Disclosure - Business Segments - Narrative (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails Business Segments - Narrative (Details) Details 54 false false R55.htm 2428417 - Disclosure - Business Segments - Schedule of Segment Reporting Information, by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails Business Segments - Schedule of Segment Reporting Information, by Segment (Details) Details 55 false false R56.htm 2429418 - Disclosure - Business Segments - Revenue by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails Business Segments - Revenue by Segment (Details) Details 56 false false R57.htm 2431419 - Disclosure - Operation Expansions - Narrative (Details) Sheet http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails Operation Expansions - Narrative (Details) Details 57 false false R58.htm 2434420 - Disclosure - Property and Equipment ??? Net (Details) Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails Property and Equipment ??? Net (Details) Details http://www.ensigngroup.net/role/PropertyandEquipmentNetTables 58 false false R59.htm 2437421 - Disclosure - Intangible Assets ??? Net - Schedule of Finite Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails Intangible Assets ??? Net - Schedule of Finite Lived Intangible Assets (Details) Details 59 false false R60.htm 2438422 - Disclosure - Intangible Assets ??? Net - Narrative (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails Intangible Assets ??? Net - Narrative (Details) Details 60 false false R61.htm 2439423 - Disclosure - Intangible Assets ??? Net - Future Amortization (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails Intangible Assets ??? Net - Future Amortization (Details) Details 61 false false R62.htm 2442424 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) Details 62 false false R63.htm 2443425 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) Details 63 false false R64.htm 2446426 - Disclosure - Restricted and Other Assets - Schedule of Restricted and Other Assets (Details) Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails Restricted and Other Assets - Schedule of Restricted and Other Assets (Details) Details 64 false false R65.htm 2447427 - Disclosure - Restricted and Other Assets - Narrative (Details) Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails Restricted and Other Assets - Narrative (Details) Details 65 false false R66.htm 2450428 - Disclosure - Other Accrued Liabilities (Details) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails Other Accrued Liabilities (Details) Details http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables 66 false false R67.htm 2452429 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 67 false false R68.htm 2455430 - Disclosure - Debt - Schedule of Long term debt (Details) Sheet http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails Debt - Schedule of Long term debt (Details) Details 68 false false R69.htm 2456431 - Disclosure - Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Notes http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Details 69 false false R70.htm 2457432 - Disclosure - Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) Sheet http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) Details 70 false false R71.htm 2460433 - Disclosure - Options and Awards - Stock Options Narrative (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails Options and Awards - Stock Options Narrative (Details) Details 71 false false R72.htm 2461434 - Disclosure - Options and Awards - Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails Options and Awards - Valuation Assumptions (Details) Details 72 false false R73.htm 2462435 - Disclosure - Options and Awards - Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails Options and Awards - Exercise Price and Fair Value (Details) Details 73 false false R74.htm 2463436 - Disclosure - Options and Awards - Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails Options and Awards - Options Outstanding Rollforward (Details) Details 74 false false R75.htm 2464437 - Disclosure - Options and Awards - Options Outstanding by Exercise Price (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails Options and Awards - Options Outstanding by Exercise Price (Details) Details 75 false false R76.htm 2465438 - Disclosure - Options and Awards - Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails Options and Awards - Intrinsic Values (Details) Details 76 false false R77.htm 2466439 - Disclosure - Options and Awards - Restricted Stock Awards Narrative (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails Options and Awards - Restricted Stock Awards Narrative (Details) Details 77 false false R78.htm 2467440 - Disclosure - Options and Awards - Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails Options and Awards - Restricted Award Rollforward (Details) Details 78 false false R79.htm 2468441 - Disclosure - Options and Awards - Long-Term Incentive Plan (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails Options and Awards - Long-Term Incentive Plan (Details) Details 79 false false R80.htm 2469442 - Disclosure - Options and Awards - Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails Options and Awards - Compensation Expense (Details) Details 80 false false R81.htm 2472443 - Disclosure - Leases - Narrative (Details) Sheet http://www.ensigngroup.net/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 81 false false R82.htm 2473444 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.ensigngroup.net/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 82 false false R83.htm 2474445 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 83 false false R84.htm 2475446 - Disclosure - Lessor - Narrative (Details) Sheet http://www.ensigngroup.net/role/LessorNarrativeDetails Lessor - Narrative (Details) Details 84 false false R85.htm 2476447 - Disclosure - Lessor - Rental Income (Details) Sheet http://www.ensigngroup.net/role/LessorRentalIncomeDetails Lessor - Rental Income (Details) Details 85 false false R86.htm 2477448 - Disclosure - Lessor - Future Minimum Lease Payments Receivable (Details) Sheet http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails Lessor - Future Minimum Lease Payments Receivable (Details) Details 86 false false R87.htm 2479449 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.ensigngroup.net/role/CommitmentsandContingencies 87 false false R88.htm 2481450 - Disclosure - Common Stock Repurchase Program (Details) Sheet http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails Common Stock Repurchase Program (Details) Details http://www.ensigngroup.net/role/CommonStockRepurchaseProgram 88 false false All Reports Book All Reports ensg-20210331.htm ensg-20210331.xsd ensg-20210331_cal.xml ensg-20210331_def.xml ensg-20210331_lab.xml ensg-20210331_pre.xml ensgq12021ex311.htm ensgq12021ex312.htm ensgq12021ex321.htm ensgq12021ex322.htm ensg-20210331_g1.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/naics/2017-01-31 http://xbrl.sec.gov/sic/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ensg-20210331.htm": { "axisCustom": 5, "axisStandard": 33, "contextCount": 313, "dts": { "calculationLink": { "local": [ "ensg-20210331_cal.xml" ] }, "definitionLink": { "local": [ "ensg-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ensg-20210331.htm" ] }, "labelLink": { "local": [ "ensg-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ensg-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ensg-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 671, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 4, "http://www.ensigngroup.net/20210331": 3, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 12 }, "keyCustom": 61, "keyStandard": 398, "memberCustom": 57, "memberStandard": 49, "nsprefix": "ensg", "nsuri": "http://www.ensigngroup.net/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.ensigngroup.net/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112103 - Disclosure - COVID-19 UPDATE", "role": "http://www.ensigngroup.net/role/COVID19UPDATE", "shortName": "COVID-19 UPDATE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - Revenue and Accounts Receivable", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivable", "shortName": "Revenue and Accounts Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119105 - Disclosure - Computation of Net Income Per Common Share", "role": "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare", "shortName": "Computation of Net Income Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Fair Value Measurements", "role": "http://www.ensigngroup.net/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Business Segments", "role": "http://www.ensigngroup.net/role/BusinessSegments", "shortName": "Business Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Operation Expansions", "role": "http://www.ensigngroup.net/role/OperationExpansions", "shortName": "Operation Expansions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132109 - Disclosure - Property and Equipment \u2014 Net", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNet", "shortName": "Property and Equipment \u2014 Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135110 - Disclosure - Intangible Assets \u2014 Net", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNet", "shortName": "Intangible Assets \u2014 Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140111 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144112 - Disclosure - Restricted and Other Assets", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssets", "shortName": "Restricted and Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148113 - Disclosure - Other Accrued Liabilities", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilities", "shortName": "Other Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151114 - Disclosure - Income Taxes", "role": "http://www.ensigngroup.net/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153115 - Disclosure - Debt", "role": "http://www.ensigngroup.net/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158116 - Disclosure - Options and Awards", "role": "http://www.ensigngroup.net/role/OptionsandAwards", "shortName": "Options and Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2170117 - Disclosure - Leases", "role": "http://www.ensigngroup.net/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2178118 - Disclosure - Commitments and Contingencies", "role": "http://www.ensigngroup.net/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2180119 - Disclosure - Common Stock Repurchase Program", "role": "http://www.ensigngroup.net/role/CommonStockRepurchaseProgram", "shortName": "Common Stock Repurchase Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Revenue and Accounts Receivable (Tables)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables", "shortName": "Revenue and Accounts Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320302 - Disclosure - Computation of Net Income Per Common Share (Tables)", "role": "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables", "shortName": "Computation of Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326303 - Disclosure - Business Segments (Tables)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsTables", "shortName": "Business Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333304 - Disclosure - Property and Equipment \u2014 Net (Tables)", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment \u2014 Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336305 - Disclosure - Intangible Assets \u2014 Net (Tables)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets \u2014 Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341306 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables)", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345307 - Disclosure - Restricted and Other Assets (Tables)", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables", "shortName": "Restricted and Other Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349308 - Disclosure - Other Accrued Liabilities (Tables)", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables", "shortName": "Other Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354309 - Disclosure - Debt (Tables)", "role": "http://www.ensigngroup.net/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2359310 - Disclosure - Options and Awards (Tables)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsTables", "shortName": "Options and Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2371311 - Disclosure - Leases (Tables)", "role": "http://www.ensigngroup.net/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfHealthCareFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Description of Business (Details)", "role": "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "shortName": "Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfHealthCareFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ic8d73b29e65345fdbb040065337030f2_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ic8d73b29e65345fdbb040065337030f2_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetImpairment", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "shortName": "Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetImpairment", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EstimatedInsuranceRecoveries", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance General and Professional (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "shortName": "Summary of Significant Accounting Policies - Self-Insurance General and Professional (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i94239c5fdf4c4387a90d3ba6883b3439_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i68d852b5de02417eab1e6caf039dcd8b_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Workers' Compensation (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails", "shortName": "Summary of Significant Accounting Policies - Self-Insurance Workers' Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i68d852b5de02417eab1e6caf039dcd8b_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EstimatedInsuranceRecoveries", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410407 - Disclosure - Summary of Significant Accounting Policies - Self Insurance Recoveries (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceRecoveriesDetails", "shortName": "Summary of Significant Accounting Policies - Self Insurance Recoveries (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i5a588d48b66a49599de3144de8313c2d_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411408 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance Health Insurance (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "shortName": "Summary of Significant Accounting Policies - Self-Insurance Health Insurance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i5a588d48b66a49599de3144de8313c2d_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413409 - Disclosure - COVID-19 UPDATE (Details)", "role": "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "shortName": "COVID-19 UPDATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i554a755c17894e35bac8270ac6f38697_D20210101-20210331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails", "shortName": "Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417411 - Disclosure - Revenue and Accounts Receivable - Disaggregation of Revenue (Details)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "shortName": "Revenue and Accounts Receivable - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i283b0826844845ac8705aa7e29588e78_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i283b0826844845ac8705aa7e29588e78_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418412 - Disclosure - Revenue and Accounts Receivable - Accounts Receivable (Details)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "shortName": "Revenue and Accounts Receivable - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421413 - Disclosure - Computation of Net Income Per Common Share (Details)", "role": "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "shortName": "Computation of Net Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i592c84e39fb84eacb177087bc10c7410_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i592c84e39fb84eacb177087bc10c7410_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "id5c74096e4ef44c19f52acaaf895cdce_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424415 - Disclosure - Fair Value Measurements - Investments (Details)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails", "shortName": "Fair Value Measurements - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "id5c74096e4ef44c19f52acaaf895cdce_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - Business Segments - Narrative (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "shortName": "Business Segments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "lang": "en-US", "name": "ensg:TransitionalAndSkilledServiceFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - Business Segments - Schedule of Segment Reporting Information, by Segment (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "shortName": "Business Segments - Schedule of Segment Reporting Information, by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "ensg:SegmentIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429418 - Disclosure - Business Segments - Revenue by Segment (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "shortName": "Business Segments - Revenue by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i6a21c5a6ab7e4789a2a60bb4bebecdf9_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:OperationalSkilledNursingBeds", "reportCount": 1, "unitRef": "bed", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431419 - Disclosure - Operation Expansions - Narrative (Details)", "role": "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "shortName": "Operation Expansions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ie02d353c246540519b14ec92ca3369b0_D20200101-20200331", "decimals": "-3", "lang": "en-US", "name": "ensg:PaymentsToAcquireBusinessAndAssetAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Property and Equipment \u2014 Net (Details)", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "shortName": "Property and Equipment \u2014 Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437421 - Disclosure - Intangible Assets \u2014 Net - Schedule of Finite Lived Intangible Assets (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "shortName": "Intangible Assets \u2014 Net - Schedule of Finite Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i83b17c4a309d4935ae7f29d7bfa5453c_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i83b17c4a309d4935ae7f29d7bfa5453c_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438422 - Disclosure - Intangible Assets \u2014 Net - Narrative (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "shortName": "Intangible Assets \u2014 Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439423 - Disclosure - Intangible Assets \u2014 Net - Future Amortization (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails", "shortName": "Intangible Assets \u2014 Net - Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442424 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details)", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ib15254e36167449e8e123c9cf46f1e08_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443425 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details)", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i9cd17833f1fc417cb4c31a2d7c948bc5_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446426 - Disclosure - Restricted and Other Assets - Schedule of Restricted and Other Assets (Details)", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails", "shortName": "Restricted and Other Assets - Schedule of Restricted and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447427 - Disclosure - Restricted and Other Assets - Narrative (Details)", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails", "shortName": "Restricted and Other Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450428 - Disclosure - Other Accrued Liabilities (Details)", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "shortName": "Other Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452429 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455430 - Disclosure - Debt - Schedule of Long term debt (Details)", "role": "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails", "shortName": "Debt - Schedule of Long term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456431 - Disclosure - Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "role": "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "shortName": "Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3669cda88dca47e499dab700707ca77c_I20191001", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:TotalNetDebtRatioMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457432 - Disclosure - Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details)", "role": "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "shortName": "Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3669cda88dca47e499dab700707ca77c_I20191001", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:TotalNetDebtRatioMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfOptionPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460433 - Disclosure - Options and Awards - Stock Options Narrative (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails", "shortName": "Options and Awards - Stock Options Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfOptionPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461434 - Disclosure - Options and Awards - Valuation Assumptions (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails", "shortName": "Options and Awards - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462435 - Disclosure - Options and Awards - Exercise Price and Fair Value (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails", "shortName": "Options and Awards - Exercise Price and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i0803eb57dfe64837bb906d82bb144f3e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463436 - Disclosure - Options and Awards - Options Outstanding Rollforward (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails", "shortName": "Options and Awards - Options Outstanding Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i0803eb57dfe64837bb906d82bb144f3e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464437 - Disclosure - Options and Awards - Options Outstanding by Exercise Price (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails", "shortName": "Options and Awards - Options Outstanding by Exercise Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "id03233e9d76143c7b0f981039f8ed321_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465438 - Disclosure - Options and Awards - Intrinsic Values (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "shortName": "Options and Awards - Intrinsic Values (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "id03233e9d76143c7b0f981039f8ed321_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466439 - Disclosure - Options and Awards - Restricted Stock Awards Narrative (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "shortName": "Options and Awards - Restricted Stock Awards Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "0", "lang": "en-US", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i0803eb57dfe64837bb906d82bb144f3e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467440 - Disclosure - Options and Awards - Restricted Award Rollforward (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "shortName": "Options and Awards - Restricted Award Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i0803eb57dfe64837bb906d82bb144f3e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468441 - Disclosure - Options and Awards - Long-Term Incentive Plan (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "shortName": "Options and Awards - Long-Term Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i63c02036ce894abfb1c773ff4942f189_I20190827", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Description of Business", "role": "http://www.ensigngroup.net/role/DescriptionofBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469442 - Disclosure - Options and Awards - Compensation Expense (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "shortName": "Options and Awards - Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:MasterLeaseAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472443 - Disclosure - Leases - Narrative (Details)", "role": "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:MasterLeaseAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473444 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "ensg:DeferredRentAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474445 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475446 - Disclosure - Lessor - Narrative (Details)", "role": "http://www.ensigngroup.net/role/LessorNarrativeDetails", "shortName": "Lessor - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i1ea48b5e963f47f8824d41121a8d1ca4_I20191001", "decimals": null, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2476447 - Disclosure - Lessor - Rental Income (Details)", "role": "http://www.ensigngroup.net/role/LessorRentalIncomeDetails", "shortName": "Lessor - Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2477448 - Disclosure - Lessor - Future Minimum Lease Payments Receivable (Details)", "role": "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails", "shortName": "Lessor - Future Minimum Lease Payments Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:FacilitiesUnderMedicareProbeReviews", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479449 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ied4bd55751fa46d4908c6914be3517a5_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:FacilitiesUnderMedicareProbeReviews", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ic004d8e4b3b6412796574b1910013ea6_I20200313", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfStockRepurchasePrograms", "reportCount": 1, "unique": true, "unitRef": "numberofrepurchaseprograms", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481450 - Disclosure - Common Stock Repurchase Program (Details)", "role": "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "shortName": "Common Stock Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "ic004d8e4b3b6412796574b1910013ea6_I20200313", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:NumberOfStockRepurchasePrograms", "reportCount": 1, "unique": true, "unitRef": "numberofrepurchaseprograms", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20210331.htm", "contextRef": "i3ffbca43452e409f80885f58ea6a1c52_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 112, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ensg_A2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Plan", "label": "2017 Plan [Member]", "terseLabel": "2017 Plan" } } }, "localname": "A2017PlanMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_A2019LTIPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 LTI Plan [Member]", "label": "2019 LTI Plan [Member]", "terseLabel": "2019 LTI Plan" } } }, "localname": "A2019LTIPlanMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "ensg_AccruedLiabilitiesStateReliefContractLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities, State Relief Contract Liabilities", "label": "Accrued Liabilities, State Relief Contract Liabilities", "terseLabel": "Unapplied state relief funds" } } }, "localname": "AccruedLiabilitiesStateReliefContractLiabilities", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_AggregateDeductibleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Deductible [Member]", "label": "Aggregate Deductible [Member]", "terseLabel": "Aggregate Deductible" } } }, "localname": "AggregateDeductibleMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_AllStatesExceptColoradoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All States Except Colorado [Domain]", "label": "All States Except Colorado [Member]", "terseLabel": "All States Except Colorado" } } }, "localname": "AllStatesExceptColoradoMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_AssembledOccupancyAcquiredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assembled occupancy acquired [Member]", "label": "Assembled occupancy acquired [Member]", "terseLabel": "Assembled occupancy" } } }, "localname": "AssembledOccupancyAcquiredMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "ensg_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "ensg_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These acquisitions were classified as asset acquisitions in accordance with ASC 805.", "label": "Asset Acquisition [Member]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_August262019RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 26, 2019 Repurchase Program [Member]", "label": "August 26, 2019 Repurchase Program [Member]", "terseLabel": "August 26, 2019 Repurchase Program" } } }, "localname": "August262019RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "ensg_BlanketAggregateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Blanket Aggregate [Member]", "label": "Blanket Aggregate [Member]", "terseLabel": "Blanket Aggregate" } } }, "localname": "BlanketAggregateMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_COVIDLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "COVID Liabilities, Current", "label": "COVID Liabilities, Current", "terseLabel": "Advance payment liabilities (Note 3)" } } }, "localname": "COVIDLiabilitiesCurrent", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_CareTrustREITMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareTrust REIT [Member]", "label": "CareTrust REIT [Member]", "terseLabel": "CareTrust REIT" } } }, "localname": "CareTrustREITMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_CashHeldInTrustForResidents": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds.", "label": "Cash Held in Trust for Residents", "terseLabel": "Cash held in trust for patients" } } }, "localname": "CashHeldInTrustForResidents", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received", "terseLabel": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsReceived", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds, Repayment", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Repaid", "negatedTerseLabel": "Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program(Note 3)" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_CostOfServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of Services", "label": "Cost of Services [Member]", "terseLabel": "Variable lease costs" } } }, "localname": "CostOfServicesMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense", "label": "Cost of Sales and General and Administrative Expense [Member]", "terseLabel": "Cost of Sales and General and Administrative Expense" } } }, "localname": "CostofSalesandGeneralandAdministrativeExpenseMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_DebtInstrumentPrePaymentFeeReductionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Pre-Payment Fee Reduction, Term", "label": "Debt Instrument, Pre-Payment Fee Reduction, Term", "terseLabel": "Debt Instrument, pre-payment fee reduction, term" } } }, "localname": "DebtInstrumentPrePaymentFeeReductionTerm", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "ensg_DeferredRentAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period.", "label": "Deferred Rent Adjustment", "terseLabel": "Amortization of deferred rent" } } }, "localname": "DeferredRentAdjustment", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "ensg_DeferredRentAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities", "label": "Deferred rent and other long-term liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "DeferredRentAndOtherLongTermLiabilities", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_DepreciationAndAmortizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation And Amortization [Member]", "label": "Depreciation And Amortization [Member]", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Service Share-based Compensation, Nonvested Awards", "label": "Employee Service Share-based Compensation, Nonvested Awards", "terseLabel": "Employee service share-based compensation, nonvested awards (in shares)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ExercisePriceRangeEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Eight [Member]", "label": "Exercise Price Range Eight [Member]", "terseLabel": "2019" } } }, "localname": "ExercisePriceRangeEightMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Five [Member]", "label": "Exercise Price Range Five [Member]", "terseLabel": "2016" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Four [Member]", "label": "Exercise Price Range Four [Member]", "terseLabel": "2015" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Nine [Member]", "label": "Exercise Price Range Nine [Member]", "terseLabel": "2020" } } }, "localname": "ExercisePriceRangeNineMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]", "terseLabel": "2012" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Seven [Member]", "label": "Exercise Price Range Seven [Member]", "terseLabel": "2018" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Six [Member]", "label": "Exercise Price Range Six [Member]", "terseLabel": "2017" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Ten [Member]", "label": "Exercise Price Range Ten [Member]", "terseLabel": "2021" } } }, "localname": "ExercisePriceRangeTenMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]", "terseLabel": "2014" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]", "terseLabel": "2013" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Zero", "label": "Exercise Price Range Zero [Member]", "terseLabel": "2011" } } }, "localname": "ExercisePriceRangeZeroMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_FacilitiesUnderMasterLeaseArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk.", "label": "Facilities Under Master Lease Arrangement", "terseLabel": "Facilities under master lease arrangement" } } }, "localname": "FacilitiesUnderMasterLeaseArrangement", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_FacilitiesUnderMedicareProbeReviews": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments", "label": "Facilities Under Medicare Probe Reviews", "terseLabel": "Facilities under Medicare probe reviews" } } }, "localname": "FacilitiesUnderMedicareProbeReviews", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "ensg_FacilitiesUnderMedicareProbeReviewsNumberOfFacilitiesResolvedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities Under Medicare Probe Reviews, Number Of Facilities Resolved In Period", "label": "Facilities Under Medicare Probe Reviews, Number Of Facilities Resolved In Period", "terseLabel": "Number of facilities resolved in period" } } }, "localname": "FacilitiesUnderMedicareProbeReviewsNumberOfFacilitiesResolvedInPeriod", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "ensg_FamilyFirstCoronavirusResponseActPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Family First Coronavirus Response Act, Payments Received", "label": "Family First Coronavirus Response Act, Payments Received", "terseLabel": "FMAP payments received" } } }, "localname": "FamilyFirstCoronavirusResponseActPaymentsReceived", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_GainLossOnOtherAssets": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property and equipment assets, gain on sale of business and insurance claims related to damaged property.", "label": "Gain (Loss) On Other Assets", "negatedLabel": "(Gain)/loss on sale of asset disposals" } } }, "localname": "GainLossOnOtherAssets", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_HealthLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Liability Insurance [Member]", "label": "Health Liability Insurance [Member]", "terseLabel": "Health Liability Insurance" } } }, "localname": "HealthLiabilityInsuranceMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Liability", "label": "Increase (Decrease) In Operating Lease, Liability", "terseLabel": "Operating lease obligations" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_InsuranceCoverageLimitTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Limit Type [Axis]", "label": "Insurance Coverage Limit Type [Axis]", "terseLabel": "Insurance Coverage Limit Type [Axis]" } } }, "localname": "InsuranceCoverageLimitTypeAxis", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "ensg_InsuranceCoverageLimitTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Limit Type [Domain]", "label": "Insurance Coverage Limit Type [Domain]", "terseLabel": "Insurance Coverage Limit Type [Domain]" } } }, "localname": "InsuranceCoverageLimitTypeDomain", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_InsuranceSubsidiaryDepositsAndInvestments": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity.", "label": "Insurance Subsidiary Deposits And Investments", "terseLabel": "Insurance subsidiary deposits and investments" } } }, "localname": "InsuranceSubsidiaryDepositsAndInvestments", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_LeaseArrangementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by group of related lease arrangements.", "label": "Lease Arrangement [Axis]", "terseLabel": "Lease Arrangement [Axis]" } } }, "localname": "LeaseArrangementAxis", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "ensg_LeaseArrangementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangement", "label": "Lease Arrangement [Domain]", "terseLabel": "Lease Arrangement [Domain]" } } }, "localname": "LeaseArrangementDomain", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "terseLabel": "Lessee leasing arrangements, operating leases, number of renewal terms" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act", "label": "Liabilities, Deferred Tax Payments Under CARES Act", "terseLabel": "Total deferred payment of social security taxes" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESAct", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESActCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act, Current", "label": "Liabilities, Deferred Tax Payments Under CARES Act, Current", "terseLabel": "Deferred payment of social security taxes, current" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESActCurrent", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESActNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent", "label": "Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent", "terseLabel": "Deferred payment of social security taxes, noncurrent" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESActNoncurrent", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Debt, net of Current Maturities and Debt Discount", "label": "Long Term Debt, net of Current Maturities and Debt Discount", "terseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "label": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "terseLabel": "Long-term debt, threshold for EBITDA ratio increase election" } } }, "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElection", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LossSensitivelimitperclaimMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss-Sensitive limit per claim", "label": "Loss-Sensitive limit per claim [Member] [Member]", "terseLabel": "Loss-Sensitive Limit Per Claim" } } }, "localname": "LossSensitivelimitperclaimMemberMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_ManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from managed care payors [Member]", "label": "Managed Care [Member]", "terseLabel": "Managed care" } } }, "localname": "ManagedCareMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_March132020RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 13, 2020 Repurchase Program", "label": "March 13, 2020 Repurchase Program [Member]", "terseLabel": "March 13, 2020 Repurchase Program" } } }, "localname": "March132020RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "ensg_March42020RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 4, 2020 Repurchase Program", "label": "March 4, 2020 Repurchase Program [Member]", "terseLabel": "March 4, 2020 Repurchase Program" } } }, "localname": "March42020RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "ensg_MasterLeaseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Lease agreements", "label": "Master Lease Agreements", "terseLabel": "Master lease agreements" } } }, "localname": "MasterLeaseAgreements", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicaid for custodial services [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicaidSkilledMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicaid for skilled services [Member]", "label": "Medicaid-skilled [Member]", "terseLabel": "Medicaid \u2014 skilled" } } }, "localname": "MedicaidSkilledMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareAcceleratedAndAdvancePaymentCARESACT": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medicare Accelerated And Advance Payment, CARES ACT", "label": "Medicare Accelerated And Advance Payment, CARES ACT", "terseLabel": "Medicare Accelerated and Advance Payment" } } }, "localname": "MedicareAcceleratedAndAdvancePaymentCARESACT", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareandMedicaidLicensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare licenses for home health and hospice segment and all other segment.", "label": "Medicare and Medicaid Licenses [Member]", "terseLabel": "Medicare and Medicaid licenses" } } }, "localname": "MedicareandMedicaidLicensesMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ensg_NonCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-California [Domain]", "label": "Non-California [Member]", "terseLabel": "Non-California" } } }, "localname": "NonCaliforniaMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Lease Expense", "label": "Non-Cash Lease Expense", "terseLabel": "Non-cash leasing arrangement" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_NoncontrollingInterestPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets.", "label": "Noncontrolling Interest [Policy Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestPolicyTextBlock", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ensg_NumberOfHealthCareFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Health Care Facilities", "label": "Number Of Health Care Facilities", "terseLabel": "Health care facilities" } } }, "localname": "NumberOfHealthCareFacilities", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfOperatingSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of operating subsidiaries entered into mortgage loans that are insured with HUD.", "label": "Number Of Operating Subsidiaries", "terseLabel": "Number of operating subsidiaries" } } }, "localname": "NumberOfOperatingSubsidiaries", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfOptionPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Option Plans", "label": "Number Of Option Plans", "terseLabel": "Number of option plans" } } }, "localname": "NumberOfOptionPlans", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties Leased", "label": "Number of Real Estate Properties Leased", "terseLabel": "Number of real estate properties leased" } } }, "localname": "NumberOfRealEstatePropertiesLeased", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties Leased with an Option to Purchase", "label": "Number of Real Estate Properties Leased with an Option to Purchase", "terseLabel": "Number of real estate properties leased with an option to purchase" } } }, "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfStockRepurchasePrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Stock Repurchase Programs", "label": "Number Of Stock Repurchase Programs", "terseLabel": "Number of stock repurchase programs" } } }, "localname": "NumberOfStockRepurchasePrograms", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "integerItemType" }, "ensg_OperatingEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Entity [Axis]", "label": "Operating Entity [Axis]", "terseLabel": "Operating Entity [Axis]" } } }, "localname": "OperatingEntityAxis", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "ensg_OperatingEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Operating Entity [Axis]", "label": "Operating Entity [Domain]", "terseLabel": "Operating Entity [Domain]" } } }, "localname": "OperatingEntityDomain", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_OperationalSeniorLivingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational Assisted Living and Independent Living Units", "label": "Operational Senior Living Units", "terseLabel": "Operational senior living units" } } }, "localname": "OperationalSeniorLivingUnits", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_OperationalSkilledNursingBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility", "label": "Operational Skilled Nursing Beds", "terseLabel": "Operational skilled nursing beds" } } }, "localname": "OperationalSkilledNursingBeds", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other states, except California, Texas and Washington", "label": "Other states, except California, Texas and Washington [Member]", "terseLabel": "Other States, Except California, Texas and Washington" } } }, "localname": "OtherStatesExceptCaliforniaTexasAndWashingtonMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_OwnedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owned Properties", "label": "Owned Properties [Member]", "terseLabel": "Owned Properties" } } }, "localname": "OwnedPropertiesMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_PaymentsToAcquireAssetAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments To Acquire Asset Acquisitions", "negatedTerseLabel": "Cash payments for asset acquisitions (Note 8)" } } }, "localname": "PaymentsToAcquireAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquireBusinessAndAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments To Acquire Business And Asset Acquisitions", "terseLabel": "Payments to acquire business and asset acquisitions" } } }, "localname": "PaymentsToAcquireBusinessAndAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquirePropertyAndEquipment": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Property And Equipment", "label": "Payments To Acquire Property And Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyAndEquipment", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PayorAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payor [Axis]", "label": "Payor [Axis]", "terseLabel": "Payor [Axis]" } } }, "localname": "PayorAxis", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "ensg_PayorDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payor [Domain]", "label": "Payor [Domain]", "terseLabel": "Payor [Domain]" } } }, "localname": "PayorDomain", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_PerFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Facility [Member]", "label": "Per Facility [Member]", "terseLabel": "Per Facility" } } }, "localname": "PerFacilityMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_PerOccurenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Occurence [Member]", "label": "Per Occurence [Member]", "terseLabel": "Per Occurence" } } }, "localname": "PerOccurenceMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringFirstThreeYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years.", "label": "Prepayment Penalty Reduced Rate During First Three Years", "terseLabel": "Prepayment penalty reduced rate during first three years" } } }, "localname": "PrepaymentPenaltyReducedRateDuringFirstThreeYears", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringTheFourthYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year.", "label": "Prepayment Penalty Reduced Rate During The Fourth Year", "terseLabel": "Prepayment penalty reduced rate during the fourth year" } } }, "localname": "PrepaymentPenaltyReducedRateDuringTheFourthYear", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateForTheFifthThroughTenthYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years.", "label": "Prepayment Penalty Reduced Rate For The Fifth Through Tenth Years", "terseLabel": "Prepayment penalty reduced rate for the fifth through tenth years" } } }, "localname": "PrepaymentPenaltyReducedRateForTheFifthThroughTenthYears", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrivatePayAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from self-pay and Other payors [Member]", "label": "Private Pay and Other [Member]", "terseLabel": "Private and other payors", "verboseLabel": "Private and other" } } }, "localname": "PrivatePayAndOtherMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "label": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "terseLabel": "Proceeds from CARES Act Provider Relief Fund (Note 3)" } } }, "localname": "ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PromissoryNote53Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note, 5.3%", "label": "Promissory Note, 5.3% [Member]", "terseLabel": "Promissory Note, 5.3%" } } }, "localname": "PromissoryNote53Member", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_PurchaseOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Option", "label": "Purchase Option [Member]", "terseLabel": "Purchase Option" } } }, "localname": "PurchaseOptionMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_QualityAssuranceFee": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days", "label": "Quality Assurance Fee", "terseLabel": "Quality assurance fee" } } }, "localname": "QualityAssuranceFee", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RealEstateSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Segment", "label": "Real Estate Segment [Member]", "terseLabel": "Real Estate" } } }, "localname": "RealEstateSegmentMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "domainItemType" }, "ensg_RemainingCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Ensign Group, Inc.", "label": "Remaining Company [Member]", "terseLabel": "Remaining Company" } } }, "localname": "RemainingCompanyMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "ensg_RentCostOfServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rent, Cost Of Servcies[Member]", "label": "Rent, Cost Of Services [Member]", "terseLabel": "Rent - cost of services" } } }, "localname": "RentCostOfServicesMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_RentCostofServices": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent cost of services", "label": "Rent Cost of Services", "terseLabel": "Rent\u2014cost of services" } } }, "localname": "RentCostofServices", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "ensg_RentalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rental", "label": "Rental [Member]", "terseLabel": "Rental revenue" } } }, "localname": "RentalMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "label": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "terseLabel": "Repayment of Medicare Accelerated and Advance Payment Program" } } }, "localname": "RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ResidentRefundsPayable": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments", "label": "Resident Refunds Payable", "terseLabel": "Refunds payable" } } }, "localname": "ResidentRefundsPayable", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RevenueFamilyFirstCoronavirusResponseActPaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Family First Coronavirus Response Act, Payments Received", "label": "Revenue, Family First Coronavirus Response Act, Payments Received", "terseLabel": "Revenue, FMAP payments received" } } }, "localname": "RevenueFamilyFirstCoronavirusResponseActPaymentsReceived", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SegmentIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segment Income (Loss)", "label": "Segment Income (Loss)", "terseLabel": "Segment income (loss)" } } }, "localname": "SegmentIncomeLoss", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SelfInsuranceRetentionPerClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Self-insurance retention per claim [Member]", "label": "Self-insurance retention per claim [Member]", "terseLabel": "Self-Insurance Retention Per Claim" } } }, "localname": "SelfInsuranceRetentionPerClaimMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Assisted and Independent Living Facilities", "label": "Senior Living Facilities", "terseLabel": "Senior living facilities" } } }, "localname": "SeniorLivingFacilities", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SeniorLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted Living Facilities [Member]", "label": "Senior Living Facilities [Member]", "terseLabel": "Senior Living Facilities" } } }, "localname": "SeniorLivingFacilitiesMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number", "terseLabel": "Share-based compensation arrangement by share-based payment award, options, expected to vest, number (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "terseLabel": "Other than options, conversion to reduce shares availability" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value", "terseLabel": "Black-Scholes Fair Value" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversiontoReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability", "terseLabel": "Conversion to reduce shares availability" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversiontoReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_SharebasedCompensationRestrictedAwardsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Restricted Awards, Exercise Price", "label": "Share-based Compensation, Restricted Awards, Exercise Price", "terseLabel": "Share-based compensation, restricted awards, exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationRestrictedAwardsExercisePrice", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ensg_SkilledNursingAssistedLivingAndIndependentLivingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing, Assisted Living and Independent Living Facilities", "label": "Skilled Nursing, Assisted Living and Independent Living Facilities", "terseLabel": "Skilled nursing, assisted living and independent living facilities" } } }, "localname": "SkilledNursingAssistedLivingAndIndependentLivingFacilities", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledNursingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Operations", "label": "Skilled Nursing Operations [Member]", "terseLabel": "Skilled Nursing Operations" } } }, "localname": "SkilledNursingOperationsMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_StockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock awards [Member]", "label": "Stock awards [Member]", "terseLabel": "Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors" } } }, "localname": "StockAwardsMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "ensg_StopLossInsuranceLimitPerClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stop-Loss Insurance limit per claim[Member]", "label": "Stop-Loss Insurance limit per claim [Member]", "terseLabel": "Stop-Loss Insurance Limit Per Claim" } } }, "localname": "StopLossInsuranceLimitPerClaimMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_ThePennantGroupInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Pennant Group, Inc.", "label": "The Pennant Group, Inc. [Member]", "terseLabel": "The Pennant Group, Inc." } } }, "localname": "ThePennantGroupInc.Member", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdAmendedCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Amended Credit Facility [Member]", "label": "Third Amended Credit Facility [Member]", "terseLabel": "Third Amended Credit Facility" } } }, "localname": "ThirdAmendedCreditFacilityMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartyTenantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Tenants [Member]", "label": "Third Party Tenants [Member]", "terseLabel": "Other third-party" } } }, "localname": "ThirdPartyTenantsMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Tenants Under Triple Net Lease Arrangements", "label": "Third Party Tenants Under Triple Net Lease Arrangements [Member]", "terseLabel": "Third Party Tenants Under Triple Net Lease Arrangements" } } }, "localname": "ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_TotalMedicaidAndMedicareRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total revenue from Medicaid and Medicare [Member]", "label": "Total Medicaid and Medicare Revenue [Member]", "terseLabel": "Total Medicare and Medicaid", "verboseLabel": "Total Medicaid and Medicare" } } }, "localname": "TotalMedicaidAndMedicareRevenueMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "ensg_TotalNetDebtRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Maximum", "label": "Total Net Debt Ratio, Maximum", "terseLabel": "Total net debt ratio, maximum" } } }, "localname": "TotalNetDebtRatioMaximum", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMaximumAfterIncreaseElection": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Maximum After Increase Election", "label": "Total Net Debt Ratio, Maximum After Increase Election", "terseLabel": "Total net debt ratio, maximum after increase election" } } }, "localname": "TotalNetDebtRatioMaximumAfterIncreaseElection", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Minimum", "label": "Total Net Debt Ratio, Minimum", "terseLabel": "Total net debt ratio, minimum" } } }, "localname": "TotalNetDebtRatioMinimum", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "pureItemType" }, "ensg_TransitionalAndSkilledServiceFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transitional And Skilled Service Facilities", "label": "Transitional And Skilled Service Facilities", "terseLabel": "Transitional and skilled service facilities" } } }, "localname": "TransitionalAndSkilledServiceFacilities", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_TransitionalAndSkilledServicesAndSeniorLivingCampuses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses", "label": "Transitional And Skilled Services And Senior Living Campuses", "terseLabel": "Transitional and skilled services and senior living campuses" } } }, "localname": "TransitionalAndSkilledServicesAndSeniorLivingCampuses", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_TransitionalandSkilledServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transitional and Skilled Services Segment", "label": "Transitional and Skilled Services Segment [Member]", "terseLabel": "Transitional and Skilled Services" } } }, "localname": "TransitionalandSkilledServicesSegmentMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_TruistBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Truist Bank [Member]", "label": "Truist Bank [Member]", "terseLabel": "Truist" } } }, "localname": "TruistBankMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "ensg_VariousLandlordsMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various Landlords[Member]", "label": "Various Landlords [Member] [Member]", "terseLabel": "Various Landlords" } } }, "localname": "VariousLandlordsMemberMember", "nsuri": "http://www.ensigngroup.net/20210331", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "naics_ZZ524292": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "524292 Third Party Administration of Insurance and Pension Funds [Member]", "terseLabel": "Third-Party Payor" } } }, "localname": "ZZ524292", "nsuri": "http://xbrl.sec.gov/naics/2017-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "sic_Z8051": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "8051 Services, Skilled Nursing Care Facilities [Member]", "terseLabel": "8051 Services, Skilled Nursing Care Facilities" } } }, "localname": "Z8051", "nsuri": "http://xbrl.sec.gov/sic/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationEliminationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidation, Eliminations [Member]", "terseLabel": "Intercompany Eliminations" } } }, "localname": "ConsolidationEliminationsMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r153", "r166", "r167", "r168", "r169", "r171", "r173", "r177" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r153", "r166", "r167", "r168", "r169", "r171", "r173", "r177" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r53", "r100" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r184", "r291", "r296", "r543" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r312", "r314", "r467", "r468", "r469", "r470", "r471", "r472", "r491", "r540", "r544" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r312", "r314", "r467", "r468", "r469", "r470", "r471", "r472", "r491", "r540", "r544" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r184", "r291", "r296", "r543" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Parent Company [Member]", "terseLabel": "Parent Company" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r180", "r291", "r294", "r492", "r539", "r541" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]", "verboseLabel": "Insurance Policy [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r180", "r291", "r294", "r492", "r539", "r541" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]", "verboseLabel": "Insurance Policy [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r302", "r312", "r314", "r467", "r468", "r469", "r470", "r471", "r472", "r491", "r540", "r544" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r302", "r312", "r314", "r467", "r468", "r469", "r470", "r471", "r472", "r491", "r540", "r544" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r181", "r182", "r291", "r295", "r542", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r181", "r182", "r291", "r295", "r542", "r553", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "stpr_CO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COLORADO", "terseLabel": "Colorado" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "TEXAS" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "OTHER ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r186" ], "calculation": { "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r23", "r520" ], "calculation": { "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "totalLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r23", "r186", "r187" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $11,090 and $8,718 at March\u00a031, 2021 and December 31, 2020, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "auth_ref": [ "r362", "r507", "r531" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.", "label": "Accrual for Taxes Other than Income Taxes", "terseLabel": "Property taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r18", "r20", "r370", "r499", "r524" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued Income Taxes", "terseLabel": "Income tax payable" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r242" ], "calculation": { "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life (Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r104", "r105", "r106", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r316", "r319", "r359", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Employee stock award compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r319", "r349", "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r192", "r206", "r208", "r210" ], "calculation": { "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Less: allowance for doubtful accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r87", "r431" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r87", "r225", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r161", "r168", "r175", "r203", "r398", "r403", "r419", "r497", "r522" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r52", "r98", "r203", "r398", "r403", "r419" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r311", "r313" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r311", "r313", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Operation Expansions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r31", "r89" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, fair value disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r83", "r89", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r420" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease)/increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashSurrenderValueOfLifeInsurance": { "auth_ref": [ "r10", "r35" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity.", "label": "Cash Surrender Value of Life Insurance", "terseLabel": "Cash surrender value of life insurance related to deferred compensation plan" } } }, "localname": "CashSurrenderValueOfLifeInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash, uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralizedDebtObligationsMember": { "auth_ref": [ "r198", "r303" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by a pool of assets.", "label": "Collateralized Debt Obligations [Member]", "terseLabel": "Mortgage loans and promissory notes" } } }, "localname": "CollateralizedDebtObligationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r256", "r508", "r530" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 15, 17 and 18)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r253", "r254", "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: $0.001 par value; 100,000 shares authorized; 57,744 and 54,953 shares issued and outstanding at March\u00a031, 2021, respectively, and 57,417 and 54,626 shares issued and outstanding at December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r142", "r143", "r184", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r142", "r143", "r184", "r416", "r417", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r142", "r143", "r184", "r416", "r417", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r142", "r143", "r184", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r140", "r142", "r143", "r144", "r416", "r418" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r142", "r143", "r184", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r272", "r273", "r292" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Resident advances" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r177", "r179" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "All Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r66", "r492" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r64" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expense:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r141", "r184" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r18", "r19", "r498", "r501", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate margin" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r259", "r501", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Mortgage loans and promissory notes", "verboseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r101", "r262", "r263", "r264", "r265", "r429", "r430", "r432", "r518" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r433" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Cash surrender value of life insurance related to deferred compensation plan" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r35", "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r365", "r366" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r87", "r99", "r375", "r381", "r382", "r383" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Escrow deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r87", "r156" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r291", "r294", "r295", "r296", "r297", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "OPTIONS AND AWARDS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r266", "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r18", "r20", "r500", "r523" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividends payable", "verboseLabel": "Accrued dividends declared" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r198", "r303", "r310" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "Debt Security, Corporate, US" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share attributable to The Ensign Group, Inc.:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r61", "r109", "r110", "r111", "r112", "r113", "r117", "r119", "r125", "r126", "r127", "r131", "r132", "r513", "r535" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic income per share attributable to The Ensign Group, Inc. (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r61", "r109", "r110", "r111", "r112", "r113", "r119", "r125", "r126", "r127", "r131", "r132", "r513", "r535" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted income per share attributable to The Ensign Group, Inc.(in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128", "r129", "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "COMPUTATION OF NET INCOME PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Total income tax provision" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued wages and related liabilities (Note 3)" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock-based compensation expense related to stock options", "verboseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r104", "r105", "r106", "r108", "r114", "r116", "r135", "r205", "r261", "r266", "r353", "r354", "r355", "r377", "r378", "r421", "r422", "r423", "r424", "r425", "r426", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r35" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Long-term insurance losses recoverable asset" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceRecoveriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both [Abstract]" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r409", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r410", "r464", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r303", "r304", "r309", "r310", "r410", "r464" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r303", "r304", "r309", "r310", "r410", "r465" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r464", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r95", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r200", "r201", "r207", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r232" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 7.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r234" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r234" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r234" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r234" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r234" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r226", "r229", "r232", "r236", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Year" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r232", "r494" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r226", "r231" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r232", "r493" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r69", "r87", "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "terseLabel": "Gain on deferral investment" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability.", "label": "General Liability [Member]", "terseLabel": "General Liability" } } }, "localname": "GeneralLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r221", "r222", "r496" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Goodwill and intangible asset impairment" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r95", "r223", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r315", "r317", "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HealthInsuranceProductLineMember": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Product line consisting of insurance against loss by illness or injury.", "label": "Health Insurance Product Line [Member]", "terseLabel": "Health" } } }, "localname": "HealthInsuranceProductLineMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r196", "r199", "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity", "terseLabel": "Debt securities, held-to-maturity" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r87", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r95", "r239", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r65", "r88", "r109", "r110", "r111", "r112", "r124", "r127", "r396" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Net income attributable to The Ensign Group, Inc." } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r394", "r397" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "verboseLabel": "Less: net income attributable to noncontrolling interests" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r161", "r167", "r171", "r174", "r177", "r495", "r510", "r516", "r536" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r98", "r107", "r161", "r167", "r171", "r174", "r177", "r203", "r397", "r419" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r57", "r61", "r107", "r109", "r110", "r111", "r112", "r119", "r125", "r126", "r509", "r511", "r513", "r532" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Basic net income from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r57", "r61", "r107", "r109", "r110", "r111", "r112", "r119", "r125", "r126", "r127", "r513", "r532", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Diluted net income from continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r369", "r371", "r374", "r379", "r384", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r115", "r116", "r159", "r367", "r380", "r385", "r537" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r56", "r95", "r363", "r364", "r371", "r372", "r373", "r376", "r558" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation liability" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedTerseLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Increase (Decrease) in Self Insurance Reserve", "terseLabel": "Accrued self-insurance liabilities" } } }, "localname": "IncreaseDecreaseInSelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r120", "r121", "r122", "r127" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Plus: incremental shares from assumed conversion (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r228", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r235" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other indefinite-lived intangibles", "verboseLabel": "Medicare and Medicaid licenses" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r228", "r235" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS \u2014 NET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r58", "r155", "r428", "r431", "r515" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r80", "r84", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r68", "r154" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest and other income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r70", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "terseLabel": "Deferral investment expense" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases and Leasehold Improvements" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Operating leases of lessee, contingent rentals, basis spread on variable rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r451" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Lessor, Operating Lease, Payments to be Received, Maturity" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 7.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r455" ], "calculation": { "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding, pledged amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r98", "r169", "r203", "r399", "r403", "r404", "r419" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r98", "r203", "r419", "r503", "r528" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r98", "r203", "r399", "r403", "r404", "r419" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityReserveEstimatePolicy": { "auth_ref": [ "r95", "r551" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).", "label": "Liability Reserve Estimate, Policy [Policy Text Block]", "terseLabel": "Self-Insurance" } } }, "localname": "LiabilityReserveEstimatePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue": { "auth_ref": [ "r204" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period.", "label": "Life Insurance, Corporate or Bank Owned, Change in Value", "negatedTerseLabel": "Cash surrender value of life insurance policy premiums" } } }, "localname": "LifeInsuranceCorporateOrBankOwnedChangeInValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r38", "r101" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedTerseLabel": "Less: current maturities", "terseLabel": "Current maturities of long-term debt", "verboseLabel": "Amount outstanding, current" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r258" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.", "label": "Malpractice Loss Contingency, Accrual, Undiscounted", "terseLabel": "Malpractice loss contingency, accrual, undiscounted" } } }, "localname": "MalpracticeLossContingencyAccrualUndiscounted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r50", "r98", "r203", "r419", "r502", "r527" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distribution to noncontrolling interest holder" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Less:" } } }, "localname": "MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r85", "r88" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r54", "r55", "r60", "r88", "r98", "r107", "r109", "r110", "r111", "r112", "r115", "r116", "r124", "r161", "r167", "r171", "r174", "r177", "r203", "r419", "r512", "r533" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to The Ensign Group, Inc.", "verboseLabel": "Net income attributable to the Ensign Group, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r54", "r55", "r115", "r116", "r401", "r406" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r104", "r105", "r106", "r266", "r394" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r19", "r501", "r525" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Mortgage loans and promissory notes", "verboseLabel": "Notes Payable Other Payables" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of businesses acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r167", "r171", "r174", "r177" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r444", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r134", "r454", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Operating lease, lease income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r134", "r458" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Operating Lease, Lease Income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Year" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r437" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r437" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current lease liabilities", "terseLabel": "Lease liabilities\u2014current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r437" ], "calculation": { "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities\u2014less current portion", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r439", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r436" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "auth_ref": [ "r134", "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.", "label": "Operating Lease, Variable Lease Income", "terseLabel": "Operating lease, variable lease income" } } }, "localname": "OperatingLeaseVariableLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LessorRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r449", "r452" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r448", "r452" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r434", "r435", "r459" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessor's operating leases.", "label": "Lessor, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r177" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r408" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r41" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "totalLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "RESTRICTED AND OTHER ASSETS" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash financing and investing activity:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other income (expense), net", "totalLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherRestrictedAssets": { "auth_ref": [ "r35" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.", "label": "Other Restricted Assets", "terseLabel": "Capital improvement reserves with landlords and lenders" } } }, "localname": "OtherRestrictedAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestrictedAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other.", "label": "Other Restricted Assets, Noncurrent", "terseLabel": "Restricted and other assets", "totalLabel": "Restricted and other assets" } } }, "localname": "OtherRestrictedAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r74" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Payments for Deposits on Real Estate Acquisitions", "negatedLabel": "Escrow deposits" } } }, "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r73", "r75", "r102" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other restricted assets" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r78" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of shares of common stock (Note 19)" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r78" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r75" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r29", "r30" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r6", "r8", "r219", "r220" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromDepositsOnRealEstateSales": { "auth_ref": [ "r72" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow related to amounts received in advance from a potential buyer showing or confirming an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Proceeds from Deposits on Real Estate Sales", "terseLabel": "Escrow deposits used to fund acquisitions" } } }, "localname": "ProceedsFromDepositsOnRealEstateSales", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "auth_ref": [ "r73", "r82" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.", "label": "Proceeds from Insurance Settlement, Investing Activities", "terseLabel": "Cash proceeds from insurance proceeds" } } }, "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r77" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from revolving credit facility and other debt (Note 15)" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "auth_ref": [ "r102" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.", "label": "Proceeds from (Payments to) Noncontrolling Interests", "terseLabel": "Non-controlling interest distribution" } } }, "localname": "ProceedsFromPaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r73" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.", "label": "Proceeds from Sales of Assets, Investing Activities", "terseLabel": "Cash proceeds from the sale of assets and ancillary business" } } }, "localname": "ProceedsFromSalesOfAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r76", "r352" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities.", "label": "Professional Malpractice Liability Insurance [Member]", "terseLabel": "General and Professional Liability" } } }, "localname": "ProfessionalMalpracticeLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r54", "r55", "r81", "r98", "r107", "r115", "r116", "r161", "r167", "r171", "r174", "r177", "r203", "r397", "r400", "r402", "r406", "r407", "r419", "r516" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLossFromRealEstateOperations": { "auth_ref": [ "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate).", "label": "Profit (Loss) from Real Estate Operations", "terseLabel": "Gain on sale of real estate" } } }, "localname": "ProfitLossFromRealEstateOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r247", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT\u2014 Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r241" ], "calculation": { "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r243", "r529" ], "calculation": { "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r32", "r95", "r243", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r241" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r63", "r209" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Property Ownership [Axis]", "terseLabel": "Real Estate Property Ownership [Axis]" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents categories of ownership of real estate properties.", "label": "Real Estate Properties [Domain]", "terseLabel": "Real Estate Properties [Domain]" } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r166", "r171" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r166", "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on revolving credit facility and other debt (Note 15)" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Stock-based compensation expense related to restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r266", "r356", "r526", "r549", "r550" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r104", "r105", "r106", "r108", "r114", "r116", "r205", "r353", "r354", "r355", "r377", "r378", "r546", "r548" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r152", "r153", "r166", "r172", "r173", "r180", "r181", "r184", "r290", "r291", "r492" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "verboseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r293", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE AND ACCOUNTS RECEIVABLE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility with Truist" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r447", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r142", "r184" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Other Indefinite-lived Intangible Assets by Major Class" } } }, "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of Common Stock Outstanding Roll Forward" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r44", "r101", "r262", "r263", "r264", "r265", "r429", "r430", "r432", "r518" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "auth_ref": [ "r123", "r127", "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r123", "r127", "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r319", "r348", "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r319", "r348", "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r226", "r231", "r493" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r226", "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Held-to-maturity Securities [Line Items]", "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "auth_ref": [ "r200", "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity [Table]", "terseLabel": "Debt Securities, Held-to-maturity [Table]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r235", "r237" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "auth_ref": [ "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Insurance Type and Tier Identifier [Axis]", "terseLabel": "Insurance Type and Tier Identifier [Axis]" } } }, "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Restricted and Other Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "verboseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r161", "r164", "r170", "r223" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r161", "r164", "r170", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r51" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Deposits with landlords" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsScheduleofRestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r148", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r177", "r184", "r539" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r148", "r150", "r151", "r161", "r165", "r171", "r175", "r176", "r177", "r178", "r180", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENTS" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self insurance reserve" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Accrued self-insurance liabilities\u2014current" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Noncurrent", "terseLabel": "Accrued self-insurance liabilities\u2014less current portion" } } }, "localname": "SelfInsuranceReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Options granted to non-employee directors (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Non-Vested Restricted Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "periodStartLabel": "Nonvested at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Weighted Average Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted Average Risk-Free Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted Average Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price of options vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Grant date intrinsic value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "netLabel": "Granted (in shares)", "verboseLabel": "Options Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Fair Value of Options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r327", "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at end of period, (in shares)", "periodStartLabel": "Balance at beginning of period, (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at end of period, (in dollars per share)", "periodStartLabel": "Balance at beginning of period, (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "terseLabel": "Schedule of Aggregate Intrinsic Value of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of options vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r318", "r324" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r95", "r320", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, lower range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Stock options vested and exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, upper range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r315", "r347" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Non-employee directors" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value of options that vested in period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r343", "r357" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r17", "r504", "r505", "r521" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investments\u2014current" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SpinoffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares.", "label": "Spinoff [Member]", "terseLabel": "Spinoff" } } }, "localname": "SpinoffMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r148", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r177", "r184", "r223", "r245", "r248", "r252", "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r104", "r105", "r106", "r108", "r114", "r116", "r135", "r205", "r261", "r266", "r353", "r354", "r355", "r377", "r378", "r421", "r422", "r423", "r424", "r425", "r426", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r104", "r105", "r106", "r135", "r492" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r21", "r22", "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Nonvested restricted awards, granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r21", "r22", "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r261", "r266", "r329" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r261", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r261", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Stock repurchase program, period in force" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r21", "r22", "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r21", "r22", "r261", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r98", "r194", "r203", "r419" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Ensign Group, Inc. stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Ensign Group, Inc. stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r98", "r104", "r105", "r106", "r108", "r114", "r203", "r205", "r266", "r353", "r354", "r355", "r377", "r378", "r394", "r395", "r405", "r419", "r421", "r422", "r426", "r547", "r548" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r97", "r266", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "COMMON STOCK REPURCHASE PROGRAM" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r427", "r460" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r427", "r460" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r427", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r427", "r460" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATEDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/LeasesNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r188", "r189", "r190", "r191", "r193", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Facility trade name", "verboseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r200", "r201", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r267" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r47", "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Common stock in treasury, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r267", "r270" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Common stock in treasury, at cost, 2,791 shares at both periods ended March\u00a031, 2021 and December 31, 2020 (Note 19)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeAndTierIdentifierDomain": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Type and Tier Identifier [Domain]", "terseLabel": "Type and Tier Identifier [Domain]" } } }, "localname": "TypeAndTierIdentifierDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceGeneralandProfessionalDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]", "terseLabel": "COVID-19 UPDATE" } } }, "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/COVID19UPDATE" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r136", "r137", "r138", "r139", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r445", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease, cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r127" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Adjusted weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding:", "verboseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r117", "r127" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding for basic net income per share (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WhollyOwnedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate properties and units within those properties that are wholly owned.", "label": "Wholly Owned Properties [Member]", "terseLabel": "Wholly Owned Properties" } } }, "localname": "WhollyOwnedPropertiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WorkersCompensationInsuranceMember": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death.", "label": "Workers' Compensation Insurance [Member]", "terseLabel": "Workers' Compensation" } } }, "localname": "WorkersCompensationInsuranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "325", "URI": "http://asc.fasb.org/extlink&oid=6384439&loc=d3e42048-111605" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r408": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "Note 1", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "Note 3", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r459": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888252" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884803&loc=SL65671395-207642" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/subtopic&trid=2560295" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9100-115647" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9113-115647" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9127-115647" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r571": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r572": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r573": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r574": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r575": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r576": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/subtopic&trid=114868817" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080549-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 108 0001125376-21-000077-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-21-000077-xbrl.zip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�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end